International Association for the Study of Lung Cancer

IASLC 17TH WORLD CONFERENCE ON LUNG CANCER

Program Book

WCLC 2016 TOGETHER AGAINST LUNG CANCER

FOLLOW US ON TWITTER @IASLC #WCLC2016
FOLLOW US ON FACEBOOK.COM/IASLC

BECOME A MEMBER OF IASLC
WWW.IASLC.ORG
Immuno-Oncology and Lung Cancer: Emerging Data and Recent Developments

Monday, 5 December 2016 | 12:45–14:15
Messe Wien Exhibition & Congress Center
Hall D, Plenary Room
Vienna, Austria

Presentations Include:

- **Developments in the Use of I-O Monotherapy in Lung Cancers**
  - Enriqueta Felip, MD, PhD
  - Vall d’Hebron University Hospital
  - Barcelona, Spain

- **Rationale for Studying I-O Combo Therapies to Address Unmet Needs in Lung Cancer**
  - Matthew Hellmann, MD
  - Memorial Sloan Kettering Cancer Center
  - New York, United States

- **Clinical Lessons Learned for the Use of I-O Therapies**
  - Jürgen Wolf, MD, PhD
  - University Hospital of Cologne
  - Cologne, Germany

This presentation was approved by the IASLC 17th World Conference on Lung Cancer Program Committee as an independent activity held in conjunction with the IASLC 17th World Conference on Lung Cancer. This presentation is not sponsored or endorsed by IASLC.
## Table of Contents

**SECTION 1  WELCOME**
- Welcome Message 5
- Conference Sponsors 7
- Conference Summary 8

**SECTION 2  IASLC AND COMMITTEES**
- International Association for the Study of Lung Cancer 10
- Guests of Honor 11
- Committees 12
  - Regional Organizing Committee 12
  - Core Program Committee 12
  - Program Committees 12
  - International Scientific Advisory Committee 15

**SECTION 3  GENERAL CONFERENCE INFORMATION**
- Registration 18
- Onsite Services and General Information 22
- Press and Media 31
- Information for Invited Speakers and Abstract Presenters 32
- CME Accreditation 34
- Vienna Information 36

**SECTION 4  EXHIBIT INFORMATION**
- Location, Events and Poster Information 40
- Exhibitor Listing 42
- Exhibit Floor Plan 43
- Exhibitor Descriptions 44

**SECTION 5  IASLC AND CONFERENCE AWARDS**
- IASLC Distinguished Awards 50
- IASLC Fellowship Award Winners 54
- IASLC International Mentorship Award Winners 55
- WCLC 2016 Young Investigator Award Winners 58
- WCLC 2016 Developing Nation Award Winners 59
- IASLC/WCLC 2016 Patient Advocacy Award Winners 60
- WCLC 2016 Lectureship Award Winners 60
- WCLC 2016 Communications Workshop Award Winners 61
### TABLE OF CONTENTS

**SECTION 6**  
CONFERENCE PROGRAM  
| Program at a Glance | 64  
| Sessions at a Glance by Day | 66  
| Sessions at a Glance by Track | 74  
| Workshops, Hands-On Training and Special Sessions | 82  
| Industry Supported Symposia | 84  
| Plenary Sessions | 85  
| Networking Opportunities | 86  

**SECTION 7**  
DAILY SCIENTIFIC PROGRAM  
| Saturday, December 3 | 88  
| Sunday, December 4 | 90  
| Monday, December 5 | 96  
| Tuesday, December 6 | 112  
| Wednesday, December 7 | 130  

**SECTION 8**  
POSTER SESSIONS  
| Monday, December 5 | 144  
| Tuesday, December 6 | 166  
| Wednesday, December 7 | 188  

**SECTION 9**  
AUTHOR INDEX  
| Author Index | 210  

**SECTION 10**  
MAPS AND FLOOR PLANS  
| Maps and Floor Plans | 250  

---

**Conference Secretariat**  
International Conference Services Ltd. (ICS)  
Suite 300, 1201 West Pender Street  
Vancouver, BC, Canada V6E 2V2  
Phone +1 604 681 2153  
Fax +1 604 681 1049  
Email wclc2016@icsevents.com  
www.icsevents.com
Welcome

Welcome Message 5
Conference Sponsors 7
Conference Summary 8
Members - Claim your member pin at the IASLC Booth!

Special Offer for NEW Members at WCLC – 2 years for 1 year dues!

NEW Regular Members – US $250.00 (2017–2018)
NEW Developing Country and Allied Health Members – US $50.00 (2017–2018)

Join during the Conference to receive a member pin and tote bag.

<table>
<thead>
<tr>
<th>Member Category</th>
<th>1 Year Dues (2017)</th>
<th>3 Year Dues (2017-2019)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Regular Member</td>
<td>US $250</td>
<td>US $600</td>
</tr>
<tr>
<td>Developing Country or Allied Professional Member</td>
<td>US $50</td>
<td>US $150</td>
</tr>
<tr>
<td>Fellow/Resident/Trainee</td>
<td>Complimentary</td>
<td></td>
</tr>
<tr>
<td>Survivor</td>
<td>Complimentary</td>
<td></td>
</tr>
</tbody>
</table>

Save $150 on 3-year membership

IASLC MEMBERSHIP BENEFITS INCLUDE

- Collaboration with a global team of thoracic oncology experts and leaders
- Member access to Journal of Thoracic Oncology, the premier journal in lung cancer, as well as the latest classification and staging publications
- Multidisciplinary education including latest in ground-breaking research and treatment of thoracic malignancies

And much more!
Visit www.IASLC.org for more details.

Ask about discounted membership offers for partner societies!
Dear Friends, Colleagues, Sponsors, Supporters and Exhibitors,

On behalf of IASLC and the organizers, I welcome you to the IASLC 17th World Conference on Lung Cancer in Vienna.

IASLC WCLC 2016 with the theme Active Prevention, Accurate Diagnosis, Advanced Care is a multidisciplinary Conference and covers all scientific advances in prevention, early detection, diagnosis and treatment of lung cancer and other thoracic cancers. Major topics of the World Conference are tobacco control, early detection, the 8th TNM classification, molecular analyses, novel therapeutic targets, immune checkpoint inhibitors, and results from clinical practice-changing phase III trials. These advances will be presented in plenary sessions, scientific sessions, oral and mini oral sessions as well as poster sessions. The Conference will also provide updates on the state-of-the-art management of lung cancer.

More than 2,000 abstracts have been selected for oral or poster presentations. Poster presentations will be an important part of the Conference. Posters will be on display in the exhibition hall, just beside the industry exhibition, for the whole day with presenter presence at time slots in the morning and afternoon. This should facilitate interaction between presenters and participants.

IASLC WCLC 2016 will provide you with a great opportunity to exchange scientific advances and clinical experiences with colleagues from all over the world. It will be an excellent opportunity for initiating or strengthening ongoing co-operations. This will benefit lung cancer patients from around the globe.

Vienna is an international city in the heart of Europe and host to many international organizations including the United Nations. I hope you will be inspired by the Viennese culture and way of living, make new friendships and become part of the global IASLC community.

I warmly welcome you in Vienna.

Yours sincerely,

Robert Pirker, MD
IASLC WCLC 2016 Conference President
STRIVING TO OUTSMART CANCER. TOGETHER.


At AbbVie, we build bonds with oncologists, patients, payers, advocacy groups, health authorities, and other pharmaceutical companies, because we know that advancing the science of this devastating disease is not something that one person, or even one company, can do alone.

Together we can conduct research that deepens our understanding of the disease and its pathways, to ultimately develop new molecules that make a transformational improvement in cancer care.
IASLC and the 17th World Conference on Lung Cancer gratefully acknowledges the generous support of its Conference Sponsors.

**DIAMOND SPONSORS**

Lilly

**PLATINUM SPONSORS**

Bristol-Myers Squibb

**GOLD SPONSORS**

AstraZeneca

**SILVER SPONSOR**

**BRONZE SPONSORS**

Roche

MSD

Pfizer Oncology

**SUPPORTERS**

Celgene

ARIAD

Boehringer Ingelheim

**CONTRIBUTORS**

Abbvie

prime Oncology

Thermo Fisher Scientific

Janssen Oncology

IASLC and the 17th World Conference on Lung Cancer would also like to sincerely thank the following organizations for providing medical educational grants:
CONFERENCE SUMMARY

LOCATION
All WCLC 2016 sessions will take place at the Messe Wien Exhibition & Congress Center, Messeplatz 1, A-1021 Vienna

[Exit U2 Station ‘Krieau’]

Please exit at Krieau Station and not Messe Prater Station.

Registration & Delegate Help Desk Hours
FOYER D

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, December 3</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, December 4</td>
<td>07:30 – 20:45</td>
</tr>
<tr>
<td>Monday, December 5</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>07:00 – 16:00</td>
</tr>
</tbody>
</table>

Exhibit Hours
HALL B (EXHIBIT HALL)

All day refreshments and light snacks will be served in the Exhibit Hall throughout opening hours.

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, December 4</td>
<td>20:45 – 21:45</td>
</tr>
<tr>
<td></td>
<td>(Welcome Reception)</td>
</tr>
<tr>
<td>Monday, December 5</td>
<td>09:30 – 16:30</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>09:30 – 16:30</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>09:30 – 16:30</td>
</tr>
</tbody>
</table>

Speaker Ready Room Hours
HALL C

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, December 3</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, December 4</td>
<td>07:30 – 20:45</td>
</tr>
<tr>
<td>Monday, December 5</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>07:00 – 16:00</td>
</tr>
</tbody>
</table>

IASLC Business Meeting
SCHUBERT 2, LEVEL ONE

Light Refreshments will be provided.

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tuesday, December 6</td>
<td>14:30 – 15:00</td>
</tr>
</tbody>
</table>

Poster Pick Up Counter
HALL B (EXHIBIT HALL)
EXHIBIT INFORMATION BOOTH

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, December 4</td>
<td>20:45 – 21:45</td>
</tr>
<tr>
<td></td>
<td>(Welcome Reception)</td>
</tr>
<tr>
<td>Monday, December 5</td>
<td>09:00 – 15:45</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>09:00 – 15:45</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>09:00 – 11:00</td>
</tr>
</tbody>
</table>

Media Room
BRASSERIE, LEVEL ONE

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, December 4</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Monday, December 5</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>07:00 – 18:00</td>
</tr>
</tbody>
</table>
IASLC and Committees

<table>
<thead>
<tr>
<th>Committees</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>International Association for the Study of Lung Cancer</td>
<td>10</td>
</tr>
<tr>
<td>Guests of Honor</td>
<td>11</td>
</tr>
<tr>
<td>Committees</td>
<td>12</td>
</tr>
<tr>
<td>Regional Organizing Committee</td>
<td>12</td>
</tr>
<tr>
<td>Core Program Committee</td>
<td>12</td>
</tr>
<tr>
<td>Program Committees</td>
<td>12</td>
</tr>
<tr>
<td>International Scientific Advisory Committee</td>
<td>15</td>
</tr>
</tbody>
</table>
The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes nearly 6,000 lung cancer specialists in over 100 countries.

IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

The IASLC mission is:

To embrace the study of the etiology, epidemiology, prevention, diagnosis, treatment and all other aspects of lung cancer and other thoracic malignancies

To provide education and information about lung cancer and other thoracic malignancies to IASLC members, to the medical community at large, and to the public

To use all available means to eliminate lung cancer and other thoracic malignancies as a health threat for the individual patient and throughout the world

IASLC STAFF

Fred R. Hirsch
Chief Executive Officer
fred.hirsch@ucdenver.edu

Pia Hirsch
Director of Education
Corporate Relations and Governance
pia.hirsch@iaslc.org

Kristin M. Richeimer
Director of Membership
kristin.richeimer@iaslc.org

Murry Wynes
Scientific Projects Manager
murry.wynes@iaslc.org

Jacinta Wiens
Scientific Projects Specialist
jacinta.wiens@iaslc.org

Becky Bunn
Projects Specialist
becky.bunn@iaslc.org

John Skadow
Director of Finance
john.skadow@iaslc.org

Michelle Martinez
Data and Technical Analyst
michelle.martinez@iaslc.org

Adam Mohrbacher
Content Specialist
adam.mohrbacher@iaslc.org

Carlos Ferreira
Continuing Medical Education
Compliance Specialist
Carlos.ferreira@iaslc.org

Michelle Gruver
Fellowship Coordinator
michelle.gruver@iaslc.org

Kristin Schultz
Membership Coordinator
kristin.schultz@iaslc.org

Karen Muth
Executive Assistant to the CEO
karen.muth@iaslc.org

Mary Todd
Managing Editor JTO
mary.todd@iaslc.org

Paul Silvey
Education Programs Coordinator
paul.silvey@iaslc.org

Vengie Lau
Asia Support
vengie.lau@iaslc.org
GUESTS OF HONOR

Heinz Fischer  
Former Federal President  
of the Republic of Austria  
(2004–2016)

Tabaré Vázquez  
President of Uruguay

Alfred Gusenbauer  
Former Federal Chancellor  
of the Republic of Austria  

Harald zur Hausen  
Nobel Laureate  
Germany

IASLC  
BOARD OF DIRECTORS  
2015 – 2017

OFFICERS

President  
David Carbone, USA

President Elect  
Giorgio Scagliotti, Italy

Past President  
Tony Mok, Hong Kong

Chief Executive Officer  
Fred R. Hirsch, USA

Treasurer  
David R. Gandara, USA

BOARD OF DIRECTORS

Michael Boyer, Australia  
Laurie Gaspar, USA  
David Harpole, USA  
Norihiko Ikeda, Japan  
Pasi A. Janne, USA  
Keith Kerr, UK  
Francoise Mornex, France  
Yuichiro Ohe, Japan  

Solangé Peters, Switzerland  
Robert Pirker, Austria  
Martin Reck, Germany  
Miyako Satouchi, Japan  
William D. Travis, USA  
Heather Wakelee, USA  
Yi-Long Wu, China

IASLC FOUNDATION BOARD

David Carbone, USA  
David R. Gandara, USA  
Giorgio Scagliotti, Italy  

Tony Mok, Hong Kong  
Fred R. Hirsch, USA  
Ivar Samren, Denmark  

Marc Braunstein, USA  
Lauren Fisher, USA  
Kathy Weber, USA
COMMITTEES

CONFERENCE PRESIDENT
Robert Pirker, Austria

REGIONAL ORGANIZING COMMITTEE
Otto Chris Burghuber, Austria
Martin Filipits, Austria
Christian Herold, Austria
Wolfgang Hilbe, Austria
Walter Klepetko, Austria
Michael Rolf Müller, Austria
Gyula Ostoros, Hungary
Lubos Petruzela, Czech Republic
Robert Pirker, Austria
Helmut Popper, Austria
Richard Pötter, Austria
Herbert Watzke, Austria
Christoph Zielinski, Austria
Sabine Zöchbauer-Müller, Austria

CORE PROGRAM COMMITTEE
Robert Pirker, Austria (Chair)
Hisao Asamura, Japan
Michael Boyer, Australia
Karin Dieckmann, Austria
Wilfried Eberhardt, Germany
Martin Filipits, Austria
Kwun Fong, Australia
Fred R. Hirsch, USA
Rudolf M. Huber, Germany
Walter Klepetko, Austria
Gabor Kovacs, Hungary
Christian Manegold, Germany
Gyula Ostoros, Hungary
Helmut Popper, Austria
Herbert Watzke, Austria
Caicun Zhou, China
Christoph Zielinski, Austria
Sabine Zöchbauer-Müller, Austria

PROGRAM COMMITTEES

Advanced NSCLC
Robert Pirker, Austria (Chair)
David R. Gandara, USA (Co-Chair)
Tanja Cuker, Slovenia
Koichi Goto, Japan
Cesare Gridelli, Italy
Jaroslaw Kuzdzal, Poland
Rogerio Lilenbaum, USA
Reza Malayeri, Iran
Christian Manegold, Germany
Sergey Orloff, Russia
Rogerio Lilenbaum, USA
Elisabeth Quoix, France
Eduardo Richardet, Argentina
Martin Schuler, Germany
Takashi Seto, Japan
Sumitha Thongprasert, Thailand
Li Zhang, China

Chemotherapy/Targeted Therapy
Robert Pirker, Austria (Chair)
Rolf Stahel, Switzerland (Co-Chair)
Oscar Arrieta, Mexico
Filippo de Marinis, Italy
Oliver Gautschi, Switzerland
Roy Herbst, USA
Pasi A. Jänne, USA
Julian Molina, USA
Kazuhiro Nakagawa, Japan
Kenneth O’Byrne, Australia
Qing Zhou, China
Shun Lu, China
Branimir Sikic, USA
Jean Charles Soria, France
Kostas Syrigos, Greece
Joachim von Pawel, Germany
Jurgen Wolf, Germany
James Chih-Hsin Yang, Taiwan
Caicun Zhou, China

Biology
Martin Filipits, Austria (Chair)
Roman Thomas, Germany (Co-Chair)
David Carbone, USA
Balasz Dome, Hungary
Ramaseswamy Govindan, USA
John Minna, USA
Tetsuya Mitsudomi, Japan
Leonhard Müller, Austria
Jacek Niklinski, Poland
Kazuto Nishio, Japan
Rafael Rosell, Spain
Benjamin Solomon, Australia
Charles Swanton, UK

Early Stage NSCLC
Michael Rolf Müller, Austria (Chair)
Glenwood Goss, Canada (Co-Chair)
Frank Griesinger, Germany
Norihiko Ikeda, Japan
Miroslav Kozliowski, Poland
Thierry Le Chevalier, France
Bernward Passlick, Germany
Lubos Petruzela, Czech Republic
Giorgio Scagliotti, Italy
Suresh Senan, Netherlands
Heather Wakelee, USA
Education/Publication/Career Development

Alex Adjei, USA (Chair)
Peter Bezinec, Slovakia (Co-Chair)
Jean Yves Douillard, France
Ednim Hamzah, Malaysia
Barbara Melosky, Canada
Judit Moldvay, Hungary
Masayuki Noguchi, Japan
Silvia Novello, Italy
Gunta Purkalne, Latvia
Carlos Silva, Argentina
Navneet Singh, India
Ross Soo, Singapore
Irina Strambu, Romania

Immunology and Immunotherapy

Christoph Zielinski, Austria (Chair)
Charles Butts, Canada (Co-Chair)
Maya Gottfried, Israel
Raffit Hassan, USA
Tony Mok, China
Marcin Moniuszko, Poland
Anna Nowak, Australia
Martin Reck, Germany
David Spigel, USA
Johan Vansteenkiste, Belgium

Seiki Hasegawa, Japan
Muzaffer Metintas, Turkey
Takashi Nakano, Japan
Meinoshin Okumura, Japan
Harvey Pass, USA
Arnaud Scherpereel, France
Jan van Meerbeeck, Belgium
Nico van Zandwijk, Australia

Locally Advanced NSCLC

Wilfried Eberhardt, Germany (Chair)
Francoise Mornex, France (Co-Chair)
Michael Boyer, Australia
Rafal Dziazdziuszko, Poland
Hans Hoffmann, Germany
Kaoru Kubota, Japan
Keunchil Park, South Korea
Georg Stamatis, Germany
Everett Vokes, USA
Walter Weder, Switzerland
Milada Zemanova, Czech Republic

Nurses

Liz Darlison, UK (Chair)
Melissa Culligan, USA
Beth Ivimey, Australia
Peter Koren, Slovenia
Iveta Nohavova, Czech Republic
John White, UK

Pathology

Helmut Popper, Austria (Chair)
Keith Kerr, UK (Co-Chair)
Vera Capelozzi, Brazil
Wendy Cooper, Australia
Gerhard Dekan, Austria
Adi F. Gazdar, USA
Fred R. Hirsch, USA
Andrew Nicholson, UK
Masayuki Noguchi, Japan
Wlodzimierz Olszewski, Poland
Iver Petersen, Germany
Ales Ryska, Czech Republic
Philipp Schnabel, Germany
Jozsef Timar, Hungary
William Travis, USA
Yasushi Yatabe, Japan

Patients Support and Advocacy Group

Ingeborg Beunders, Austria (Chair)
Stefania Vallone, Italy (Co-Chair)
Bonnie Addario, USA
Franz Buchberger, Austria
Szymon Chrostowski, Poland
Sandra Karabatic, Croatia
Paweł Moszumanski, Poland
Christina Ng, Malaysia
Shani Shilo, Israel
Andreja Skufca-Smrdel, Slovenia

Pulmonology

Gyula Ostoros, Hungary (Chair)
Rudolf M Huber, Germany (Co-Chair)
Eric Edell, USA
Salih Emri, Turkey
Kwun Fong, Australia
Felix Herth, Germany
Vitezslav Kolek, Czech Republic
Anne-Pascale Meert, Belgium
Yoichi Nakanishi, Japan
Nevena Secen, Serbia
Ruxandra Ulemanu, Romania
Konstantinos Zarogoulidis, Greece

Radiology/Staging/Screening

Helmut Prosch, Austria (Chair)
Peter Goldstraw, UK (Co-Chair)
Hisao Asamura, Japan
John Field, UK
Jhingook Kim, South Korea
Pierre Massion, USA
Michael Rolf Müller, Austria
Edward F. Patz, USA
Ramon Rami-Porta, Spain
Stefan Schönberg, Germany
Rob J van Klaveren, Netherlands
Jiri Votruba, Czech Republic
Ignacio Wistuba, USA

Radiotherapy
Karin Dieckmann, Austria (Chair)
Jacek Jassem, Poland (Co-Chair)
David Ball, Australia
Michael Baumann, Germany
Hak Choy, USA
Laurie Gaspar, USA
Satoshi Ishikura, Japan
Antonio Juretic, Croatia
Rolf Lewensohn, Sweden
Yuko Nakayama, Japan
Richard Potter, Austria
Umberto Ricardi, Italy
Deniz Yalman, Turkey

Scientific Co-Operation/ Co-operative Groups
Thomas Brodowicz, Austria (Chair)
Clarissa Mathias, Brazil (Co-Chair)
Benjamin Besse, France
Haruyuki Fukuda, Japan
Jin Soo Lee, South Korea
Yuichiro Ohe, Japan
Solange Peters, Switzerland
Suresh Ramalingam, USA
Tora Shibata, Japan
Michael Thomas, Germany
Carlos Vallejos Sologuren, Peru
Ufuk Yilmaz, Turkey

Supportive & Palliative Care/ Ethics
Herbert Watzke, Austria (Chair)
Jean Klastersky, Belgium (Co-Chair)
Gouri Shankar Bhattacharyya, India
Nathan Cherny, Israel
Jeffrey Crawford, USA
Lutz Freitag, Germany
Richard Lim, Malaysia
Jennifer Temel, USA
Arschang Valipour, Austria

Trial Design/Statistics
Lothar Pilz, Germany (Chair)
Stefan Michiels, France (Co-Chair)
Daniel Shao-Weng Tan, Singapore
Yu Shyr, USA
Kurt Ulm, Germany

Regional Aspects/Health Policy/ Public Health
Christoph Zielinski, Austria (Chair)
Nagahiro Saijo, Japan (Co-Chair)
Carlos Barrios, Brazil
Digambar Behera, India
Paul A. Bunn, Jr, USA
Tudor Ciuleanu, Romania
Jaime de la Garza, Mexico
Rabab Gaafar, Egypt
Vera Gorbunova, UK
Gilberto de Lima Lopes, Brazil
Tatiana Vidaurre-Rojas, Peru

SCLC/Neuroendocrine Tumors
Sabine Zöchbauer-Müller, Austria (Chair)
Jens Benn Sørensen, Denmark (Co-Chair)
Andrea Arzizzoni, Italy
Hideo Kunishoh, Japan
Seppo Langer, Denmark
Primo Lara, USA
Cecile Le Pechoux, France
Eric Lim, UK
Nevin Murray, Canada
Pieter E Postmus, Netherlands
Jean Louis Pujol, France
Berend Jan Slotman, Netherlands

Surgery
Walter Klepetko, Austria (Chair)
Dominique Grunenwald, France (Co-Chair)
Alessandro Brunelli, UK
Saulius Cicenas, Lithuania
Young Tae Kim, South Korea
Anthony Linegar, South Africa
Oleg Pikin, Russia
C.S. Pramesh, India
Kenji Suzuki, Japan
Alper Toker, Turkey
Masahiro Tsuboi, Japan
Eric Vallieres, USA
Shun-ichi Watanabe, Japan
Yi Long Wu, China

Young Investigators
Maximilian Hochmair, Austria (Chair)
Amanda Tufman, Germany (Co-Chair)
Luigi De Petris, Sweden
Georgia Hardavella, UK
Miroslaw Kozlowski, Poland
Prasanta R. Mohapatra, India
Fedor Moiseenko, Russia
Milla Petrova, Bulgaria
Mirjana Rajer, Slovenia
Thanayan Reungwetwattana, Thailand
Matthias Scheffler, Germany
Bojan Zaric, Serbia
INTERNATIONAL SCIENTIFIC ADVISORY COMMITTEE

Myung-Ju Ahn, South Korea
Kurt Aigner, Austria
Kathy Albain, USA
Gerhard Ambrosch, Austria
Athanasios Argiris, USA
Madeleine Arns, Austria
Jair Bar, Israel
Fabrice Barlesi, France
Chandra P. Belani, USA
Walter Berger, Austria
Daniel C. Betticher, Switzerland
Fiona Blackhall, UK
Philip Bonomi, USA
Elisabeth Brambilla, France
Odd Terje Brustugun, Norway
Jacques Cadranel, France
Priscilla Cagoula, Philippines
Ross Camidge, USA
Frederico Cappuzzo, Italy
Andres Felipe Cardona Zorrilla, Colombia
Desmond Carney, Ireland
Christos Chouaid, France
Hak Choy, USA
Tsai Chun-Ming, Taiwan
Lucio Crino, Italy
Walter J Curran, USA
Paul de Leyn, Belgium
Mircea Dediu, Romania
Karl-Matthias Deppermann, Germany
Hendrik Diemann, Germany
Steven Dubinett, USA
Simon Eckman, Sweden
Josef Eckmayr, Austria
Mark Edelman, USA
Lawrence Einhorn, USA
David Ettinger, USA
Corinne Faivre-Finn, UK
Enriqueta Felip, Spain
Panos Fidias, USA
Berthold Fischer, Germany
Pierre Fournel, France
Wilbur Franklin, USA
Martin Fruh, Switzerland
Christian Geltner, Austria
Vassilis Georgoulas, Greece
Giuseppe Giaccione, USA
Robert Godal, Slovakia
Richard Gralla, USA
Richard Greil, Austria
Alexandru Grigorescu, Romania
Bjorn Gronberg, Norway
Nasser Hanna, USA
Liber Havel, Czech Republic
Vera Hirsh, Canada
Mohamed Ibrahim A Wahid, Malaysia
David Jablons, USA
Antti Jekunen, Finland
James Jett, USA
Bruce Johnson, USA
David Johnson, USA
Dragana Jovanovic, Serbia
Dimitar Kalev, Bulgaria
Ahmad Kamal bin Mohamed, Malaysia
Peter Kasan, Slovakia
Terufumi Kato, Japan
Karen Kelly, USA
Izidor Kern, Slovenia
Klaus Kirchbacher, Austria
Rainer Kolb, Austria
Paris Kosmidis, Greece
Viljem Kovac, Slovenia
Krassimir Koyov, Bulgaria
Mark Kris, USA
Maciej Krzakowski, Poland
Johan Kurnianda, Indonesia
Gyorgy Lang, Austria
Corey Langer, USA
Natasha Leighl, Canada
Zhang Li, China
Bo Lu, USA
Thomas Lynch, USA
Jorge Madrid, Chile
Aaron Mansfield, USA
Alexander Marx, Germany
Mohammadeza Masjedi, Iran
Peter Meldgaard, Denmark
Anders Mellemgaard, Denmark
Patrick Micke, Sweden
Andrea Mohn-Staudner, Austria
Judit Moldvay, Hungary
Denis Moro-Sibilot, France
James L. Mulshine, USA
Bruno Niederle, Germany
Eeva-Maija Nieminen, Finland
Jan Nyman, Sweden
Mary O’Brien, UK
Georg Pall, Austria
William Pao, USA
Vali Papadimitrakopoulou, USA
Ugo Pastorino, Italy
Nick Pavlakis, Australia
Luis Paz-Ares, Spain
Tobias Peikert, USA
Roman Perez-Soler, USA
Bransilav Perin, Serbia
Maurice Perol, France
Christoph Pöttgen, Germany
Luis R. Raez, USA
Rodryg Ramlau, Poland
Dennis Ramon M. Tuttud, Philippines
Niels Reinmuth, Germany
Sacha Rothschild, Switzerland
Charles Rudin, USA
Ravi Salgia, USA
Miroslav Samarzija, Croatia
Hellmut Samonigg, Austria
Joan Schiller, USA
Wolfgang Schütte, Germany
Jean-Paul Sculier, Belgium
Martin Sebastian, Germany
Monika Serke, Germany
B. Shadmehr, Iran
Frances A Shepherd, Canada
Maria Sibilia, Austria
George Simon, USA
Jana Skrickova, Czech Republic
Egbert Smit, Netherlands
Mark Socinski, USA
Pierre-Jean Souquet, France
David Stewart, Canada
Leopold Stiebellehner, Austria
Philipp Strobelt, Germany
Michael Studnicka, Austria
Martin Stuschke, Germany
Noorwati Sutandyo, Indonesia
Shahrokh Taghavi, Austria
Nick Thatcher, UK
Erik Thunnissen, Netherlands
Ming Tsao, Canada
Pál Vádász, Hungary
Paul van Houtte, Belgium
Paul van Schil, Belgium
Marielle Varella-Garcia, USA
Antonio Villalon, Philippines
Anne Warth, Germany
Virginie Westeel, France
Jia Wia, China
Rainer Wiewrodt, Germany
Antoinette Wozniak, USA
Faruk Zorlu, Turkey
A randomized, open-label, active-controlled, Phase II study investigating intravenous anetumab ravtansine (BAY 94–9343) or vinorelbine in patients with advanced or metastatic malignant pleural mesothelioma overexpressing mesothelin and progressed on first-line platinum/pemetrexed-based chemotherapy.

**STUDY SCHEMA**

**PATIENT POPULATION:**
- Unresectable or metastatic malignant pleural mesothelioma (MPM) patients failing Standard of Care (SoC) 1st-line therapy
- Mesothelin overexpression
- ECOG Performance Status of 0 or 1
- Age ≥18 years
- Life expectancy of at least 3 months
- No corneal epitheliopathy

**PRIMARY OUTCOME MEASURES:**
- Progression Free Survival (PFS)

**SECONDARY OUTCOME MEASURES:**
- Overall Survival (OS)
- Patient Reported Outcomes (PRO)
- Objective Response Rate (ORR)
- Duration of Response (DOR)
- Disease Control Rate (DCR)
- Safety

**OTHER:**
- PK
- Immunogenicity
- Biomarkers

**RANDOMIZATION 2:1**
- Anetumab ravtansine 6.5 mg/kg Q3W
- Vinorelbine 30 mg/m² QW

**KEY INCLUSION CRITERIA**
- Histological documentation of malignant pleural mesothelioma (MPM) overexpressing mesothelin
- Unresectable locally advanced or metastatic MPM after locally confirmed progression on 1st-line treatment with platinum in combination with pemetrexed
- Measurable disease according to mRECIST for MPM
- Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1
- Life expectancy of at least 3 months
- Adequate bone marrow, liver and renal function
- Left ventricular ejection fraction (LVEF) ≥50% or the lower limit of normal (LLN) according to local institution ranges of normality

**KEY EXCLUSION CRITERIA**
- More than one previous systemic anti-cancer therapy line
- Patients with corneal epitheliopathy or any eye disorder that may predispose patients to this condition at the discretion of the investigator in consultation with the ophthalmologist/optometrist
- Symptomatic brain metastases or meningeal tumors or other uncontrolled metastases in the central nervous system
- Evidence of history of bleeding diathesis
- Ongoing or active infection (bacterial, fungal, or viral) of National Cancer Institute’s Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 4.03 Grade > 2
- Pre-existing cardiac conditions

**ABOUT ANETUMAB RAVTANSINE**

Anetumab ravtansine is an investigational antibody-drug conjugate which binds to mesothelin. It consists of a human anti-mesothelin antibody directed against the cell surface glycoprotein mesothelin linked to a cytotoxic agent.

**TRIAL SPONSOR:** Bayer AG, D-51368 Leverkusen, Germany

Anetumab ravtansine is an investigational agent currently in clinical trials and is not approved by the FDA, EMA, or other health authorities. The efficacy and safety of anetumab ravtansine has not been established, and this information is being provided only for the purpose of providing an overview of clinical trials for recruitment.
# General Conference Information

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Registration</td>
<td>18</td>
</tr>
<tr>
<td>Onsite Services and General Information</td>
<td>22</td>
</tr>
<tr>
<td>Press and Media</td>
<td>31</td>
</tr>
<tr>
<td>Information for Invited Speakers and Abstract Presenters</td>
<td>32</td>
</tr>
<tr>
<td>CME Accreditation</td>
<td>34</td>
</tr>
<tr>
<td>Vienna Information</td>
<td>36</td>
</tr>
</tbody>
</table>
REGISTRATION

REGISTRATION FOR ALL ATTENDEES (DELEGATES, EXHIBITORS, MEDIA, ACCOMPANYING PERSON) IS LOCATED AT THE MESSE WIEN EXHIBITION & CONGRESS CENTER, FOYER D

REGISTRATION COUNTERS

**Delegate Help Desk**
SUPPORTED BY [Janssen](#) Oncology
FOYER D REGISTRATION AREA

<table>
<thead>
<tr>
<th>Day</th>
<th>Hours</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Dec. 3</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, Dec. 4</td>
<td>07:30 – 20:45</td>
</tr>
<tr>
<td>Monday, Dec. 5</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Tuesday, Dec. 6</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Wednesday, Dec. 7</td>
<td>07:00 – 16:00</td>
</tr>
</tbody>
</table>

If you require assistance or any information regarding the Conference, please see the staff at the Delegate Help Desk.

**Registered Delegates**
For all delegates who have registered online and paid in full before arriving at the Conference.

Note: All delegates who registered but have not yet paid (full) please proceed to the Outstanding Payment Counter.

**Invited Faculty Registration**
For all invited faculty members (speakers, chairs, discussants)

Note: Abstract Presenters can pick up their materials at the counter ‘Registered Delegates’

**Exhibitor Registration**
For all Exhibitor Staff

**New Registration/Outstanding Payments/Additional Tickets and Purchases**
For all delegates who:

- have not yet registered for the Conference
- have pre-registered but not yet (fully) paid
- want to purchase additional items (subject to availability):
  - WCLC 2016 Together against Lung Cancer Tickets
  - MTE Session Tickets
  - Mozart’s Requiem Tickets [SOLD OUT]
  - Hands-On Training and Workshop Tickets
REGISTRATION MATERIALS AND BADGES

Registration Materials

SUPPORTED BY Bristol-Myers Squibb

- Name Badge including barcode for tickets
- Ribbons (if applicable)
- Abstract USB Stick*
- Mini Pocket Program*
- Delegate Bag Voucher*

*not included in Accompanying Person Registration

Delegate Bags

SUPPORTED BY Bristol-Myers Squibb

- Printed Program Book**
- Printed Abstract Book**
- Invitation Flyers for Industry Supported Symposia
- Additional Promotional Flyers from Sponsors and Exhibitors
- IASLC Information/Folder

**only if printed version selected at time of registration

Name Badges

Delegates and guests are requested to wear their name badge at all times in order to participate in the Scientific Sessions, Exhibition and Networking Opportunities.

Lost Badge/Name Changes

A 50€ fee applies for any reprints due to onsite name changes or lost badges.

BADGE COLOR IDENTIFICATION

DELEGATE | BLUE

- Full access to Scientific Sessions (except ticketed MTE Sessions, Hands-On Training Sessions and Workshops)
- Exhibit Hall access including Networking Opportunities and Welcome Reception
- Delegate Bag including all materials
- Printed Program Book (if selected), Mini Pocket Program
- Abstract USB Stick and Abstract Book (if printed version selected)
- Book (if printed version selected)
- Eligible to purchase tickets for the WCLC 2016 Together against Lung Cancer – at the Hofburg
- Virtual Meeting Pass
- One Public Transportation Ticket – Covers all networks within the city of Vienna, including: underground, train, tram and buses (and nighttime buses). Unlimited use for the duration of your pass.

SINGLE DAY | RED

- Full access to Scientific Sessions (except ticketed MTE Sessions) on day of attendance
- Exhibit Hall access including Networking Opportunities on day of attendance
- Delegate Bag including all materials
- Printed Program Book (if selected), Mini Pocket Program
- Abstract USB Stick and Abstract Book (if printed version selected)
- Welcome Reception (if Sunday is day of attendance)
- Eligible to purchase tickets for the WCLC 2016 Together against Lung Cancer – at the Hofburg
- Virtual Meeting Pass
- One Day Public Transportation Ticket – Covers all networks within the city of Vienna, including: underground, train, tram and buses (and nighttime buses). Unlimited use for the day of your attendance.

EXHIBITOR | GREEN

- Exhibit Hall access including Networking Opportunities on day of attendance
- Delegate Bag including all materials
- Printed Program Book (if selected), Mini Pocket Program
- Abstract USB Stick and Abstract Book (if printed version selected)
- Virtual Meeting Pass
- One Public Transportation Ticket – Covers all networks within the city of Vienna, including: underground, train, tram and buses (and nighttime buses). Unlimited use for the day of your attendance.

ACCOMPANYING PERSON | YELLOW

- Exhibit Hall access including Networking Opportunities
- Welcome Reception
- Ticket for the WCLC 2016 Together against Lung Cancer – at the Hofburg

WWWW.IASLC.ORG | PROGRAM BOOK | IASLC 17TH WORLD CONFERENCE ON LUNG CANCER
Together against Lung Cancer

IASLC 17TH WORLD CONFERENCE ON LUNG CANCER

WEDNESDAY, DECEMBER 7, 2016
19:00–23:00 | HOFBURG

TICKETS: 99 € | AVAILABLE AT THE REGISTRATION DESK

PLEASE JOIN US FOR
AN EVENING AT THE HOFBURG
Now available

Staging Manual in Thoracic Oncology
and Staging Handbook in Thoracic Oncology

Visit the IASLC booth in the Exhibit Hall for more information

Booth # 2714
ONSITE SERVICES AND GENERAL INFORMATION

IASLC WCLC 2016 OFFICIAL MOBILE APP

Download the free IASLC WCLC 2016 mobile app for a convenient way to stay up-to-date via your phone or tablet. View the full scientific schedule, abstracts, exhibit information including floor plan and company descriptions, and general Conference and venue information on our easy to use app!

The app is compatible with all iOS devices (iPhone, iPod Touch and iPad), newer Blackberry devices and all Android mobile devices. Timely updates on program or room changes will be distributed through the mobile app via notification alerts.

IASLC WCLC 2016 VIRTUAL MEETING

All audio and webcast recordings including presentations, abstracts and electronic versions of most posters will be available in the Virtual Meeting within 24 hours.

Check your name badge for login details.

JOIN THE CONVERSATION!
IASLC WCLC 2016 OFFICIAL SOCIAL MEDIA ACCOUNTS

Share your experience and images from IASLC WCLC 2016 with colleagues and friends via Twitter and Facebook. Our official social media feeds throughout the Conference can be followed @IASLC. We encourage you to tag your posts with #WCLC2016.

Follow us on Twitter @IASLC #WCLC2016
Facebook.com/IASLC
ABSTRACTS

Abstracts selected for IASLC WCLC are presented in Oral, Mini Oral and Poster Sessions. The top 4 abstracts are presented in the Presidential Symposium on Tuesday, December 6, 08:35–10:25, and the top 4 immunotherapy abstracts in the Plenary Session on Wednesday, December 7, 08:45–09:40.

All accepted and confirmed abstracts are published in a supplement of the Journal of Thoracic Oncology, which will be posted online on the JTO website in January 2017.

All accepted and confirmed abstracts except for those included in Press Releases and/or Press Conferences are also available on the Abstract USB Stick which is handed out along with your registration kit.

If you requested a printed version of the Abstract Book, please pick it up along with your delegate bag at the Delegate Bag Pick Up, Foyer D.

ABSTRACTS ONLINE

Attendees are invited to view all accepted abstracts in the virtual meeting available on the Conference website or simply by scanning below code. The Virtual Meeting allows searching for abstracts, topics, presenters, sessions and keywords, selecting abstracts of interest and building your own personal Conference calendar.

GET THE WCLC 2016 VIRTUAL MEETING AT
http://library.iaslc.org

ACCREDITATION

▶ See CME Certificate

ATTIRE

Business casual is appropriate. Room temperature can vary in session rooms. We encourage attendees to dress in layers for their personal comfort. Attire for the WCLC 2016 Together against Lung Cancer event at the Hofburg on Wednesday, December 7 is formal (suit/evening dress).

ATM

Two ATMs are located in the ‘Mall’ connecting the Plenary Hall with the Exhibit Hall and the Session Rooms at Messe Wien.

BAGGAGE CHECK

▶ See coat check (located in Hall C)

BREAKFAST

The Conference does not provide breakfast except for the following sessions:

▶ Young Investigator’s Session (Hall C8) – Sunday, December 4 from 08:00 – 11:45.

▶ Joint IASLC - Chinese Society for Clinical Oncology - Chinese Alliance Against Lung Cancer Session (Stolz 1) – Sunday, December 4 from 08:00 – 11:45.

▶ Meet the Expert Sessions (various rooms) – every morning from 07:30 – 08:30.

▶ International Society of Nurses in Cancer Care (ISNCC) and Bristol-Myers Squibb Foundation Collaborative Workshop (sign up required) (Schubert 4, Level One) – Sunday, December 4 from 08:00 – 12:00

SUPPORTED BY Bristol-Myers Squibb
ONSITE SERVICES AND GENERAL INFORMATION

CAMERAS AND CELL PHONES

No cameras or video cameras are allowed in any event during IASLC WCLC. As a courtesy to fellow attendees, please turn off cell phones during scientific sessions.

CERTIFICATE OF ATTENDANCE

International attendees can request a ‘Certificate of Attendance’ by completing the Conference Evaluation Form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your Certificate of Attendance.

CHARGING STATIONS

Charging Stations are located throughout Hall B (Exhibit Hall) allowing delegates to power up their cell phones, tablets, laptops and other electronic devices for free.

CME ACCREDITATION AND CME CERTIFICATE

This activity is planned for AMA PRA Category 25.5 Credit(s)™. Please see page 34 in this book for further information.

International attendees can request a ‘CME Certificate’ by completing the Conference Evaluation Form available on the Conference website at the conclusion of the Conference. After completing the evaluation form you will be able to download your Certificate of Attendance.

Delegates will only receive credits for the session they actually attended and were scanned for. Ensure that you get your badge scanned when going into a session!

COAT AND BAGGAGE CHECK

A coat and baggage check is available at the Messe Wien Exhibition & Congress Center.

Saturday, December 3:
The coat and baggage check will be located in Foyer D.

Sunday, December 4 – Wednesday, December 7:
The coat and baggage check will be located at the back of Hall C.

This service is provided at no charge to delegates.

DELEGATE BAG RETURN

If you do not want to take home your Delegate Bag, please return it to the Delegate Bag Pick Up Counter in the Registration Area, Foyer D.

DELEGATE LOUNGES

Delegate Lounges are located in Hall B (Exhibit Hall). These lounges are specifically designed to provide a comfortable seating area for delegates to rest, conduct brief meetings or network with colleagues.

DIRECTIONAL SIGNAGE

Directional signage is displayed throughout the Messe Wien Exhibition & Congress Center to assist delegates with locating session rooms and events.
**EMERGENCY SERVICES AND FIRST AID**

**EMERGENCY NUMBER** +43 1 72720 7122

**using your mobile phone**

1. **Raise the alarm**
   - Operate fire alarm or call: +43 1 72720 7122
   - Tell the operator:
     - WHERE the fire is
     - WHAT has happened
     - HOW MANY people are injured
     - WHAT injuries do they have
     - WAIT to answer further questions

2. **Leave the building**
   - Assist vulnerable people
   - Close doors
   - Leave via the marked escape routes
   - DO NOT use the elevators
   - Follow instructions

3. **Fight fire**
   - Use the fire extinguishers

**EVALUATIONS**

A Conference evaluation survey will be e-mailed to all delegates after the Conference. Please help us to improve the Conference by completing your survey.

**EXHIBITS**

The exhibits are an integral part of the experience at IASLC WCLC and will feature the latest in technology and research. The exhibits are located in Hall B (Exhibit Hall) at the Messe Wien Exhibition & Congress Center.

Refreshments and light snacks free of charge to all delegates will be provided during Exhibit Hall Hours.

**FOOD AND BEVERAGES**

Snacks and beverages will be provided at no charge to delegates between 09:30–16:30 in Hall B (Exhibit Hall), Monday – Wednesday.

Several restaurants at Messe Wien are also open to purchase food & beverages.

**HIGHLIGHT OF THE DAY EBlast**

**SUPPORTED BY**

- Bristol-Myers Squibb
- Roche
- Boehringer Ingelheim

Each morning (Sunday – Wednesday) the Conference will provide an update to their delegates via email highlighting the best sessions and presentations taking place that day. The eNews will also include any speaker or room updates to make sure delegates always have the most up to date information.

**IASLC**

**IASLC BUSINESS MEETING**

All IASLC Members are invited to attend the IASLC Business Meeting on Tuesday, December 6 from 14:30 –15:00 in Schubert 2, Level One. Light refreshments will be provided. IASLC WCLC Travel and Advocacy Award Winners will be presented with their award.

**IASLC BOOTH**

Please visit the IASLC Booth (#2714) for updates on membership, society-sponsored meetings, events, and general information.

**INTERNET CAFÉ**

Keep in touch with home and office! The Internet Café is located in Hall B (Exhibit Hall) attached to the Exhibit Showcase Theater. Computers with internet and printers are available to delegates on a complimentary basis. The Internet Cafe is open during Exhibit Hall Hours. Internet sessions are limited to 15 minute per delegate.

**WEB SITE**

www.IASLC.org
**ONSITE SERVICES AND GENERAL INFORMATION**

**LOST AND FOUND**
Lost and Found items should be returned/claimed at the Delegate Help Desk in the Registration Area.

**MEDIA ROOM**
Located in the Brasserie on Level One is the designated Media Work Room. Wireless internet and a copier are available. Please see page 31 in this brochure for further information.

**NEWSPAPER**
A daily Conference Newspaper will be available from Sunday to Wednesday at no charge to Conference delegates. The Newspaper will be distributed at various points through the Congress Center to report on scientific and clinical developments. A PDF version of each edition will also be available on the Conference website.

**PARKING**
Please use multi-storey car park D.
Price per hour: 3,00€

**POSTERS ONLINE**
All abstracts accepted for poster presentation will be presented as traditional printed posters to be displayed on poster boards in Hall B (Exhibit Hall). However, in addition to the printed poster, presenters are required to submit an electronic version of his or her posters to be made available in the Virtual Meeting. A link to the Virtual Meeting is available on the Conference website. The online ePoster library is searchable by posters, keywords, topics as well as authors.

**PRESS**
Please see page 31 in this brochure for further information.

**PUBLIC TRANSPORTATION**
Vienna has one of the most modern and efficient public transportation networks (5 underground lines, 28 tram routes and 84 bus routes, 23 night buses) in Europe.

To help you get around, IASLC will provide each Delegate with one Public Transportation Ticket at registration to cover all networks within the city of Vienna. Networks include: underground, train, tram and buses, including nightline buses. Unlimited use for duration of your pass. Please note this does NOT include the City Airport Train (CAT).

**RESTAURANTS**
There are plenty of restaurants choices in the city centre of Vienna. The staff at the Delegate Help Desk will be happy to assist with recommendations and bookings.

**SESSION RECORDINGS**
All oral sessions are recorded (slides and audio) and will be made available as a Virtual Meeting through the IASLC Virtual Library within 24 hours. The WCLC 2016 Virtual Meeting is included in your registration and can be accessed through library.iaslc.org. Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your WCLC 2016 confirmation email. After you enter your Access Code and confirm your account details, you’ll be able to view any presentations that have been marked as “Now Available”.

To start viewing, please visit: library.iaslc.org
SHIPPING NEEDS

Delegates may use the Rock-It Cargo, located within the Exhibit Hall at the Messe Wien Exhibition & Congress Center, for all shipping needs and questions.

SMOKING

Smoking is prohibited in all areas of the Messe Wien Exhibition & Congress Center.

SPEAKER READY ROOM

The designated Speaker Ready Room is located in Hall C. All Presenters are required to submit and/or preview their slides at least 24 hours prior to their scheduled presentation to ensure compatibility with the Conference AV Equipment.

Hours of Operation:

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, December 3</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, December 4</td>
<td>07:30 – 20:45</td>
</tr>
<tr>
<td>Monday, December 5</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>07:00 – 16:00</td>
</tr>
</tbody>
</table>

VIRTUAL MEETING

Digital recordings of Oral Presentations (slides and audio) will be available through the IALSC Virtual Library within 24 hours of the scheduled session.

Access to the WCLC 2016 Virtual Meeting is available at no cost for all registered Delegates and can be accessed through library.iaslc.org.

Your personal Virtual Meeting Access Code is the same as your Delegate ID Number and can be found on your badge or through your WCLC 2016 confirmation email. After you enter your Access Code and confirm your account details, you’ll be able to view any presentations that have been marked as "Now Available".

VOLUNTEERS

Volunteers are working throughout the Congress Center and are happy to assist with any questions delegates may have regarding the Conference or the Congress Center. Delegates can easily locate them by their staff shirts.

WEBCAST

Plenary Sessions will be webcasted and made available in the Virtual Meeting within 24 hours.

For further information please see Virtual Meeting

WIRELESS INTERNET

WCLC is providing free Wi-Fi throughout the Messe Wien Exhibition & Congress Center. To ensure a positive Wi-Fi experience for all users please do not use your own wireless Hotspot device. These additional Wi-Fi devices create significant RF interference which can interfere with all Wi-Fi networks, therefore please turn these Hotspot devices off.

To connect to the Wi-Fi, connect to the network WCLC 2016 and open a browser for Internet access.

Disclaimer

The organizers have made every attempt to ensure that all information in this publication is correct. The organizers take no responsibility for changes to the program or any loss that may occur as a result of changes to the program. Some of the information provided in this publication has been provided by external sources. Although every effort has been made to ensure the accuracy, currency and reliability of the content, the organizers accept no responsibility in that regard.
The IASLC Foundation was created in 2014 to facilitate educational and scientific purposes within the IASLC—notably to fund fellowships and young investigator awards for researchers around the globe working to find new ways to conquer thoracic malignancies.

Since 2000, the IASLC has provided more than 80 researchers with fellowships. Fellowship grants have been awarded to medical doctors and scientists throughout the world, including Italy, the United States, Japan, Spain, Australia, France, China, Denmark, Ireland, Taiwan, Germany, Thailand, Poland, and Canada. We want to continue to grow these opportunities by awarding an increased number of fellowships to encourage even more groundbreaking research and worldwide collaboration.

To do that, we need your help.

Please visit www.iaslc.org/foundation to make a gift today.
FIND YOUR WAY TO BRIGHT IDEAS

Visit Boehringer Ingelheim at booth 2424 to find out more about our research areas, and how we’re already making the future brighter for people with cancer.

Copyright © 2016. Boehringer Ingelheim International GmbH. All rights reserved. October 2016. Procedure ID: 5499
The most authoritative voice in oncology research and health policy

The Lancet Oncology is the trusted resource you need to stay informed of the important clinical advances in your field. Our comprehensive coverage includes:

- **Articles**: original research that advocates change in oncological practice
- **Reviews**: comprehensive overviews that are clinically focused and up-to-date on major oncological topics
- **Commentary**: informative opinion on important recent advances in oncology practice and clinical research
- **Personal Views and Policy Views**: expert interpretation of recent evidence and its translation for decision makers
- **Cancer and Society**: profiles, reviews of books and other media, features on topical issues, and news on research advances

Discover more at www.thelancet.com/oncology
PRESS AND MEDIA

PRESS AND MEDIA REPRESENTATIVES

Press and Media passes are issued to journalists, including photographers and freelance journalists based on below requirements.

Journalists, including photographers must work exclusively for the outlet for which they are credentialed (exceptions for freelance journalists as detailed below). Journalists who use their media privileges to work for non-credentialed organizations will have their privileges revoked.

Freelance journalists including photographers may work for multiple publications, as long as they confirm in advance that those publications are eligible for media registration.

PRESS AND MEDIA ACCESS

Pre-registered Press and Media representatives are required to check in at the regular Registration Counters. Non registered Press and Media representatives should proceed to the New Registration counter. Media and press credential is required to receive a Press/Media Badge.

Media Room

BRASSERIE, LEVEL ONE

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, December 4</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Monday, December 5</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>07:00 – 18:00</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>07:00 – 18:00</td>
</tr>
</tbody>
</table>

Wireless internet access, power bars and a copier are available in the Media Room to assist credentialed media representatives.

PRESS CONFERENCES

SCHUBERT 1, LEVEL ONE

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sunday, December 4</td>
<td>10:30 – 11:45</td>
</tr>
<tr>
<td>Monday, December 5</td>
<td>10:30 – 11:45</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>10:30 – 11:45</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>10:30 – 11:45</td>
</tr>
</tbody>
</table>

Please check the Conference website for daily topics and titles.

USE OF IASLC WCLC SCIENTIFIC PROGRAM CONTENT

Please be aware that the information and materials displayed and/or presented at all sessions of this meeting are the property of the World Conference on Lung Cancer and it’s presenters and cannot be photographed, copied, photocopied, transformed to electronic format, reproduced or distributed without the written permission of the International Association for the Study of Lung Cancer. Use of the WCLC/IASLC name and/or logo in any fashion by any commercial entity for any purpose is expressly prohibited without the express written permission of the International Association for the Study of Lung Cancer.

COPYRIGHT

Reproduction of materials such as abstract data, posters, presentation slides, etc., requires first obtaining permission from the listed author(s) and/or presenter(s). Photography of sessions, trade show booths, event setup, etc., is prohibited by IASLC/WCLC. The WCLC has a designated staff photographer and can provide WCLC 2016 event photography for journalists who wish to run photos of the event in their given media. Please contact Becky Bunn, IASLC Project Specialist at Becky.Bunn@iaslc.org for any press and media related questions.
INFORMATION FOR INVITED FACULTY AND ABSTRACT PRESENTERS

Invited Speakers as well as Oral and Mini Oral Abstract Presenters must include a slide with their financial disclosure information.

Without a disclosure slide you will not be allowed to present!

REGISTRATION

FOYER D

Invited Faculty
‘Invited Faculty’ Registration Counter
(Session Chairs, Invited Speakers, Abstract Discussants)

Abstract Presenters
‘Registered Delegate’ Counter

Registration Hours

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Dec. 3</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, Dec. 4</td>
<td>07:30 – 20:45</td>
</tr>
<tr>
<td>Monday, Dec. 5</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Tuesday, Dec. 6</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Wednesday, Dec. 7</td>
<td>07:00 – 16:00</td>
</tr>
</tbody>
</table>

SPEAKER READY ROOM

All Invited Speakers and Discussants as well as Oral and Mini Oral Abstract Presenters are required to report to the Speaker Ready Room at least 24 hours prior to their scheduled presentation in order to upload their presentation slides or to check their previously uploaded slides.

NO FILE SUBMISSIONS WILL BE ACCEPTED IN THE SESSION ROOMS.

Computers are available to preview and upload presentations. Presenters should make sure all fonts appear as expected and all sound/video clips are working properly. The final version must be submitted to the Speaker Ready Room, no presentation submissions will be accepted in the Session Rooms.

Speaker Ready Room
HALL C

<table>
<thead>
<tr>
<th>Day</th>
<th>Time</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, Dec. 3</td>
<td>14:00 – 18:00</td>
</tr>
<tr>
<td>Sunday, Dec. 4</td>
<td>07:30 – 20:45</td>
</tr>
<tr>
<td>Monday, Dec. 5</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Tuesday, Dec. 6</td>
<td>07:00 – 16:30</td>
</tr>
<tr>
<td>Wednesday, Dec. 7</td>
<td>07:00 – 16:00</td>
</tr>
</tbody>
</table>

ORAL ABSTRACT PRESENTERS

- You will have a total of 10 minutes; 8 minutes of presentation, followed by 2 minutes time for questions from the audience. Time limits will be strictly enforced.
- You are asked to prepare a PPT Presentation with a maximum of 10 slides (not including title and disclosure slide). It is recommended to use the IASLC template in 16:9 format.
- Please be in room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.

MINI ORAL PRESENTERS

- You will have a total of 6 minutes (no Q&A). Time limits will be strictly enforced.
- Please be in room for your session 10 minutes before the start time of the session. The Session Chairs will start and end strictly on time.
- You are asked to prepare a PPT Presentation with a maximum of 6 slides (not including title and disclosure slide). It is recommended to use the IASLC template in 16:9 format.
- All presenters MUST include statement disclosing any conflict of interest related to your abstract as the first slide of your presentation.
POSTER PRESENTERS

SUPPORTED BY Bristol-Myers Squibb

All Poster Presentations/Boards are located in Hall B (Exhibit Hall) and each Poster Board is identified by a professionally lettered sign with the assigned Poster Number. The Poster Board Number corresponds with the pre-assigned Poster Number provided in your confirmation letter and printed in the Abstract Book and this Program Book.

Poster Display Time 09:30 – 16:30 each day
Poster Presenters Present 10:25 – 11:00
14:30 – 15:45 on day of their poster session

POSTER PRINTING SERVICE

If you have ordered to have your poster printed by the Conference at an additional charge, you may pick up your poster onsite.

Poster Pick Up Counter
HALL B (EXHIBIT HALL)
EXHIBIT INFORMATION BOOTH

Sunday, December 4 20:45 – 21:45 (Welcome Reception)
Monday, December 5 09:00 – 15:45
Tuesday, December 6 09:00 – 15:45
Wednesday, December 7 09:00 – 11:00
CME ACCREDITATION

CREDIT STATEMENT
IASLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

IASLC designates this live activity for a maximum of 27 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Delegates will only receive credits for the session they actually attended and were scanned for. Ensure that you get your badge scanned when going into a session!

GOAL & PURPOSE
The WCLC is an educational and scientific event which, due to its multidisciplinary nature, will cover all aspects of the management of lung cancers, mesothelioma, thymic and other thoracic malignancies.

Participants will learn about tobacco control and smoking cessation programs and how to implement them in their daily practice. Participants will update their knowledge on early detection and screening.

The Conference will provide lectures on accurate diagnosis, including molecular diagnosis, state-of-the-art treatment of thoracic malignancies, and recent diagnostic and therapeutic advances. Participants will learn about palliative care and its implementation in daily practice.

Participants will be informed about the possibilities for continuous medical education. They will learn about clinical trial designs and how to become successful investigators of co-operative research groups. The Conference will also allow participants to be better informed about patient support and advocacy groups.

Overall, the participants of the WCLC will benefit in regard to learning the best clinical practice in the area of lung cancer and other thoracic malignancies.

TARGET AUDIENCE
This CME live Conference is designed to meet the educational needs of healthcare professionals who diagnose and treat patients with lung cancer, including medical oncologists, thoracic surgeons, pulmonologists, radiation oncologists, radiologists, pathologists, advanced practice nurses, and physician assistants.

FINANCIAL/COMMERCIAL RELATIONSHIPS & COI DISCLOSURES
The 17th World Conference on Lung Cancer (WCLC) is planned and implemented in accordance with the Essential Areas and Policies of the Accreditation Council for Continuing Medical Education (ACCME) through the International Association for the Study of Lung Cancer (IASLC).

All official Learning Conference Sessions will be accredited except for the Poster Display Sessions, Hands-On Training Sessions, and Industry Supported Symposia.

All individuals able to influence or control content of any CME certified activity that will be presented were required to complete an electronic Financial Relationships/Conflicts of Interest Disclosure Form prior to the Conference. In addition, abstract submitters will have to provide disclosure information for all co-authors at the time of abstract submission.

Individuals who refused to disclose relevant financial relationships were eliminated from presenting at the Conference.

A Conflict of Interest (COI) is created and exists when individuals are in a position to control the content of CME, or their spouses/partners, that have a relevant personal financial relationship within the past 12 months with a commercial interest that produces, markets, re-sells, or distributes health care goods or services consumed by, or used on, patients that benefits the individual in any financial amount, and therefore may bias their opinions and teachings. This may include receiving a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or any other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research and clinical trials), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities for which remuneration is received or expected.

This IASLC CME educational activity was planned and developed to: uphold academic standards to ensure balance, independence, objectivity, and scientific rigor; adhere to requirements to protect health information under the Health Insurance Portability and Accountability Act of 1996 (HIPAA); and, include a mechanism to inform learners when unapproved or unlabeled uses of therapeutic products or agents are discussed or referenced.

IASLC CME assures that the planners/reviewers/authors/faculty/peer reviewers et al. conflicts of interest are identified, reviewed and resolved from all individuals involved in the development or those able to influence and control the content of a CME activity. IASLC CME assures that disclosure is given prior to an educational activity being delivered to learners.

All commercial relationships and conflicts of interest were identified and thoroughly vetted by the IASLC Ethics Committee, CME Subcommittee, and/or an independent reviewer. COI was evaluated by the Board of Directors of the IASLC for fair balance, scientific objectivity of studies utilized in this activity, and patient care recommendations. IASLC CME is committed to providing its learners with high-quality CME activities and related materials that promote improvements or quality in health care and not a specific proprietary business interest of a commercial entity.

All non-FDA approved uses of products must be clearly identified. Disclosures may be made in form of a slide, printed material, or oral statement. Each presenter should reveal his/her disclosure information during his/her presentation, preferably with the visual aid of a slide.
LEARNING OBJECTIVES

At the end of the Conference the attendee will be able to:

- Identify effective global lung cancer prevention strategies.
- Improve their ability to participate in tobacco control and smoking cessation programs.
- Recognize the current approaches and strategies for early detection and screening of lung cancer.
- Demonstrate the best methods to implement multidisciplinary tumor boards into community practices.
- Examine evidence-based therapeutic regimens for early stage and locally advanced NSCLC.
- Distinguish evidence-based therapeutic regimens for metastatic NSCLC based on biomarker status and patient/tumor characteristics.
- Define best practices regarding the application of targeted therapies for metastatic NSCLC in frontline and then subsequent settings following acquired resistance to the targeted therapy.
- Describe current and emerging immunotherapy strategies in the context of clinical trials findings and patient selection in metastatic NSCLC.
- Integrate clinical data on maintenance therapy in NSCLC to determine which patients would benefit most from a maintenance regimen.
- Review the clinical significance of optimal biopsy, specimen flow and molecular testing for personalized medicine in non-academic settings.
- Illustrate the molecular pathways that hold promise for therapeutic intervention.
- Outline current therapeutic approaches for limited and extensive small cell lung cancer (SCLC).
- Describe current therapeutic approaches for patients with mesothelioma and thymoma.
- Predict optimal and best practice approaches for supportive and palliative care of patients with thoracic cancers.
- Evaluate the support and survivorship resources available for lung cancer patients and their families.
- Illustrate important aspects of clinical trial design and master protocols.
- Explain to more junior investigators and students on research and technology advances, and encourage them to initiate investigations in lung cancer research.

OFFICIAL LANGUAGE

The official language of the IASLC 17th World Conference on Lung Cancer is English.

DISCLAIMER

The information presented at the IASLC World Conference on Lung Cancer is that of the contributing faculty and does not necessarily represent the views of the International Association for the Study of Lung Cancer and/or any named commercial entity providing financial support. Specific therapies discussed may not be approved and/or specified for use as indicated by the faculty presenters. Therefore, before prescribing any medication, please review the complete prescribing information, including indications, contraindications, warnings, precautions, and adverse effects.

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

TO RECEIVE CME CREDIT

A Conference electronic evaluation form will be emailed to learners after the Conference. Participants that wish to receive CME credit will have to complete the online evaluation form in order to receive their CME certificate.

CME credits will only be provided for the sessions that learners are scanned in for. The CME certificate will be ready for you to print or save upon completion.

Delegates will only receive credits for the session they actually attended and were scanned for. Ensure that you get your badge scanned when going into a session!

This information is used not only to evaluate the present activity, but also to plan for future programs.

Your opinion is very valuable!

Thank you for your participation.
Austria's capital offers a unique blend of imperial traditions and stunning architecture. Famous for its many cultural events, classical concerts, imperial architecture, coffee houses, cozy wine taverns, and the very special Viennese charm.

Vienna's cityscape is characterized by the abundance of baroque buildings created mostly under the rule of Empress Maria Theresia and Emperor Franz Joseph who was largely responsible for the monumental architecture around the Ringstraße.

Prime landmarks are the Schloss Schönbrunn (the former imperial summer residence), the vast Hofburg (Imperial Palace), the gothic St. Stephen's Cathedral, the Giant Ferris Wheel in the Prater (Vienna's old recreational park), and the Spanish Riding School with their world-famous Lipizzaner horses.

Vienna owes much of its international fame to the many celebrated composers who lived and worked here including Strauss, Mozart, Beethoven and Haydn. The Vienna Philharmonic Orchestra is one of the world's best, the Staatsoper one of the world's leading opera houses, and the Vienna Boys' Choir one of the world's most famous choirs.

In Vienna, old coffee houses and rustic wine taverns stand alongside with top restaurants and shops, time-honored events alternate with internationally-acclaimed extravaganzas to create a unique and very special ambiance.
CONSIDER YOUR OPTIONS FOR ALK+ NSCLC

NOW ENROLLING PATIENTS WITH ALK+ NSCLC. Ensartinib* (X-396) is a potent ALK inhibitor being developed by Xcovery. eXalt3 is a randomized phase III clinical trial to assess the efficacy of ensartinib in patients with advanced ALK+ NSCLC.

KEY INCLUSION CRITERIA: Stage 3B/4 NSCLC, ALK+, ≥ 18 years of age, no prior ALK TKI, may have received one prior line of chemotherapy.

NCT02767804

FOR MORE INFORMATION:
Contact Xcovery at +1 561-835-9356 or clinicaltrials@xcovery.com

*Xcovery is an investigational medication and is not approved for use in any market at this time.

11780 US Hwy One • Suite 202 • Palm Beach Gardens, FL 33408, USA • XCOVERY.COM
Exhibit Information

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Location, Events and Poster Information</td>
<td>40</td>
</tr>
<tr>
<td>Exhibitor Listing</td>
<td>42</td>
</tr>
<tr>
<td>Exhibit Floor Plan</td>
<td>43</td>
</tr>
<tr>
<td>Exhibitor Descriptions</td>
<td>44</td>
</tr>
</tbody>
</table>
EXHIBIT EVENTS

Welcome Reception
SUPPORTED BY Bristol-Myers Squibb
Sunday, December 4 20:45 – 21:45

Networking Opportunities
Monday, December 5  10:25 – 11:00 and 14:30 – 15:45
Tuesday, December 6 10:25 – 11:00 and 14:30 – 15:45
Wednesday, December 7 10:25 – 11:00 and 14:30 – 15:45
Refreshments and snacks will be provided at no charge for all delegates during Exhibit Hall Hours.

Poster Sessions
Presenter Attendance during morning and afternoon Networking Opportunities

Exhibit Showcase Sessions
in the Exhibit Showcase Theater

MONDAY, DECEMBER 5
Roche Tissue Diagnostics 10:25 – 10:55
When H&E is not enough: Immunostaining & biomarker trends and EQA surveillance in lung cancer diagnostics
Modern approaches to staining lung biopsy samples and current EQA data on ALK and PD-L1.

TUESDAY, DECEMBER 6
Boehringer Ingelheim 10:25 – 10:55
Giotrif: 10 Reasons to Use Afatinib in Lung Cancer
Vargatef: Providing Benefits Even Where you May Not Expect It

WEDNESDAY, DECEMBER 7
Otsuka Pharmaceutical 10:25 – 10:55
Relevance and management of hyponatremia in lung cancer – current perspectives
Hyponatremia is the most frequent electrolyte and body fluid balance disturbance encountered in hospital clinical practice. It is considered an unfavorable prognostic factor in patients with cancer and differential diagnosis is challenging.1,2
The objective of the Exhibit Showcase Session by Prim. Assoc. Prof. Daz Dr. Marcus Säemann, Wilhelminenspital Wien, Austria is to discuss current challenges in the diagnosis and treatment of patients with hyponatremia, with emphasis on aspects of cancer patients.
POSTER SESSIONS

All poster presentations have been assigned a consecutive publication number for locating the abstract/poster in this Program Book, the Abstract Book and the Poster Boards in Hall B (Exhibit Hall).

P1: Poster Session 1  Monday, December 5
P2: Poster Session 2  Tuesday, December 6
P3: Poster Session 3  Wednesday, December 7

Poster Display Time:  09:30 – 16:30 each day
Poster Presenters Present:  10:25 – 11:00
  14:30 – 15:45
  (Afternoon Networking Opportunities) each day

Poster Pick Up Counter
HALL B (EXHIBIT HALL)
EXHIBIT INFORMATION BOOTH

Poster Presenters who had their poster printed by the Conference, can pick up their poster at the Poster Pick Up Counter at the Exhibit Information Booth in the Exhibit Hall during the following times:

Sunday, December 4  20:45 – 21:45
  (Welcome Reception)
Monday, December 5  09:00 – 15:45
Tuesday, December 6  09:00 – 15:45
Wednesday, December 7  09:00 – 11:00

Posters Online

Posters Online

In addition to the printed posters, each presenter is required to submit an electronic version of their poster to be made available in the Virtual Meeting library.

A link to the ePoster library is available on the Conference website. The online ePoster library is searchable by posters, keywords, topics as well as authors.
## EXHIBITOR LISTING

### By Exhibitor

<table>
<thead>
<tr>
<th>EXHIBITOR NAME</th>
<th>Booth #</th>
</tr>
</thead>
<tbody>
<tr>
<td>3D Systems Healthcare</td>
<td>2718</td>
</tr>
<tr>
<td>AbbVie Inc</td>
<td>2008</td>
</tr>
<tr>
<td>ARIAD Pharmaceuticals</td>
<td>2611</td>
</tr>
<tr>
<td>AstraZeneca</td>
<td>3219</td>
</tr>
<tr>
<td>Bayer Healthcare Pharmaceuticals, Inc.</td>
<td>1808</td>
</tr>
<tr>
<td>Boehringer Ingelheim</td>
<td>2424</td>
</tr>
<tr>
<td>Bristol-Myers Squibb</td>
<td>2000</td>
</tr>
<tr>
<td>Bruker microCT</td>
<td>1705</td>
</tr>
<tr>
<td>Celgene Corporation</td>
<td>3215</td>
</tr>
<tr>
<td>Elsevier</td>
<td>3806</td>
</tr>
<tr>
<td>Epigenomics AG</td>
<td>2227</td>
</tr>
<tr>
<td>ESTS</td>
<td>3813</td>
</tr>
<tr>
<td>Global Lung Cancer Coalition</td>
<td>3823</td>
</tr>
<tr>
<td>Guardant Health, Inc.</td>
<td>1408</td>
</tr>
<tr>
<td>IASLC</td>
<td>2714</td>
</tr>
<tr>
<td>IncellDx</td>
<td>2311</td>
</tr>
<tr>
<td>Lilly Oncology</td>
<td>3208</td>
</tr>
<tr>
<td>MEDIAN Technologies</td>
<td>1706</td>
</tr>
<tr>
<td>Medtronic</td>
<td>2412</td>
</tr>
<tr>
<td>Merck/Pfizer</td>
<td>3204</td>
</tr>
<tr>
<td>MeVis Medical Solutions AG</td>
<td>1707</td>
</tr>
<tr>
<td>MSD</td>
<td>2305</td>
</tr>
<tr>
<td>Myriad Genetic Laboratories, Inc.</td>
<td>1508</td>
</tr>
<tr>
<td>National Lung Cancer Forum For Nurses</td>
<td>3808</td>
</tr>
<tr>
<td>Novartis Oncology</td>
<td>2400</td>
</tr>
<tr>
<td>Novocure GmbH</td>
<td>1709</td>
</tr>
<tr>
<td>OncoDNA</td>
<td>1811</td>
</tr>
<tr>
<td>Panagene Inc.</td>
<td>1409</td>
</tr>
<tr>
<td>Pfizer Oncology</td>
<td>3200</td>
</tr>
<tr>
<td>Polish Lung Cancer Group</td>
<td>3809</td>
</tr>
<tr>
<td>Roche Ltd</td>
<td>1400</td>
</tr>
<tr>
<td>Roche Ltd. Business Lounge</td>
<td>1425</td>
</tr>
<tr>
<td>Roche Tissue Diagnostics</td>
<td>1805</td>
</tr>
<tr>
<td>Rocket Medical Plc</td>
<td>1708</td>
</tr>
<tr>
<td>Scanlan International, Inc.</td>
<td>2719</td>
</tr>
<tr>
<td>Thermo Fisher Scientific</td>
<td>3804</td>
</tr>
<tr>
<td>Wisepress Ltd.</td>
<td>3819</td>
</tr>
</tbody>
</table>

### By Booth Number

<table>
<thead>
<tr>
<th>Booth #</th>
<th>EXHIBITOR NAME</th>
</tr>
</thead>
<tbody>
<tr>
<td>1400</td>
<td>Roche Ltd</td>
</tr>
<tr>
<td>1408</td>
<td>Guardant Health, Inc.</td>
</tr>
<tr>
<td>1409</td>
<td>Panagene Inc.</td>
</tr>
<tr>
<td>1425</td>
<td>Roche Ltd. Business Lounge</td>
</tr>
<tr>
<td>1508</td>
<td>Myriad Genetic Laboratories, Inc.</td>
</tr>
<tr>
<td>1705</td>
<td>Bruker microCT</td>
</tr>
<tr>
<td>1706</td>
<td>MEDIAN Technologies</td>
</tr>
<tr>
<td>1707</td>
<td>MeVis Medical Solutions AG</td>
</tr>
<tr>
<td>1708</td>
<td>Rocket Medical Plc</td>
</tr>
<tr>
<td>1709</td>
<td>Novocure GmbH</td>
</tr>
<tr>
<td>1805</td>
<td>Roche Tissue Diagnostics</td>
</tr>
<tr>
<td>1808</td>
<td>Bayer Healthcare Pharmaceuticals, Inc.</td>
</tr>
<tr>
<td>1811</td>
<td>OncoDNA</td>
</tr>
<tr>
<td>2000</td>
<td>Bristol-Myers Squibb</td>
</tr>
<tr>
<td>2008</td>
<td>AbbVie Inc</td>
</tr>
<tr>
<td>2227</td>
<td>Epigenomics AG</td>
</tr>
<tr>
<td>2305</td>
<td>MSD</td>
</tr>
<tr>
<td>2311</td>
<td>IncellDx</td>
</tr>
<tr>
<td>2400</td>
<td>Novartis Oncology</td>
</tr>
<tr>
<td>2412</td>
<td>Medtronic</td>
</tr>
<tr>
<td>2424</td>
<td>Boehringer Ingelheim</td>
</tr>
<tr>
<td>2611</td>
<td>ARIAD Pharmaceuticals</td>
</tr>
<tr>
<td>2714</td>
<td>IASLC</td>
</tr>
<tr>
<td>2718</td>
<td>3D Systems Healthcare</td>
</tr>
<tr>
<td>2719</td>
<td>Scanlan International, Inc.</td>
</tr>
<tr>
<td>3200</td>
<td>Pfizer Oncology</td>
</tr>
<tr>
<td>3204</td>
<td>Merck/Pfizer</td>
</tr>
<tr>
<td>3208</td>
<td>Lilly Oncology</td>
</tr>
<tr>
<td>3215</td>
<td>Celgene Corporation</td>
</tr>
<tr>
<td>3219</td>
<td>AstraZeneca</td>
</tr>
<tr>
<td>3804</td>
<td>Thermo Fisher Scientific</td>
</tr>
<tr>
<td>3806</td>
<td>Elsevier</td>
</tr>
<tr>
<td>3808</td>
<td>National Lung Cancer Forum For Nurses</td>
</tr>
<tr>
<td>3809</td>
<td>Polish Lung Cancer Group</td>
</tr>
<tr>
<td>3813</td>
<td>ESTS</td>
</tr>
<tr>
<td>3819</td>
<td>Wisepress Ltd.</td>
</tr>
<tr>
<td>3823</td>
<td>Global Lung Cancer Coalition</td>
</tr>
</tbody>
</table>
EXHIBITOR DESCRIPTIONS

3D SYSTEMS HEALTHCARE 2718

3D Systems is a leader in 3D modeling, simulation training and 3D printing of personalized medicine. Training simulators include the BRONCH Mentor™ and the BRONCH Express portable desktop simulator, co-developed with CHEST. These platforms guide trainees through flexible bronchoscopy procedures, offering designated skill tasks alongside complete clinical procedures.

w 3dsystems.com

ABBVIE INC 2008

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company’s mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world’s most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @ abbvie on Twitter or view careers on our Facebook or LinkedIn page.

w abbbvie.com

ARIAD PHARMACEUTICALS, INC. 2611

We are ARIAD, an orphan oncology company focused on transforming the lives of cancer patients with breakthrough medicines.

w ariad.com

ASTRAZENECA 3219

AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammatory, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide.

w astrazeneca.com

BAYER HEALTHCARE PHARMACEUTICALS, INC. 1808

Bayer is committed to delivering SCIENCE FOR A BETTER LIFE by advancing a portfolio of innovative treatments. Bayer’s oncology franchise now includes three oncology products and several other compounds in various stages of clinical development. Together, these products reflect the company’s approach to research, which prioritizes targets and pathways with the potential to impact the way that cancer is treated.

w bayer.com

BOEHRINGER INGELHEIM 2424

Boehringer Ingelheim is committed to delivering novel anti-cancer agents that address unmet needs across a broad range of solid and haematological malignancies. For lung cancer, Boehringer Ingelheim has two agents approved in many countries for specific NSCLC sub-types. The oncology portfolio is supported by a strong early pipeline and an active partnering strategy to further strengthen our presence in this key therapeutic area.

w inoncology.com

BRISTOL-MYSQUIBB 2000

Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. Our medicines are helping millions of people around the world in their fight against cancer, cardiovascular disease, hepatitis C, HIV and rheumatoid arthritis.

w bms.com

BRUKER MICROCT 1705

Bruker microCT develops and produces microCT scanners with unparalleled resolution and performance both in-vivo and ex-vivo. Fast GPU reconstruction and comprehensive analysis software is standard, with versatile volume of interest selection, morphometric and micro-densitometric parameters, customizable batch operations and 3D visualization-animation. For more information, please visit bruker.com.

w bruker.com
Celgene Corporation (Nasdaq: CELG) is a global biopharmaceutical company that is helping healthcare providers turn incurable cancers into chronic, manageable diseases, as well as manage serious inflammatory conditions through innovative therapies. This dedication to medical progress goes hand-in-hand with our industry-leading patient support and access programs. Together, these aspects form the core of our commitment to patients worldwide.

Celgene Corporation

Elsevier is the world-leading provider of scientific, technical, and medical information solutions, and publisher of world-class journals. Elsevier Health Solutions is keen to offering Healthcare Professionals comprehensive Resource Centres to help educate and improve patient outcome. Visit the Elsevier stand (#3806) for more information.

Epigenomics is a developer of a novel blood test for the verification of positive lung cancer imaging tests. Epi proLung utilizes two methylated DNA markers (SHOX2 and PTGER4) to minimize unnecessary invasive diagnostic procedures and potential complications. Stop by booth 2227.

ESTS is the largest international general thoracic surgery organization with over 1450 members from all Continents. Our mission is to improve quality in our specialty: from clinical and surgical management of patients to education, training and credentialing of thoracic surgeons worldwide.

The Global Lung Cancer Coalition promotes global understanding of the burden of lung cancer and the right of patients to effective early detection, better treatment and supportive care. Serving as the international voice of lung cancer patients, the Global Lung Cancer Coalition is committed to improving disease outcomes for all.

Guardant360 is the most comprehensive biopsy-free tumor sequencing test. Measuring ctDNA via a simple blood-draw, the test identifies clinically relevant SNVs, CNVs, fusions and indels to provide real-time tumor response across all active disease sites.

The International Association for the Study of Lung Cancer (IASLC) is the only global organization dedicated to the study of lung cancer. Founded in 1974, the association’s membership includes nearly 6,000 lung cancer specialists in over 100 countries. IASLC members work to enhance the understanding of lung cancer among scientists, members of the medical community and the public. IASLC publishes the Journal of Thoracic Oncology, a valuable resource for medical specialists and scientists who focus on the detection, prevention, diagnosis and treatment of lung cancer.

IncellDx, Inc. is a single cell diagnostics company committed to advancing Precision Medicine by offering transformative diagnostic and prognostic clinical patient information based on an innovative technology platform that enables simultaneous cell classification and single cell analysis of proteomic and genomic biomarkers.

For more than 50 years, Lilly has been dedicated to delivering life-changing medicines and support to people living with cancer and those who care for them. Lilly is determined to build on this heritage and continue making life better for all those affected by cancer around the world. To learn more about Lilly’s commitment to people with cancer, please visit www.LillyOncology.com.

Median Technologies develops advanced medical imaging software and provides services dedicated to cancer screening programs, oncology clinical trials and clinical practice. As regards CT lung cancer screening, Median targets regional programs, develops and implements ad-hoc regional solutions, collectively monitored, using its CE-Marked/FDA-Cleared Lesion Management Solutions (LMS) as its core engine.
MEDTRONIC 2412

As a global leader in medical technology, services and solutions, Medtronic improves the lives and health of millions of people each year. Let’s take healthcare Further, Together. Visit booth #2412 to learn more about how our innovative solutions are being used to aid in the diagnosis of Lung Cancer.

W medtronic.com

MSD 2305

Today’s Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work with customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships that donate and deliver our products to the people who need them.

W merck.com

MERCK/PFIZER 3204

Immuno-oncology is a top priority for Merck and Pfizer. The global strategic alliance between Merck and Pfizer enables the companies to benefit from each other’s strengths and capabilities and further explore the therapeutic potential of avelumab, an investigational anti-PD-L1 antibody initially discovered and developed by Merck. The immuno-oncology alliance will jointly develop and commercialize avelumab and advance Pfizer’s PD-1 antibody. The alliance is focused on developing high-priority international clinical programs to investigate avelumab, as a monotherapy, as well as combination regimens, and is striving to find new ways to treat cancer.

MEVIS MEDICAL SOLUTIONS AG 1707

MeVis Medical Solutions AG develops software for medical imaging with the aim to improve quality and efficiency in lung cancer detection. MeVis’ portfolio includes image reading software for lung cancer screening programs, PACs integrated lung CAD, as well as a web-based interactive radiological training platform for healthcare professionals.

W mevis.de

MYRIAD GENETIC LABORATORIES, INC. 1508

Myriad Genetics is a leading molecular and companion diagnostics company dedicated to making a difference in patients’ lives through the discovery and commercialization of transformative products that assess a person’s risk of developing disease, aid in a timely and accurate diagnosis, determine the risk of disease progression and recurrence and guide personalized treatment decisions.

W myriad.com

NATIONAL LUNG CANCER FORUM FOR NURSES 3808

The NLCFN is a registered charity (charity number 1160011) providing networking and support to nurses specialising in the care of people with lung cancer and mesothelioma. The organisation aims to support its members through innovative education programmes, professional development support, promotion of research and audit and providing a voice for lung cancer nurse specialists.

W nlcfn.org.uk

NOVARTIS 2400

Novartis Oncology is a global leader in improving outcomes for patients. We seek to transform cancer care through distinctive scientific and clinical strategies focused on developing targeted, immuno-oncology and combination therapies to create more effective options for patients.

W novartisoncology.com

NOVOCURE GMBH 1709

Novocure (NASDAQ: NVCR) is an oncology company pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. Headquartered in Jersey Isle, Novocure’s US operations are based in Portsmouth, NH and New York, NY. Additionally, the company has offices in Switzerland, Germany and Japan and a research center in Haifa, Israel.

W novocure.com

ONCODNA 1811

OncoDNA, The Cancer Theranostics Company, is the European leading oncology company providing solutions for cancer treatments, at the same time contributing to the knowledge applied to the fight against cancer. OncoDNA’s team is fully dedicated to help oncologists worldwide developing services to enable better treatment choices and treatment efficacy monitoring. The reports and the results from both services are displayed in a dynamic way through the web platform OncoSHARE in order to allow an easy and fast reading.

W oncodna.com
PANAGENE INC. 1409

PANAGENE is the exclusive PNA and PNA based molecular diagnostic reagent provider.

Real-time PCR based PANAGENE kits facilitate more reliable MDx tests in short time in your site directly PANAMutypertm R series (EGFR, KRAS, NRAS, BRAF) provide you multiplex genotyping information in high sensitivity (0.1%) with plasma and tissue samples.

W novartisoncology.com

PFIZER ONCOLOGY 3200

Pfizer Oncology is committed to pursuing innovative treatments that are helping to redefine life with cancer. As an oncology leader with one of the most robust oncology pipelines in the industry, we are focused on translating scientific breakthroughs into clinical application. Additionally, we are dedicated to working collaboratively with the community to make a positive impact on people’s lives.

W pfizer.com/research/therapeutic_areas/oncology

POLISH LUNG CANCER GROUP - POLGRP 3809

Polish Lung Cancer Group – PolGRP multidisciplinary association established in 2002. Its primary role is didactic and educational equally spreading lung cancer knowledge in Poland. Every year in November organizes annual conference with IASLC accreditation also awarded to “Best of WCLC” meeting. Its Lung Cancer Registry contains above 30,000 records.

W polgrp.org.pl

ROCHE 1400

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve people’s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare – a strategy that aims to fit the right treatment to each patient in the best way possible.

W roche.com

ROCHE TISSUE DIAGNOSTICS 1805

Roche is the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare.

W roche.com

ROCKET MEDICAL 1708

Rocket Medical

UK based, award winning designer and manufacturer of single use medical devices.

Specialising in chest drainage, we continually develop our range of established and create new products to help improve patients’ lives:

Ambulatory Pneumothorax Device, Chest Drainage Bottles & Bags, Chest Drainage Catheters & Kits, Indwelling Pleural Catheter, Portable Suction

W rocketmedical.com

SCANLAN INTERNATIONAL, INC. 2719

Roche is the world leader in in-vitro diagnostics and tissue-based cancer diagnostics, and a front runner in diabetes management. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalized healthcare.

W scanlaninternational.com

THERMO FISHER SCIENTIFIC 3804

Thermo Fisher Scientific Inc. is the world leader in serving science. Our mission is to enable our customers to make the world healthier, cleaner and safer. We help our customers accelerate life sciences research, solve complex analytical challenges, improve patient diagnostics and increase laboratory productivity. For more information, please visit www.thermofisher.com.

W thermofisher.com

WISEPRESS LTD. 3819

W wisepress.com
Stay up to date with the WCLC 2016 MOBILE APP

Introducing the WCLC 2016 Meeting App!

Get 24-hour access to all Conference related information

Access to full scientific program information including abstracts

Available for iPhone, iPad and Android

DOWNLOAD THE APP ON GOOGLE PLAY OR THE APP STORE

JOIN THE WCLC 2016 CONVERSATION!

FOLLOW US ON TWITTER @IASLC #WCLC2016
FOLLOW US ON FACEBOOK.COM/IASLC
# IASLC and Conference Awards

<table>
<thead>
<tr>
<th>Award Type</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>IASLC Distinguished Awards</td>
<td>50</td>
</tr>
<tr>
<td>IASLC Fellowship Award Winners</td>
<td>54</td>
</tr>
<tr>
<td>IASLC International Mentorship Award Winners</td>
<td>55</td>
</tr>
<tr>
<td>WCLC 2016 Young Investigator Award Winners</td>
<td>58</td>
</tr>
<tr>
<td>WCLC 2016 Developing Nation Award Winners</td>
<td>59</td>
</tr>
<tr>
<td>IASLC/WCLC 2016 Patient Advocacy Award Winners</td>
<td>60</td>
</tr>
<tr>
<td>WCLC 2016 Lectureship Award Winners</td>
<td>60</td>
</tr>
<tr>
<td>WCLC 2016 Communications Workshop Award Winners</td>
<td>61</td>
</tr>
</tbody>
</table>
The IASLC Distinguished Award Winners will receive their awards during the Opening Ceremony Sunday, December 4 19:00 – 20:45

**IASLC PAUL A. BUNN, JR. SCIENTIFIC AWARD**
(FORMERLY IASLC SCIENTIFIC AWARD)

The IASLC Scientific Award is given to an IASLC scientist for lifetime scientific contributions in thoracic malignancy research and who has also contributed to the organization’s development.

Dr. Herbst is Ensign Professor of Medicine, Professor of Pharmacology, Chief of Medical Oncology, and Associate Director for Translational Research at Yale Cancer Center (YCC) and Yale School of Medicine, New Haven, CT.

He has led phase I development of several targeted agents for non-small cell lung cancer (NSCLC), including gefitinib, erlotinib, cetuximab, and bevacizumab. He co-led BATTLE-1 and co-leads the BATTLE-2 clinical trial. He served as co-leader of the Developmental Therapeutics Program for the YCC Support Grant. Herbst’s laboratory work focuses on immunotherapy angiogenesis, EGFR/VEGFR inhibition in NSCLC and targeting KRAS-activated pathways. This has been translated from preclinical to clinical settings in multiple Phase II and III studies.

Herbst has authored or co-authored more than 300 publications, including peer-reviewed articles, abstracts, and book chapters. His work appears in many prominent journals, such as the Journal of Clinical Oncology, Clinical Cancer Research, Lancet, and the New England Journal of Medicine. Work published in Nature was awarded the 2015 Herbert Pardes Clinical Research Excellence Award by the Clinical Research Forum.

Herbst was a member of the National Cancer Policy Forum, for which he organized an IOM meeting focused on policy issues in personalized medicine. He is a member of the American Association of Cancer Research and chairs their Tobacco Task Force, as well as the American Society of Clinical Oncology. He is a fellow of the American College of Physicians and an elected member of the Association of American Physicians. He is vice chair for development of therapeutic strategies for Southwestern Oncology Group’s Lung Committee, principal investigator of the SWOG 0819 trial, and steering committee chair for the Lung Master Protocol. In 2015, his Yale team was awarded a lung cancer SPORE by the NCI, and he serves as a principal investigator for the AACR/Stand Up to Cancer Dream Team grant.
IASLC MERIT AWARD

The IASLC Merit Award is given to a member of IASLC who has made an extraordinary contribution to the organization’s development.

Sumitra Thongprasert is Emeritus Professor at the Faculty of Medicine, Maharaj Nakorn Chiang Mai University in Chiang Mai, Thailand. She is a director of the Center of Excellent in Cancer at the Bangkok Hospital Chiang Mai, Thailand. Prof. Thongprasert received her undergraduate and medical degrees at Chiang Mai University, completing her Instructor in Medicine training in 1984. During this time she also trained in haematology/oncology at the Memorial Sloan-Kettering Cancer Center in New York, USA. Professor Thongprasert’s main areas of interest include lung cancer treatment, quality of life and targeted therapy for lung cancer patients. In particular she has been involved in numerous non-small cell lung cancer (NSCLC) studies including the FASTACT-2 and IPASS trials. She is also interested in the access of treatment and has published on cost-utility and budget impact, as well as on the effect of treatment on quality of life. Professor Thongprasert currently holds various positions including the Special Content Editor for the Journal of Thoracic Oncology, as well as being the past board member of IASLC. Recently she had received the ESMO Women for Oncology award from the European Society of Medical Oncology (ESMO). She is also the Chair of the Asia-Pacific Lung Cancer Conference 2016 (APLCC 2016).

Keunchil Park is Professor of the Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Prof. Park is Director of the Innovative Cancer Medicine Institute, Samsung Medical Center.

Professor Park has served as Chair of the Scientific Committee of the Korean Cancer Association, Chair of the Lung Cancer Committee of the Korean Cancer Study Group (KCSG). Prof. Park also served as Chairman of the Board of Directors, Korean Association for Clinical Oncology (KACO) since June 2010 until May 2012. Prof. Park has been also very actively involved in and served many international activities, such as the Scientific Secretary of the 12th World Conference on Lung Cancer (WCLC, Sept., 2007), and the President of the 4th Asia Pacific Lung Cancer Conference (Dec., 2010). He served the IASLC as the Board of Directors since 2009 to 2013. Prof. Park is Co-President with Prof. Hisao Asamura of the 18th WCLC, Oct 15-18, 2017, Yokhama, Japan. He is an Associate Editor for the Journal of Thoracic Oncology (JTO). Prof. Park has recently joined the International Cancer Genome Consortium (ICGC) with the Korean Lung Cancer Genome Projects and is a member of the ICGC International Scientific Steering Committee since 2013. Prof. Park is the organizing Chairman of the 13th ICGC workshop to be held Jun 13-15, 2017 in Seoul, Korea. Prof. Park is the Chair of the Korea Actionable Genome Consortium (KAGC) which was launched 2016.

Prof. Park’s main interests include translational researches as well as early clinical trials for the upper aero-digestive tract cancers, especially lung cancer. Recently Dr. Park is leading several early clinical trials of the targeted agents as well as many pre-clinical development programs internationally. Prof. Park has several book chapters and authored more than 300 peer-reviewed publications in national and international journals.
JOSEPH W. CULLEN PREVENTION/EARLY DETECTION AWARD

The Joseph W. Cullen Award is given to an IASLC scientist for lifetime scientific achievements in prevention research of thoracic malignancies.

Ugo Pastorino is Director of the Thoracic Surgery Division at the Istituto Nazionale Tumori in Milan (INTM) since 2003. Graduated in Medicine in 1979 at the University of Milan and then specialist in Emergency Surgery, Oncology and Thoracic Surgery. From 1980 to 1994, has been working as Thoracic Surgeon at INTM, with several periods of study abroad. In 1994 he was appointed as Consultant Thoracic Surgeon and honorary Senior Lecturer at the Royal Brompton Hospital in London. From 1998 to 2002, has been Director of the Thoracic Surgery Division at the European Institute of Oncology (IEO). From 2010 to February 2014 has been Director of the Surgery Department and from October 2014 to September 2015 has been Scientific Director, at the INTM.

Peculiar features of surgical activity have been the innovative techniques of minimally invasive lung resection, muscle-sparing thoracotomies and broncho-vascular reconstruction; trans-manubrial approach to apical chest tumors; management of T4 tumors with SVC and major vessel resection; volume reduction for concurrent emphysema; induction chemotherapy and pulmonary metastasectomy.

Clinical research focus on diagnosis and treatment of primary and secondary lung cancer, use of PET scan for staging of thoracic malignancies, salvage surgery of lung metastases and mediastinal tumors, biology of lung carcinogenesis and chemoprevention of smoking-induced cancers. In 1991 he launched the International Registry of Lung Metastases.

He has conducted clinical trials involving 20,645 patients/subjects:
- 6 randomized clinical trials of 4,029 patients;
- 8 non randomized clinical trials of 8,273 patients;
- 1 randomized clinical trial of 4,099 high risk subjects;
- 5 non randomized clinical trials of 5035 high risk subjects.

He is the principal investigator of three on-going prospective trials on lung cancer screening with LDCT and circulating miRNAs.

Author of 319 papers on Journals with Impact Factor (IF 1221.408 – IFm 508.616). The H-index is 47.

MARY J. MATTHEWS PATHOLOGY/TRANSLATIONAL RESEARCH AWARD

The Mary J. Matthews Award is given to an IASLC scientist for lifetime scientific achievements in pathology-translational research of thoracic malignancies.

Keith Kerr graduated BSc with first class honours in Pathology in 1978, MB,ChB in 1981, MRCPATH in 1988, FRCPATH in 1998 and was elected Honorary FRCP(Ed) in 2006. He has been a Consultant Pathologist in Aberdeen since 1989. He was awarded an Honorary Chair in Pulmonary Pathology by the University of Aberdeen in 2006.

Throughout his career, he has worked in diagnostic histopathology with a special interest in Thoracic Pathology, whilst keeping close links with the clinical practice of thoracic medicine, especially thoracic oncology. He has an active research interest in his own laboratory and through national and international collaboration. He enjoys under- and postgraduate teaching.

He has had a career long interest in lung cancer. He has been a member of IASLC for 16 years and contributed to the last 7 WCLC meetings, including as invited faculty. He is a member of the IASLC Pathology Panel. He was elected to the IASLC Board of Directors for four years, 2013-2017. He is a member of ESMO and serves on the ESMO Lung Educational Faculty. He is Pathology Chair for the ETOP Lungscape group. He served on the international Pulmonary Pathology Society council and is a British Thoracic Society member of more than 30 years. He was a member of the panel for the 2004 and 2015 WHO lung cancer classifications. He is a member of the International Mesothelioma Panel, and served as Pathology chair for the EORTC lung cancer group from 2006-2014. He has worked on numerous clinical research lung cancer trials groups (SLCF, NCRI, UKLS), guideline development for lung cancer diagnosis and management (RCPATH, SIGN, NICE, BTS, ESMO, IASLC/ETOP, IASLC/CAP/AMP), Conference scientific committees (ELCC, ESMO, BTOG) and other lung cancer organization committees (UKLCC, BTOG). He is currently involved in the revision of the BTS Mesothelioma guidelines and is a panel member for the revision of the CAP/IASLC/AMP guidelines for molecular pathology testing in lung cancer.

He is a regular invited speaker and faculty member at major international Conferences, both in Pathology and in Thoracic Oncology. He is an Associate Editor for the Journal of Thoracic Oncology.
# Previous IASLC Distinguished Award Winners

<table>
<thead>
<tr>
<th>Year</th>
<th>IASLC Merit Award</th>
<th>IASLC Mary J. Matthews Pathology/Translational Research Award</th>
<th>IASLC Joseph W. Cullen Prevention/Early Detection Award</th>
<th>IASLC Paul A. Bunn, Jr. Scientific Award (Formerly IASLC Scientific Award)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1991</td>
<td>Clifton Mountain</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1994</td>
<td>Y. Shimosato/N. Bleehen</td>
<td>Geno Saccamanno</td>
<td>Jesse Steinfeld</td>
<td>Robert Ginsberg</td>
</tr>
<tr>
<td>1997</td>
<td>Heine H. Hansen</td>
<td>William Travis</td>
<td>Clifford Douglas</td>
<td>John D. Minna</td>
</tr>
<tr>
<td>2000</td>
<td>Desmond Carney</td>
<td>Yokio Shimosato</td>
<td></td>
<td>Daniel C. Ihde</td>
</tr>
<tr>
<td>2003</td>
<td>Paul A. Bunn, Jr.</td>
<td>Adi Gazdar</td>
<td>Paul van Houtte</td>
<td></td>
</tr>
<tr>
<td>2005</td>
<td>Harubumi Kato</td>
<td>Elisabeth Brambilla</td>
<td>Nigel Gray</td>
<td>Thierry LeChevalier</td>
</tr>
<tr>
<td>2007</td>
<td>Peter Goldstraw</td>
<td>Fred R. Hirsch</td>
<td>James Mulshine</td>
<td>Frances Shepherd</td>
</tr>
<tr>
<td>2009</td>
<td>Giorgio Scagliotti</td>
<td>Masayuki Noguchi</td>
<td>Stephen Lam</td>
<td>Bruce E. Johnson/Thomas Lynch</td>
</tr>
<tr>
<td>2011</td>
<td>David Ball</td>
<td>Philip Hasleton</td>
<td>John K. Field</td>
<td>Nagahiro Saijo</td>
</tr>
<tr>
<td>2013</td>
<td>Jim Jett</td>
<td>Tetsuya Mitsudomi</td>
<td>Pieter E. Postmus</td>
<td>David R. Gandara</td>
</tr>
<tr>
<td>2015</td>
<td>Harvey Pass</td>
<td>Ming Tsao</td>
<td>Jacek Jassem</td>
<td>Yi-Long Wu</td>
</tr>
</tbody>
</table>
IASLC FELLOWSHIP AWARD WINNERS

2016 – 2017

ESRA AKBAY
UT Southwestern Medical Center, Dallas, Texas, USA

VALSAMO ANAGNOSTOU
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University, Baltimore, Maryland, USA

LUIZ HENRIQUE ARAUJO
Brazilian National Cancer Institute, INCA, Brazil

PUEY LING CHIA
Olivia Newton-John Cancer Research Institute, Austin Health, Victoria, Australia

SIDDHARTHA DEVARAKONDA
Washington University School of Medicine, St. Louis, Michigan, USA

JULIE GEORGE
Department of Translational Genomics, University of Cologne, Cologne, Germany

ROBIN MJELLE
Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology NTNU, Norway

NICOLAS REYNOIRD
Institute Albert Banoit, Centre Recherche INSERM U1209- CNRS- UGA, Grenoble, France

APICHAT TANTRAWORASIN
Department of Thoracic Surgery, Icahn School of Medicine at Mount Sinai, New York, USA

2015 – 2016

MARK M. AWAD
Harvard Medical School & the Dana-Farber Cancer Institute, Boston, Massachusetts, USA

PUEY LING CHIA
Olivia Newton-John Cancer Research Institute, Austin Health, Victoria, Australia

JILL LARSEN
QIMR Berghofer Medical Research Institute, Brisbane, Australia

COLIN LINDSAY
Institut Gustave-Roussy, Paris, France

YOICHIRO MITSUISHI
Dana-Farber Cancer Institute, Boston, Massachusetts, USA

SARA PILOTTO
University of Verona, G.B. Rossi Academic Hospital, Verona, Italy

ADRIAN G. SACHER
Dana-Farber Cancer Institute, Boston, Massachusetts, USA

KENICHI SUDA
Kinki University Faculty of Medicine, Osaka-Sayama, Japan

APICHAT TANTRAWORASIN
Faculty of Medicine, Chiang Mai University, Chiang Mai, Thailand

SILVESTRE VICENT
Center for Applied Medical Research (CIMA), Pamplona, Spain

2014 – 2016: IASLC – APLCC

PIYADA SITTHIDEATPHALBOON
Chulalongkorn University and King Chulalongkorn Memorial Hospital, Bangkok, Thailand

2014 – 2016

YAYI HE
Shanghai Pulmonary Hospital, Tongji University, Shanghai, China
The IASLC International Mentorship Award Winners will receive their award during the IASLC Business Meeting
SCHUBERT 2, LEVEL ONE
Tuesday, Dec. 6 14:30 – 15:00

SILVIA JOSEFINA AYALA LEÓN
National Cancer Institute Prof. Manuel Riveros, Paraguay
P1.01-051: Predictor Variables to ECOG Scale of Performance Status in Lung Cancer at a Developing Country in Latin America
MENTOR: JAN VAN MEERBEECK
University Hospital Antwerp, Belgium

MAY MYAT CHO
Southeast Asia Tobacco Control Alliance, Thailand
OA17.06: Make the World Beautiful and Healthy by Making Your Country Smoke Free: Case Study between Iceland and Thailand?
MENTOR: ROBERT PIRKER
Medical University of Vienna, Austria

SANDHYA C. ACHARYA
National Academy of Medical Sciences, Bir Hospital, Nepal
P1.01-048: Factors Contributing Delays during Management of Lung Cancer: A Study from Tertiary Level Hospital in Nepal
MENTOR: CHRISTOPH ZIELINSKI
Medical University Vienna, Austria

CHANCHAI CHARONPONGSUNTORN
Ramathibodi Hospital, Thailand
P3.02b-017: Sequence of EGFR-TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC
MENTOR: RAFAEL ROSELL
Germans Trias i Pujol Health Sciences Institute and Hospital, Spain

PAOLA DE LA IGLESIA
Hospital Italiano de Buenos Aires, Argentina
P1.02-029: Infrequent Staining Patterns in ALK Immunohistochemistry: Correlation with Fish Analysis
MENTOR: NIE PELED
Davidoff Cancer Center, Israel

IHSAN ALLOUBI
CHU Oujda, Morocco
P3.04-032: Sternal Reconstruction with a Custom-Made Titanium Neosternum after Resection of a Solitary Breast Cancer Metastasis
MENTOR: ERIC LIM
Royal Brompton Hospital, London UK

FÁBIO CHAVES
University of Algarve, Portugal
P3.02b-081: Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non-Small-Cell Lung Cancer: A Network Meta-Analysis
MENTOR: LUCIO CRINO
University Hospital of Perugia, Italy

MARISOL ARROYO HERNANDEZ
Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico
P3.02b-107: Efficacy of Afatinib and Gefitinib in Lung Adenocarcinoma with EGFR Gene Mutation as 2nd or 3rd Line Treatment
MENTOR: FABRICE BARLESI
Hospital NordChemin des Bourrely, France

KEZHEN CHEN
Peking University People’s Hospital, China
MA17.03: Identifying Genomic Alteration and Inter-Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and ctDNA
MENTOR: MARK KRASNIK
Rigshospitalet, Denmark

CAROLINA GABAY
Instituto de Oncología Angel H. Roffo, University of Buenos Aires, Argentina
P1.02-010: Frequency of Uncommon EGFR Mutations in NSCLC in an Argentinean University Institution
MENTOR: GIORGIO SCAGLIOTTI
University of Torino, Italy

SHAO-DONG HONG
Sun Yat-sen University Cancer Center, China
OA21.01: Pooled Analysis of the Incidence and Risk of Treatment-Related Pneumonitis with Anti-PD-1/PD-L1 Therapies in Cancer Patients
MENTOR: PAUL BAAS
The Netherlands Cancer Institute, Netherlands
OMER GIRAY INTEPE
Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey
P3.04-040: A Rare Case of Intrathoracic Mass: Intrathoracic Desmoid Tumor
MENTOR: PAUL VAN SCHIL
University Hospital Antwerp, Belgium

DEEPAK JAIN
All India Institute of Medical Sciences, India
P1.02-028: Detection of Oncogenic Drivers in Pleural Effusions and Archived FNA Smears of Pulmonary Adenocarcinoma
MENTOR: LUKAS BUBENDORF
Institute for Pathology, Switzerland

ASHISH JAKHETIYA
All India Institute of Medical Sciences, India
P1.08-076: Recurrence Patterns in Lung Cancer Patients Treated with Protocol Based Multimodality Treatment at a Tertiary Care Cancer Center in India
MENTOR: WALTER WEDER
Universitätsspital Zürich, Switzerland

MILICA KONTIC
Clinical Centre of Serbia, Serbia
P1.05-010: Aberrant Promoter Methylation of ESR1 and CDH13 Gene Are an Independent Prognostic Marker in Surgically Resected Non-Small Cell Lung Cancer
MENTOR: NICOLAS GIRARD
Lyon University Hospital, France

TOMI KOVACEVIC
Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia
P3.05-011: Importance of Assessment of Malnutrition Risk in Lung Cancer Patients
MENTOR: JOHAN VANSTEENKISTE
University Hospitals KU Leuven, Belgium

VINAYA KUMAR JR
IRCH, All India Institute of Medical Sciences (AIIMS), India
P1.03-072: Mediastinal Lymphnodes Staging by PET CT for Resectable Non-Small Cell Lung Cancer in a Tuberculosis Endemic Country
MENTOR: WILFRIED EBERHARDT
University Hospital Essen, Germany

ROSA LUZ LUNA PALENCIA
Instituto Nacional de Cancerología, Mexico
P1.06-007: Radical Treatment of Synchronous Oligometastatic Non-Small Cell Lung Cancer (NSCLC)
MENTOR: JACEK JASSEM
Medical University of Gdansk, Poland

JOSE NICOLAS MINATTA
Hospital Italiano, Argentina
P3.02b-070: NSCLC with Detectable EGFR Mutation: Institutional Experience
MENTOR: JAMES SPICER
King’s College London, UK

XIAOMIN NIU
Shanghai Chest Hospital, Shanghai Jiao Tong University, China
P3.02b-041: Genome-Wide Screen of DNA Methylation Changes Reveals GABBR2 as a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib
MENTOR: FIONA BLACKHALL
The Christie NHS Foundation Trust, UK

PIERPAOLO PASTINA
Azienda Ospedaliera Universitaria Senese, Italy
P2.05-057: Baseline Inflammatory and Immunological Profile Predict the Survival of NSCLC Patients Undergone Palliative Radiotherapy
MENTOR: SURESH SENAN
VU University Medical Center, Netherlands

SANDRA PERDOMO
International Agency for Research on Cancer (IARC-WHO), France
MA11.05: A Case-Control Study to Test the Use of ctDNA in the Early Detection of SCLC Reveals TP53 Mutations in Non-Cancer Controls
MENTOR: CAROLINE DIVE
Cancer Research UK Manchester Institute, UK
FAWAZ PULLISHERY  
Educare Institute of Dental Sciences, India  
P3.05-012: Assessment of the Impact of Palliative Care on the Quality of Life in Advanced Non-Small Cell Lung Cancer Patients - A Longitudinal Study  
MENTOR: MARTIN FILIPITS  
Medical University of Vienna, Austria

CHANTUE SU  
Shanghai Pulmonary Hospital, Tongji University School of Medicine, China  
P2.03b-092: Predictive and Prognostic Effect of Circulating Tumor Cells in Non-Small Cell Lung Cancer Treated with Targeted Therapy  
MENTOR: MARY O'BRIEN  
The Royal Marsden Hospital, UK

ADAM SZPECHCINSKI  
National Institute of Tuberculosis and Lung Diseases, Poland  
P2.01-079: The Serum Levels of Alpha-1 Antitrypsin Are Strongly Associated with Its Local Production by Tumor Cells in NSCLC Patients  
MENTOR: CELINE MASCAUX  
Chemin Des Bourrely, France

VIKAS TALREJA  
Tata Memorial Hospital, India  
P3.02b-055: Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC  
MENTOR: LUIS PAZ ARES  
Ares Hospital Universitario Doce de Octubre, Spain

SATHEESH THUNGAPPA  
HCG Bangalore Institute of Oncology Speciality Centre, India  
P2.03b-064: Genomic Profiling in Non-Small Cell Lung Cancer: New Hope for Personalized Medicine  
MENTOR: CHRISTIAN ROLFO  
University of Antwerp, Belgium

YI-CHEN ZHANG  
Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences, China  
P3.02b-095: Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR-Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs  
MENTOR: BENJAMIN BESSE  
Institut Gustave Roussy, France

FENGYING WU  
Shanghai Pulmonary Hospital, Tongji University, China  
P3.02c-025: Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non-Squamous Non-Small-Cell Lung Cancer  
MENTOR: SIMON EKMAN  
Karolinska University Hospital, Sweden

DANIELA XHEMALAJ  
University Hospital of Lung Diseases, Albania  
P1.01-009: Smoking and Lung Cancer: Data from the Single Center in Albania  
MENTOR: ALES RYSKA  
Charles University Medical Faculty Hospital, Czech Republic

SHI XIAOHUA  
Peking Union Medical College Hospital, China  
P2.03b-021: Screening for Major Oncogene Alterations in Adenosquamous Lung Carcinoma Using PCR Coupled with Next Generation and Sanger Sequencing Methods  
MENTOR: JOHAN BOTLING  
Uppsala University Hospital, Sweden
The WCLC 2016 Young Investigator Award Winners will receive their award during the IASLC Business Meeting SCHUBERT 2, LEVEL ONE Tuesday, Dec. 6 14:30 – 15:00

**DIANA BECKER-SANTOS**  
British Columbia Cancer Research Centre, Canada  
MA02.03: Expression of Oncofetal miRNAs Inactivates NFIB, a Developmental Transcription Factor Linked to Tumour-Aggressiveness in Lung Adenocarcinoma

**JI AN HWANG**  
Asan Medical Center, South Korea  
MA05.05: Genomic Profiles of Lung Cancer Associated with Idiopathic Pulmonary Fibrosis

**TAKAHIRO KARASAKI**  
Graduate School of Medicine, The University of Tokyo, Japan  
MA15.01: Immunogram for Cancer-Immunity Cycle towards Personalized Immunotherapy of Lung Cancer

**ELLY MARCQ**  
University of Antwerp, Belgium  
OA02.07: Characterization of the Tumor Microenvironment and Investigation of Immune Checkpoint Expression in Malignant Pleural Mesothelioma

**KRISTA WINK**  
Maastro Clinic, Netherlands  
OA09.06: Metformin Use during Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

**SANDRA ORTIZ-CUARAN**  
Centre Léon Berard, France  
P3.02c-059: CD70 Immune Checkpoint Ligand is Associated with Epithelial-To-Mesenchymal Transition in Non-Small Cell Lung Cancer

**SARA RICCIARDI**  
University Hospital of Pisa, Italy  
OA09.01: The Number or the Position is the Main Prognostic Factor for N2 NSCLC? A Validation of New IASLC N Staging Proposal

**KADIR SARUN**  
Asbestos Diseases Research Institute, Australia  
OA02.05: Expression of miR-223 in Mesothelioma Xenografts Originates from Stromal Cells in the Tumour Microenvironment

**HAO-RAN ZHAI**  
Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, Southern Medical University, China  
MA17.05: Evolutionary Trajectories of Molecular Progression in Different Sub-types of Primary Lung Adenocarcinomas

**KYLE WANG**  
University of North Carolina Hospitals, USA  
OA24.03: Cardiac Toxicity after Radiation for Stage III NSCLC: Pooled Analysis of Dose-Escalation Trials Delivering 70-90 Gy
The WCLC 2016 Developing Nation Award Winners will receive their award during the IASLC Business Meeting
SCHUBERT 2, LEVEL ONE
Tuesday, Dec. 6 14:30 – 15:00

ANDREY AKOPOV
Pavlov First State Medical University, Russia
P3.04-002: Reducing the Amount of Resection after Induction Photodynamic and Chemotherapy in Inoperable Non-Small Cell Lung Cancer

MANI BHARGAVA
ICFAI University, India
P3.02c-002: Mannosylated Poly (Propylene Imine) Dendrimer Mediated Lung Delivery of Anticancer Bioactive

WEIJING CAI
Shanghai Pulmonary Hospital, China
MA15.03: The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD-1 Blockade in Advanced NSCLC

ARUN CHANDRASEKHARAN
Tata Memorial Hospital, India
P3.02b-094: Rebiopsy Post Progression in EGFR Mutated Lung Cancer

ZHONG-YI DONG
Guangdong Lung Cancer Institute, Guangdong General Hospital, China
MA15.10: Potential Predictive Value of TP53 and KRAS Mutation Status for Response to PD-1 Blockade Immunotherapy in Lung Adenocarcinoma

ALOK GOEL
Tata Memorial Hospital, India
P3.02b-007: Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung

GAURAV KUMAR
GMERS Medical College, India
P1.01-005: First of Its Kind Study in India Finds That Government’s Ban on Gutka (Highly Popular Smokeless Tobacco Product) DID NOT Increase Smoking at All

DENISSE LEE
National Cancer Institute, Mexico
P2.03b-083: Soluble Angiogenic Factors as Predictive Biomarkers of Response to Docetaxel plus Nintedanib as Second Line Therapy in NSCLC

TATIANE MONTELLA
Neotorax, Brazil
P1.02-083: Gene Fusion Profile in Lung Adenocarcinoma Patients in Brazil

ISIS NASCIMENTO
University of São Paulo, Brazil
P3.01-060: Aptamers as a Tool to Detect Lung Cancer Stem Cells

VIKTORIA NIKULINA
Taras Shevchenko National University of Kyiv, Ukraine
P2.01-091: The Anticancer Effect of Techoic Acids on Lewis Lung Carcinoma Model

SHENXIANG REN
Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, China
MA04.03: Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC

AHMED SALEM
Ain Shams University, Egypt
P3.03-041: FAS/FASL Genetic Polymorphisms Impact on Clinical Outcome of Malignant Pleural Mesothelioma

AYAZ SHAHID
Jamia Hamdard University, India
P1.01-020: Chemopreventive Effect of Catchin Hydrates against Benzo(a)Pyrene Induced Lung Carcinogenesis in Mice: Plausible Role of ALDH1

NAVNEET SINGH
Postgraduate Institute of Medical Education and Research (PGIMER), India
P2.06-030: Optimum Duration of Vitamin B12/Folate Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy: The PEMVTASTART Randomized Trial

CHANDRASHEKHAR THUMMALA
HALLY SREE RAMAREDDY
International Medical University, Malaysia
OA04.01: Educational and Wealth Inequalities in Tobacco Use Among Men and Women in 54 Low and Middle Income Countries

ANA PAULA TEIXEIRA
National Cancer Institute-Ministry of Health, Brazil
P1.01-001: Reduction of Cigarette Consumption Through a National Policy for Tobacco Control in Brazil

DAWEI YANG
Zhongshan Hospital Fudan University, China
OA12.05: Noninvasive CT-Based Image Biopsy System (iBiopsy) for Early Stage Lung Adenocarcinoma

SHUANG ZHAO
West China Hospital, Sichuan University, China
MA17.11: Knockdown of Akt2 Suppresses Tumorigenesis and Raf1 Overexpression Offsets This Effect in Non-Small Cell Lung Cancer

YUE ZHAO
Fudan University Shanghai Cancer Center, China
P2.01-009: Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer
The IASLC Patient Advocacy Award Winners will receive their award during the IASLC Business Meeting

**SCHUBERT 2, LEVEL ONE**
Tuesday, Dec. 6 14:30 – 15:00

**WCLC 2016 LECTURESHIP AWARD WINNERS**

The WCLC 2016 Lectureship Award Winners will receive their award before their presentation in the Abstract Session.

**Dan Idhe Lectureship Award**
- Combined Modality

**KRISTA WINK**
Maastro Clinic, Netherlands

OA09.06: Metformin Use During Concurrent Chemoradiotherapy for Locally Advanced Non-Small Cell Lung Cancer (NSCLC)

**Robert Ginsberg Lectureship Award**
- Surgery

**AKI KOBAYASHI**
Mie University Graduate School of Medicine, Japan

OA15.02: Survival Outcomes in Sublobar Resection for Clinical T1N0M0 Non-Small Cell Lung Cancer: Wedge Resection or Segmentectomy

**Clifton Mountain Lectureship Award**
- Surgery/Staging

**HAO-RAN ZHAI**
Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong, China

MA17.05: Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas

**Tsuguo Naruke Lectureship Award**
- Staging

**RYUICHI WASEDA**
Fukuoka University, Japan

OA15.05: Anatomical Pulmonary Segmentectomy and Sub-Subsegmentectomy for Lung Cancer Using the Novel Fluorescence Technique with Vitamin B2

**Adi Gazdar Lectureship Award**
- Translational Research

**JONATHAN RIESS**
University of California Davis Cancer Center, USA

OA10.01: Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade

---

**Heine Hansen Lectureship Award**
- Small Cell Lung Cancer

**MARIANNA CHRISTODOULOU**
The Christie NHS Foundation Trust, UK

OA05.06: Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial

**Clifton Mountain Lectureship Award**
- Surgery/Staging

**ELIZABETH DESSUREAULT**
Canada

**LILLIAN LEIGH**
Australia

**IDE MILLS**
USA

**KAZUO HASEGAWA**
Japan

**EWELINA SZMYTKE**
Poland

---

**The IASLC Patient Advocacy Award Winners**

**SUPPORTED BY**

Bristol-Myers Squibb
WCLC 2016 COMMUNICATIONS WORKSHOP AWARD WINNERS

SUPPORTED BY

ANNE-MARIE BAIRD
Trinity College Dublin/St. James’s Hospital, UK

MARTA DIEZ-FERRER
Hospital Universitari de Bellvitge, Spain

SHAAN DUDANI
The Ottawa Hospital Cancer Centre, Canada

PANKAJ KUMAR GARG
University College of Medical Sciences, University of Delhi, India

ADELE HUG
Royal Surrey County Hospital, UK

MANUEL KELLER
University of Bern, Switzerland

PEEY SEI KOK
NHMRC Clinical Trial Centre, Australia

PEI-YING LIN
National Taiwan University Hospital, Taiwan

R LAKSHMI NARASIMHAN
PGIMER (Postgraduate Institute of Medical Education and Research), India

XIAOMIN NIU
Shanghai Chest Hospital, Shanghai Jiao Tong University, China

SEYE OMIYEFA
Youth Action on Tobacco Control and Health, Nigeria

JONATHAN RIESS
UC Davis Cancer Center, USA

AHMED SALEM
University of Manchester, UK

ANDREAS SALTOS
H. Lee Moffitt Cancer Center and Research Institute, USA

MATTHEW SMELTZER
University of Memphis, USA

CHUNXIA SU
Shanghai Pulmonary Hospital, China

SALOMON TENDLER
Karolinska University Hospital, Sweden

ILKE TUNALI
Namik Kemal University, Turkey

SHO WATANABE
National Cancer Center Hospital, Japan

MENG WELLIVER
The Ohio State University Comprehensive Cancer Center, USA

GAVITT WOODARD
University of California, San Francisco, USA

TING-HUI WU
National Taiwan University Hospital, Taiwan

ANDREW YAM
Crown Princess Mary Cancer Care Centre, Australia
WCLC 2016 VIRTUAL MEETING

Access WCLC 2016 sessions, anytime, anywhere.

Included in your Conference registration

Check the front of your name badge for your Delegate ID Number as it’s also your Virtual Library Access Code

No more missing out on presentations

INCLUDES

- Abstracts
- Presentation slides
- Audio/video recordings of presentations
- Electronic version of most posters

GET THE WCLC 2016 VIRTUAL MEETING AT http://library.iaslc.org
Conference Program

<table>
<thead>
<tr>
<th>Section</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conference Program</td>
<td>61</td>
</tr>
<tr>
<td>Program at a Glance</td>
<td>64</td>
</tr>
<tr>
<td>Sessions at a Glance by Day</td>
<td>66</td>
</tr>
<tr>
<td>Sessions at a Glance by Track</td>
<td>74</td>
</tr>
<tr>
<td>Workshops, Hands-On Training and Special Sessions</td>
<td>82</td>
</tr>
<tr>
<td>Industry Supported Symposia</td>
<td>84</td>
</tr>
<tr>
<td>Plenary Sessions</td>
<td>85</td>
</tr>
<tr>
<td>Networking Opportunities</td>
<td>86</td>
</tr>
</tbody>
</table>
PROGRAM AT A GLANCE

**SATURDAY**  
DECEMBER 3, 2016

- **Workshops** (08:00–18:00)
- **Industry Supported Symposium supported by ARIAD Pharmaceuticals Inc.** (12:00–13:30)
- **Industry Supported Symposium supported by Pfizer Oncology** (13:45–15:15)
- **Plenary Session: Tobacco Control** (09:00–10:20)

**SUNDAY**  
DECEMBER 4, 2016

- **Opening Plenary Session** (19:00–20:45)
- **Welcome Reception** (20:45–21:45)

**MONDAY**  
DECEMBER 5, 2016

- **Meet the Expert Sessions** (07:30–08:30)
- **Industry Supported Symposium supported by Pfizer Oncology** (15:30–17:00)
- **Industry Supported Symposium supported by Eli Lilly and Company** (17:15–18:45)
- **Industry Supported Symposium supported by Bristol-Myers Squibb** (12:45–14:15)
- **Industry Supported Symposium supported by prIME Oncology** (17:45–19:15)
- **Science Highlights Sessions** (07:30–08:30)
- **Opposed Industry Symposia** (07:30–08:30)

**PROGRAM AT A GLANCE**

- **Workshops** (08:00–18:00)
- **Opening Plenary Session** (19:00–20:45)
- **Welcome Reception** (20:45–21:45)

**SATURDAY**  
DECEMBER 3, 2016

- **Workshops** (08:00–11:45)
- **Young Investigators Session** (08:00–11:45)
- **Opening Plenary Session** (19:00–20:45)
- **Welcome Reception** (20:45–21:45)

**SUNDAY**  
DECEMBER 4, 2016

- **Workshops** (08:00–11:45)
- **Plenary Session: Tobacco Control** (09:00–10:20)
- **Press Conference** (10:30–11:45)
- **Educational, Science, Oral and Mini Oral Sessions** (11:00–12:30)

**MONDAY**  
DECEMBER 5, 2016

- **Meet the Expert Sessions** (07:30–08:30)
- **Industry Supported Symposium supported by Pfizer Oncology** (13:45–15:15)
- **Industry Supported Symposium supported by Merck-Pfizer Alliance** (15:30–17:00)
- **Industry Supported Symposium supported by Bristol-Myers Squibb** (12:45–14:15)
- **Industry Supported Symposium supported by Eli Lilly and Company** (17:15–18:45)
- **Industry Supported Symposium supported by prIME Oncology** (17:45–19:15)
### TUESDAY
#### DECEMBER 6, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30–08:30</td>
<td>Ticketed Sessions</td>
</tr>
<tr>
<td>11:00–12:30</td>
<td>Educational, Science, Oral and Mini Oral Sessions</td>
</tr>
<tr>
<td>12:45–14:15</td>
<td>Industry Supported Symposium supported by Novartis</td>
</tr>
<tr>
<td>14:30–15:45</td>
<td>Educational, Science, Oral and Mini Oral Sessions</td>
</tr>
<tr>
<td>15:45–19:15</td>
<td>Industry Supported Symposium supported by Roche</td>
</tr>
<tr>
<td>16:00–17:30</td>
<td>Educational, Science, Oral and Mini Oral Sessions</td>
</tr>
</tbody>
</table>

### WEDNESDAY
#### DECEMBER 7, 2016

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
<tbody>
<tr>
<td>09:00–10:15</td>
<td>Plenary Session: Immune Checkpoint Inhibitors in Advanced NSCLC</td>
</tr>
<tr>
<td>09:45–10:15</td>
<td>Plenary Keynote Lecture</td>
</tr>
<tr>
<td>12:45–14:15</td>
<td>Industry Supported Symposium supported by MSD Oncology</td>
</tr>
<tr>
<td>14:30–15:45</td>
<td>Educational, Science, Oral and Mini Oral Sessions</td>
</tr>
<tr>
<td>16:00–18:00</td>
<td>Closing Plenary Session</td>
</tr>
<tr>
<td>19:00–23:00</td>
<td>WCLC 2016 Together against Lung Cancer Ticketed Event</td>
</tr>
</tbody>
</table>
## Sessions at a Glance

### By Day

<table>
<thead>
<tr>
<th>Track</th>
<th>#</th>
<th>Session Title</th>
<th>Date</th>
<th>Start</th>
<th>End</th>
<th>Room</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>SATURDAY, DECEMBER 3, 2016</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>WS01</td>
<td>Young Investigator Research and Communication Training (By invitation only)</td>
<td>Saturday, Dec. 3</td>
<td>08:00</td>
<td>17:00</td>
<td>Schubert 1-4</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>WS02</td>
<td>IASLC Supporting the Implementation of Global CT Screening</td>
<td>Saturday, Dec. 3</td>
<td>09:00</td>
<td>18:00</td>
<td>Strauss 1</td>
</tr>
<tr>
<td></td>
<td></td>
<td>Policy Dialogue: Tobacco Control in Central Europe: Status - Goals - Challenges</td>
<td>Saturday, Dec. 3</td>
<td>14:00</td>
<td>16:00</td>
<td>Strauss 2</td>
</tr>
<tr>
<td><strong>SUNDAY, DECEMBER 4, 2016</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>WS03</td>
<td>IASLC meets ESTI: Imaging in Lung Cancer Staging and Diagnosis</td>
<td>Sunday, Dec. 4</td>
<td>08:00</td>
<td>11:45</td>
<td>Strauss 2</td>
</tr>
<tr>
<td></td>
<td>JCES01</td>
<td>Joint IASLC - Chinese Society for Clinical Oncology - Chinese Alliance Against Lung Cancer Session (Sign up required)</td>
<td>Sunday, Dec. 4</td>
<td>08:00</td>
<td>11:45</td>
<td>Stolz 1</td>
</tr>
<tr>
<td></td>
<td>YI01</td>
<td>Clinical Trials &amp; Scientific Mentoring</td>
<td>Sunday, Dec. 4</td>
<td>08:00</td>
<td>11:45</td>
<td>Hall C8</td>
</tr>
<tr>
<td>MESOTHELIOMA/THYMIC MALIGNS/Eosophageal cancer/other thoracic malignancies</td>
<td>WS04</td>
<td>Mesothelioma Workshop (Ticketed Session)</td>
<td>Sunday, Dec. 4</td>
<td>08:00</td>
<td>11:00</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>NURSES</td>
<td>WS05</td>
<td>International Society of Nurses in Cancer Care (ISNCC) &amp; BMS Foundation Collaborative Workshop (Sign up required)</td>
<td>Sunday, Dec. 4</td>
<td>08:00</td>
<td>12:00</td>
<td>Schubert 4</td>
</tr>
<tr>
<td></td>
<td>WS06</td>
<td>Management of Lung Cancer Patients Through Innovative Laboratory Testing Across the Clinical Continuum Workshop (Sign up required)</td>
<td>Sunday, Dec. 4</td>
<td>08:00</td>
<td>12:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>ISS01</td>
<td>Current and Emerging Treatments for Patients with ALK+ NSCLC - ARIAD Pharmaceuticals Inc.</td>
<td>Sunday, Dec. 4</td>
<td>12:00</td>
<td>13:30</td>
<td>Strauss 3</td>
<td></td>
</tr>
<tr>
<td>NURSES</td>
<td>WS07</td>
<td>International Thoracic Oncology Nursing Forum (ITONF) and Mesothelioma Satellite Workshop: Innovating Lung Cancer and Mesothelioma Care (Ticketed Session)</td>
<td>Sunday, Dec. 4</td>
<td>13:30</td>
<td>18:30</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>ISS02</td>
<td>ALK and ROS1 in NSCLC: Optimising the Continuum of Care - Pfizer Oncology</td>
<td>Sunday, Dec. 4</td>
<td>13:45</td>
<td>15:15</td>
<td>Lehar 3-4</td>
<td></td>
</tr>
<tr>
<td></td>
<td>ISS03</td>
<td>Non-Small Cell Lung Cancer: The Programmed Death-Ligand 1 (PD-L1) Receptor as a Target for Monotherapy and in Combination - Merck-Pfizer Alliance</td>
<td>Sunday, Dec. 4</td>
<td>15:30</td>
<td>17:00</td>
<td>Hall C2</td>
</tr>
<tr>
<td></td>
<td>ISS04</td>
<td>Treatment Selection Strategies in Advanced NSCLC - A Symphony of Views - Eli Lilly and Company</td>
<td>Sunday, Dec. 4</td>
<td>17:15</td>
<td>18:45</td>
<td>Hall C1</td>
</tr>
<tr>
<td>PL01</td>
<td>Opening Plenary Session</td>
<td>Sunday, Dec. 4</td>
<td>19:00</td>
<td>20:45</td>
<td>Hall D (Plenary Hall)</td>
<td></td>
</tr>
<tr>
<td>TRACK</td>
<td>#</td>
<td>SESSION TITLE</td>
<td>DATE</td>
<td>START</td>
<td>END</td>
<td>ROOM</td>
</tr>
<tr>
<td>-------</td>
<td>---</td>
<td>----------------</td>
<td>------</td>
<td>-------</td>
<td>-----</td>
<td>------</td>
</tr>
<tr>
<td>EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION</td>
<td>SH01</td>
<td>WCLC 2016 Scientific Highlights</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>NSCLC/NEUROENDOCRINE TUMORS</td>
<td>SH02</td>
<td>WCLC 2016 Scientific Highlights</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION</td>
<td>MTE01</td>
<td>Strategies to Improve Tobacco Control in Central European Countries (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE02</td>
<td>Advances in Pathology (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE03</td>
<td>Basics of Molecular Biology for the Clinician (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>MTE04</td>
<td>Screening for Lung Cancer (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>SURGERY</td>
<td>MTE05</td>
<td>Where is the Place of Surgery for N2 Disease? (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>RADIOTherapy</td>
<td>MTE06</td>
<td>Radiotherapy Techniques in Lung Cancer (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>ADVANCED NSCLC, CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>MTE07</td>
<td>Treatment of Elderly Patients with Lung Cancer (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>EARLY STAGE NSCLC, LOCALLY ADVANCED NSCLC, CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>MTE08</td>
<td>Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>MTE09</td>
<td>Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors in Advanced NSCLC (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>ISS05</td>
<td>Orchestrating Progress for Patients with Squamous Cell Lung Cancer - Eli Lilly and Company</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 2</td>
<td></td>
</tr>
<tr>
<td>ISS06</td>
<td>The Changing Treatment Paradigm After Progression in Advanced EGFR-Mutated NSCLC - PeerVoice</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Stolz 2</td>
<td></td>
</tr>
<tr>
<td>WS08</td>
<td>Special Session: CAP/IASLC/AMP Guidelines for Molecular Testing in Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 1</td>
<td></td>
</tr>
<tr>
<td>EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION</td>
<td>PL02</td>
<td>Distinguished Lecture &amp; Plenary Session: Tobacco Control</td>
<td>Monday, Dec. 5</td>
<td>08:45</td>
<td>10:20</td>
<td>Hall D (Plenary Hall)</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY, CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>ED01</td>
<td>Biology of Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>PALLIATIVE CARE/ETHICS</td>
<td>ED02</td>
<td>Palliative Care in Lung Cancer: A Global Challenge</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING, LOCALLY ADVANCED NSCLC</td>
<td>SC01</td>
<td>Staging Before and After Induction Therapy for N2 Disease</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING, PULMONOLOGY</td>
<td>SC02</td>
<td>Multifocal Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>RADIOTherapy</td>
<td>SC03</td>
<td>Advances in Radiation Oncology</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>SC04</td>
<td>EGFR Tyrosine Kinase Inhibitors: A Model for Successful Drug Development</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>SC05</td>
<td>Novel Drugs in Thoracic Cancers</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C2</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>IA01</td>
<td>Multidisciplinary Diagnosis of Lung Cancer in the Era of Molecular Medicine</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>IA02</td>
<td>Interactive Session Staging Group I (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 3</td>
</tr>
<tr>
<td>NURSES, EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION</td>
<td>NU01</td>
<td>Prevention</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>TRACK</td>
<td>#</td>
<td>SESSION TITLE</td>
<td>DATE</td>
<td>START</td>
<td>END</td>
<td>ROOM</td>
</tr>
<tr>
<td>-----------------</td>
<td>----</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>--------</td>
<td>--------</td>
<td>-------</td>
</tr>
<tr>
<td>PATIENT SUPPORT AND ADVOCACY GROUPS</td>
<td>PA01</td>
<td>Lung Cancer Diagnosis and Care: Identifying and Improving Community Standards</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>SURGERY</td>
<td>OA01</td>
<td>Risk Assessment and Follow up in Surgical Patients</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>MESOTHELIOMA/ THYMIC MALIGNANCIES/ ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>OA02</td>
<td>Novel Targets and Biomarkers in Malignant Pleural Mesothelioma</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY</td>
<td>OA03</td>
<td>Immunotherapy Checkpoint Inhibitors in Advanced NSCLC</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C8</td>
</tr>
<tr>
<td>EPIDEMIOLOGY/ TOBACCO CONTROL AND CESSATION/ PREVENTION</td>
<td>OA04</td>
<td>Epidemiology and Prevention of Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>RADIOLOGY/ STAGING/SCREENING</td>
<td>MA01</td>
<td>Improvement and Implementation of Lung Cancer Screening</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>SCLC/ NEUROENDOCRINE TUMORS</td>
<td>OA05</td>
<td>Treatment Advances in SCLC</td>
<td>Monday, Dec. 5</td>
<td>14:20</td>
<td>15:50</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>OA06</td>
<td>Prognostic &amp; Predictive Biomarkers</td>
<td>Monday, Dec. 5</td>
<td>14:20</td>
<td>15:50</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>SURGERY</td>
<td>OA07</td>
<td>Lymph Node Metastases and Other Prognostic Factors for Local Spread</td>
<td>Monday, Dec. 5</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MA02</td>
<td>RNA in Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>EPIDEMIOLOGY/ TOBACCO CONTROL AND CESSATION/ PREVENTION</td>
<td>MA03</td>
<td>Epidemiology, Risk Factors and Screening</td>
<td>Monday, Dec. 5</td>
<td>14:20</td>
<td>15:50</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>EPIDEMIOLOGY/ TOBACCO CONTROL AND CESSATION/ PREVENTION</td>
<td>ED03</td>
<td>Global Tobacco Control Policies: Advances &amp; Challenges</td>
<td>Monday, Dec. 5</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C1</td>
</tr>
<tr>
<td>SCLC/ NEUROENDOCRINE TUMORS</td>
<td>ED04</td>
<td>Bronchopulmonary Carcinoids</td>
<td>Monday, Dec. 5</td>
<td>14:30</td>
<td>15:45</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>JTO</td>
<td></td>
<td>Meet the JTO Editor</td>
<td>Monday, Dec. 5</td>
<td>14:30</td>
<td>15:15</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>PATIENT SUPPORT AND ADVOCACY GROUPS</td>
<td>IA03</td>
<td>What are the Lung Cancer Patients Needs in the Different Countries?</td>
<td>Monday, Dec. 5</td>
<td>14:30</td>
<td>15:45</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>RADIOLOGY/ STAGING/SCREENING</td>
<td>PC01</td>
<td>Invasive Mediastinal Staging for N2 Disease</td>
<td>Monday, Dec. 5</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C2</td>
</tr>
<tr>
<td>MESOTHELIOMA/ THYMIC MALIGNANCIES/ ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>SC06</td>
<td>Novel Therapies in Malignant Pleural Mesothelioma and Thymic Malignancies</td>
<td>Monday, Dec. 5</td>
<td>14:30</td>
<td>15:45</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>RADIOLOGY/ STAGING/SCREENING</td>
<td>ED05</td>
<td>The 8th Edition of the TNM Staging System</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>PALLIATIVE CARE/ ETHICS</td>
<td>ED06</td>
<td>Symptom Management in Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>EPIDEMIOLOGY/ TOBACCO CONTROL AND CESSATION/ PREVENTION</td>
<td>SC07</td>
<td>New Challenges for Lung Cancer: Waterpipes and E-Cigarettes</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>PULMONOLOGY, SURGERY</td>
<td>SC08</td>
<td>IASLC-ESTS Joint Symposium: The Borderline Patient</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>TRACK / REGIONAL ASPECTS/ HEALTH POLICY/ PUBLIC HEALTH</td>
<td>SESSION #</td>
<td>SESSION TITLE</td>
<td>DATE</td>
<td>START</td>
<td>END</td>
<td>ROOM</td>
</tr>
<tr>
<td>---------------------------------------------------------</td>
<td>------------</td>
<td>---------------</td>
<td>------</td>
<td>-------</td>
<td>-----</td>
<td>------</td>
</tr>
<tr>
<td>RADIOTherapy, REGIONAL ASPECTS/ HEALTH POLICY/ PUBLIC HEALTH</td>
<td>SC09</td>
<td>Radiotherapy for a Global Cancer</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C8</td>
</tr>
<tr>
<td>ADVANCED NSCLC, CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY</td>
<td>SC10</td>
<td>Squamous Cell NSCLC</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY</td>
<td>SC11</td>
<td>ALK, ROS1 and Rare Mutations in NSCLC</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY</td>
<td>SC12</td>
<td>Anticancer Drug Development in the 21st Century</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C2</td>
</tr>
<tr>
<td>RADIOTHERAPY</td>
<td>IA04</td>
<td>Interactive Session Target Delineation: Group I (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 3</td>
</tr>
<tr>
<td>NURSES</td>
<td>NU02</td>
<td>Preparing Patients for Treatment</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>PATIENT SUPPORT AND ADVOCACY GROUPS</td>
<td>PA02</td>
<td>Access to Care - Equal Chances in the World?</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>OA08</td>
<td>Targeted Therapies in Brain Metastases</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>MA04</td>
<td>HER2, PS3, KRAS and Other Targets in Advanced NSCLC</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>PULMONOLOGY</td>
<td>MA05</td>
<td>Innovative Techniques in Pulmonology and the Impact on Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>LOCALLY ADVANCED NSCLC</td>
<td>MA06</td>
<td>Locally Advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>ISS08</td>
<td></td>
<td>Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus in EGFR-Targeted Therapy - A prIME Oncology Satellite Symposium Supported by Boehringer Ingelheim Pharma GmBH &amp; Co. KG.</td>
<td>Monday, Dec. 5</td>
<td>17:45</td>
<td>19:15</td>
<td>Hall C7</td>
</tr>
</tbody>
</table>

**TUESDAY, DECEMBER 6, 2016**

<table>
<thead>
<tr>
<th>TRACK / REGIONAL ASPECTS/ HEALTH POLICY/ PUBLIC HEALTH</th>
<th>SESSION #</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>START</th>
<th>END</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>EARLY STAGE NSCLC, LOCALLY ADVANCED NSCLC, SURGERY</td>
<td>SH03</td>
<td>WCLC 2016 Scientific Highlights</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>RADIOLOGY/ STAGING/SCREENING, PULMONOLOGY</td>
<td>SH04</td>
<td>WCLC 2016 Scientific Highlights</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE10</td>
<td>Unique Biologic Aspects of Tobacco-Induced Lung Cancer (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE11</td>
<td>The Clinical Impact of the 2015 WHO Classification of Lung Tumors (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE12</td>
<td>Clinically Relevant Signal Transduction Pathways (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY, CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY</td>
<td>MTE13</td>
<td>Basic Immunology for the Clinician (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>RADIOLOGY/ STAGING/SCREENING, PULMONOLOGY</td>
<td>MTE14</td>
<td>How to Implement Screening/Early Detection in Routine Practice (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>RADIOLOGY/ STAGING/SCREENING, SURGERY</td>
<td>MTE15</td>
<td>Lymph Node Mapping in Lung Cancer (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY</td>
<td>MTE16</td>
<td>Precision Medicine in NSCLC: Lessons Learned and Perspectives (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>ADVANCED NSCLC, CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY</td>
<td>MTE17</td>
<td>Maintenance Therapy Versus Early Second-Line Therapy in Advanced NSCLC (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>SCLC/ NEUROENDOCRINE TUMORS</td>
<td>MTE18</td>
<td>Perspectives in the Systemic Treatment of Small-Cell Lung Cancer (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>CHEMOTHERAPY/ TARGETED THERAPY/ IMMUNOTHERAPY, TRIAL DESIGN/ STATISTICS</td>
<td>MTE19</td>
<td>Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>RADIOTHERAPY</td>
<td>MTE20</td>
<td>Radiotherapy of Locally Advance NSCLC: Selecting the Right Patient for the Right Radiotherapy (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>TRACK</td>
<td>#</td>
<td>SESSION TITLE</td>
<td>DATE</td>
<td>START</td>
<td>END</td>
<td>ROOM</td>
</tr>
<tr>
<td>-------</td>
<td>-----</td>
<td>---------------------------------------------------------------------------------</td>
<td>------------------</td>
<td>--------</td>
<td>--------</td>
<td>-------------</td>
</tr>
<tr>
<td>ISS</td>
<td>09</td>
<td>Targeted Therapy on the Horizon for SCLC - AbbVie</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>PL</td>
<td>03</td>
<td>Presidential Symposium</td>
<td>Tuesday, Dec. 6</td>
<td>08:35</td>
<td>10:25</td>
<td>Hall D</td>
</tr>
<tr>
<td>ED</td>
<td>07</td>
<td>Classification and Druggable Targets of Thoracic Tumors</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>SC13</td>
<td></td>
<td>Interaction of COPD and Lung Cancer - Consequences for Early Diagnosis and Management</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>SC14</td>
<td></td>
<td>Immunotherapy of NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C2</td>
</tr>
<tr>
<td>SC15</td>
<td></td>
<td>Clinical Trials: How to Set Priorities?</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C8</td>
</tr>
<tr>
<td>IA05</td>
<td></td>
<td>The Practical use of the TNM Classifications for Thoracic Cancers</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>IA06</td>
<td></td>
<td>Interactive Session Staging Group II (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 3</td>
</tr>
<tr>
<td>NU03</td>
<td></td>
<td>Supporting Patients Receiving Treatment</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>PA03</td>
<td></td>
<td>Patient Support and Involvement in Research</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>OA09</td>
<td></td>
<td>Locally Advanced NSCLC: Innovative Treatment Strategies</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>OA10</td>
<td></td>
<td>EGFR Mutations</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>OA11</td>
<td></td>
<td>Angiogenesis in Advanced Lung Cancer</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>OA12</td>
<td></td>
<td>SBRT and Other Issues in Early Stage NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>MA07</td>
<td></td>
<td>ALK-ROS1 in Advanced NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>MA08</td>
<td></td>
<td>Treatment Monitoring in Advanced NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>ISS10</td>
<td></td>
<td>Novel First-Line Treatment Strategies for ALK+ NSCLC: From Evidence to Practice - Novartis</td>
<td>Tuesday, Dec. 6</td>
<td>12:45</td>
<td>14:15</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>OA13</td>
<td></td>
<td>Immunotherapy in Malignant Pleural Mesothelioma: Current Status of Trials and New Approaches</td>
<td>Tuesday, Dec. 6</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>MA09</td>
<td></td>
<td>Immunotherapy Combinations</td>
<td>Tuesday, Dec. 6</td>
<td>14:20</td>
<td>15:50</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>MA10</td>
<td></td>
<td>Facing the Real World: New Staging System and Response Evaluation in Immunotherapy</td>
<td>Tuesday, Dec. 6</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>MA11</td>
<td></td>
<td>Novel Approaches in SCLC and Neuroendocrine Tumors</td>
<td>Tuesday, Dec. 6</td>
<td>14:20</td>
<td>15:50</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>MA12</td>
<td></td>
<td>Miscellaneous Biology/Pathology</td>
<td>Tuesday, Dec. 6</td>
<td>14:20</td>
<td>15:50</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>ED08</td>
<td></td>
<td>Early-Stage NSCLC: State-of-the-Art Treatment and Perspectives</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:50</td>
<td>Hall C2</td>
</tr>
<tr>
<td>ED09</td>
<td></td>
<td>Advances in Lung Cancer Screening</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:50</td>
<td>Hall C8</td>
</tr>
<tr>
<td>SC16</td>
<td></td>
<td>Superior Sulcus Tumors</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:50</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>TRACK</td>
<td># SESSION TITLE</td>
<td>DATE</td>
<td>START</td>
<td>END</td>
<td>ROOM</td>
<td></td>
</tr>
<tr>
<td>-------------------------------------------</td>
<td>----------------------------------------------------------------------------------</td>
<td>----------------</td>
<td>---------</td>
<td>---------</td>
<td>------------</td>
<td></td>
</tr>
<tr>
<td>REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH</td>
<td>SC17 Lung Cancer: A Global Cancer with Different Regional Challenges</td>
<td>Tuesday, Dec. 6</td>
<td>14:20</td>
<td>15:50</td>
<td>Strauss 1</td>
<td></td>
</tr>
<tr>
<td>CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>PC02 By 2030 Chemotherapy will Remain Standard of Care for the Majority of Patients with NSCLC Stages I-IV</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C7</td>
<td></td>
</tr>
<tr>
<td>NURSES</td>
<td>NU04 Managing Toxicity</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:45</td>
<td>Schubert 5</td>
<td></td>
</tr>
<tr>
<td>PATIENT SUPPORT AND ADVOCACY GROUPS</td>
<td>PA04 Focus on Advocacy and Communication: Joint IASLC/Global Lung Cancer Coalition Session (GLCC)</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:45</td>
<td>Schubert 6</td>
<td></td>
</tr>
<tr>
<td>LOCALLY ADVANCED NSCLC</td>
<td>ED10 Locally Advanced NSCLC: State-of-the-Art Treatment</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C1</td>
<td></td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>SC18 Precision Screening for Lung Cancer</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Lehar 1-2</td>
<td></td>
</tr>
<tr>
<td>PATIENT SUPPORT AND ADVOCACY GROUPS</td>
<td>NU04 Managing Toxicity</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:45</td>
<td>Schubert 5</td>
<td></td>
</tr>
<tr>
<td>PATIENT SUPPORT AND ADVOCACY GROUPS</td>
<td>OA14 Nurses in Care for Lung Cancer and in Research</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 5</td>
<td></td>
</tr>
<tr>
<td>PATIENT SUPPORT AND ADVOCACY GROUPS</td>
<td>OA15 Sublobar Resections for Early Stage NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Stolz 2</td>
<td></td>
</tr>
<tr>
<td>PATIENT SUPPORT AND ADVOCACY GROUPS</td>
<td>OA16 Improving the Quality of Lung Cancer Care - Patients Perspective</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 6</td>
<td></td>
</tr>
<tr>
<td>REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH</td>
<td>OA17 Aspects of Health Policies and Public Health</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 6</td>
<td></td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>MA13 Modern Technologies and Biological Factors in Radiotherapy</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Stolz 1</td>
<td></td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>MA14 Immunotherapy in Advanced NSCLC: Biomarkers and Costs</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Strauss 2</td>
<td></td>
</tr>
<tr>
<td>ISS11</td>
<td>Harnessing the Power of Immunotherapy and Targeted Therapy: Translating Evidence Into Practice - Roche</td>
<td>Tuesday, Dec. 6</td>
<td>17:45</td>
<td>19:15</td>
<td>Hall C2</td>
<td></td>
</tr>
</tbody>
</table>

**WEDNESDAY, DECEMBER 7, 2016**

<table>
<thead>
<tr>
<th>TRACK</th>
<th># SESSION TITLE</th>
<th>DATE</th>
<th>START</th>
<th>END</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>ADVANCED NSCLC, CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>SH05 WCLC 2016 Scientific Highlights</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>SH06 WCLC 2016 Scientific Highlights</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION</td>
<td>WS09 Special Workshop: Tobacco Free Portfolios</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MTE21 Next Generation Sequencing (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>RADIOLOGY/STAGING/SCREENING</td>
<td>MTE22 Perspectives in Lung Cancer Imaging (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>TRACK</td>
<td>#</td>
<td>SESSION TITLE</td>
<td>DATE</td>
<td>START</td>
<td>END</td>
</tr>
<tr>
<td>-------</td>
<td>---</td>
<td>----------------</td>
<td>------</td>
<td>-------</td>
<td>-----</td>
</tr>
<tr>
<td>ED</td>
<td>ED</td>
<td>EDUCATIONAL SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>IA</td>
<td>IA</td>
<td>INTERACTIVE SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISS</td>
<td>ISS</td>
<td>INDUSTRY SUPPORTED SYMPOSIUM</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MA</td>
<td>MA</td>
<td>MINI ORAL ABSTRACT SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTE</td>
<td>MTE</td>
<td>MEET THE EXPERT SESSION (TICKETED)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SC</td>
<td>SC</td>
<td>SCIENTIFIC SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>NU</td>
<td>NU</td>
<td>NURSES SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>OA</td>
<td>OA</td>
<td>ORAL ABSTRACT SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PA</td>
<td>PA</td>
<td>PATIENT ADVOCACY SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PC</td>
<td>PC</td>
<td>PRO CON SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>PL</td>
<td>PL</td>
<td>PLENARY SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>SH</td>
<td>SH</td>
<td>SCIENTIFIC HIGHLIGHT SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS</td>
<td>WS</td>
<td>WORKSHOP</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>YI</td>
<td>YI</td>
<td>YOUNG INVESTIGATOR SESSION</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

- **SESSIONS AT A GLANCE**

- **BY DAY**

<table>
<thead>
<tr>
<th>TRACK</th>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>START</th>
<th>END</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTE23</td>
<td>MTE23</td>
<td>Biomarker Characterization: Challenges and Perspectives (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 3</td>
</tr>
<tr>
<td>MTE24</td>
<td>MTE24</td>
<td>Immunochemistry of Biomarkers for Immune Checkpoint Inhibitors (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>MTE25</td>
<td>MTE25</td>
<td>Radiotherapy in Small Cell Lung Cancer (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>MTE26</td>
<td>MTE26</td>
<td>EGFR Targeted Therapies: Lessons Learned (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>MTE27</td>
<td>MTE27</td>
<td>Treatment of Lung Cancer Patients with Poor Performance Status (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>MTE28</td>
<td>MTE28</td>
<td>Implementation of Precision Medicine in Routine Practice: The Latin American Experience (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>MTE29</td>
<td>MTE29</td>
<td>Advances in Malignant Pleural Mesothelioma (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>MTE30</td>
<td>MTE30</td>
<td>Non-intubated Thoracic Surgery (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>MTE26</td>
<td>MTE26</td>
<td>EGFR Targeted Therapies: Lessons Learned (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>MTE27</td>
<td>MTE27</td>
<td>Treatment of Lung Cancer Patients with Poor Performance Status (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>MTE28</td>
<td>MTE28</td>
<td>Implementation of Precision Medicine in Routine Practice: The Latin American Experience (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>SC24</td>
<td>SC24</td>
<td>Management of Indeterminate Pulmonary Nodules</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C2</td>
</tr>
<tr>
<td>SC25</td>
<td>SC25</td>
<td>The Role of Surgeons in Multimodality Clinical Trials</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>SC26</td>
<td>SC26</td>
<td>Angiogenesis Inhibition: Advances &amp; Perspectives</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>SC27</td>
<td>SC27</td>
<td>PS3 and KRAS Mutations in NSCLC</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>SC28</td>
<td>SC28</td>
<td>Novel Clinical Trial Designs</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>SC29</td>
<td>SC29</td>
<td>Access, Value Assessments and Affordability of Novel Therapies</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>TRACK</td>
<td>#</td>
<td>SESSION TITLE</td>
<td>DATE</td>
<td>START</td>
<td>END</td>
<td>ROOM</td>
</tr>
<tr>
<td>-------</td>
<td>---</td>
<td>----------------</td>
<td>------</td>
<td>-------</td>
<td>-----</td>
<td>------</td>
</tr>
<tr>
<td>MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>OA18</td>
<td>New Insights in the Treatment of Thymic Malignancies</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>EARLY STAGE NSCLC</td>
<td>OA19</td>
<td>Translational Research in Early Stage NSCLC</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 3</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>OA20</td>
<td>Immunotherapy and Markers</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>PALLIATIVE CARE/ETHICS</td>
<td>OA21</td>
<td>Palliative and Supportive Care for Lung Cancer Patients</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>ISS12</td>
<td>Immuno-Oncology: A Renaissance in the Treatment of Lung Cancer – MSD Oncology</td>
<td>Wednesday, Dec. 7</td>
<td>12:45</td>
<td>14:15</td>
<td>Lehar 3-4</td>
<td></td>
</tr>
<tr>
<td>MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>OA22</td>
<td>Novel Trials and Biomarkers in Malignant Pleural Mesothelioma</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>ADVANCED NSCLC</td>
<td>OA23</td>
<td>EGFR Targeted Therapies in Advanced NSCLC</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>RADIOTHERAPY</td>
<td>OA24</td>
<td>Radiotherapy of Lung Cancer: Recent Developments</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>MA15</td>
<td>Immunotherapy Prediction</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
<td>MA16</td>
<td>Novel Strategies in Targeted Therapy</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>BIOLOGY/PATHOLOGY</td>
<td>MA17</td>
<td>Genetic Drivers</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>SCLC/NEUROENDOCRINE TUMORS</td>
<td>ED14</td>
<td>Small Cell Lung Cancer</td>
<td>Wednesday, Dec. 7</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C2</td>
</tr>
<tr>
<td>MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES</td>
<td>ED15</td>
<td>Thymic Malignancies: Update on Treatment</td>
<td>Wednesday, Dec. 7</td>
<td>14:30</td>
<td>15:50</td>
<td>Hall C1</td>
</tr>
<tr>
<td>SURGERY</td>
<td>SC30</td>
<td>Novel Approaches and Regulation in Surgical Education</td>
<td>Wednesday, Dec. 7</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C8</td>
</tr>
<tr>
<td>REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH/SCIENTIFIC CO-OPERATION/RESEARCH GROUPS</td>
<td>SC31</td>
<td>Together Against Lung Cancer – A Strategy for Success in the 21st Century</td>
<td>Wednesday, Dec. 7</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C7</td>
</tr>
<tr>
<td>RADIOTherapy</td>
<td>Y102</td>
<td>Basics of Radio-Oncology</td>
<td>Wednesday, Dec. 7</td>
<td>14:30</td>
<td>15:45</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>NURSES</td>
<td>NU05</td>
<td>Survivorship</td>
<td>Wednesday, Dec. 7</td>
<td>14:30</td>
<td>15:45</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>PL05</td>
<td>Closing Plenary Session: A Life in Thoracic Oncology - Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer</td>
<td>Wednesday, Dec. 7</td>
<td>16:00</td>
<td>18:00</td>
<td>Hall C1</td>
<td></td>
</tr>
<tr>
<td>#</td>
<td>SESSION TITLE</td>
<td>DATE</td>
<td>START</td>
<td>END</td>
<td>ROOM</td>
<td></td>
</tr>
<tr>
<td>---</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------</td>
<td>--------</td>
<td>--------</td>
<td>-------</td>
<td></td>
</tr>
<tr>
<td>MTE07</td>
<td>Treatment of Elderly Patients with Lung Cancer (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 1-2</td>
<td></td>
</tr>
<tr>
<td>MA04</td>
<td>HER2, PS3, KRAS and Other Targets in Advanced NSCLC</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Lehar 3-4</td>
<td></td>
</tr>
<tr>
<td>OA08</td>
<td>Targeted Therapies in Brain Metastases</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 1</td>
<td></td>
</tr>
<tr>
<td>SC10</td>
<td>Squamous Cell NSCLC</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Strauss 1</td>
<td></td>
</tr>
<tr>
<td>MTE17</td>
<td>Maintenance Therapy Versus Early Second-Line Therapy in Advanced NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 3</td>
<td></td>
</tr>
<tr>
<td>MA06</td>
<td>ALK-ROS1 in Advanced NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 1-2</td>
<td></td>
</tr>
<tr>
<td>MA08</td>
<td>Treatment Monitoring in Advanced NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 3-4</td>
<td></td>
</tr>
<tr>
<td>OA11</td>
<td>Angiogenesis in Advanced Lung Cancer</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 2</td>
<td></td>
</tr>
<tr>
<td>MA14</td>
<td>Immunotherapy in Advanced NSCLC: Biomarkers and Costs</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Strauss 2</td>
<td></td>
</tr>
<tr>
<td>SH05</td>
<td>WCLC 2016 Scientific Highlights</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C1</td>
<td></td>
</tr>
<tr>
<td>ED11</td>
<td>Advanced NSCLC: State-of-the-Art Treatment</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C8</td>
<td></td>
</tr>
<tr>
<td>OA23</td>
<td>EGFR Targeted Therapies in Advanced NSCLC</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 2</td>
<td></td>
</tr>
</tbody>
</table>

### BIOLOGY/PATHOLOGY

<table>
<thead>
<tr>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>START</th>
<th>END</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>MTE02</td>
<td>Advances in Pathology (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>MTE03</td>
<td>Basics of Molecular Biology for the Clinician (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>SH01</td>
<td>WCLC 2016 Scientific Highlights</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>ED01</td>
<td>Biology of Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>IA01</td>
<td>Multidisciplinary Diagnosis of Lung Cancer in the Era of Molecular Medicine</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>MA02</td>
<td>RNA in Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>OA06</td>
<td>Prognostic &amp; Predictive Biomarkers</td>
<td>Monday, Dec. 5</td>
<td>14:20</td>
<td>15:50</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>MTE10</td>
<td>Unique Biologic Aspects of Tobacco-Induced Lung Cancer (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>MTE11</td>
<td>The Clinical Impact of the 2015 WHO Classification of Lung Tumors (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>#</td>
<td>SESSION TITLE</td>
<td>DATE</td>
<td>START</td>
<td>END</td>
<td>ROOM</td>
</tr>
<tr>
<td>------</td>
<td>-------------------------------------------------------------------------------</td>
<td>-----------------------</td>
<td>---------</td>
<td>---------</td>
<td>-----------</td>
</tr>
<tr>
<td>MTE12</td>
<td>Clinically Relevant Signal Transduction Pathways (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>MTE13</td>
<td>Basic Immunology for the Clinician (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>ED07</td>
<td>Classification and Druggable Targets of Thoracic Tumors</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>OA10</td>
<td>EGFR Mutations</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>MA12</td>
<td>Miscellaneous Biology/Pathology</td>
<td>Tuesday, Dec. 6</td>
<td>14:20</td>
<td>15:50</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>SC21</td>
<td>Predictive Biomarkers for Outcome of Systemic Therapy in NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>MTE21</td>
<td>Next Generation Sequencing (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>MTE23</td>
<td>Biomarker Characterization: Challenges and Perspectives (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 3</td>
</tr>
<tr>
<td>MTE24</td>
<td>Immunohistochemical Assessment of Biomarkers for Immune Checkpoint Inhibitors</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>OA20</td>
<td>Immunotherapy and Markers</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>SC26</td>
<td>Angiogenesis Inhibition: Advances &amp; Perspectives</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>SC27</td>
<td>PS3 and KRAS Mutations in NSCLC</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>MA17</td>
<td>Genetic Drivers</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Lehar 1-2</td>
</tr>
</tbody>
</table>

### CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY

<p>| MTE07 | Treatment of Elderly Patients with Lung Cancer (Ticketed Session)             | Monday, Dec. 5        | 07:30   | 08:30   | Lehar 1-2 |
| MTE08 | Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives(Ticketed Session) | Monday, Dec. 5        | 07:30   | 08:30   | Lehar 3-4 |
| MTE09 | Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors in Advanced NSCLC (Ticketed Session) | Monday, Dec. 5        | 07:30   | 08:30   | Stolz 1   |
| ED01  | Biology of Lung Cancer                                                        | Monday, Dec. 5        | 11:00   | 12:30   | Hall C1   |
| OA03  | Immunotherapy Checkpoint Inhibitors in Advanced NSCLC                         | Monday, Dec. 5        | 11:00   | 12:30   | Hall C8   |
| SC04  | EGFR Tyrosine Kinase Inhibitors: A Model for Successful Drug Development      | Monday, Dec. 5        | 11:00   | 12:30   | Hall C7   |
| SC05  | Novel Drugs in Thoracic Cancers                                               | Monday, Dec. 5        | 11:00   | 12:30   | Hall C2   |
| SC10  | Squamous Cell NSCLC                                                           | Monday, Dec. 5        | 16:00   | 17:30   | Strauss 3 |
| SC11  | ALK, ROS1 and Rare Mutations in NSCLC                                          | Monday, Dec. 5        | 16:00   | 17:30   | Lehar 1-2 |
| SC12  | Anticancer Drug Development in the 21st Century                                | Monday, Dec. 5        | 16:00   | 17:30   | Hall C2   |
| MTE13 | Basic Immunology for the Clinician (Ticketed Session)                         | Tuesday, Dec. 6       | 07:30   | 08:30   | Schubert 5|
| MTE16 | Precision Medicine in NSCLC: Lessons Learned and Perspectives (Ticketed Session) | Tuesday, Dec. 6       | 07:30   | 08:30   | Strauss 2 |
| MTE17 | Maintenance Therapy Versus Early Second-Line Therapy in Advanced NSCLC (Ticketed Session) | Tuesday, Dec. 6       | 07:30   | 08:30   | Strauss 3 |
| MTE19 | Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice (Ticketed Session) | Tuesday, Dec. 6       | 07:30   | 08:30   | Stolz 1   |
| ED07  | Classification and Druggable Targets of Thoracic Tumors                       | Tuesday, Dec. 6       | 11:00   | 12:30   | Hall C1   |
| SC14  | Immunotherapy of NSCLC                                                         | Tuesday, Dec. 6       | 11:00   | 12:30   | Hall C2   |
| MA09  | Immunotherapy Combinations                                                    | Tuesday, Dec. 6       | 14:20   | 15:50   | Strauss 2 |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>START</th>
<th>END</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>PC02</td>
<td>By 2030 Chemotherapy will Remain Standard of Care for the Majority of Patients with NSCLC Stages I-IV</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C7</td>
</tr>
<tr>
<td>SC21</td>
<td>Predictive Biomarkers for Outcome of Systemic Therapy in NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>SC22</td>
<td>Selection and Monitoring of Patients for Immune Checkpoint Inhibitors</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C8</td>
</tr>
<tr>
<td>MTE23</td>
<td>Biomarker Characterization: Challenges and Perspectives (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 3</td>
</tr>
<tr>
<td>MTE24</td>
<td>Immunohistochemical Assessment of Biomarkers for Immune Checkpoint Inhibitors (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>MTE26</td>
<td>EGFR Targeted Therapies: Lessons Learned (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>MTE27</td>
<td>Treatment of Lung Cancer Patients with Poor Performance Status (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>MTE28</td>
<td>Implementation of Precision Medicine in Routine Practice: The Latin American Experience (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>SH05</td>
<td>WCLC 2016 Scientific Highlights</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>PL04a</td>
<td>Immune Checkpoint Inhibitors in Advanced NSCLC</td>
<td>Wednesday, Dec. 7</td>
<td>08:45</td>
<td>09:40</td>
<td>Hall D (Plenary Hall)</td>
</tr>
<tr>
<td>ED11</td>
<td>Advanced NSCLC: State-of-the-Art Treatment</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C8</td>
</tr>
<tr>
<td>SC26</td>
<td>Angiogenesis Inhibition: Advances &amp; Perspectives</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>SC27</td>
<td>PS3 and KRAS Mutations in NSCLC</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>SC29</td>
<td>Access, Value Assessments and Affordability of Novel Therapies</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>MA15</td>
<td>Immunotherapy Prediction</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Schubert 1</td>
</tr>
<tr>
<td>MA16</td>
<td>Novel Strategies in Targeted Therapy</td>
<td>Wednesday, Dec. 7</td>
<td>14:20</td>
<td>15:50</td>
<td>Strauss 2</td>
</tr>
</tbody>
</table>

**EARLY STAGE NSCLC**

| MTE08 | Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives (Ticketed Session) | Monday, Dec. 5 | 07:30 | 08:30| Lehar 3-4 |
| SH03 | WCLC 2016 Scientific Highlights                                             | Tuesday, Dec. 6  | 07:30 | 08:30| Hall C1 |
| OA12 | SBRT and Other Issues in Early Stage NSCLC                                  | Tuesday, Dec. 6  | 11:00 | 12:30| Strauss 2 |
| ED08 | Early-Stage NSCLC: State-of-the-Art Treatment and Perspectives              | Tuesday, Dec. 6  | 14:30 | 15:50| Hall C2 |
| OA19 | Translational Research in Early Stage NSCLC                                 | Wednesday, Dec. 7 | 11:00 | 12:30| Schubert 3 |

**EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION**

<p>| MTE01 | Strategies to Improve Tobacco Control in Central European Countries (Ticketed Session) | Monday, Dec. 5 | 07:30 | 08:30| Schubert 1 |
| SH01 | WCLC 2016 Scientific Highlights                                             | Monday, Dec. 5  | 07:30 | 08:30| Hall C1 |
| PL02 | Distinguished Lecture and Plenary Session: Tobacco Control                 | Monday, Dec. 5  | 08:45 | 10:20| Hall D (Plenary Hall) |
| NU01 | Prevention                                                                  | Monday, Dec. 5  | 11:00 | 12:30| Schubert 5 |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>START</th>
<th>END</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>OA04</td>
<td>Epidemiology and Prevention of Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 4</td>
</tr>
<tr>
<td>MA03</td>
<td>Epidemiology, Risk Factors and Screening</td>
<td>Monday, Dec. 5</td>
<td>14:20</td>
<td>15:50</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>ED03</td>
<td>Global Tobacco Control Policies: Advances &amp; Challenges</td>
<td>Monday, Dec. 5</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C1</td>
</tr>
<tr>
<td>SC07</td>
<td>New Challenges for Lung Cancer: Waterpipes and E-Cigarettes</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>IA08</td>
<td>Tobacco &amp; Youth</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C2</td>
</tr>
<tr>
<td>WS09</td>
<td>Special Workshop: Tobacco Free Portfolios</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>ED12</td>
<td>Regional Tobacco Control Policies: Advances &amp; Challenges</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C7</td>
</tr>
</tbody>
</table>

### LOCALLY ADVANCED NSCLC

| MTE08 | Immunootherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives (Ticketed Session) | Monday, Dec. 5 | 07:30 | 08:30 | Lehar 3-4 |
| SC01  | Staging Before and After Induction Therapy for N2 Disease                      | Monday, Dec. 5     | 11:00 | 12:30 | Lehar 3-4 |
| PC01  | Invasive Mediastinal Staging for N2 Disease                                     | Monday, Dec. 5     | 14:30 | 15:45 | Hall C2  |
| MA06  | Locally advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices  | Monday, Dec. 5     | 16:00 | 17:30 | Strauss 2 |
| SH03  | WCLC 2016 Scientific Highlights                                                 | Tuesday, Dec. 6    | 07:30 | 08:30 | Hall C1  |
| OA09  | Locally Advanced NSCLC: Innovative Treatment Strategies                         | Tuesday, Dec. 6    | 11:00 | 12:30 | Strauss 3 |
| ED10  | Locally Advanced NSCLC: State-of-the-Art Treatment                              | Tuesday, Dec. 6    | 16:00 | 17:30 | Hall C1  |

### MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNancies

| WS04  | Mesothelioma Workshop                                                           | Sunday, Dec. 4      | 08:00 | 11:00 | Stolz 2  |
| OA02  | Novel Targets and Biomarkers in Malignant Pleural Mesothelioma                  | Monday, Dec. 5      | 11:00 | 12:30 | Stolz 2  |
| SC06  | Novel Therapies in Malignant Pleural Mesothelioma and Thymic Malignancies       | Monday, Dec. 5      | 14:30 | 15:45 | Strauss 3 |
| OA13  | Immunotherapy in Malignant Pleural Mesothelioma: Current Status of Trials and New Approaches | Tuesday, Dec. 6    | 14:20 | 15:50 | Stolz 1  |
| MTE29 | Advances in Malignant Pleural Mesothelioma (Ticketed Session)                   | Wednesday, Dec. 7   | 07:30 | 08:30 | Stolz 1  |
| ED13  | Treatment of Malignant Pleural Mesothelioma                                    | Wednesday, Dec. 7   | 11:00 | 12:30 | Hall C1  |
| OA18  | New Insights in the Treatment of Thymic Malignancies                             | Wednesday, Dec. 7   | 11:00 | 12:30 | Schubert 2 |
| OA22  | Novel Trials and Biomarkers in Malignant Pleural Mesothelioma                   | Wednesday, Dec. 7   | 14:20 | 15:50 | Strauss 3 |
| ED15  | Thymic Malignancies: Update on Treatment                                        | Wednesday, Dec. 7   | 14:30 | 15:50 | Hall C1  |

### NURSES

<p>| WS05  | International Society of Nurses in Cancer Care (ISNCC) &amp; BMS Foundation Collaborative Workshop (Sign up required) | Sunday, Dec. 4 | 08:00 | 12:00 | Schubert 4 |
| WS07  | International Thoracic Oncology Nursing Forum (ITONF) and Mesothelioma Satellite Workshop: Innovating Lung Cancer and Mesothelioma Care (Ticketed Session) | Sunday, Dec. 4  | 13:30 | 18:30 | Schubert 2 |
| NU01  | Prevention                                                                     | Monday, Dec. 5     | 11:00 | 12:30 | Schubert 5 |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>START</th>
<th>END</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td>NU02</td>
<td>Preparing Patients for Treatment</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>NU03</td>
<td>Supporting Patients Receiving Treatment</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>NU04</td>
<td>Managing Toxicity</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:45</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>OA14</td>
<td>Nurses in Care for Lung Cancer and in Research</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>NU05</td>
<td>Survivorship</td>
<td>Wednesday, Dec. 7</td>
<td>14:30</td>
<td>15:45</td>
<td>Schubert 5</td>
</tr>
</tbody>
</table>

### Palliative Care/Ethics

| ED02 | Palliative Care in Lung Cancer: A Global Challenge | Monday, Dec. 5        | 11:00 | 12:30 | Strauss 3 |
| ED06 | Symptom Management in Lung Cancer                 | Monday, Dec. 5        | 16:00 | 17:30 | Stolz 1   |
| SH06 | WCLC 2016 Scientific Highlights                   | Wednesday, Dec. 7     | 07:30 | 08:30 | Hall C7   |
| OA21 | Palliative and Supportive Care for Lung Cancer Patients | Wednesday, Dec. 7  | 11:00 | 12:30 | Schubert 5 |

### Patient Support and Advocacy Groups

| PA01 | Lung Cancer Diagnosis and Care: Identifying and Improving Community Standards | Monday, Dec. 5        | 11:00 | 12:30 | Schubert 6 |
| IA03 | What are the Lung Cancer Patients Needs in the Different Countries?         | Monday, Dec. 5        | 14:30 | 15:45 | Schubert 2 |
| PA02 | Access to Care - Equal Chances in the World?                                   | Monday, Dec. 5        | 16:00 | 17:30 | Schubert 6 |
| PA03 | Patient Support and Involvement in Research                                    | Tuesday, Dec. 6       | 11:00 | 12:30 | Schubert 6 |
| PA04 | Focus on Advocacy and Communication: Joint IASLC/GLC Lung Cancer Coalition Session (GLCC) | Tuesday, Dec. 6  | 14:30 | 15:45 | Schubert 6 |
| OA16 | Improving the Quality of Lung Cancer Care - Patients Perspective             | Tuesday, Dec. 6       | 16:00 | 17:30 | Schubert 6 |
| SC29 | Access, Value Assessments and Affordability of Novel Therapies                | Wednesday, Dec. 7     | 11:00 | 12:30 | Strauss 1  |

### Pulmonology

<p>| SC02 | Multifocal Lung Cancer                                                      | Monday, Dec. 5        | 11:00 | 12:30 | Strauss 1 |
| MA05 | Innovative Techniques in Pulmonology and the Impact on Lung Cancer          | Monday, Dec. 5        | 16:00 | 17:30 | Strauss 1 |
| SC08 | IASLC-ESTS Joint Symposium: The Borderline Patient                          | Monday, Dec. 5        | 16:00 | 17:30 | Hall C7   |
| SH04 | WCLC 2016 Scientific Highlights                                             | Tuesday, Dec. 6       | 07:30 | 08:30 | Hall C7   |
| SC13 | Interaction of COPD and Lung Cancer - Consequences for Early Diagnosis and Management | Tuesday, Dec. 6  | 11:00 | 12:30 | Stolz 1   |
| SC19 | Interventional Pulmonology in Diagnosis and Treatment of Thoracic Malignancies | Tuesday, Dec. 6  | 16:00 | 17:30 | Lehar 3-4  |
| SC24 | Management of Indeterminate Pulmonary Nodules                               | Wednesday, Dec. 7     | 11:00 | 12:30 | Hall C2   |</p>
<table>
<thead>
<tr>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>START</th>
<th>END</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>RADIOLOGY/STAGING/SCREENING</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>WS02</td>
<td>IASLC Supporting the Implementation of Global CT Screening</td>
<td>Saturday, Dec. 3</td>
<td>09:00</td>
<td>18:00</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>WS03</td>
<td>IASLC meets ESTI: Imaging in Lung Cancer Staging and Diagnosis</td>
<td>Sunday, Dec. 4</td>
<td>08:00</td>
<td>11:45</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>MTE04</td>
<td>Screening for Lung Cancer (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 5</td>
</tr>
<tr>
<td>IA02</td>
<td>Interactive Session Staging Group I (Ticketed Session)</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 3</td>
</tr>
<tr>
<td>MA01</td>
<td>Improvement and Implementation of Lung Cancer Screening</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>SC01</td>
<td>Staging Before and After Induction Therapy for N2 Disease</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>SC02</td>
<td>Multifocal Lung Cancer</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>PC01</td>
<td>Invasive Mediastinal Staging for N2 Disease</td>
<td>Monday, Dec. 5</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C2</td>
</tr>
<tr>
<td>ED05</td>
<td>The 8th Edition of the TNM Staging System</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>MTE14</td>
<td>How to Implement Screening/Early Detection in Routine Practice (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>MTE15</td>
<td>Lymph Node Mapping in Lung Cancer (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>SH04</td>
<td>WCLC 2016 Scientific Highlights</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>IA05</td>
<td>The Practical Use of the TNM Classifications for Thoracic Cancers</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>IA06</td>
<td>Interactive Session Staging Group II (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 3</td>
</tr>
<tr>
<td>SC13</td>
<td>Interaction of COPD and Lung Cancer - Consequences for Early Diagnosis and Management</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>MA10</td>
<td>Facing the Real World: New Staging System and Response Evaluation in Immunotherapy</td>
<td>Tuesday, Dec. 6</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>ED09</td>
<td>Advances in Lung Cancer Screening</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:50</td>
<td>Hall C8</td>
</tr>
<tr>
<td>SC16</td>
<td>Superior Sulcus Tumors</td>
<td>Tuesday, Dec. 6</td>
<td>14:30</td>
<td>15:50</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>SC18</td>
<td>Precision Screening for Lung Cancer</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td>MTE22</td>
<td>Perspectives in Lung Cancer Imaging (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 2</td>
</tr>
</tbody>
</table>

|     | **RADIOTherapy**                                                             |                       |         |         |        |
| MTE06| Radiotherapy Techniques in Lung Cancer (Ticketed Session)                     | Monday, Dec. 5        | 07:30   | 08:30   | Strauss 3 |
| SC03| Advances in Radiation Oncology                                               | Monday, Dec. 5        | 11:00   | 12:30   | Strauss 2 |
| IA04| Interactive Session Target Delineation: Group I (Ticketed Session)           | Monday, Dec. 5        | 16:00   | 17:30   | Schubert 3 |
| SC09| Radiotherapy for a Global Cancer                                             | Monday, Dec. 5        | 16:00   | 17:30   | Hall C8 |
| MTE20| Radiotherapy of Locally Advance NCSLC: Selecting the Right Patient for the Right Radiotherapy (Ticketed Session) | Tuesday, Dec. 6      | 07:30   | 08:30   | Stolz 2 |
| IA07| Interactive Session Target Delineation: Group II (Ticketed Session)          | Tuesday, Dec. 6       | 16:00   | 17:30   | Schubert 3 |
| MA13| Modern Technologies and Biological Factors in Radiotherapy                  | Tuesday, Dec. 6       | 16:00   | 17:30   | Stolz 1 |
| MTE25| Radiotherapy in Small Cell Lung Cancer (Ticketed Session)                    | Wednesday, Dec. 7     | 07:30   | 08:30   | Schubert 5 |
| SH06| WCLC 2016 Scientific Highlights                                             | Wednesday, Dec. 7     | 07:30   | 08:30   | Hall C7 |
# SESSION TITLE | DATE | START | END | ROOM
--- | --- | --- | --- | ---
OA24 Radiotherapy of Lung Cancer: Recent Developments | Wednesday, Dec. 7 | 14:20 | 15:50 | Stolz 1
YI02 Basics of Radio-Oncology | Wednesday, Dec. 7 | 14:30 | 15:45 | Strauss 1
SC09 Radiotherapy for a Global Cancer | Monday, Dec. 5 | 16:00 | 17:30 | Hall C8
SC17 Lung Cancer: A Global Cancer with Different Regional Challenges | Tuesday, Dec. 6 | 14:20 | 15:50 | Strauss 1
OA17 Aspects of Health Policies and Public Health | Tuesday, Dec. 6 | 16:00 | 17:30 | Schubert 1
MTE28 Implementation of Precision Medicine in Routine Practice: The Latin American Experience (Ticketed Session) | Wednesday, Dec. 7 | 07:30 | 08:30 | Lehar 3-4
SH06 WCLC 2016 Scientific Highlights | Wednesday, Dec. 7 | 07:30 | 08:30 | Hall C7
SC31 Together Against Lung Cancer - A Strategy for Success in the 21st Century | Wednesday, Dec. 7 | 14:30 | 15:45 | Hall C7
SC23 The Importance of Co-Operative Groups | Tuesday, Dec. 6 | 16:00 | 17:30 | Strauss 3
SC31 Together Against Lung Cancer - A Strategy for Success in the 21st Century | Wednesday, Dec. 7 | 14:30 | 15:45 | Hall C7
SH02 WCLC 2016 Scientific Highlights | Monday, Dec. 5 | 07:30 | 08:30 | Hall C7
OA05 Treatment Advances in SCLC | Monday, Dec. 5 | 14:20 | 15:50 | Strauss 2
ED04 Bronchopulmonary Carcinoids | Monday, Dec. 5 | 14:30 | 15:45 | Lehar 1-2
MTE18 Perspectives in the Systemic Treatment of Small-Cell Lung Cancer (Ticketed Session) | Tuesday, Dec. 6 | 07:30 | 08:30 | Lehar 1-2
MA11 Novel Approaches in SCLC and Neuroendocrine Tumors | Tuesday, Dec. 6 | 14:20 | 15:50 | Strauss 3
MTE25 Radiotherapy in Small Cell Lung Cancer (Ticketed Session) | Wednesday, Dec. 7 | 07:30 | 08:30 | Schubert 5
ED14 Small Cell Lung Cancer | Wednesday, Dec. 7 | 14:30 | 15:45 | Hall C2
<table>
<thead>
<tr>
<th>#</th>
<th>SESSION TITLE</th>
<th>DATE</th>
<th>START</th>
<th>END</th>
<th>ROOM</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td><strong>SURGERY</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTE05</td>
<td>Where is the Place of Surgery for N2 Disease?</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Schubert 6</td>
</tr>
<tr>
<td>OA01</td>
<td>Risk Assessment and Follow up in Surgical Patients</td>
<td>Monday, Dec. 5</td>
<td>11:00</td>
<td>12:30</td>
<td>Schubert 2</td>
</tr>
<tr>
<td>OA07</td>
<td>Lymph Node Metastases and Other Prognostic Factors for Local Spread</td>
<td>Monday, Dec. 5</td>
<td>14:20</td>
<td>15:50</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>SC08</td>
<td>IASLC-ESTS Joint Symposium: The Borderline Patient</td>
<td>Monday, Dec. 5</td>
<td>16:00</td>
<td>17:30</td>
<td>Hall C7</td>
</tr>
<tr>
<td>MTE15</td>
<td>Lymph Node Mapping in Lung Cancer (Ticketed Session)</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>SH03</td>
<td>WCLC 2016 Scientific Highlights</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Hall C1</td>
</tr>
<tr>
<td>OA15</td>
<td>Sublobar Resections for Early Stage NSCLC</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>SC20</td>
<td>Small is Beautiful: Impact of Surgical Approach</td>
<td>Tuesday, Dec. 6</td>
<td>16:00</td>
<td>17:30</td>
<td>Strauss 1</td>
</tr>
<tr>
<td>MTE30</td>
<td>Non-intubated Thoracic Surgery (Ticketed Session)</td>
<td>Wednesday, Dec. 7</td>
<td>07:30</td>
<td>08:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>SC25</td>
<td>The Role of Surgeons in Multimodality Clinical Trials</td>
<td>Wednesday, Dec. 7</td>
<td>16:00</td>
<td>17:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>SC30</td>
<td>Novel Approaches and Regulation in Surgical Education</td>
<td>Wednesday, Dec. 7</td>
<td>14:30</td>
<td>15:45</td>
<td>Hall C8</td>
</tr>
<tr>
<td></td>
<td><strong>TRIAL DESIGN/STATISTICS</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>MTE19</td>
<td>Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Stolz 1</td>
</tr>
<tr>
<td>SC15</td>
<td>Clinical Trials: How to Set Priorities?</td>
<td>Tuesday, Dec. 6</td>
<td>11:00</td>
<td>12:30</td>
<td>Hall C8</td>
</tr>
<tr>
<td>SC28</td>
<td>Novel Clinical Trial Designs</td>
<td>Wednesday, Dec. 7</td>
<td>11:00</td>
<td>12:30</td>
<td>Lehar 1-2</td>
</tr>
<tr>
<td></td>
<td><strong>INDUSTRY SUPPORTED SYMPOSIA</strong></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ISS01</td>
<td>Current and Emerging Treatments for Patients with ALK+ NSCLC - ARIAD</td>
<td>Sunday, Dec. 4</td>
<td>12:00</td>
<td>13:30</td>
<td>Strauss 3</td>
</tr>
<tr>
<td>ISS02</td>
<td>ALK and ROS1 in NSCLC: Optimising the Continuum of Care - Pfizer Oncology</td>
<td>Sunday, Dec. 4</td>
<td>13:45</td>
<td>15:15</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>ISS03</td>
<td>Non-Small Cell Lung Cancer: The Programmed Death-Ligand 1 (PD-L1) Receptor</td>
<td>Sunday, Dec. 4</td>
<td>15:30</td>
<td>17:00</td>
<td>Hall C2</td>
</tr>
<tr>
<td>ISS04</td>
<td>Treatment Selection Strategies in Advanced NSCLC: A Symphony of Views - Eli Lilly and Company</td>
<td>Sunday, Dec. 4</td>
<td>17:15</td>
<td>18:45</td>
<td>Hall C1</td>
</tr>
<tr>
<td>ISS05</td>
<td>Orchestrating Progress for Patients with Squamous Cell Lung Cancer - Eli Lilly and Company</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Strauss 2</td>
</tr>
<tr>
<td>ISS06</td>
<td>The Changing Treatment Paradigm After Progression in Advanced EGFR-Mutated NSCLC - PeerVoice</td>
<td>Monday, Dec. 5</td>
<td>07:30</td>
<td>08:30</td>
<td>Stolz 2</td>
</tr>
<tr>
<td>ISS07</td>
<td>Immuno-Oncology and Lung Cancer: Emerging Data and Recent Developments - Bristol-Myers Squibb</td>
<td>Monday, Dec. 5</td>
<td>12:45</td>
<td>14:15</td>
<td>Hall D (Plenary Hall)</td>
</tr>
<tr>
<td>ISS08</td>
<td>Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus in EGFR-Targeted Therapy - A prIME Oncology Satellite Symposium Supported by Boehringer Ingelheim Pharma GmbH &amp; Co. KG.</td>
<td>Monday, Dec. 5</td>
<td>17:45</td>
<td>19:15</td>
<td>Hall C7</td>
</tr>
<tr>
<td>ISS09</td>
<td>Targeted Therapy on the Horizon for SCLC - AbbVie</td>
<td>Tuesday, Dec. 6</td>
<td>07:30</td>
<td>08:30</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>ISS10</td>
<td>Novel First-Line Treatment Strategies for ALK+ NSCLC: From Evidence to Practice - Novartis</td>
<td>Tuesday, Dec. 6</td>
<td>12:45</td>
<td>14:15</td>
<td>Lehar 3-4</td>
</tr>
<tr>
<td>ISS11</td>
<td>Advances in the Treatment of NSCLC: Harnessing the Power of Immunotherapy and Targeted Therapy: Translating Evidence Into Practice - Roche</td>
<td>Tuesday, Dec. 6</td>
<td>17:45</td>
<td>19:15</td>
<td>Hall C2</td>
</tr>
<tr>
<td>ISS12</td>
<td>Immuno-Oncology: A Renaissance in the Treatment of Lung Cancer - MSD Oncology</td>
<td>Wednesday, Dec. 7</td>
<td>12:45</td>
<td>14:15</td>
<td>Lehar 3-4</td>
</tr>
</tbody>
</table>
WORKSHOPS AND SPECIAL SESSIONS

SATURDAY, DECEMBER 3, 2016

08:00 – 17:00 Schubert 1-4, Level One

Workshop: WS01 - Young Investigator Research and Communication Training
      (BY APPLICATION AND INVITATION ONLY)

The workshop will address how to structure and deliver effective presentations on clinical research, and how to deal with resulting questions effectively. The workshop will comprise two teaching lectures by a lead coach. These will be entertaining and will simultaneously teach and illustrate the principles under discussion. After each lecture participants will break into groups to engage in interactive practical exercises. Every delegate will be expected to participate, including giving a presentation.

09:00 – 18:00 Strauss 1

Workshop: WS02 - IASLC Supporting the Implementation of Global CT Screening
      (TICKETED SESSION: SOLD OUT)
Track: Radiology/Staging/Screening

THE CT SCREENING WORKSHOP REGISTRATION COST INCLUDES: BUFFET LUNCH & DINNER
CPD ACCREDITED WORKSHOP (6 POINTS)

Objectives:
1. This IASLC SSAC Workshop will provide an overview of the recent advances in lung cancer screening.
2. To provide a forum to discuss the pertinent issues around implementation, which will impact on all health services as they move towards implementation.
3. What can be achieved in the next three years and recommendation for the IASLC Exec as to how they can support leadership in this area of lung cancer.
4. The consensus from this workshop will be published.

18:00 Networking Dinner

SUNDAY, DECEMBER 4, 2016

08:00 – 11:00 Stolz 2

WS04 - Mesothelioma Workshop
      (TICKETED SESSION: 25€)
Chair: Michele Carbone, USA

08:00 – 11:45 Stolz 1

JCSE01 - Joint IASLC-Chinese Society for Clinical Oncology – Chinese Alliance Against Lung Cancer Session

CONTINENTAL BREAKFAST PROVIDED

08:00 – 11:45 Strauss 2

Workshop: WS03 - IASLC Meets ESTI: Imaging in Lung Cancer Staging and Diagnosis
Track: Radiology/Staging/Screening

08:00 – 11:45 Hall C8

Young Investigator Session: YI01a Clinical Trials & Scientific Mentoring

Clinical Trials: Design, Publication & Interpretation
CONTINENTAL BREAKFAST PROVIDED

08:00 – 12:00 Schubert 4, Level One

Workshop: WS05 - International Society of Nurses in Cancer Care (ISNCC) & Bristol-Myers Squibb Foundation Collaborative Workshop
      (SIGN UP REQUIRED)

How to Develop a Comprehensive System of Care for Lung Cancer Patients
08:00 – 13:00 Strauss 1, Level One

**Hands-On Training Session:**
Management of Lung Cancer Patients Through Innovative Laboratory Testing Across the Clinical Continuum

**Roche**

10:30 – 11:45 Schubert 1, Level One

Press Conference

13:30 – 18:30 Schubert 2, Level One

**International Thoracic Oncology Nursing Forum (ITONF)** (TICKETED SESSION: 25€)

Chair: Glenda Colburn, Australia

---

**MONDAY, DECEMBER 5**

10:25 – 10:55 Exhibit Showcase Theater

**Exhibit Showcase Session: Roche Tissue Diagnostics**

When H&E is not enough: Immunostaining & biomarker trends and EQA surveillance in lung cancer diagnostics

Modern approaches to staining lung biopsy samples and current EQA data on ALK and PD-L1.

10:30 – 11:45 Schubert 1, Level One

Press Conference

---

**TUESDAY, DECEMBER 6**

10:25 – 10:55 Exhibit Showcase Theater

**Exhibit Showcase Session: Boehringer Ingelheim**

Giotrif: 10 Reasons to Use Afatinib in Lung Cancer

Vargatef: Providing Benefits Even Where you May Not Expect It

10:30 – 11:45 Schubert 1, Level One

Press Conference

---

14:30 – 15:00 Schubert 2, Level One

**IASLC Business Meeting**

LIGHT REFRESHMENTS PROVIDED

INCLUDING AWARD PRESENTATIONS AND UPDATES ON IASLC ACTIVITIES, FUTURE MEETINGS, ETC.

---

**WEDNESDAY, DECEMBER 7**

10:25 – 10:55 Exhibit Showcase Theater

**Exhibit Showcase Session: Otsuka Pharmaceutical**

Relevance and management of hyponatremia in lung cancer – current perspectives

Hyponatremia is the most frequent electrolyte and body fluid balance disturbance encountered in hospital clinical practice. It is considered an unfavorable prognostic factor in patients with cancer and differential diagnosis is challenging.

The objective of the “Exhibit Showcase Session” by Prim. Assoc. Prof. Doz. Dr. Marcus Säemann, Wilhelminenspital Wien, Austria is to discuss current challenges in the diagnosis and treatment of patients with hyponatremia, with emphasis on aspects of cancer patients.

10:30 – 11:45 Schubert 1, Level One

Press Conference
INDUSTRY SUPPORTED SYMPOSIA

SUNDAY, DECEMBER 4

12:00 – 13:30 SYMPOSIUM SUPPORTED BY ARIAD PHARMACEUTICALS INC.: Current and Emerging Treatments for Patients with ALK+ NSCLC STRAUSS 3

13:45 – 15:15 SYMPOSIUM SUPPORTED BY PFIZER ONCOLOGY: ALK and ROS1 in NSCLC: Optimising The Continuum of Care LEHAR 3–4

15:30 – 17:00 SYMPOSIUM SUPPORTED BY MERCK-PFIZER ALLIANCE: Non-Small Cell Lung Cancer: The Programmed Death-Ligand 1 (PD-L1) Receptor as a Target for Monotherapy and in Combination HALL C2

17:45 – 19:15 SYMPOSIUM SUPPORTED BY PRIME ONCOLOGY: Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus in EGFR-Targeted Therapy A prIME Oncology satellite symposium supported by Boehringer Ingelheim Pharma GmbH & Co. KG HALL C7

TUESDAY, DECEMBER 6

07:30 – 08:30 SYMPOSIUM SUPPORTED BY ABBVIE: Orchestrating Progress for Patients with Squamous Cell Lung Cancer STRAUSS 2

07:30 – 08:30 SYMPOSIUM SUPPORTED BY PEERVOICE: The Changing Treatment Paradigm After Progression in Advanced EGFR-Mutated NSCLC STOLZ 2

12:45 – 14:15 SYMPOSIUM SUPPORTED BY NOVARTIS: Novel Treatment Strategies for ALK+ NSCLC: From Evidence to Practice LEHAR 3–4


MONDAY, DECEMBER 5

07:30 – 08:30 SYMPOSIUM SUPPORTED BY ELI LILLY AND COMPANY: Targeted Therapy on the Horizon for SCLC LEHAR 3–4

WEDNESDAY, DECEMBER 7

12:45 – 14:15 SYMPOSIUM SUPPORTED BY MSD ONCOLOGY: Immuno-Oncology: A Renaissance in the Treatment of Lung Cancer LEHAR 3–4
SUNDAY, DECEMBER 4
19:00 – 20:45   OPENING PLENARY SESSION (PL01)
HALL D (PLENARY HALL)

Welcome Address
Robert Pirker, Austria, Conference President

Welcome Address
David Carbone, USA, IASLC President

Distinguished Award Winner Presentations
Fred Hirsch, USA, IASLC CEO

Performance by the Vienna Boys Choir

Keynote Lecture: Is Smoking a Sole Factor in Lung Cancer Development?
Harald zur Hausen, Nobel Laureate, Germany

Performance by the Vienna Boys Choir

MONDAY, DECEMBER 5
08:45 – 09:00   DISTINGUISHED LECTURE (PL02A)
HALL D (PLENARY HALL)

CHAIRS: ROBERT PIRKER, AUSTRIA, DAVID CARBONE, USA & FRED HIRSCH, USA

Welcome Address
Heinz Fischer, Former Federal President of the Republic of Austria (2004-2016)

09:00 – 10:20   PLENARY SESSION (PL02B): TOBACCO CONTROL
HALL D (PLENARY HALL)

CHAIRS: CAROLYN DRESLER, USA & PETER GOLDSTRAW, UK

Implementing Tobacco Control Measures in Uruguay
Tabaré Vázquez, President of Uruguay

Framework Convention on Tobacco Control: Its impact on Global Health
Vera da Costa e Silva, Switzerland

Free Trade & Investment Agreement Threatens Public Health
Zarihah Zain, Malaysia

Tobacco Control
Luke Clancy, Ireland

TUESDAY, DECEMBER 6
08:35 – 10:25   PLENARY SESSION (PL03):
PRESIDENTIAL SYMPOSIUM
HALL D (PLENARY HALL)

CHAIRS: DAVID CARBONE, USA & ROBERT PIRKER, AUSTRIA

Presidential Address
David Carbone, USA

Lung Cancer Staging – Changing the Clinical Practice
Ramon Rami-Porta, Spain

Top 4 Rated Abstracts with Discussants
Tetsuya Mitsudomi, Japan, Jacek Jassem, Poland, Fiona Blakhall, UK & David R. Gandara, USA

WEDNESDAY, DECEMBER 7
08:35 – 10:25   PLENARY SESSION (PL04A):
IMMUNE CHECKPOINT INHIBITORS IN ADVANCED NSCLC
HALL D (PLENARY HALL)

CHAIRS: JEAN-CHARLES SORIA, FRANCE & CAICUN ZHOU, CHINA

Top 4 Immunotherapy Abstracts with Discussant
Michael Boyer, Australia

09:45 – 10:15   PLENARY KEYNOTE LECTURE (PL04B)
HALL D (PLENARY HALL)

CHAIRS: FRED HIRSCH, USA & ROBERT PIRKER, AUSTRIA

The Role of Doctors in a Globalized World
Alfred Gusenbauer, Former Federal Chancellor of the Republic of Austria

16:00 – 18:00   CLOSING PLENARY SESSION (PL05):
A LIFE IN THORACIC ONCOLOGY - REFLECTIONS FROM GIANTS ON MILESTONES IN THE TREATMENT ADVANCES IN LUNG CANCER
HALL C1

CHAIRS: PAUL BUNN, JR., USA & TONY MOK, HONG KONG

Pathology - Adi Gazdar, USA
Surgery - Peter Goldstraw, UK
Radio-Oncology - David Ball, Australia
Translational Lung Cancer Research - Nagahiro Saijo, Japan
Chemotherapy - Thierry Le Chevalier, France
Targeted Therapy - Frances Shepherd, Canada
A Wise Man's Conclusion - Lawrence Einhorn, USA
Welcome to Yokohama for WCLC 2017 - Hisao Asamura, Japan
Farewell - Robert Pirker, Austria
SUNDAY, DECEMBER 4

WELCOME RECEPTION

Inclusive with full Conference and Accompanying Person Registration.

After the Opening Plenary Session, delegates will move into Hall B (Exhibit Hall) for the Welcome Reception with local wines and canapés, allowing you the opportunity to mix and mingle with colleagues, friends and exhibitors.

Welcome Reception 20:45 – 21:45

HALL B (EXHIBIT HALL)

MONDAY, DECEMBER 5 – WEDNESDAY, DECEMBER 7

MONDAY, DECEMBER 5 – WEDNESDAY, DECEMBER 7

HALL B (EXHIBIT HALL) 09:30 – 16:30

Join peers, colleagues, sponsors and exhibitors in the Exhibit Hall (Hall B) for a variety of networking opportunities from Monday to Wednesday.

THERE ARE MANY REASONS TO VISIT THE EXHIBIT HALL:

◆ Check out the Poster Sessions with more than 500 posters each day. Different sets of posters will be displayed each day and presenters will be present at their poster board from 14:15 – 15:45.
◆ Interact with exhibiting companies on the show floor and learn more about their newest products.
◆ Get a jump start on the day with a hot cup of barista coffee right before diving into the educational sessions!
◆ Take a break and recharge before a busy afternoon while enjoying a free light lunch in the Exhibit Hall.
◆ If you are a coffee addict – check out the barista stations on the exhibit floor providing a variety of hot espresso beverages free of charge during exhibit hours.
◆ Reconnect with fellow colleagues.
◆ Take time to check your email at one of the internet stations.
◆ Charge your mobile devices or laptops at one of the charging stations.
◆ Enjoy a meal in the Exhibit Hall Restaurant.
◆ Take the opportunity to unwind from sessions. Sit down with clients, friends or colleagues at one of the many seating spots in the exhibit hall.

WEDNESDAY, DECEMBER 7

WCLC 2016

TOGETHER AGAINST LUNG CANCER 19:00 – 23:00

Join us in the fight against lung cancer for an evening dinner at the Hofburg Vienna.
## Daily Scientific Program

<table>
<thead>
<tr>
<th>Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Saturday, December 3</td>
<td>88</td>
</tr>
<tr>
<td>Sunday, December 4</td>
<td>90</td>
</tr>
<tr>
<td>Monday, December 5</td>
<td>96</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>112</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>130</td>
</tr>
</tbody>
</table>
**Session 2**

12.00 Lung Cancer Screening Experience in Australia
Kwun Fong, The Prince Charles Hospital, Australia

13.00 Lunch

**Session 3**

**Chair:** JAVIER ZULUETA, SPAIN

14.00 Lung Cancer Specific Biomarker - Breath Test
Nir Peled, Davidoff Cancer Center, RMC, Kaplan St, Petach Tiqwa, Israel

Sputum – the Revisited Biomarker for Lung Cancer Screening
Javier Zulueta, Department of Pneumology University Hospital University of Navarra Avda, Spain

15.00 The Airway Transcriptome
Avrum Spira, Boston University, School of Medicine, USA

16.00 Coffee Break

**Session 4**

16.15 Lung Cancer Screening – A Pneumologist’s Viewpoint
Javier Zulueta, Department of Pneumology University Hospital University of Navarra Avda, Spain

17.15 Opportunities to Enhance the Cost Effectiveness of CT Screening Through the Integration of Tobacco Cessation
Bill Evans, Professor Emeritus in the Department of Oncology, McMaster University, Canada

18.15 Networking Dinner
CPD Accredited Workshop (6 points)

---

**Session 1**

**Chair:** NIR PELED, ISRAEL

09:10 Lung Cancer Screening – A 20 Year Experience
Claudia Henschke, Mount Sinai NY, USA

10:10 Lung Cancer Screening Trials in Europe
Giulia Veronesi, Cancer Center Humanitas, Italy

11:10 Coffee Break

---

**WS02a: IASLC Special Symposium on Lung Cancer CT Screening**

**Room:** STRAUSS 3
**Chairs:** NIR PELED, ISRAEL, JAVIER ZULUETA, SPAIN, CLAUDIA HENSCHKE, USA & GIULIA VERONESI, ITALY

**Objectives:**
1. The Special Symposium on Lung Cancer CT Screening: Meet the experts, will provide an overview of the lung CT cancer screening.
2. To provide the IASLC Membership with an opportunity to discuss the major issues of CT screening with the experts in the field.

09:00 Welcome to the Special Symposium
Nir Peled, Israel

---

**WS02: IASLC Supporting the Implementation of Global CT Screening (Ticketed Session) – FULL**

**Track:** RADIOLOGY/STAGING/SCREENING
**Room:** STRAUSS 1
**Chairs:** JOHN FIELD, UK & JAMES MULSHINE, USA

09:00 – 19:00

**WS02.01: Welcome and Aims of Workshop**
John Field, UK

---

**WS01: Young Investigator Research and Communication Training (by invitation only)**

**Room:** SCHUBERT 1 & SCHUBERT 2, LEVEL ONE
**Chairs:** LLOYD BRACEY, UK

08:00 – 17:00
Session 1: Integrating Smoking Cessation into Future Lung Cancer CT Screening Programmes - Utilizing the 'Teachable Moment'

09:10 WS02.02: Personalise Tobacco Cessation in the CT Screening Setting
Jamie Ostroff, USA

09:25 WS02.03: Opportunities to Enhance the Cost Effectiveness of CT screening Through the Integration of Tobacco Cessation
William Evans, McMaster University, Canada

09:40 Discussion

Session 2: Radiological Imaging and Work-Up

CHAIRS: HEIDI SCHMIDT, CANADA, ARNIE DEVARAJ, UK, PIERRE MASSION, USA & NIR PELED, ISRAEL

09:50 WS02.05: CT Scan Detected Nodule Management Protocol
Matthijs Oudkerk, University of Groningen, Netherlands

10:05 WS02.06: Innovative Approaches to Quantitative Imaging Quality Control for Lung Cancer Screening
Ricardo Avila, Accuemtra, LLC, USA

10:20 WS02.07: Opportunities to Advance Lung Cancer Screening Approaches Using Data Registries
David Yankelevitz, Icahn School of Medicine at Mount Sinai, USA

10:35 WS02.08: Progress in Advancing Lung Cancer Screening Internationally
John Field, The University of Liverpool, UK

10:50 Discussion

11:00 Coffee Break

Session 3: Integration of Molecular Biomarkers and Utilisation of CT for CHD & COPD

CHAIRS: GABRIELLA SOZZI, FONDAZIONE IRCCS ISTITUTO NAZIONALE DEL TUMORI INT, ITALY & JAVIER ZULIETA, VISIONGATE, USA & LIE SHIYUAN, CHINA

11:30 WS02.11: The Power of Micro Simulation Modelling in Lung Cancer Screening
Kevin Ten Haaf, The Netherlands

11:45 WS02.12: ImAlife
Rozemarijn Vliegenthart, University Medical Center Groningen, Netherlands

12:00 WS02.13: Lung CT Screening: Complementary Benefits - CHD & COPD
Claudia Henschke, Icahn School of Medicine at Mount Sinai, USA

12:15 Discussion

12:30 Lunch

Session 4: The Current Global Implementation of CT Lung Cancer Screening Programs Outside the USA

CHAIRS: MATTHIJS OUDKERK, THE NETHERLANDS, KWUN FONG, AUSTRALIA, DAVID BALDWIN, UK, SHUN-ICHI WATANABE, JAPAN & ROBERT SMITH, USA

13:30 WS02.16: The Shanghai Screening Trial
Liu Shi-Yuan, China

13:50 WS02.17: Update on Low-dose CT Lung Cancer Screening Implementation in USA
James Mulshine, Rush University, USA

14:00 WS02.18: The Current Implementation Plan in Canada
Stephen Lam, British Columbia Cancer Agency, Canada

14:10 WS02.19: Surgical Status of Screen Detected Lung Cancer - Future Prospective?
Shun-ichi Watanabe, National Cancer Center Hospital, Japan

14:20 WS02.20: Lung Cancer Screening in Australia
Kwun Fong, The Prince Charles Hospital UQ Thoracic Res Centre, Australia

14:30 WS02.21: Developing Lung Cancer Screening Plans in South America
Ricardo Terra, Brazil

14:40 WS02.22: Annual or Biennial Lung Cancer Screening - What Is the Evidence?
David Yankelevitz, USA

14:50 WS02.23: Netherlands & Europe Awaiting the NELSON Publication Prior to Implementation
Harry De Koning, The Netherlands

15:00 WS02.24: US National Lung Cancer Round Table
Robert Smith, Erasmus University Medical Center, USA

15:10 Discussion

15:50 Tea Break

16:20 – 17:30 Session 5: (Round Table Discussion)
What can be achieved in the next three years and recommendation for the IASLC Executive as to how they can support leadership in this area of lung cancer.

18:00 Networking Dinner

14:00 – 16:00 Policy Dialogue: Tobacco Control in Central Europe: Status - Goals - Challenges
ROOM: STRAUSS 2
08:00 – 11:45 WS03: IASLC Meets ESTI: Imaging in Lung Cancer Staging and Diagnosis
TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: STRAUSS 2
CHAIRS: HELMUT PROSCH, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA & RAMON RAMI–PORTA, HOSPITAL UNIVERSITARI MUTUA TERRASSA, AND CIBERES LUNG CANCER GROUP, SPAIN

WS03.01: T Stage
Helmut Prosch, Austria

WS03.02: N Stage
Cornelia Schäfer–Prokop, Hannover School of Medicine, Netherlands

WS03.03: M Stage
Nicola Sverzellati, Italy

WS03.04: Ultrasound– and CT–Guided Biopsies for the Diagnosis of Lung Cancer
Gerhard Mostbeck, Wilhelminenspital and Otto Wagner Hospital, Vienna, Austria

08:00 – 09:45 YI01a: Clinical Trials & Scientific Mentoring
ROOM: HALL C8

Clinical Trials
CHAIR: LUIGI DE PETRIS, INSTITUTION, SWEDEN

08:00 YI01a.01: How to Implement an Idea/Hypothesis into a Clinical Trial
Carlos Silva, Hospital Britanico De Buenos Aires, Argentina

08:20 YI01a.02: Basic Statistical Considerations
Lothar Pilz, University of Heideberg, Medical Faculty Mannheim, Germany

08:40 YI01a.03: How to Effectively Publish your Results: Suggestions from the JTO Editor
Alex Adjei, USA

09:00 YI01a.04: Critical Eye on Practice Changing Literature
Jin Soo Lee, National Cancer Center, South Korea

09:30 Coffee Break

Scientific Mentoring
CHAIRS: AMANDA TUFMAN, LUDWIG MAXIMILIAN UNIVERSITY OF MUNICH, GERMANY & ALEX ADJEI, ROSWELL PARK CANCER INSTITUTE, USA

09:45 YI01b.01: Important Factors for a Professional Career
Martin Edelman, University of Maryland, USA

08:00 – 11:00 WS04: Mesothelioma Workshop
(Ticketed Session)
TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES
ROOM: STOLZ 2
CHAIRS: MICHELE CARBONE, USA

08:00 WS04.01: Debate – Extrapleural Pneumonectomies Should NOT be Performed for Pleural Mesothelioma
David Jablons, USA, Raja Flores, USA & Isabelle Schmitt–Opitz, Switzerland

08:50 Q&A
09:00  WS04.02: Debate – Immunotherapy Does NOT Work in Mesothelioma
Hedy Kindler, USA, Luciano Mutti, UK, Paul Bass, The Netherlands & Daniel Sterman, USA

09:50  Q&A

10:00  WS04.03: Debate – Induction Chemotherapy is Better than Postoperative Adjuvant Therapy for Early Stage Pleural Mesothelioma
Anne Tsao, USA, Walter Weder, Switzerland, Marc de Perrot, Canada, Wickii Vigneswaran, USA

10:50  Q&A

08:00 – 12:00  WS05: International Society of Nurses in Cancer Care (ISNCC) & BMS Foundation Collaborative Workshop
(Sign up Required)
TRACK:  NURSES
ROOM:  SCHUBERT 4

08:00  How to Develop a Comprehensive System of Care for Lung Cancer Patients – Bristol–Myers Squibb

08:00 – 12:30  WS06: Management of Lung Cancer Patients Through Innovative Laboratory Testing Across the Clinical Continuum Workshop
(Sign up Required)
ROOM:  STRAUSS 1
COFFEE & PASTRIES OFFERED

08:00  WS06.01: Opening Remarks
Felix JF Herth, Thoraxklinik at University of Heidelberg and Translational Lung Research Center (TLRC), Germany

08:15  WS06.02: Serum–based Protein Tumor Markers
Rafael Molina, University of Barcelona, Spain

09:00  WS06.03: Lung Panel IHC, PD–L1, ALK, ROS1, EGFR
Fernando Lopez–Rios, Hospital Universitario HM Sanchinarro, Spain

09:55  WS06.04: EGFR Plasma
David Gonzalez De Castro, Queens University, UK

10:40  WS06.05: Sequencing Data
Maximilian Diehn, Stanford University, USA

11:25  WS06.06: Summary
Keith Miller, USA, Rafael Molina, Spain, Fernando Lopez-Rios, Spain, David Gonzalez de Castro, UK, Max Diehn, USA & Felix Herth, Germany

11:40  WS06.07: Panel Discussion
Keith Miller, USA, Rafael Molina, Spain, Fernando Lopez-Rios, Spain, David Gonzalez de Castro, UK, Max Diehn, USA & Felix Herth, Germany

12:15  Closing with Boxed Lunches

08:00 – 11:45  JCES01: Joint IASLC – Chinese Society for Clinical Oncology – Chinese Alliance Against Lung Cancer Session
ROOM:  STOLZ 1
CHAIRS:  FRED R. HIRSCH, UNIVERSITY OF COLORADO CANCER CENTER, USA & CHUNXUE BAI, ZHONGSHAN HOSPITAL, FUDAN UNIVERSITY, CHINA

08:00  Breakfast and Informal Networking

08:20  JCES01.02: Welcome and Introduction
ChunXue Bai, Zhongshan Hospital, Fudan University, China
Fred R. Hirsch, University of Colorado Cancer Center, USA
Yi Long Wu, Guangdong Lung Cancer Institute, China

Discovering the East: Precision Medicine in China

08:30  JCES01.03: Perspectives on Precision Medicine for Early Stage NSCLC
Jie Hu, Zhongshan Hospital Fudan University, China

08:50  JCES01.04: Liquid Biopsy in Monitoring Dynamic Changes of Driver Genes in Advanced NSCLC
Qing Zhou, Guangdong Lung Cancer Institute; Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences, China

09:10  JCES01.05: New Clinical Trials on Gene Alteration in China
Shun Lu, Shanghai Chest Hospital, Jiao Tong University, China

Precision Medicine – Perspectives from the West

09:30  JCES01.06: European Perspective Phase I Strategy
Christian Diego Rolfo, Belgium

09:50  JCES01.07: North American Perspective
Paul Bunn, Jr., USA

10:10  Break
Abstract Presentations from China Related to Precision Medicine

10:30 JCES01.09: A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR-TKI Resistance
Wenxian Wang, Zhejiang Cancer Hospital, China

10:40 JCES01.10: Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer
Yue Zhao, Fudan University Shanghai Cancer Center, China

10:50 JCES01.11: Altered Expression of Programmed Death–Ligand 1 after Neo–Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma
Zhengbo Song, Zhejiang Cancer Hospital, China

11:00 JCES01.12: Discussant Oral Abstracts
James Chih–Hsin Yang, National Taiwan University and NTU Cancer Center, Taiwan

11:15 JCES01.13: Discussant Posters
Xu–chao Zhang, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

POSTERS – ON DISPLAY IN FOYER

JCES01.14: Mutational Profiling of Non–Small–Cell Lung Cancer Patients Resistant to First–Generation EGFR Tyrosine Kinase Inhibitors Using next Generation Sequencing
Ying Jin, Zhejiang Cancer Hospital, China

JCES01.15: Analysis of Genomic Alterations and Heterogeneity in Pulmonary Adenoid Cystic Carcinoma by Next–Generation Sequencing
Min Li, Xiangya Hospital, Central South University, China

JCES01.16: A MET Inhibitor in the Treatment of Metastatic Non-Small Cell Lung Cancer with MET Amplification
Junling Li, Cancer Institute & Hospital, Peking Union Medical College/Chinese Academy of Medical Science, China

JCES01.17: A Phase I Dose Expansion Study of Epitinib to Evaluate Efficacy and Safety in EGFR Mutation Positive (EGFRm+) NSCLC Patients with Brain Metastasis
Qing Zhou, Guangdong Lung Cancer Institute; Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences, China

JCES01.18: Dual Positive PD–L1 and CD8+ TIL Represents a Predominant Subtype in NSCLC and Correlates with Augmented Immunogenicity
Si–Yang Liu, Guangdong Lung Cancer Institute; Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

JCES01.19: Clinicopathologic Characteristics, Genetic Variability and Therapeutic Options of RET Rearrangement Patients in Lung Adenocarcinoma
Zhengbo Song, Zhejiang Cancer Hospital, China

JCES01.20: Patients with R01 Rearrangement Positive Non–Small Cell Lung Cancer Benefit from Pemetrexed–Based Chemotherapy
Zhengbo Song, Zhejiang Cancer Hospital, China

JCES01.21: Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection
Zhengbo Song, Zhejiang Cancer Hospital, China

JCES01.22: Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Patients with Non–Small Cell Lung Carcinoma
Ting Xu, Peking University Cancer Hospital and Institute, China

JCES01.23: EGFR Mutation Status Analysis in Cerebrospinal Fluid and Plasma of Advanced Lung Adenocarcinoma with Brain Metastases
Zhe Liu, Beijing Chest Hospital, Capital Medical University, China

JCES01.24: Molecular Mechanism of Transformation from Adenocarcinoma to Small–Cell Lung Cancer after EGFR–TKI
Zhong–Yi Dong, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

11:30 JCES01.25: Closing Remarks

10:30 – 11:45 PR01: Press Conference
ROOM: SCHUBERT 1, LEVEL ONE
For information on topics and speakers, please visit the Press & Media page on the Conference website at wclc2016.iaslc.org/press-media/press-media/

12:00 – 13:30 ISS01: Current and Emerging Treatments for Patients with ALK+ NSCLC – ARIAD Pharmaceuticals Inc.
ROOM: STRAUSS 3
CHAIRS: CHRISTOPH ZIELINSKI, MEDICAL UNIVERSITY VIENNA, AUSTRIA & D. ROSS CAMIDGE, UNIVERSITY OF COLORADO, USA

12:00 ISS01.01: Welcome & Introduction
Christoph Zielinski, Medical University Vienna, Austria & D. Ross Camidge, University Colorado, USA

12:05 ISS01.02: ALK Inhibitors: Current Treatments and Sequencing
Christoph Zielinski, Medical University Vienna, Austria

12:20 Q&A Panel Discussion – All

12:30 ISS01.03: The Future of ALK Inhibitors: How the Treatment Paradigm May Change
D. Ross Camidge, University Colorado, USA
Clinical Trials – Supporting Trials and Our Patients

Chair: Mary Duffy, Australia

16:00
WS07.08: Clinical Trial Participation – The Nurses Role
Massey Nematollahi, Canada

16:15
WS07.09: Lung Cancer Nurse Attitudes to Clinical Research in the UK
John McPhelim, UK

16:30
WS07.10: Considerations for Surgical Clinical Trials
Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA

16:45
Q&A – Panel Discussion

Changing Face of Lung Cancer

Chair: Mary Duffy, Australia

16:50
WS07.11: Frailty Assessment Prior to Treatment Initiation
Patsy Yates, Australia

17:10
WS07.12: A Glimpse into Lung Cancer Nursing in Denmark
Marianne Cumberland, Denmark

17:25
WS07.13 New Lung Cancer Patient Resource
Silvia Novello, Italy

17:35
Q&A

Smoking Cessation in Lung Cancer and Mesothelioma Patients

17:40
WS07.14: Vapping – A Good Smoking Cessation Tool?
Sanjay Agrawal, UK

17:55
WS07.15: Smoking Cessation – It’s the Nurses Role?
Caitlin Broderick, Australia

18:10
Q&A

18:25
Close
Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA

Globalization of Nursing in Lung Cancer and Mesothelioma Care

13:30
WS07.01: Opening – Welcome
Maria Guerin, Aintree University Hospital, UK

13:35
WS07.02: Leveraging Technology and Social Media in Nursing
Anne Ireland, City of Hope National Medical Center, USA

14:00
WS07.03: E-health and Future Technologies in Evidence Based Nursing Care
Roma Maguire, University of Surrey, UK

14:20
WS07.04: Nursing Management in Japan
Sarah Nagamatsu, Japan

14:35
Q&A – Panel Discussion

Immunotherapy – The New Kid on the Block

14:40
WS07.05: Immunotherapy Challenges in Lung Cancer & Mesothelioma
Sanjay Popat, Royal Marsden Hospital, UK

15:05
WS07.06: Nursing Opportunities & Challenges for Immunotherapy
Beth Eaby-Sandy, University of Pennsylvania Health System, USA

15:20
WS07.07: Nurse Led Follow up Clinics – Effective in Immunotherapy?
Mary Duffy, Peter MacCallum Cancer Centre, Australia

15:40
Break
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Chair/Presenter</th>
<th>Details</th>
</tr>
</thead>
</table>
| 13:45 – 15:15 | ISS02: ALK and ROS1 in NSCLC: Optimising the Continuum of Care – Pfizer Oncology | | TRACK: INDUSTRY SUPPORTED SYMPOSIUM  
ROOM: LEHAR 3–4  
CHAIR: BENJAMIN SOLOMON, PETER MACCALLUM CANCER CENTRE, AUSTRALIA |
| 13:45 | ISS02.01: Welcome & Introduction | Benjamin Solomon, Peter MacCallum Cancer Centre, Australia | |
| 13:50 | ISS02.02: The Importance of Molecular Testing in NSCLC | Benjamin Solomon, Peter MacCallum Cancer Centre, Australia | |
| 14:00 | ISS02.03: ALK+ NSCLC: How Can We Maximise Clinical Outcome Today? | Nicolas Girard, Hospices Civils de Lyon, France | |
| 14:20 | ISS02.04: Clinical Consequences of Resistance to ALK Inhibitors | Christine Lovly, Vanderbilt University School of Medicine, USA | |
| 14:40 | Panel Discussion | All Faculty | |
| 14:50 | ISS02.06: ROS1+ NSCLC: Clinical Data and Experience | Benjamin Solomon, Peter MacCallum Cancer Centre, Australia | |
| 15:05 | ISS02.07: Panel Discussion | All Faculty | |
| 15:15 | ISS02.08: Meeting Close | | |
| 15:30 – 17:00 | ISS03: Non-Small Cell Lung Cancer: The Programmed Death-ligand 1 (PD-L1) Receptor as a Target for Monotherapy and in Combination – Merck–Pfizer Alliance | | TRACK: INDUSTRY SUPPORTED SYMPOSIUM  
ROOM: HALL C2  
CHAIRS: SANJAY POPAT, ROYAL MARSDEN HOSPITAL, UK |
| 15:30 | ISS03.01: Welcome and Overview | Sanjay Popat, Royal Marsden Hospital, UK | |
| 15:45 | ISS03.02: Anti-PD-L1 Monotherapy in Non-Small Cell Lung Cancer (NSCLC): Overview of the Trials Examining Anti-PD-L1 Monotherapy in NSCLC | Rosalyn Juergens, McMaster University – Juravinski Cancer Centre, Canada | |
| 16:00 | ISS03.03: Anti–PD–L1 Combined with Other Agents in NSCLC: Established and Novel Targeted Agents | Jhanelle Gray, Moffitt Cancer Center, USA | |
| 16:15 | ISS03.04: Anti-PD-L1 Combined with Other Agents in NSCLC: Immuno-oncology Combinations | Sacha Rothschild, University Hospital Basel, Switzerland | |
| 16:30 | ISS03.05: Anti–PD–L1 Agents: Opportunities for Differentiation | Hossein Borghaei, Fox Chase Cancer Center, USA | |
| 16:45 | ISS03.06: Closing Remarks and Q&A | Sanjay Popat, Royal Marsden Hospital, UK | |
| 17:15 – 18:45 | ISS04: Treatment Selection Strategies in Advanced NSCLC – A Symphony of Views – Eli Lilly and Company | | TRACK: INDUSTRY SUPPORTED SYMPOSIUM  
ROOM: HALL C1  
CHAIRS: GIORGIO SCAGLIOTTI, UNIVERSITY OF TURIN, ITALY & TONY MOX, THE CHINESE UNIVERSITY OF HONG KONG, CHINA |
| 17:15 | ISS04.01: Welcome & Introduction | Giorgio Scagliotti, University of Turin, Italy & Tony Mok, The Chinese University of Hong Kong, China | |
| 17:20 | ISS04.02: Orchestral Manoeuvres of the Immuno Checkpoints: Targeted or Untargeted Agents? | Joachim Aerts, Erasmus MC Cancer Centre, Netherlands | |
| 17:45 | ISS04.03: Variation on a Theme: Angiogenesis Inhibition Across Treatment Lines | Maurice Pérol, Centre Léon Bérard, France | |
| 18:05 | ISS04.04: Keys to Biomarker Driven Choices in 2nd Line | Luis Paz-Ares, Hospital Universitario Doce de Octubre, Spain | |
| 18:25 | ISS04.05: Is the Score Yet Written? | Giorgio Scagliotti, University of Turin, Italy | |
| 18:30 | ISS04.06: Discussion: The Unfinished Symphony | Tony Mok, The Chinese University of Hong Kong, China | |
19:00 – 20:45  ➔  PL01: Opening Plenary Session

ROOM:  HALL D (PLENARY HALL)

Welcome Address
Robert Pirker, Austria, Conference President

Welcome Address
David Carbone, USA, IASLC President

Distinguished Award Winner Presentations
Fred Hirsch, USA, IASLC CEO

Performance by the Vienna Boys Choir

Keynote Lecture: Is Smoking a Sole Factor in Lung Cancer Development?
Harald zur Hausen, Nobel Laureate, Germany

Performance by the Vienna Boys Choir

20:45 – 21:45  🍽  WELCOME RECEPTION

NETWORKING OPPORTUNITY
ROOM:  HALL B (EXHIBIT HALL)
SNACKS AND DRINKS PROVIDED
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>MTE01: Strategies to Improve Tobacco Control in Central European Countries (Ticketed Session)</td>
<td>Martina Pötschke–Langer, German Cancer Research Center, Germany &amp; Manfred Neuberger, Medical University of Vienna, Austria</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE02: Advances in Pathology (Ticketed Session)</td>
<td>Lukas Bubendorf, University Hospital Basel, Switzerland</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE03: Basics of Molecular Biology for the Clinician (Ticketed Session)</td>
<td>Antonio Marchetti, University of Chieti, Italy</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE04: Screening for Lung Cancer (Ticketed Session)</td>
<td>Christine Berg, Johns Hopkins Medicine, USA &amp; Nir Peled, Davidoff Cancer Center, Israel</td>
</tr>
</tbody>
</table>

**MONDAY ▶ DECEMBER 5**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30</td>
<td>SH01: WCLC 2016 Scientific Highlights – Prevention, Biology, Pathology</td>
<td>Carolyn Dresler, Center for Tobacco Products USA FDA, USA</td>
</tr>
<tr>
<td>07:30</td>
<td>SH01.01: Prevention</td>
<td>Joan Schiller, UT Southwestern, USA</td>
</tr>
<tr>
<td>07:50</td>
<td>SH01.02: Biology</td>
<td>Roman Thomas, Center for Integrated Oncology Cologne/Bonn, University of Cologne, Germany</td>
</tr>
<tr>
<td>08:10</td>
<td>SH01.03: Pathology</td>
<td>Keith Kerr, Aberdeen University Medical School, UK</td>
</tr>
<tr>
<td>07:30</td>
<td>SH02: WCLC 2016 Scientific Highlights – SCLC, Mesothelioma and Thymic Malignancies</td>
<td>Joan Schiller, UT Southwestern, USA</td>
</tr>
<tr>
<td>07:30</td>
<td>SH02.01: SCLC</td>
<td>Joan Schiller, UT Southwestern, USA</td>
</tr>
<tr>
<td>07:50</td>
<td>SH02.02: Malignant Pleural Mesothelioma</td>
<td>Anna Nowak, University of Western Australia, Australia</td>
</tr>
<tr>
<td>08:10</td>
<td>SH02.03: Thymic Malignancies &amp; Esophageal Cancer</td>
<td>Peter Hohenberger, Mannheim University Medical Center, Germany</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE01: Strategies to Improve Tobacco Control in Central European Countries (Ticketed Session)</td>
<td>Martina Pötschke–Langer, German Cancer Research Center, Germany &amp; Manfred Neuberger, Medical University of Vienna, Austria</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE02: Advances in Pathology (Ticketed Session)</td>
<td>Lukas Bubendorf, University Hospital Basel, Switzerland</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE03: Basics of Molecular Biology for the Clinician (Ticketed Session)</td>
<td>Antonio Marchetti, University of Chieti, Italy</td>
</tr>
<tr>
<td>07:30</td>
<td>MTE04: Screening for Lung Cancer (Ticketed Session)</td>
<td>Christine Berg, Johns Hopkins Medicine, USA &amp; Nir Peled, Davidoff Cancer Center, Israel</td>
</tr>
</tbody>
</table>

**SESSION: MEET THE EXPERT (TICKETED SESSION)**

**TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION**

**ROOM: SCHUBERT 1, LEVEL ONE**
07:30 – 08:30 MTE05: Where is the Place of Surgery for N2 Disease? (Ticketed Session)
TRACK: SURGERY
ROOM: SCHUBERT 6
Corinne Faivre-Finn, The University of Manchester and The Christie NHS Foundation Trust, UK & Paul van Schil, Antwerp University Hospital, Belgium

07:30 MTE06.01: Radiotherapy Techniques in Lung Cancer (Ticketed Session)
TRACK: RADIOTHERAPY
ROOM: STRAUSS 3
Ritsuko Komaki, MD Anderson Cancer Center, USA & Martin Stuschke, West German Cancer Center, University of Duisburg-Essen, Germany

07:30 – 08:30 MTE07: Treatment of Elderly Patients with Lung Cancer (Ticketed Session)
TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: LEHAR 1–2
Corey Langer, University of Pennsylvania, USA

07:30 – 08:30 MTE08: Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives (Ticketed Session)
TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: LEHAR 3–4
Frank Griesinger, Pius–Hospital Oldenburg, Germany & Charles Butts, Cross Cancer Institute, Canada

07:30 – 08:30 MTE09: Biomarkers for Targeted Therapies and Immune Checkpoint Inhibitors in Advanced NSCLC (Ticketed Session)
TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: STOLZ 1
Jie Wang, Cancer Hospital Chinese Academy of Medical Sciences, China & Sabine Zöchbauer-Müller, Medical University of Vienna, Austria

07:30 – 08:30 WS08: Special Session: CAP/IASLC/AMP Guidelines for Molecular Testing in Lung Cancer
TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: STRAUSS 1
SPEAKERS AND CHAIRS: MING-SOUND TSAO, CANADA & DR. YASUSHI YATABE, JAPAN

07:30 – 08:30 ISS05: Orchestrating Progress for Patients with Squamous Cell Lung Cancer – Eli Lilly and Company
TRACK: INDUSTRY SUPPORTED SYMPOSIUM
ROOM: STRAUSS 2
CHAIRS: SILVIA NOVELLO, UNIVERSITY OF TURIN, ITALY

07:30 – 08:30 ISS05.01: Squamous Cell Lung Cancer – A Different Tune
Johan Vansteenkiste, University Hospital KU Leuven, Belgium

07:30 – 08:30 ISS05.02: Hitting the Right Notes for Clinical Efficacy
John Gosney, Institution, Country

07:30 – 08:30 ISS05.03: Fine Tuning Patient Outcomes by Selecting the Right Treatment, for the Right Patient, at the Right Time
David R. Gandara, UC Davis Comprehensive Cancer Center, USA

07:30 – 08:30 ISS05.04: Harmonising Patients Understanding of their Diagnosis and Treatment Plan: Introducing the Squamous Cell Lung Cancer Patient Booklet
Silvia Novello, University of Turin, Italy

07:30 – 08:30 ISS05.05: Where is the Place of Surgery for N2 Disease? (Ticketed Session)
Corinne Faivre-Finn, The University of Manchester and The Christie NHS Foundation Trust, UK & Paul van Schil, Antwerp University Hospital, Belgium

07:30 – 08:30 ISS05.06: Radiotherapy Techniques in Lung Cancer (Ticketed Session)
Ritsuko Komaki, MD Anderson Cancer Center, USA & Martin Stuschke, West German Cancer Center, University of Duisburg-Essen, Germany

07:30 – 08:30 ISS05.07: Treatment of Elderly Patients with Lung Cancer (Ticketed Session)
Corey Langer, University of Pennsylvania, USA

07:30 – 08:30 ISS05.08: Immunotherapy in Early and Locally Advanced NSCLC: Challenges and Perspectives (Ticketed Session)
Frank Griesinger, Pius–Hospital Oldenburg, Germany & Charles Butts, Cross Cancer Institute, Canada

07:30 – 08:30 Discussion
07:30 – 08:30  ISS06: The Changing Treatment Paradigm After Progression in Advanced EGFR-Mutated NSCLC – PeerVoice
TRACK: INDUSTRY SUPPORTED SYMPOSIUM
ROOM: STOLZ 2
CHAIR: JAMES YANG (MODERATOR), NATIONAL TAIWAN UNIVERSITY AND NTU CANCER CENTER, TAIWAN

07:30  ISS06.01: Introduction: The Path Forward in Advanced EGFR-Mutated NSCLC
James Yang (Moderator), National Taiwan University and NTU Cancer Center, Taiwan

07:35  ISS06.02: Emerging Algorithm for Advanced EGFR-Mutated NSCLC After Progression
Anders Mellemgaard, Herlev University Hospital, Denmark

07:45  ISS06.03: Best Practices for Managing Advanced EGFR-Mutated NSCLC After Progression
Howard West, Swedish Cancer Institute, USA

07:55  ISS06.04: Panel Discussion: Overcoming Obstacles Managing Advanced EGFR-Mutated NSCLC After Progression
All Faculty

08:15  ISS06.05: Conclusions & Questions
James Yang (Moderator), National Taiwan University and NTU Cancer Center, Taiwan

08:45 – 09:00  PL02a: Distinguished Lecture
ROOM: HALL D (PLENARY HALL)
CHAIRS: ROBERT PIRKER, AUSTRIA, DAVID CARBNE, USA & FRED HIRSCH, USA

09:00  PL02a.01: Heinz Fischer, Former Federal President of the Republic of Austria (2004 – 2016)

09:00 – 10:20  PL02b: Tobacco Control
TRACK: TOBACCO CONTROL
ROOM: HALL D (PLENARY HALL)
CHAIRS: CAROLYN DRESLER, CENTER FOR TOBACCO PRODUCTS USA FDA, USA

09:00  PL02b.01: Implementing Tobacco Control Measures in Uruguay
President Dr. Tabaré Vázquez, Uruguay

09:25  PL02b.02: Framework Convention on Tobacco Control: Its impact on Global Health
Vera Da Costa E Silva, WHO Framework Convention on Tobacco Control, Switzerland

09:45  PL02b.03: Free Trade & Investment Agreement Threatens Public Health
Zarihah Zain, Lincoln University College Malaysia, Malaysia

10:00  PL02b.04: Tobacco Control
Luke Clancy, TobaccoFree Research Institute Ireland, Ireland

10:25 – 11:00  NETWORKING OPPORTUNITY & POSTER PRESENTERS PRESENT FOR P1 POSTERS
Hall B (Exhibit Hall)
Refreshments provided

10:30 – 11:45  PR02: Press Conference
ROOM: SCHUBERT 1, LEVEL ONE
For information on topics and speakers, please visit the Press & Media page on the Conference website at wclc2016.iaslc.org/press-media/press-media/

11:00 – 12:30  ED01: Biology of Lung Cancer
TRACK: BIOLOGY/PATHOLOGY
ROOM: HALL C1
CHAIRS: RAFAEL ROSELL, CATALAN INSTITUTE OF ONCOLOGY; GERMANS TRIAS I PUJOL HEALTH SCIENCES INSTITUTE AND HOSPITAL, SPAIN & MARTIN FILIPITS, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA

11:00  ED01.01: Understanding Biology: The Road to Cure?
David Carbone, The Ohio State Wexner Medical Center, USA

11:25  ED01.02: Tobacco Carcinogens and Lung Cancer Susceptibility
Stephen Hecht, University of Minnesota, USA

11:50  ED01.03: Insights from TCGA
Ramaswamy Govindan, Washington University School of Medicine, USA
11:00 – 12:30  ED02: Palliative Care in Lung Cancer: A Global Challenge

TRACK: PALLIATIVE CARE/ETHICS
ROOM: STRAUSS 3
CHAIRS: JEFFREY CRAWFORD, DUKE CANCER INSTITUTE, USA & JEAN, INSTITUT JULES BORDET, BELGIUM

11:00  ED02.01: Palliative Care and its Importance for Patients with Lung Cancer
Herbert Watzke, Medical University of Vienna, Austria

11:20  ED02.02: Palliative Care in South America
Luis Alberto Mas Lopez, Instituto Nacional de Enfermedades Neoplásicas, Peru

11:40  ED02.03: Palliative Care in India
Gouri Shankar Bhattacharyya, Fortis Hospital, Anandapur, India

12:00  ED02.04: Palliative Care in South-East Asia
Richard Lim, Selayang Hospital, Malaysia

12:20  ED02.05: Palliative Care in Iran
Reza Malayeri, Firoozgar Hospital, Iran

11:00 – 12:30  SC02: Multifocal Lung Cancer

TRACK: PULMONOLOGY
ROOM: STRAUSS 1
CHAIRS: GIULIANA VERONESI, HUMANITAS RESEARCH HOSPITAL, ITALY & SAULUS CICENAS, NATIONAL CANCER INSTITUTE, ITALY

11:00  SC02.01: Multiple Primary Lung Cancers Versus Lung Metastases: Pathological Differential Diagnosis
Erik Thunnissen, VU University Medical Center, Netherlands

11:20  SC02.02: Surgical Choices for Patients with Multifocal Lung Cancer
Scott Swanson, Brigham and Women's Hospital, USA

11:40  SC02.03: Surgery for Ground Glass Opacity: Sublobar Resection?
Shun-ichi Watanabe, National Cancer Center Hospital, Japan

12:00  SC02.04: Interactive Presentation of Clinical Cases with Multifocal Lung Cancer
Alper Toker, Istanbul University Istanbul Medical School, Turkey

11:00 – 12:30  SC03: Advances in Radiation Oncology

TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: LEHAR 3–4
CHAIRS: BERNWARD PASSLICK, UNIVERSITY OF FREIBURG, GERMANY & GERHARD MOSTBECK, WILHELMENSPITAL AND OTTO WAGNER HOSPITAL, AUSTRIA

11:00  SC03.01: The Importance of Mediastinal Down-Staging During Induction Therapy for N2 Disease
Paul De Leyn, University Hospital Leuven, Belgium

11:20  SC03.02: PET–CT for Response Assessment During Induction Therapy of N2 NSCLC
Christoph Pöttgen, West German Cancer Center, University of Duisburg-Essen, Germany

11:35  SC03.03: EBUS/EUS for Staging During Induction Therapy of N2 NSCLC
Franz Stanzel, Institution, Germany

11:50  SC03.04: The Role of Mediastinoscopy in Induction Therapy of N2 NSCLC
Sergi Call, Hospital Universitari Mutua Terrassa, Spain

12:05  SC03.05: Video-Thoracoscopy for Staging of N2 NSCLC During Induction Therapy
Thomas D’Amico, Duke Cancer Institute, USA

12:20  Q&A
11:00 – 12:30 SC04: EGFR Tyrosine Kinase Inhibitors: A Model for Successful Drug Development

**TRACK:** CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
**ROOM:** HALL C7
**CHAIRS:** SUMITRA THONGPRASERT, BANGKOK CHIANGMAI HOSPITAL, THAILAND & OLIVER GAUTSCHI, LUZERNENER KANTONSSPITAL, SWITZERLAND

11:00 SC04.01: First- and Second Generation EGFR Tyrosine Kinase Inhibitors
James Chih–Hsin Yang, National Taiwan University and NTU Cancer Center, Taiwan

11:20 SC04.02: Management of Resistance to EGFR Tyrosine Kinase Inhibitors
Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Japan

11:40 SC04.03: Sequencing of EGFR Tyrosine Kinase Inhibitors
Keunchil Park, Samsung Med Ctr, Sungkyunkwan University School of Medicine, South Korea

12:00 SC04.04: Liquid Biopsies for Dynamic Monitoring of EGFR Mutations in Lung Cancer
Martin Schuler, University Hospital Essen, Germany

12:20 Q&A

11:00 – 12:30 SC05: Novel Drugs in Thoracic Cancers

**TRACK:** CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
**ROOM:** HALL C2
**CHAIRS:** ROY HERBST, YALE SCHOOL OF MEDICINE & NAGAHIRO SAJO, JAPANESE SOCIETY MEDICAL ONCOLOGY

11:00 SC05.01: Immunotherapy in Malignant Pleural Mesothelioma
Raffit Hassan, National Cancer Institute, USA

11:20 SC05.02: Novel Cytotoxic Drugs in Lung Cancer
Jean–Charles Soria, Gustave Roussy, France

11:40 SC05.03: Novel Tyrosine Kinase Inhibitors in Lung Cancer
Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University, China

12:00 SC05.04: Lung Cancer Vaccines: An Update
Elisabeth Quoix, Hôpitaux universitaires de Strasbourg Nouvel Hôpital Civil, France

12:20 Q&A

11:00 – 12:30 IA01: Multidisciplinary Diagnosis of Lung Cancer in the Era of Molecular Medicine

**ROOM:** STOLZ 1
**CHAIRS:** KWUN FONG, THE PRINCE CHARLES HOSPITAL/UNIVERSITY OF QUEENSLAND, AUSTRALIA & ALES RYSKA, CHARLES UNIVERSITY MEDICAL FACULTY AND UNIVERSITY HOSPITAL, CZECH REPUBLIC

11:00 IA01.01: The Role Pathology for Diagnosis and Treatment of Lung Cancer
Helmut Popper, Medical University Graz, Austria

11:20 IA01.02: What Endoscopic Techniques can Contribute for Specimen Acquisition
Arschang Valipour, Otto-Wagner-Spital, Austria

11:40 IA01.03: What Every Lung Pathologist Needs to Know About Thoracic Surgery
Hans Hoffmann, Thoraxklinik, University of Heidelberg, Germany

12:00 IA01.04: Does Cytological Material Fit All – Lessons from EBUS/Bronchoscopy
Wlodzimierz Olszewski, Institute of Oncology, Poland

11:00 – 12:30 NU01: Prevention

**TRACK:** NURSES
**ROOM:** SCHUBERT 5
**CHAIRS:** LIZ DARLISON, UNIVERSITY HOSPITAL LEICESTER, UK & IVETA NOHAVOVA, CHARLES UNIVERSITY PRAGUE, CZECH REPUBLIC

11:00 NU01.01: China at the Crossroads: Findings from the ITC China Project on the Current State of Tobacco Control in China
Geoffrey Fong, University of Waterloo, Canada

11:20 NU01.02: Global View of Smoking Cessation
Stella Bialous, UCSF School of Nursing, USA

11:40 NU01.03: The Role of Oncology Nurses & Smoking Cessation
Iveta Nohavova, Charles University Prague, Czech Republic

12:00 NU01.04: Stigma in Lung Cancer
Janine Cataldo, University of California, San Francisco, USA

11:00 – 12:30 IA02: Interactive Session Staging Group I (Ticketed Session)

**TRACK:** RADIOLOGY/STAGING/SCREENING
**ROOM:** SCHUBERT 3
**COORDINATORS:** KARIN DIECKMANN, AUSTRIA & HELMUT PROSCH, AUSTRIA

11:00 IA02.01: Interactive Session Staging
Libor Havel, Czech Republic, Anna Kerpel-Fronius, Hungary & Elisabeth Stiefsohn, Austria

*Please note that this session is a duplicate of the session on Tuesday*

11:00 – 12:30 SC02: EGFR Tyrosine Kinase Inhibitors

**TRACK:** CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
**ROOM:** HALL C7
**CHAIRS:** SUMITRA THONGPRASERT, BANGKOK CHIANGMAI HOSPITAL, THAILAND & OLIVER GAUTSCHI, LUZERNENER KANTONSSPITAL, SWITZERLAND

11:00 SC02.01: First- and Second Generation EGFR Tyrosine Kinase Inhibitors
James Chih–Hsin Yang, National Taiwan University and NTU Cancer Center, Taiwan

11:20 SC02.02: Management of Resistance to EGFR Tyrosine Kinase Inhibitors
Tetsuya Mitsudomi, Kindai University Faculty of Medicine, Japan

11:40 SC02.03: Sequencing of EGFR Tyrosine Kinase Inhibitors
Keunchil Park, Samsung Med Ctr, Sungkyunkwan University School of Medicine, South Korea

12:00 SC02.04: Liquid Biopsies for Dynamic Monitoring of EGFR Mutations in Lung Cancer
Martin Schuler, University Hospital Essen, Germany

12:20 Q&A

11:00 – 12:30 NU02: Prevention

**TRACK:** NURSES
**ROOM:** SCHUBERT 5
**CHAIRS:** LIZ DARLISON, UNIVERSITY HOSPITAL LEICESTER, UK & IVETA NOHAVOVA, CHARLES UNIVERSITY PRAGUE, CZECH REPUBLIC

11:00 NU02.01: China at the Crossroads: Findings from the ITC China Project on the Current State of Tobacco Control in China
Geoffrey Fong, University of Waterloo, Canada

11:20 NU02.02: Global View of Smoking Cessation
Stella Bialous, UCSF School of Nursing, USA

11:40 NU02.03: The Role of Oncology Nurses & Smoking Cessation
Iveta Nohavova, Charles University Prague, Czech Republic

12:00 NU02.04: Stigma in Lung Cancer
Janine Cataldo, University of California, San Francisco, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
</table>
| 11:00 | OA01: Lung Cancer Diagnosis and Care: Identifying and Improving Community Standards | Track: Patient Support and Advocacy Groups  
Room: Schubert 6  
Chairs: Bonnie J. Addario, Bonnie J. Addario Lung Cancer Foundation, USA & Blaz Bajec, Cancer Patients’ Association of Slovenia, Slovenia |
| 11:00 | OA02: Novel Targets and Biomarkers in Malignant Pleural Mesothelioma | Track: Malignant Pleural Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies  
Room: Stolz 2  
Chairs: Luis E. Raez, Memorial Cancer Institute, USA & Marko Jakopovich, University Hospital Centre Zagreb, Croatia |
| 11:00 | OA03: Impact of Increasing Age on Cause-Specific Mortality and Morbidity in Stage I NSCLC Patients: A Competing Risk Analysis | Takashi Eguchi, Memorial Sloan Kettering Cancer Center, USA |
| 11:00 | OA04: Discussant | Alessandro Brunelli, St. James’s University Hospital, UK |
| 11:00 | OA05: The Impact of Lung Age on Postoperative Complications in Patients with Lung Cancer Combined with Pulmonary Fibrosis and Emphysema | Masahito Naito, Kitasato University School of Medicine, Japan |
| 11:00 | OA06: Early Post-Operative Ambulation after Thoracic Surgery – The WAVE Experience | Sandeep Khandhar, CVTS, USA |
| 11:00 | PA01: The Importance of Patient Access to Molecular Testing and Novel Therapies | Janet Freeman-Daily, #LCSM Chat (LCSM = Lung Cancer Social Media), USA |
| 11:00 | PA02: The Route to Diagnosis: Impacting Survival by Changing the System | Thomas Newsom-Davis, Chelsea and Westminster NHS Foundation Trust, UK |
| 11:00 | PA03: Establishing a Paradigm for High Quality Lung Cancer Treatment | David Leduc, Addario Lung Cancer Foundation, USA |
| 11:00 | PA04: Nurse-Led Lung Cancer Support Service | Claire Mulvihill, Lung Foundation Australia, Australia |
| 11:00 | PA05: Lung Cancer Management in Turkey | Seda Kansu, Pembe Hanim, Turkey |
| 11:00 | OA01: Risk Assessment and Follow up in Surgical Patients | Track: Surgery  
Room: Schubert 2, Level One  
Chairs: Wen-Zhao Zhong, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China & Eric Lim, Royal Brompton Hospital, UK |
| 11:00 | OA02: The microRNA-15/16 Family Regulates Tumour Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma | Karin Schelch, Asbestos Diseases Research Institute, Australia |
| 11:00 | OA03: A Lung Cancer Surgical Mortality Risk-Prediction Algorithm to Inform Lung Cancer Screening Shared Decision-Making | Joshua Roth, Fred Hutchinson Cancer Research Center, USA |
| 11:00 | OA04: Institutional-Based Differences in the Quality and Outcomes of US Lung Cancer Resections | Raymond Osarogiagbon, Baptist Cancer Center, USA |
| 11:00 | OA05: Lung Cancer Management in Turkey | Seda Kansu, Pembe Hanim, Turkey |
| 11:00 | OA06: Early Post-Operative Ambulation after Thoracic Surgery – The WAVE Experience | Sandeep Khandhar, CVTS, USA |
| 11:00 | OA07: Alternative Follow-Up Methods Based on Recurrence Patterns after Surgery for Non-Small Cell Lung Cancer | Katsuya Watanabe, Yokohama Medical Center, Japan |
| 11:00 | OA08: Discussant | Thomas Klikovits, Medical University Vienna, Austria |
| 11:00 | OA09: The microRNA-15/16 Family Regulates Tumour Cell Growth via Fibroblast Growth Factor Signals in Malignant Pleural Mesothelioma | Karin Schelch, Asbestos Diseases Research Institute, Australia |
| 11:00 | OA10: Discussant | Michaela Kirschner, University Hospital Zurich, Switzerland |
11:45  OA02.05: Expression of miR–223 in Mesothelioma Xenografts Originates from Stromal Cells in the Tumour Microenvironment
Kadir Sarun, Asbestos Diseases Research Institute, Australia

11:55  OA02.06: Converting Tumor–Mediated PD–L1 Inhibition into CAR T–Cell Costimulation to Potentiate Thoracic Cancers Immunotherapy
Prasad Adusumilli, Memorial Sloan Kettering Cancer Center, USA

12:05  OA02.07: Characterization of the Tumor Microenvironment and Investigation of Immune Checkpoint Expression in Malignant Pleural Mesothelioma
Elly Marcq, University of Antwerp, Belgium

12:15  OA02.08: Discussant
Michael Grusch, Medical University Vienna, Austria

11:00 – 12:30  OA03: Immunotherapy Checkpoint Inhibitors in Advanced NSCLC
TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: HALL C8
CHAIR: LUCIO CRINÒ, PERUGIA HOSPITAL, ITALY

11:00  OA03.01: First–Line Nivolumab Monotherapy and Nivolumab plus Ipilimumab in Patients with Advanced NSCLC: Long–Term Outcomes from CheckMate 012
Scott Gettinger, Yale Cancer Center, USA

11:10  OA03.02: Atezolizumab as 1L Therapy for Advanced NSCLC in PD–L1–Selected Patients: Updated ORR, PFS and OS Data from the BIRCH Study
Marina Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

11:20  OA03.03: JAVELIN Solid Tumor: Safety and Clinical Activity of Avelumab (Anti–PD–L1) as First–Line Treatment in Patients with Advanced NSCLC
Claire Verschraegen, University of Vermont Cancer Center, USA

11:30  OA03.04: Discussant
Edward Garon, UCLA Medical Center, USA

11:45  OA03.05: Analysis of Early Survival in Patients with Advanced Non–Squamous NSCLC Treated with Nivolumab vs Docetaxel in CheckMate 057
Solange Peters, University of Lausanne, Switzerland

11:55  OA03.06: Evaluation of Toxicity Profile of PD–1 versus PD–L1 Inhibitors in Non–Small Cell Lung Cancer (NSCLC)
Rathi Pillai, Winship Cancer Institute, Emory University, USA

12:05  OA03.07: KEYNOTE–010: Durable Clinical Benefit in Patients with Previously Treated, PD–L1–Expressing NSCLC Who Completed Pembrolizumab
Roy Herbst, Yale School of Medicine, Yale Cancer Center, and Smilow Cancer Hospital, USA

12:15  OA03.08: Discussant
Paul Mitchell, Austin Health, Australia

11:00 – 12:30  OA04: Epidemiology and Prevention of Lung Cancer
TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION
ROOM: SCHUBERT 4
CHAIRS: LUBOŠ PETRUZELKA, CHARLES UNIVERSITY, CZECH REPUBLIC & SURENDRAR SHASTRI, TATA MEMORIAL CENTER, INDIA

11:00  OA04.01: Educational and Wealth Inequalities in Tobacco Use among Men and Women in 54 Low–And–Middle–Income Countries
Chandrasekhar Sreramareddy, International Medical University, Malaysia

11:10  OA04.02: Smoking Behavior in Patients with Early Stage Non–Small Cell Lung Cancer: A Report from ECOG–ACRIN 1505 Trial
Suresh Ramalingam, Winship Cancer Institute of Emory University, USA

11:20  OA04.03: Preliminary Results of a Low Cost Intervention to Improve Tobacco Cessation Practices within a Large University Health System
Douglas Arenberg, University of Michigan, USA

11:30  OA04.04: Discussant
Gilberto Lopes, HCor Onco, Oncoclinicas do Brasil and Johns Hopkins University, Brazil

11:45  OA04.05: Chronic Inflammation, NSAIDS and the Risk of Lung Cancer Death
Marisa Bittoni, The Ohio State University, USA

11:55  OA04.06: Examining Pleiotropic Associations of Genetic Risk Variants for Chronic Obstructive Pulmonary Disease with Lung Cancer Risk
Lori Sakoda, Kaiser Permanente Northern California, USA

12:05  OA04.07: Clinical Characteristics of Lung Adenocarcinoma in the Young: Results from the Genomics of Young Lung Cancer Study
Barbara Gitlitz, University of Southern California Keck School of Medicine, USA

12:15  OA04.08: Discussant
Ruxandra Ulmeanu, Institutul Marius Nasta Bucureti, Romania

11:00 – 12:30  MA01: Improvement and Implementation of Lung Cancer Screening
TRACK: RADIOLGY/STAGING/SCREENING
ROOM: LEHAR 1–2
CHAIRS: MICHAEL STUDNICKA, UNIVERSITY OF SALZBURG, AUSTRIA & TBA

11:00  MA01.01: Detection of Lung Cancer and EGFR Mutations by Electronic Nose System
Nir Peled, Davidoff Cancer Center, Israel

11:06  MA01.02: Non–Invasive LuCED® Test for Endobronchial Dysplasia, Enabling Chemoprevention Therapy with Drugs Such as Iloprost
Javier Zulueta, VisionGate, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:12</td>
<td>MA01.03: The Non–Invasive LuCED® Test for Detection of Early Stage Lung Cancer</td>
<td>Javier Zulueta, VisionGate, USA</td>
</tr>
<tr>
<td>11:18</td>
<td>MA01.04: Discussant</td>
<td>Jiri Votruba, Czech Republic</td>
</tr>
<tr>
<td>11:30</td>
<td>MA01.05: Predictive Performances of NELSON Screening Program Based on Clinical, Metrological and Population Statistics</td>
<td>Hubert Beaumont, MEDIAN Technologies, France</td>
</tr>
<tr>
<td>11:36</td>
<td>MA01.06: Long–Term Follow–Up of Small Pulmonary Ground–Glass Nodules Stable for 3 Years: Proper Follow–Up Period and Risk Factors for Subsequent Growth</td>
<td>Choon–Taek Lee, Seoul National University Bundang Hospital, South Korea</td>
</tr>
<tr>
<td>11:42</td>
<td>MA01.07: Influence of Nodule Morphology on Inter–Reader Variability of Volume and Diameter Measurements in CT Lung Cancer Screening</td>
<td>Marjolein Heuvelmans, University Medical Center Groningen, UMC, Center for Medical Imaging – North East Netherlands, Netherlands</td>
</tr>
<tr>
<td>11:48</td>
<td>MA01.08: Discussant</td>
<td>Ricardo Santos, Instituto Tórax, Brazil</td>
</tr>
<tr>
<td>12:00</td>
<td>MA01.09: Mortality, Survival and Incidence Rates in the ITALUNG Randomised Lung Cancer Screening Trial (ITALY)</td>
<td>Eugenio Paci, Institute for Cancer Prevention and Research (ISP), Italy</td>
</tr>
<tr>
<td>12:06</td>
<td>MA01.10: Performance of ACR Lung–RADS in the 1st Brazilian Lung Cancer Screening Trial (BRELTI)</td>
<td>Ricardo Santos, Hospital Israelita Albert Einstein, Brazil</td>
</tr>
<tr>
<td>12:12</td>
<td>MA01.11: Implementation of LDCT Lung Cancer Screening into Practice. Results of Regional Early Detection Program</td>
<td>Maciej Bryl, Wielkopolskie Centrum Pulmonologii i Torakochirurgii, Poland</td>
</tr>
<tr>
<td>12:18</td>
<td>MA01.12: Discussant</td>
<td>David Yankelevitz, Icahn School of Medicine at Mount Sinai, USA</td>
</tr>
</tbody>
</table>

**12:45 – 14:15**

**ISS07: Immuno–Oncology and Lung Cancer: Emerging Data and Recent Developments – Bristol–Myers Squibb**

**Track:** INDUSTRY SUPPORTED SYMPOSIUM

**Room:** HALL D (PLENARY HALL)

**Chair:** MATTHEW HELLMANN, MEMORIAL SLOAN KETTERING CANCER CENTER, USA

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>12:45</td>
<td>ISS07.01: Welcome &amp; Introduction</td>
<td>Matthew Hellmann, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>12:55</td>
<td>ISS07.02: Developments in the Use of I–O Monotherapy in Lung Cancers</td>
<td>Enriqueta Felip, Hospital Universitari Vall d’Hebron, Spain</td>
</tr>
<tr>
<td>13:10</td>
<td>ISS07.03: Rationale for Studying I–O Combo Therapies to Address Unmet Needs in Lung Cancer</td>
<td>Matthew Hellmann, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>13:35</td>
<td>ISS07.04: Clinical Lessons Learned for the Use of I–O Therapies</td>
<td>Jürgen Wolf, Universitätsklinikum Köln, Germany</td>
</tr>
<tr>
<td>13:55</td>
<td>ISS07.05: Close &amp; Outlook</td>
<td>Matthew Hellmann, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
</tbody>
</table>

**14:20 – 15:50**

**OA05: Treatment Advances in SCLC**

**Track:** SCLC/NEUROENDOCRINE TUMORS

**Room:** STRAUSS 2

**Chairs:** ANDREA ARIZZONI, UNIVERSITY HOSPITAL, ITALY 
JEAN–LOUIS PUJOL, ARNAUD DE VILLENEUVE HOSPITAL, FRANCE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker/Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:20</td>
<td>OA05.01: Pembrolizumab in Patients with Extensive–Stage Small Cell Lung Cancer: Updated Survival Results from KEYNOTE–028</td>
<td>Patrick Ott, Dana–Farber Cancer Institute, USA</td>
</tr>
<tr>
<td>14:30</td>
<td>OA05.02: Anti–Tumor Immunity is a Key Determinant of SCLC Survivorship</td>
<td>Farhad Kosari, Mayo Clinic, USA</td>
</tr>
<tr>
<td>14:40</td>
<td>OA05.03: Single–Agent Rovalpituzumab Tesirine, a Delta–Like Protein 3 (DLL3)–Targeted Antibody–Drug Conjugate (ADC), in Small–Cell Lung Cancer (SCLC)</td>
<td>David Spigel, Sarah Cannon Research Institute/ Tennessee Oncology, USA</td>
</tr>
</tbody>
</table>
### OA05.04: Discussant
Leora Horn, Vanderbilt University Medical Center, USA

### OA05.05: Randomized Phase 2 Study: Alisertib (MLN8237) or Placebo + Paclitaxel as Second-Line Therapy for Small-Cell Lung Cancer (SCLC)
Taofeek Owonikoko, Emory University, USA

### OA05.06: Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily versus Twice-Daily RadioTherapy (CONVERT) Trial
Marianna Christodoulou, The Christie NHS Foundation Trust, UK

### OA05.07: Prognostic Value of Circulating Tumour Cells in Limited-Disease Small Cell Lung Cancer Patients Treated on the CONVERT Trial
Fabiola Fernandez-Gutierrez, CRUK Manchester Institute, UK

### OA05.08: Discussant
Jens Benn Sørensen, Finsen Centre/National University Hospital, Denmark

### OA06.04: Discussant
Ross Soo, National University Health System, Singapore

### OA06.05: Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial
Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, France

### OA06.06: Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC)
Sara Pioletto, University of Verona, Italy

### OA06.07: Evaluating Genomic Signatures Predicting Veliparib Sensitivity in Non-Small Cell Lung Cancer (NSCLC)
Lei He, AbbVie Inc., USA

### OA06.08: Discussant
Maya Gottfried, Meir Medical Center, Israel

### OA07: Lymph Node Metastases and Other Prognostic Factors for Local Spread

#### TRACK: SURGERY

#### ROOM: STOLZ 1

#### CHAIR: VITEZSLAV KOLEK, FAKULTNI NEMOCNICE OLOMOUC, CZECH REPUBLIC & TIBOR KRAJC, AUSTRIA

### OA07.01: Incidence, Local Distribution and Impact of pN2 Skip Metastasis in Patients Undergoing Curative Resection for NSCLC
Ariane Steindl, Medical University Vienna, Austria

### OA07.02: Omitting Intrapulmonary Lymph Node Retrieval May Affect the Oncological Outcome of pN0 Lung Cancer Patients: A Propensity Score Match Analysis
Nan Wu, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China

### OA07.03: Prognostic Significance of Micrometastases in Mediastinal Lymph Nodes of Patients With Radically Resected Non-Small Cell Lung Cancer
Pawel Gwódz, Pulmonary Hospital, Poland

### OA07.04: Discussant
Yi Long Wu, Guangdong Lung Cancer Institute, China

### OA07.05: Prognostic Impact of Pleural Lavage Cytology (PLC): Significance of PLC after Lung Resection
Shinya Katsumata, National Cancer Center Hospital East, Japan

### OA07.06: In Early-Stage Lung Adenocarcinomas, Survival by Tumor Size (T) is Further Stratified by Tumor Spread through Air Spaces
Takashi Eguchi, Memorial Sloan Kettering Cancer Center, USA

### OA07.07: Discussant
Mark Krasnik, Denmark

### OA08: Prognostic & Predictive Biomarkers

#### TRACK: BIOLOGY/PATHOLOGY

#### ROOM: STRAUSS 1

#### CHAIRS: FRANCES SHEPHERD, PRINCESS MARGART CANCER CENTRE, CANADA & YASUSHI YATABE, AICHI CANCER CENTER, JAPAN

### OA08.01: Clinical Utility of Circulating Tumor DNA (ctDNA) Analysis by Digital next Generation Sequencing of over 5,000 Advanced NSCLC Patients
Philipp Mack, UC Davis Cancer Center, USA

### OA08.02: Mutational Load Predicts Survival in LDCT Screening-Detected Lung Cancers
Gabriella Sozzi, Fondazione IRCCS Istituto Nazionale dei Tumori INT, Italy

### OA08.03: Transcriptome Analysis of ATM-Deficient NSCLC
Lars Petersen, University of Calgary, Canada

### OA08.04: Discussant
Ross Soo, National University Health System, Singapore

### OA08.05: Proteomic Analysis of ERCC1 Predicts Benefit of Platinum Therapy in NSCLC: A Reevaluation of Samples from the TASTE Trial
Jean-Charles Soria, Gustave Roussy Cancer Campus and University Paris-Sud, France

### OA08.06: Druggable Alterations Involving Crucial Carcinogenesis Pathways Drive the Prognosis of Squamous Cell Lung Carcinoma (SqCLC)
Sara Pioletto, University of Verona, Italy

### OA08.07: Evaluating Genomic Signatures Predicting Veliparib Sensitivity in Non-Small Cell Lung Cancer (NSCLC)
Lei He, AbbVie Inc., USA

### OA08.08: Discussant
Maya Gottfried, Meir Medical Center, Israel

### MA02: RNA in Lung Cancer

#### TRACK: BIOLOGY/PATHOLOGY

#### ROOM: STOLZ 2

#### CHAIRS: ELISABETH BRAMBILLA, INSTITUT ALBERT BONNIOT, HOPITAL ALBERT MICHALLON, FRANCE & MASAYUKI NOGUCHI, UNIVERSITY OF TSUKUBA, JAPAN

### MA02.01: Extracellular Vesicle miRNAs Regulate Gene Expression in Local Lung Adenocarcinoma Endothelial Cells
James Lawson, BC Cancer Research Center, Canada

### MA02.02: A Novel 5-miR Signature Shows Promise as a Diagnostic Tool and as a Predictor of Cisplatin Response in NSCLC
Martin Barr, St. James’s Hospital & Trinity College Dublin, Ireland

### MA02.03: Expression of Oncofetal miRNAs Inactivates NF1, a Developmental Transcription Factor Linked to Tumour Aggressiveness in Lung Adenocarcinoma
Daiana Becker-Santos, British Columbia Cancer Research Centre, Canada
14:38 MA02.04: Discussant
Luis Montuenga, CIMA. University of Navarra, Spain

14:40 – 14:46 MA02.05: Distinct Angiogenic microRNA–mRNA Expression Profiles among Subtypes of Lung Adenocarcinoma
Mirella Giordano, University of Pisa, Italy

15:02 MA02.06: Discussant
Rafael Rosell, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Spain

15:14 MA02.07: Evaluation of Exosomal miRNAs from Plasma as Potential Biomarker for NSCLC
Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

15:20 MA02.08: Deregulation of Cis–Acting Long Non–Coding RNAs in Non–Small Cell Lung Cancer
Adam Sage, BC Cancer Research Centre, Canada

15:26 MA02.09: Long Non–Coding RNA Expression from Pseudogene Loci as a Novel Mechanism of Cancer Gene Regulation
Greg Stewart, BC Cancer Research Centre, Canada

14:30 – 15:15 ED03: Global Tobacco Control Policies: Advances & Challenges
TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSION/PREVENTION
ROOM: HALL C1
CHAIRS: GABOR KOVÁCS, OKTPI, HUNGARY & XIUYI ZHI, XUANWU HOSPITAL, CAPITAL MEDICAL UNIVERSITY, CHINA

14:30 ED03.01: Tobacco Control in the Middle East
Feras Hawari, The King Hussein Cancer Foundation, Jordan

14:38 MA03.04: Discussant
Ana Jovicic, Institute for Oncology and Radiology of Serbia, Russia

14:50 MA03.05: Cost Effectiveness Analysis of CT vs Chest X–Ray (CXR) vs No Screening for Lung Cancer (LC) in the PLCO and NLST Randomized Population Trials (RPTs)
John Paul Flores, Tufts Medical Center, USA
**14:30 – 15:45**  
**ED04: Bronchopulmonary Carcinoids**  
**TRACK:** SCLC/NEUROENDOCRINE TUMORS  
**ROOM:** LEHAR 1–2  
**CHAIRS:** VERA GORBUNOVA, N. N. BLOKHIN RUSSIAN CANCER RESEARCH CENTER, RUSSIA & JOERG HUTTER, SALK INTERNATIONAL, AUSTRIA

**14:30**  
**ED04.01: Surgery in Bronchopulmonary Typical and Atypical Carcinoids**  
Pier Luigi Filosso, University of Torino, Italy

**15:00**  
**ED04.02: Systemic Therapy of Bronchopulmonary Typical and Atypical Carcinoids: Current Status and Perspectives**  
Eric Baudin, Gustave–Roussy Cancer Campus, France

**14:30 – 15:45**  
**SC06: Novel Therapies in Malignant Pleural Mesothelioma and Thymic Malignancies**  
**TRACK:** MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES  
**ROOM:** STRAUSS 3  
**CHAIRS:** ANNA NOWAK, UNIVERSITY OF WESTERN AUSTRALIA, AUSTRALIA & TAKASHI NAKANO, HYOGO COLLEGE OF MEDICINE, JAPAN

**14:30**  
**SC06.01: Comprehensive Genomic Analysis of Malignant Pleural Mesothelioma**  
Raphael Bueno, Brigham and Women’s Hospital, USA

**14:50**  
**SC06.02: Stratified Therapy for Malignant Pleural Mesothelioma**  
Dean Fennel, UK

**15:10**  
**SC06.03: Intraoperative Therapies in Malignant Pleural Mesothelioma**  
Isabelle Opitz, University Hospital Zurich, Switzerland

**15:30**  
**SC06.04: Immunotherapy of Malignant Pleural Mesothelioma and Thymic Malignancies: The End of the Beginning?**  
Jan Van Meerbeeck, Antwerp University Hospital, Belgium

**14:30 – 15:45**  
**IA03: Interactive Session: What are the Lung Cancer Patients Needs in the Different Countries?**  
**TRACK:** PATIENT SUPPORT AND ADVOCACY GROUPS (INTERACTIVE SESSION)  
**ROOM:** SCHUBERT 2, LEVEL ONE  
**CHAIRS:** STEFANIA VALLONE, ITALY, INGEBORG BEUNDERS, AUSTRIA & NELLY ENWEREM-BROMSON, IAEA/PACT, AUSTRIA

Patient needs around the world. Participants will place notes showing the needs in the countries on a map, which will be followed by a discussion. Outcome of the interactive session will be presented at the end of the Conference by Stefania Vallone and Ingeborg Beunders.

**14:30 – 15:45**  
**PC01: Pro Con Session: Invasive Mediastinal Staging for N2 Disease**  
**TRACK:** RADIOLOGY/STAGING/SCREENING, LOCALLY ADVANCED NSCLC  
**ROOM:** HALL C2  
**CHAIRS:** WALTER WEDER, UNIVERSITY HOSPITAL ZURICH, SWITZERLAND & HELMUT PROSCH, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA

**14:30**  
**PC01.01: Introduction & Vote**  
Helmut Prosch, Medical University of Vienna, Austria

**14:40**  
**PC01.02: Invasive Staging and Restaging**  
Christophe Dooms, University Hospitals KU Leuven, Belgium

**15:00**  
**PC01.03: No Invasive Staging Nor Restaging**  
Eric Lim, UK

**15:20**  
**PC01.04: Discussion & Vote**  
Walter Weder, University Hospital Zurich, Switzerland

**14:30 – 15:45**  
**P1 Posters Present for P1 Posters**  
**ROOM:** HALL B (EXHIBIT HALL)

P1.01 Epidemiology/Tobacco Control and Cessation/Prevention

P1.02 Biology/Pathology

P1.03 Radiology/Staging/Screening

P1.04 Pulmonology

P1.05 Early Stage NSCLC

P1.06 Advanced NSCLC & Chemotherapy/Targeted Therapy/Immunotherapy

P1.07 SCLC/Neuroendocrine Tumors

P1.08 Surgery
16:00 – 17:30  ED05: The 8th Edition of the TNM Staging System
TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: HALL C1
CHAIRS: PETER GOLDSWORTH, NATIONAL HEART AND LUNG INSTITUTE, UK & RAMON RAMI–PORTA, HOSPITAL UNIVERSITARI MUTUA TERRASSA, AND CIBERS LUNG CANCER GROUP, SPAIN

16:00  ED05.01: What’s New in Lung Cancer Staging?
Hisao Asamura, Keio University School of Medicine, Japan

16:25  ED05.02: Update on the Mesothelioma Staging System
Valerie Rusch, Memorial Sloan–Kettering Cancer Center, USA

16:45  ED05.03: The Thymic Epithelial Tumor Staging System
Kazuya Kondo, Tokushima University Graduate School, Japan

17:05  ED05.04: What’s New in Esophageal Cancer Staging?
Thomas Rice, Cleveland Clinic, USA

16:00 – 17:30  ED06: Symptom Management in Lung Cancer
TRACK: PALLIATIVE CARE/ETHICS
ROOM: STOLZ 1
CHAIRS: RICHARD GRALLA, ALBERT EINSTEIN COLLEGE OF MEDICINE, USA, REZA MALAYERI, IRAN

16:00  ED06.01: Causes and Management of Dyspnea
Otto Burghuber, Austria

16:15  ED06.02: Endobronchial and Pleural Palliation
Arschang Valipour, Otto Wagner Hospital, Austria

16:30  ED06.03: Pain Management
Vera Hirsh, McGill University, Royal Victoria Hospital, Canada

16:45  ED06.04: Biology and Management of Tumor Cachexia
Jeffrey Crawford, Duke Cancer Institute, USA

17:00  ED06.05: Surgery for Symptom Relief
Shahrokh Taghavi, Austria

17:15  ED06.06: Decisions in Case of Intractable Symptoms
Jean Klastersky, Institut Jules Bordet, Belgium

16:00 – 17:30  SC07: New Challenges for Lung Cancer: Waterpipes and E–Cigarettes
TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION
ROOM: STOLZ 2
CHAIRS: MARTINA POTSCHKE–LANGER, GERMAN CANCER RESEARCH CENTER, GERMANY & MANFRED NEUBERGER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIAN ACADEMY OF SCIENCE, AUSTRIA

16:00  SC07.01: Carcinogen Exposure from Waterpipe and ENDS (Electronic Nicotine Delivery Devises)
Alan Shihadeh, American University of Beirut, Lebanon

16:25  SC07.02: Health Effects of E–Cigarette Aerosol and Nicotine Exposure on the Respiratory System
Charlotte Pisinger, Glostrup Hospital, Denmark

16:50  SC07.03: Connections of Nicotine to Cancer and Its Influence on Cancer Treatment
Sergei Grando, University of California, USA

17:15  Q&A

16:00 – 17:30  SC08: IASLC–ESTS Joint Symposium: The Borderline Patient
TRACK: SURGERY
ROOM: HALL C7
CHAIRS: JAROSLAW KUŹDZAL, JAGIELLONIAN UNIVERSITY, POLAND & HANS HOFFMANN, THORAXKLINIK, UNIVERSITÄTSKLINIKUM HEIDELBERG, GERMANY

16:00  SC08.01: Impact and Management of Co–Morbidities
Alessandro Brunelli, St. James’s University Hospital, UK

16:20  SC08.02: Emphysema as a Limiting Factor for Lung Resection: How Far We Can Go?
Walter Weder, University Hospital Zurich, Switzerland

16:40  SC08.03: Surgical Issues in the Borderline Patient: Sublobar Versus Standard Resection
David Harpole, Duke University, USA

17:00  SC08.04: SABR Versus Surgery
Norihiko Ikeda, Tokyo Medical University, Japan

17:20  Q&A
16:00 – 17:30  SC09: Radiotherapy for a Global Cancer
TRACK:  RADIOTHERAPY
ROOM:  HALL C8
CHAIRS:  YUKO NAKAYAMA, KANAGAWA CANCER CENTER, JAPAN & DENIZ YALMAN, EGE UNIVERSITY, TURKEY

16:00  SC09.01: Global Access To Radiotherapy: Are We There?
David Palma, London Health Sciences Centre, Canada

16:20  SC09.02: The Quest for High Quality Affordable Radiotherapy in Developing Countries
Hak Choy, UT Southwestern Medical Center, USA

16:40  SC09.03: Machine Learning for Individualized Radiotherapy Prescription
Philippe Lambin, Maastricht University, Netherlands

17:00  SC09.04: Radiotherapy in China
Luhua Wang, Cancer Hospital, Chinese Academy of Medical Sciences, China

17:20  Q&A

16:00 – 17:30  SC10: Squamous Cell NSCLC
TRACK:  CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM:  STRAUSS 3
CHAIRS:  DAVID R. GANDARA, UC DAVIS COMPREHENSIVE CANCER CENTER, USA & MARTIN, GOETHE UNIVERSITY, GERMANY

16:00  SC10.01: Genetic Alterations as Potential Therapeutic Targets
Roman Thomas, Center for Integrated Oncology Cologne/Bonn, University of Cologne, Germany

16:20  SC10.02: EGFR Mutations in Indian Patients with Squamous Cell NSCLC
Kumar Prabhash, Tata Memorial Centre, India

16:40  SC10.03: Anti-EGFR Monoclonal Antibodies in Squamous Cell NSCLC
Robert Pirker, Medical University of Vienna, Austria

17:00  SC10.04: Second-Line Therapy and Beyond in Squamous Cell NSCLC
Silvia Novello, University of Turin, Italy

17:20  Q&A

16:00 – 17:30  SC11: ALK, ROS1 and Rare Mutations in NSCLC
TRACK:  CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM:  LEHAR 1–2
CHAIR:  DONG–WAN KIM, SEOUL NATIONAL UNIVERSITY HOSPITAL, SOUTH KOREA

16:00  SC11.01: Optimal Application & Sequence of ALK Inhibition Therapy
Benjamin Solomon, Peter MacCallum Cancer Centre, Australia

16:20  SC11.02: Resistance to ALK Inhibitor Therapy
Sai–Hong Ou, Chao Family Comprehensive Cancer Center, University of California Irvine School of Medicine, USA

16:40  SC11.03: ROS1 as a Therapeutic Target in Advanced NSCLC
Jürgen Wolf, University Hospital of Cologne, Germany

17:00  SC11.04: Rare Mutations in Lung Cancer
Oliver Gautschi, Lucerne Cantonal Hospital, Switzerland

17:20  Q&A

16:00 – 17:30  SC12: Anticancer Drug Development in the 21st Century
TRACK:  CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM:  HALL C2
CHAIRS:  LAWRENCE EINHORN, INDIANA UNIVERSITY, USA & KAORU KUBOTA, THORACIC ONCOLOGY RESEARCH GROUP, JAPAN

16:00  SC12.01: Establishment of EGFR Tyrosine Kinase Inhibitors: History and Lessons Learned for Future Drug Development
Tony Mok, The Chinese University of Hong Kong, Hong Kong

16:25  SC12.02: Molecular–Based Therapy of Lung Cancer: The Way Forward?
Charles Rudin, Memorial Sloan Kettering Cancer Center, USA

16:45  SC12.03: Implications of Patient Selection: Are we Lost in Diversification?
Yu Shyr, Vanderbilt University School of Medicine, USA

17:05  SC12.04: Drug Development: The EMA Perspective
Francesco Pignatti, European Medicines Agency, UK

17:25  Q&A

16:00 – 17:30  IA04: Interactive Session Target Delineation: Group I (Ticketed Session)
TRACK:  RADIOTHERAPY
ROOM:  SCHUBERT 3
COORDINATORS:  KAREN DIECKMANN, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA & HELMUT PROSCH, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA

16:00  IA04.01: Interactive Session Target Delineation Trainers:
Corinne Faivre-Finn, UK, Laurie Gaspar, USA, Billy Loo, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Track</th>
<th>Room</th>
<th>Chairs</th>
<th>Speakers</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00 – 17:30</td>
<td>NU02: Preparing Patients for Treatment</td>
<td>NURSES</td>
<td>SCHUBERT 5</td>
<td>DIANA BORTHWICK, EDINBURGH CANCER CENTRE, UK &amp; ANNE FRASER, ADHB, NZ</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NU02.01: Preparing Patients for Treatment. Providing Psychosocial Support for Lung Cancer Patients Preparing to Enter Treatment</td>
<td></td>
<td></td>
<td></td>
<td>Andrea Cirila Skufca Smrdel, 1. Institute of Oncology Ljubljana, 2. Cancer Patients’ Association of Slovenia, Slovenia</td>
</tr>
<tr>
<td>16:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NU02.02: Preoperative Thoracic Surgery Patient Education Program Development</td>
<td></td>
<td></td>
<td></td>
<td>Katherine Kuhns, Penn Presbyterian Medical Center, USA</td>
</tr>
<tr>
<td>16:40</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NU02.03: Ethical Decision Making</td>
<td></td>
<td></td>
<td></td>
<td>Sabine Ruppert, Vienna General Hospital, Austria</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>NU02.04: Discussant</td>
<td></td>
<td></td>
<td></td>
<td>Harald Titzer, University Hospital of Vienna, Austria</td>
</tr>
<tr>
<td>16:00 – 17:30</td>
<td>PA02: Access to Care – Equal Chances in the World?</td>
<td>PATIENT SUPPORT AND ADVOCACY GROUPS</td>
<td>SCHUBERT 6</td>
<td>CHRISTINA VAN TZE NG, SUNWAY MEDICAL CENTER, MALAYSIA &amp; SHANI SHILO, THE ISRAEL LUNG CANCER FOUNDATION, ISRAEL</td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PA02.01: Access to Care: USA</td>
<td></td>
<td></td>
<td></td>
<td>Kim Norris, Lung Cancer Foundation of America, USA</td>
</tr>
<tr>
<td>16:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PA02.02: Access to Care: South America</td>
<td></td>
<td></td>
<td></td>
<td>Patricia Mondragon, Respirando Con Valor, Mexico</td>
</tr>
<tr>
<td>16:30</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PA02.03: Access to Care: Malaysia</td>
<td></td>
<td></td>
<td></td>
<td>Christina Van Tze Ng, The Cancer Advocacy Society of Malaysia, Malaysia</td>
</tr>
<tr>
<td>16:45</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PA02.04: Access to Care: Europe</td>
<td></td>
<td></td>
<td></td>
<td>Szymon Chrostowski, Polish Cancer Patient Coalition, Poland</td>
</tr>
<tr>
<td>17:00</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PA02.05: Access to Care: Australia</td>
<td></td>
<td></td>
<td></td>
<td>Kerrie Callaghan, Lung Foundation Australia, Australia</td>
</tr>
<tr>
<td>17:15</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PA02.06: Access to Care: Israel</td>
<td></td>
<td></td>
<td></td>
<td>Shani Shilo, The Israel Lung Cancer Foundation, Israel</td>
</tr>
<tr>
<td>Time</td>
<td>Session Title</td>
<td>Track</td>
<td>Room</td>
<td>Chairs</td>
<td></td>
</tr>
<tr>
<td>--------</td>
<td>-------------------------------------------------------------------------------</td>
<td>---------------------</td>
<td>------------</td>
<td>-------------------------------------------------------------------------------------------</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>MA04: HER2, PS3, KRAS and Other Targets in Advanced NSCLC</td>
<td>ADVANCED NSCLC</td>
<td>LEHAR 3–4</td>
<td>BAOHUI HAN, SHANGHAI CHEST HOSPITAL, SHANGHAI JIAO TONG UNIVERSITY, CHINA &amp; WOLFGANG HILBE, AUSTRIA</td>
<td></td>
</tr>
<tr>
<td>16:06</td>
<td>MA04.02: Neratinib ± Temsirolimus in HER2–Mutant Lung Cancers: An International, Randomized Phase II Study</td>
<td>ADVANCED NSCLC</td>
<td>LEHAR 3–4</td>
<td>Leena Gandhi, Dana Farber Cancer Institute, USA</td>
<td></td>
</tr>
<tr>
<td>16:12</td>
<td>MA04.03: Preliminary Results of a Phase II Study about the Efficacy and Safety of Pyrotinib in Patients with HER2 Mutant Advanced NSCLC</td>
<td>ADVANCED NSCLC</td>
<td>LEHAR 3–4</td>
<td>Shengxiang Ren, Shanghai Pulmonary Hospital, Tongji University School of Medicine, Tongji University Cancer Institute, China</td>
<td></td>
</tr>
<tr>
<td>16:18</td>
<td>MA04.04: Discussant</td>
<td></td>
<td></td>
<td>Thanyanan Reungwattana, Ramathibodi Hospital, Thailand</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>MA04.05: PS3 Non–Disruptive Mutation is a Negative Predictive Factor for OS and PFS in EGFR M+ NSCLC Treated with TKI</td>
<td>ADVANCED NSCLC</td>
<td>LEHAR 3–4</td>
<td>Frank Griesinger, Pius Hospital Oldenburg, Germany</td>
<td></td>
</tr>
<tr>
<td>16:42</td>
<td>MA04.07: Impact of Major Co–Mutations on the Immune Contexture and Response of KRAS–Mutant Lung Adenocarcinoma to Immunotherapy</td>
<td>ADVANCED NSCLC</td>
<td>LEHAR 3–4</td>
<td>Ferdinandos Skoulidis, The University of Texas M. D. Anderson Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>16:48</td>
<td>MA04.08: Discussant</td>
<td></td>
<td></td>
<td>Julian Molina, Mayo Clinic in Rochester, USA</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>MA04.09: RICTOR Amplification in Non–Small Cell Lung Cancer: An Emerging Therapy Target</td>
<td>ADVANCED NSCLC</td>
<td>LEHAR 3–4</td>
<td>Jeffrey Ross, Foundation Medicine, USA</td>
<td></td>
</tr>
<tr>
<td>17:06</td>
<td>MA04.10: Lung Cancer Growth is Suppressed by CD26/DPP4–Inhibition via Enhanced NK Cell and Macrophage Recruitment</td>
<td>ADVANCED NSCLC</td>
<td>LEHAR 3–4</td>
<td>Jae-Hwi Jang, University Hospital Zürich, Switzerland</td>
<td></td>
</tr>
<tr>
<td>17:12</td>
<td>MA04.11: Mechanistic Insights into CAR T–Cell Efficacy in the Treatment of Heterogenous Antigen Expressing Lung Adenocarcinoma</td>
<td>ADVANCED NSCLC</td>
<td>LEHAR 3–4</td>
<td>Prasad Adusumilli, Memorial Sloan Kettering Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>17:18</td>
<td>MA04.12: Discussant</td>
<td></td>
<td></td>
<td>Ales Ryska, Fingerland Institute of Pathology, Czech Republic</td>
<td></td>
</tr>
<tr>
<td>16:00</td>
<td>MA05: Innovative Techniques in Pulmonology and the Impact on Lung Cancer</td>
<td>PULMONOLOGY</td>
<td>STRAUSS 1</td>
<td>JOSEF ECKMAYR, AON, AUSTRIA &amp; PRASANTA MOHAPATRA, ALL INDIA INSTITUTE OF MEDICAL SCIENCES, INDIA</td>
<td></td>
</tr>
<tr>
<td>16:06</td>
<td>MA05.02: Electromagnetic Navigation Bronchoscopy: A Prospective, Global, Multicenter Analysis of 1000 Subjects with Lung Lesions</td>
<td>PULMONOLOGY</td>
<td>STRAUSS 1</td>
<td>Sandeep Khandhar, CVTSA/Inova Cancer Center, Fairfax Hospital, USA</td>
<td></td>
</tr>
<tr>
<td>16:12</td>
<td>MA05.03: A Single EBUS–TBNA Pass Yields Sufficient DNA for Targeted Molecular Testing in Lung Cancer</td>
<td>PULMONOLOGY</td>
<td>STRAUSS 1</td>
<td>Tracy Leong, The Walter and Eliza Hall Institute of Medical Research, Australia</td>
<td></td>
</tr>
<tr>
<td>16:18</td>
<td>MA05.04: Discussant</td>
<td></td>
<td></td>
<td>Vitezslav Kolek, Fakultni Nemocnice Olomouc, Czech Republic</td>
<td></td>
</tr>
<tr>
<td>16:30</td>
<td>MA05.05: Genomic Profiles of Lung Cancer Associated with Idiopathic Pulmonary Fibrosis</td>
<td>PULMONOLOGY</td>
<td>STRAUSS 1</td>
<td>Ji An Hwang, Asan Medical Center, South Korea</td>
<td></td>
</tr>
<tr>
<td>16:42</td>
<td>MA05.07: Identifying Comorbid Disease on Chest CT Scans in a Lung Cancer Screening–Eligible Cohort</td>
<td>PULMONOLOGY</td>
<td>STRAUSS 1</td>
<td>James Finigan, National Jewish Health, USA</td>
<td></td>
</tr>
<tr>
<td>16:48</td>
<td>MA05.08: Discussant</td>
<td></td>
<td></td>
<td>Konstantinos Zarogoulidis, G. Papanikolaou Hospital, Greece</td>
<td></td>
</tr>
<tr>
<td>17:00</td>
<td>MA05.09: There is a Closely Relation between Exhaled Nitric Oxide and Radiation Pneumonitis</td>
<td>PULMONOLOGY</td>
<td>STRAUSS 1</td>
<td>Jiancheng Li, Fujian Cancer Hospital, China</td>
<td></td>
</tr>
<tr>
<td>17:06</td>
<td>MA05.10: Cell–Free DNA Testing for EGFR Mutations in Clinical Practice – Facts and Figures from an Austrian Lung Cancer Center</td>
<td>PULMONOLOGY</td>
<td>STRAUSS 1</td>
<td>David Lang, Kepler University Hospital, Austria</td>
<td></td>
</tr>
<tr>
<td>17:12</td>
<td>MA05.11: Photodynamic Therapy for Peripheral Lung Cancer Using Composite–Type Optical Fiberscope of 1.0 Mm in Diameter</td>
<td>PULMONOLOGY</td>
<td>STRAUSS 1</td>
<td>Jitsuo Usuda, Nippon Medical School, Japan</td>
<td></td>
</tr>
<tr>
<td>17:18</td>
<td>MA05.12: Discussant</td>
<td></td>
<td></td>
<td>Judit Moldvay, National Koranyi Institute of Pulmonology, Hungary</td>
<td></td>
</tr>
</tbody>
</table>
16:00 – 17:30 MA06: Locally Advanced NSCLC: Risk Groups, Biological Factors and Treatment Choices
TRACK: LOCALLY ADVANCED NSCLC
ROOM: STRAUSS 2
CHAIRS: PAUL VAN HOUTTE, INSTITUT JULES BORDET, BELGIUM & MILADA ZEMANOVÁ, 1ST FACULTY OF MEDICINE OF CHARLES UNIVERSITY IN PRAGUE, CZECH REPUBLIC

16:00 MA06.01: Overall Survival Characterization of Incidental N2 Non–Small Cell Lung Cancer over 14 Years at a Single Canadian Institution
Cara Van Der Merwe, University of Calgary, Canada

16:06 MA06.02: Does Pathological Staging Following Neoadjuvant Therapy (ypTNM) Reflect the Reality?
Huseyin Melek, Uludag University, Turkey

16:12 MA06.03: Recurrence Dynamics after Trimodality Therapy (Neoadjuvant Chemoradiation and Surgery) in Stage IIIa(N2) Lung Cancer
Jung Hee Lee, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

16:18 MA06.04: Discussant
Fan Yang, Peking University People’s Hospital, China

16:30 MA06.05: Screening for Brain Metastases in Patients with Stage III NSCLC, MRI or CT? A Prospective Study
Janna Schoenmaekers, MUMC, Netherlands

16:36 MA06.06: Tumor Microenvironment and Brain Metastases in Completely Resected Stage IIIa(N2) Non–Small Cell Lung Cancer
Qin Zhang, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

16:42 MA06.07: Impact of Type 2 Diabetes Mellitus and Its Metabolic Control on Prognosis of Unresectable Non–Small Cell Lung Cancer Patients
Milana Bergamino Sirvén, Catalan Institut of Oncology – ICO Hospital, Spain

16:48 MA06.08: Discussant
Miroslaw Kozlowski, Medical University of Białystok, Poland

17:00 MA06.09: Efficacy RENO Study Results of Oral Vinorelbine or Etoposide with Cisplatin & Chemo–Radiation in Stage III NSCLC. SLCG 10/02
Dolores Isla, University Hospital Clínico Lozano Blesa, Spain

17:06 MA06.10: A Pooled Analysis Comparing the Outcomes of Elderly to Younger Patients on NCTN Trials of Concurrent CRT for Stage 3 NSCLC
Thomas Stinchcombe, Duke University, USA

17:12 MA06.11: Phase II Study of Nimotuzumab + Concurrent Chemoradiotherapy (CRT) for Stage III Non–Small Cell Lung Cancer (NSCLC): 5-Year Follow–Up Results
Kazushige Hayakawa, Kitasato University, Japan

17:18 MA06.12: Discussant
Philip Bonomi, Rush University Medical Center, USA

17:45 – 19:15 ISS08: Reaching New Heights in the Management of Non-Small Cell Lung Cancer: Focus on EGFR-Targeted Therapy – A priME Oncology satellite symposium supported by Boehringer Ingelheim Pharma GmbH & Co. KG
TRACK: INDUSTRY SUPPORTED SYMPOSIUM
ROOM: HALL C7
CHAIRS: MARTIN SCHULER, UNIVERSITY HOSPITAL ESSEN, GERMANY

17:45 ISS08.01: Welcome & Warm-up Quiz
Martin Schuler, University Hospital Essen, Germany

17:50 ISS08.02: Key Decision Points for Personalized Patient Care of Advanced Non–Small Cell Lung Cancer (NSCLC)
Martin Schuler, University Hospital Essen, Germany

18:00 ISS08.03: Managing EGFR–Mutant Adenocarcinoma: What is the Optimal First–Line Approach?
Barbara Melosky, British Columbia Cancer Agency, Canada

18:20 ISS08.04: Tackling Acquired Resistance to EGFR–Targeted Therapy: Evaluating Current and Emerging Treatment Strategies
Keunchil Park, Samsung Med Ctr, Sungkyunkwan School of Med, South Korea

18:40 ISS08.05: Contemporary Management of Squamous Cell Carcinoma: What is the Role of EGFR–Targeted Therapy in the Era of Immunotherapy?
Marianne Nicolson, Aberdeen Royal Infirmary, UK

18:48 ISS08.06: Quiz Questions Revisited and Questions from the Audience
Martin Schuler, University Hospital Essen, Germany

19:10 ISS08.07: priME Points™
Martin Schuler, University Hospital Essen, Germany

19:15 Adjourn
**TUESDAY ➤ DECEMBER 6**

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Location</th>
<th>Chair/Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>07:30 – 08:30</td>
<td>SH03: WCLC 2016 Scientific Highlights – Surgery and Early Stage NSCLC I – III</td>
<td>HALL C1</td>
<td>Walter Klepetko, Medical University Vienna, Austria</td>
</tr>
<tr>
<td>07:30</td>
<td>SH03.01: Surgery</td>
<td></td>
<td>Saulus Cicenas, National Cancer Institute, Lithuania</td>
</tr>
<tr>
<td>07:50</td>
<td>SH03.02: NSCLC Stage I–II</td>
<td></td>
<td>Bernward Passlick, University Hospital Freiburg, Germany</td>
</tr>
<tr>
<td>08:10</td>
<td>SH03.03: NSCLC Stage III</td>
<td></td>
<td>Virginie Westeel, Jean–Minjoz Hospital, France</td>
</tr>
<tr>
<td>08:10</td>
<td>SH04: WCLC 2016 Scientific Highlights – Screening, Radiology, Staging, Pulmonology</td>
<td>HALL C7</td>
<td>Jiri Votruba, Charles University Hospital &amp; Czech Republic &amp; Sylvia Hartl, Institution, Austria</td>
</tr>
<tr>
<td>07:30</td>
<td>SH04.01: Screening</td>
<td></td>
<td>James Jett, National Jewish Health, USA</td>
</tr>
<tr>
<td>07:50</td>
<td>SH04.02: Radiology/Staging</td>
<td></td>
<td>Wilfried Eberhardt, Germany</td>
</tr>
<tr>
<td>08:10</td>
<td>SH04.03: Pulmonology</td>
<td></td>
<td>Egbert Smit, Netherlands Cancer Institute, The Netherlands</td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE10: Unique Biologic Aspects of Tobacco–Induced Lung Cancer (Ticketed Session)</td>
<td>SCHUBERT 1, LEVEL ONE</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE10.01: Unique Biologic Aspects of Tobacco–Induced Lung Cancer</td>
<td></td>
<td>Mauro Papotti, University of Turin, Italy</td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE11: The Clinical Impact of the 2015 WHO Classification of Lung Tumors (Ticketed Session)</td>
<td>SCHUBERT 2, LEVEL ONE</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE11.01: The Clinical Impact of the 2015 WHO Classification of Lung Tumors</td>
<td></td>
<td>Andrew Nicholson, Royal Brompton and Harefield NHS Foundation Trust, UK &amp; Masayuki Noguchi, University of Tsukuba, Japan</td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE12: Clinically Relevant Signal Transduction Pathways (Ticketed Session)</td>
<td>SCHUBERT 4</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE12.01: Clinically Relevant Signal Transduction Pathways</td>
<td></td>
<td>Balazs Dome, Medical University of Vienna, Austria &amp; Ming Sound, Princess Margaret Cancer Centre, Canada</td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE13: Basic Immunology for the Clinician (Ticketed Session)</td>
<td>SCHUBERT 5</td>
<td></td>
</tr>
<tr>
<td>07:30</td>
<td>MTE13.01: Basic Immunology for the Clinician</td>
<td></td>
<td>Marcin Moniuszko, Medical University of Bialystok, Poland &amp; Edgardo Santos, Lynn Cancer Institute, USA</td>
</tr>
<tr>
<td>Time</td>
<td>Session</td>
<td>Track</td>
<td>Room</td>
</tr>
<tr>
<td>--------------</td>
<td>-------------------------------------------------------------------------</td>
<td>------------------------------</td>
<td>-------------</td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE14: How to Implement Screening/Early Detection in Routine Practice</td>
<td>Radiology/Staging/Screening</td>
<td>Lehár 1–2</td>
</tr>
<tr>
<td></td>
<td>(Ticketed Session)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MTE14.01: How to Implement Screening/Early Detection in Routine Practice</td>
<td>Harry De Koning, Erasmus MC, The Netherlands &amp; Sam Janes, UK</td>
<td></td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE15: Lymph Node Mapping in Lung Cancer (Ticketed Session)</td>
<td>Radiology/Staging/Screening</td>
<td>Stolz 1</td>
</tr>
<tr>
<td></td>
<td>MTE15.01: Lymph Node Mapping in Lung Cancer</td>
<td>Kenji Suzuki, Juntendo University Hospital, Japan &amp; David Waller, Glenfield Hospital, UK</td>
<td></td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE16: Precision Medicine in NSCLC: Lessons Learned and Perspectives</td>
<td>Chemo/Targeted Therapy/Immunotherapy</td>
<td>Strauss 2</td>
</tr>
<tr>
<td></td>
<td>(Ticketed Session)</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>MTE16.01: Precision Medicine in NSCLC: Lessons Learned and Perspectives</td>
<td>Terufumi Kato, Kanagawa Cancer Center, Japan &amp; Christian Manegold, Medical Faculty Mannheim, University of Heidelberg, Germany</td>
<td></td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE17: Maintenance Therapy Versus Early Second–Line Therapy in Advanced NSCLC (Ticketed Session)</td>
<td>Advanced NSCLC</td>
<td>Strauss 3</td>
</tr>
<tr>
<td></td>
<td>MTE17.01: Maintenance Therapy Versus Early Second–Line Therapy in Advanced NSCLC</td>
<td>Tudor Ciuleanu, Institutul Oncologic “Prof. Dr. Ion Chiricuta” Cluj Napoca, Romania &amp; Panos Fidias, Massachusetts General Hospital, USA</td>
<td></td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE18: Perspectives in the Systemic Treatment of Small–Cell Lung Cancer</td>
<td>Chemo/NEUROENDOCRINE TUMORS</td>
<td>Stolz 1</td>
</tr>
<tr>
<td></td>
<td>MTE18.01: Perspectives in the Systemic Treatment of Small–Cell Lung Cancer</td>
<td>Mary O’Brien, Royal Marsden Hospital, UK &amp; Pieter Postmus, Independent, UK</td>
<td></td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE19: Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice (Ticketed Session)</td>
<td>Chemo/Targeted Therapy/Immunotherapy</td>
<td>Stolz 2</td>
</tr>
<tr>
<td></td>
<td>MTE19.01: Monitoring of Treatment Outcome in Clinical Trials and in Routine Practice</td>
<td>Richard Gralla, Albert Einstein College of Medicine, USA &amp; Kostas Syrigos, University of Athens, Greece</td>
<td></td>
</tr>
<tr>
<td>07:30 – 08:30</td>
<td>MTE20: Radiotherapy of Locally Advance NSCLC: Selecting the Right Patient for the Right Radiotherapy (Ticketed Session)</td>
<td>Radiotherapy</td>
<td>Stolz 2</td>
</tr>
<tr>
<td></td>
<td>MTE20.01: Radiotherapy of Locally Advance NSCLC: Selecting the Right Patient for the Right Radiotherapy</td>
<td>Dirk De Ruyscher, Maastricht University Medical Center, The Netherlands</td>
<td></td>
</tr>
</tbody>
</table>
09:45  PL03.07: First–line Ceritinib Versus Chemotherapy in Patients With ALK–rearranged (ALK+) NSCLC: A Randomized, Phase 3 Study (ASCEND–4)
Gilberto De Castro Jr, Instituto do Câncer do Estado de São Paulo, Brazil

09:55  PL03.08: Discussant
Fiona Blackhall, Christie Hospital NHS Foundation Trust, UK

10:05  PL03.09: Phase 3 Study of Ganetespib, a Heat Shock Protein 90 Inhibitor, with Docetaxel versus Docetaxel in Advanced Non–Small Cell Lung Cancer (GALAXY–2)
Rathi Pillai, Winship Cancer Institute, Emory University, USA

10:15  PL03.10: Discussant
David R. Gandara, UC Davis Comprehensive Cancer Center, USA

10:25 – 11:00  NETWORKING OPPORTUNITY & POSTER PRESENTERS PRESENT FOR P2 POSTERS
Hall B (Exhibit Hall)
Refreshments provided

10:30 – 11:45  PR03: Press Conference
ROOM: SCHUBERT 1, LEVEL ONE
For information on topics and speakers, please visit the Press & Media page on the Conference website at wclc2016.iaslc.org/press-media/press-media/
### SC13: Interaction of COPD and Lung Cancer – Consequences for Early Diagnosis and Management

**Track:** Radiology/Staging/Screening  
**Room:** Hall C8  
**Chairs:** Anée-Pascale Meert, Institut Jules Bordet, Belgium & Konstantinos Zargaroudis, G. Papanikolaou Hospital, Greece

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>SC13.01</td>
<td>Kwan Fong</td>
<td>Prince Charles Hospital UQ, Australia</td>
</tr>
<tr>
<td>11:20</td>
<td>SC13.02</td>
<td>Stephen Lam</td>
<td>British Columbia Cancer Agency, Canada</td>
</tr>
<tr>
<td>11:40</td>
<td>SC13.03</td>
<td>Gyula Ostoros</td>
<td>Orszagos Koranyi TBC es Pulmonologial Intezet, Hungary</td>
</tr>
<tr>
<td>12:00</td>
<td>SC13.04</td>
<td>Yoichi Nakanishi</td>
<td>Kyushu University, Japan</td>
</tr>
<tr>
<td>12:20</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SC14: Immunotherapy of NSCLC

**Track:** Chemotherapy/Targeted Therapy/Immunotherapy  
**Room:** Hall C2  
**Chairs:** Naier Rizvi, Columbia University Medical Center, USA & Christoph Zielinski, Medical University of Vienna, Austria

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>SC14.01</td>
<td>Roy Herbst</td>
<td>Yale School of Medicine, Yale Cancer Center, USA</td>
</tr>
<tr>
<td>11:20</td>
<td>SC14.02</td>
<td>Luis Paz-Ares</td>
<td>Hospital universitario Doce de Octubre, Spain</td>
</tr>
<tr>
<td>11:40</td>
<td>SC14.03</td>
<td>David Spigel</td>
<td>Sarah Cannon, USA</td>
</tr>
<tr>
<td>11:55</td>
<td>SC14.04</td>
<td>Branimir Sikic</td>
<td>Stanford University, USA</td>
</tr>
<tr>
<td>12:10</td>
<td>SC14.05</td>
<td>Anne-Marie Dingemans</td>
<td>Maastricht University Medical Center, Netherlands</td>
</tr>
</tbody>
</table>

### SC15: Clinical Trials: How to set Priorities?

**Track:** Trial Design/Statistics  
**Room:** Hall C8  
**Chairs:** Rolf Stahel, University Hospital Zurich, Switzerland & Yi Long Wu, Guangdong Lung Cancer Institute, China

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>SC15.01</td>
<td>Suresh Ramalingam</td>
<td>Winship Cancer Institute of Emory University, USA</td>
</tr>
<tr>
<td>11:15</td>
<td>SC15.02</td>
<td>Rolf Stahel</td>
<td>University Hospital Zurich, Switzerland</td>
</tr>
<tr>
<td>11:30</td>
<td>SC15.03</td>
<td>Yi Long Wu</td>
<td>Guangdong Lung Cancer Institute, China</td>
</tr>
<tr>
<td>11:45</td>
<td>SC15.04</td>
<td>Yuichiro Ohe</td>
<td>National Cancer Center Hospital, Japan</td>
</tr>
<tr>
<td>12:00</td>
<td>SC15.05</td>
<td>Gilberto Castro</td>
<td>University of Sao Paulo, Brazil</td>
</tr>
<tr>
<td>12:15</td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
11:00 – 12:30 IA06: Interactive Session Staging Group II (Ticketed Session)
TRACK: RADIOLOGY/STAGING/SCREENING
ROOM: SCHUBERT 3
COORDINATORS: KARIN DIECKMANN, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA & HELMUT PROSCH, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA

11:00 IA06.01: Interactive Session Staging
Libor Havel, Czech Republic, Anna Kerpel-Fronius, Hungary & Elisabeth Stiefsohn, Austria

11:00 – 12:30 NU03: Supporting Patients Receiving Treatment
TRACK: NURSES
ROOM: SCHUBERT 5
CHAIRS: VANESSA BEATTIE, Aintree University Hospital, UK & MARY DUFFY, PETER MACCALLUM CANCER CENTRE, AUSTRALIA

11:00 NU03.01: Supporting Patients Undergoing Radical Treatments EPD – MARS Study
Angela Tod, The University of Sheffield, UK

11:00 NU03.02: Ehealth and Remote Patient Monitoring and Supportive Care in Thoracic Oncology
Roma Maguire, University of Surrey, UK

11:40 NU03.03: Supportive Care in Patients Receiving Systemic Therapy
Tanja Cufer, University Clinic Golnik, Slovenia

12:00 Q&A

11:00 – 12:30 PA03: Patient Support and Involvement in Research
TRACK: PATIENT SUPPORT AND ADVOCACY GROUPS
ROOM: SCHUBERT 6
CHAIRS: JENNIFER KING, LUNG CANCER ALLIANCE, USA & PAWEL MUSZUMANSKI, INSTITUTION, POLAND

11:00 PA03.01: Central European Lung Cancer Patient Network (CELCAPANET)
Franz Buchberger, Lungenkrebsforum Austria, Austria

11:15 PA03.02: Psycho-Social and Communication Needs of Cancer Patients: Romanian Results
Csaba Dégi, Romania, Romania

11:30 PA03.03: How to Live with Lung Cancer? The Slovenian Lung Cancer Patient Support
Andreja Cirila Skufca Smrdel, 1. Institute of Oncology Ljubljana, 2. Cancer Patients’ Association of Slovenia, Slovenia

11:45 PA03.04: Patient Involvement in the Evaluation of Cancer Medicines: The EMA Experience
Nathalie Bere, European Medicines Agency, UK

12:00 Q&A

11:00 – 12:30 OA09: Locally Advanced NSCLC: Innovative Treatment Strategies
TRACK: LOCALLY ADVANCED NSCLC
ROOM: STRAUSS 3
CHAIRS: WALTER CURRAN, WINSHIP CANCER INSTITUTE, USA & MYUNG-JU AHN, SAMSUNG MEDICAL CENTER, SOUTH KOREA

11:00 OA09.01: The Number or the Position is the Main Prognostic Factor for N2 NSCLC? A Validation of New IASLC N Staging Proposal
Sara Ricciardi, Division of Thoracic Surgery, University Hospital of Pisa, Italy

11:10 OA09.02: Should Surgery Be Part of the Multimodality Treatment for Stage IIIB Non–Small Cell Lung Cancer
Stephane Collaud, Marie Lannelongue Hospital, France

11:20 OA09.03: Randomized Controlled Study Comparing Adjuvant versus Neo–Adjuvant Chemotherapy in Resectable Stage IB to IIIA NSCLC
Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

11:30 OA09.04: Discussant
Masahiro Tsuboi, National Cancer Center Hospital East, Japan

11:45 OA09.05: Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (FAZA) to Assess Tumor Hypoxia in Non–Small Cell Lung Cancer (NSCLC)
Alexander Sun, University of Toronto, Canada

11:55 OA09.06: Metformin Use during Concurrent Chemoradiotherapy for Locally Advanced Non–Small Cell Lung Cancer (NSCLC)
Krista Wink, Maastro Clinic, Netherlands

12:05 OA09.07: Individual Isotoxic RT Dose Escalation Based on V20 and Advanced? Technologies Benefit Stage – NSCLC Treated with CCRT
Baosheng Li, Shandong Cancer Hospital, China

12:15 OA09.08: Discussant
Paul Van Houtte, Institut Jules Bordet, Belgium

11:00 – 12:30 OA10: EGFR Mutations
TRACK: BIOLOGY/PATHOLOGY
ROOM: STRAUSS 1
CHAIRS: JAMES SPICER, GUY’S & ST. THOMAS’ NHS TRUST; KING’S COLLEGE LONDON, UK & TERUFUMI KATO, KANAGAWA CANCER CENTER, JAPAN

11:00 OA10.01: Comprehensive Genomic Profiling and PDX Modeling of EGFR Exon 20 Insertions: Evidence for Osimertinib Based Dual EGFR Blockade
Jonathan Riess, UC Davis Comprehensive Cancer Center, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>OA10.02: Association of Variations in HLA–Class II and Other Loci with Susceptibility to EGFR–Mutated Lung Adenocarcinoma</td>
<td>Takashi Kohno, National Cancer Center Research Institute, Japan</td>
</tr>
<tr>
<td>11:10</td>
<td>OA10.03: YAP–NOTCH and STAT3 Signaling Rebound as a Compensatory Response to Gefitinib or Osimertinib Treatment in EGFR Mutant Lung Cancer</td>
<td>Rafael Rosell, Catalan Institute of Oncology, Spain</td>
</tr>
<tr>
<td>11:30</td>
<td>OA10.04: Discussant</td>
<td>Hossein Borghaei, Fox Chase Cancer Center, USA</td>
</tr>
<tr>
<td>11:45</td>
<td>OA10.05: EGFR Gene Mutations Affect Tumor–Infiltrating Stromal Cell Components in Early–Stage Lung Adenocarcinoma</td>
<td>Toshiyuki Shima, Keio University School of Medicine, Japan</td>
</tr>
<tr>
<td>11:55</td>
<td>OA10.06: Characteristics and Outcomes of Patients with Lung Cancer Harboring Multiple Molecular Alterations (Biomarker IFCT Study)</td>
<td>Julien Mazières, Centre Hospitalier Universitaire, France</td>
</tr>
<tr>
<td>12:05</td>
<td>OA10.07: Report on Liquid Biopsies from Advanced Lung Adenocarcinoma Patients and Correlation with Their Tumor Biopsy Profiles</td>
<td>Edgardo Santos, Lynn Cancer Institute/Florida Atlantic University, USA</td>
</tr>
<tr>
<td>12:15</td>
<td>OA10.08: Discussant</td>
<td>Frederico Cappuzzo, AUSL della Romagna, Italy</td>
</tr>
</tbody>
</table>

**ED**: EDUCATIONAL SESSION  **IA**: INTERACTIVE SESSION  **ISS**: INDUSTRY SUPPORTED SYMPOSIUM  **MA**: MINI ORAL ABSTRACT SESSION  **MTE**: MEET THE EXPERT SESSION (TICKETED)  **NU**: NURSES SESSION  **OA**: ORAL ABSTRACT SESSION  **PA**: PATIENT ADVOCACY SESSION  **PC**: PRO CON SESSION  **PL**: PLENARY SESSION  **SC**: SCIENTIFIC SESSION  **SH**: SCIENTIFIC HIGHLIGHT SESSION  **WS**: WORKSHOP  **YI**: YOUNG INVESTIGATOR SESSION
11:00 – 12:30 MA07: ALK–ROS1 in Advanced NSCLC

TRACK: ADVANCED NSCLC
ROOM: LEHAR 1–2
CHAIRS: NAVNEET SINGH, POSTGRADUATE INSTITUTE OF MEDICAL EDUCATION AND RESEARCH (PGIMER), INDIA & JÜRGEN WOLF, UNIVERSITÄTSKLINIKUM KÖLN, GERMANY

11:00 MA07.01: Updated Pooled Analysis of CNS Endpoints in Two Phase II Studies of Alectinib in ALK+ NSCLC
Sai–Hong Ignatius Ou, University of California, Irvine School of Medicine, USA

11:06 MA07.02: Updated Efficacy and Safety Data from the Phase 2 NP28761 Study of Alectinib in ALK–Positive Non–Small–Cell Lung Cancer
Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA

11:12 MA07.03: Alectinib (ALC) versus Crizotinib (CRZ) in ALK–Positive Non–Small Cell Lung Cancer (ALK+ NSCLC): Primary Results from Phase III Study (J–ALEX)
Young Kim, Kyoto University, Japan

11:18 MA07.04: Discussant
Benjamin Besse, Gustave Roussy, France

11:30 MA07.05: EUCROSS: A European Phase II Trial of Crizotinib in Advanced Adenocarcinoma of the Lung Harboring ROS1 Rearrangements – Preliminary Results
Sebastian Michels, University Hospital of Cologne, Germany

11:36 MA07.06: Crizotinib in ROS1 Rearranged or MET Deregulated Non–Small–Cell Lung Cancer (NSCLC): Preliminary Results of the METROS Trial
Lorenza Landi, Istituto Toscano Tumori, Italy

11:42 MA07.07: Ceritinib in ROS1–Rearranged Non–Small–Cell Lung Cancer: An Update of Korean Nationwide Phase II Study
Byoung Chul Cho, Yonsei Cancer Center, Yonsei University College of Medicine, South Korea

11:48 MA07.08: Discussant
Enriqueta Felip, Hospital Universitari Vall d’Hebron, Spain

12:00 MA07.09: Mass Spectrometry Profiling and Imaging Platform for Novel Precision Drug Resistance Biomarkers Discovery in EML4–ALK Lung Adenocarcinoma
Patrick Ma, WVU Cancer Institute, USA

11:00 – 12:30 MA08: Treatment Monitoring in Advanced NSCLC

TRACK: ADVANCED NSCLC
ROOM: LEHAR 3–4
CHAIRS: ROMAN PEREZ–SOLER, MONTEFIORE MEDICAL CENTER, USA & THANYANAN REUNGWETWATTANA, RAMATHIBODI HOSPITAL, THAILAND

11:00 MA08.01: A Highly Sensitive Next–Generation Sequencing Platform for Detection of NSCLC EGFR T790M Mutation in Urine and Plasma
Heather Wakelee, Stanford Cancer Institute, USA

11:06 MA08.02: Clinical Research Platform into Molecular Testing, Treatment, Outcome (CRISP): A Prospective German Registry in Stage IV NSCLC AIO–TRK–0315
Frank Griesinger, Pius Hospital Oldenburg, Germany

11:12 MA08.03: Osimertinib vs Platinum–Pemetrexed for T790M–Mutation Positive Advanced NSCLC (AURA3): Plasma ctDNA Analysis
Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences, China

11:18 MA08.04: Discussant
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

11:30 MA08.05: Depth of Response to First–Line EGFR TKI Does Not Predict Survival in EGFR–Mutated NSCLC Patients
Ting–Hui Wu, National Taiwan University Hospital, Taiwan

11:36 MA08.06: Impact of Depth of Response (DpR) on Survival in Patients with Advanced NSCLC Treated with First–Line Chemotherapy
Daniel Morgensztern, Washington University School of Medicine in St. Louis, USA

11:42 MA08.07: Prospective Sequential Counts of Total CTC or cKIT+CTC in Advanced NSCLC with 1st Line Chemotherapy (POLICE)
Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China
11:48 MA08.08: Discussant
Aaron Mansfield, Mayo Clinic, USA

12:00 MA08.09: Monitoring Plasma EGFR Mutations during First Line Treatment with EGFR TKIs in NSCLC Patients
Katja Mohorcic, University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia

12:06 MA08.10: Detection of the T790M Mutation of EGFR in Plasma of Advanced NSCLC Patients with Acquired Resistance to EGFR-TKI (WJOG8014LTR)
Koichi Azuma, Kurume University School of Medicine, Japan

12:12 MA08.11: Monitoring the Emergence of EGFR T790M cDNA in Urine from EGFR Mutated NSCLC Patients to Predict Response to 3rd Generation Anti–EGFR TKIs
Hatim Husain, UCSD Moores Cancer Center, USA

12:18 MA08.12: Discussant
Martin Filipits, Medical University of Vienna, Austria

12:45 – 14:15 ISS10: Novel Treatment Strategies for ALK+ NSCLC: From Evidence to Practice – Novartis

12:45 ISS10.01: Welcome & Introduction
Solange Peters, Lausanne University Hospital CHUV, Switzerland

12:50 ISS10.02: ALK+ NSCLC: Not Your Typical Patients
Heather Wakelee, Stanford University School of Medicine, USA

13:05 ISS10.03: Optimizing Outcomes for Your ALK+ NSCLC Patients
Fabrice Barlesi, Aix–Marseille University, France

13:20 ISS10.04: The Future of ALK+ NSCLC Treatment and What this Implies for Your Clinical Practice
Daniel Shao–Weng Tan, National Cancer Centre Singapore, Singapore

13:40 ISS10.05: Panel Discussion: Challenges in Sequencing Therapy for Your ALK+ NSCLC Patients
All Faculty

14:10 ISS10.06: Conclusion and Close
Solange Peters, Lausanne University Hospital CHUV, Switzerland


14:25 OA13.01: A Phase II Study of Nivolumab in Malignant Pleural Mesothelioma (NivoMes): with Translational Research (TR) Biopies
Paul Baas, The Netherlands Cancer Institute, Netherlands

14:30 OA13.02: Phase II Trial of Pembrolizumab in Patients with Malignant Mesothelioma (MM): Interim Analysis
Hedy Kindler, University of Chicago, USA

14:40 OA13.03: Long–Term Overall Survival for Patients with Malignant Pleural Mesothelioma on Pembrolizumab Enrolled in KEYNOTE–028
Evan Alley, University of Pennsylvania, USA

14:50 OA13.04: Discussant
Cornelius Waller, Universitätsklinikum Freiburg, Germany

15:05 OA13.05: Somatic Genetic Alterations and Immune Microenvironment in Malignant Pleural Mesothelioma
Wickii Vigneswaran, Loyola University Health System, USA

15:15 OA13.06: Autologous Dendritic Cells Loaded with Allogeneic Tumor Cell Lysate (Pheralys®) in Patients with Mesothelioma: Final Results of a Phase I Study
Joachim Aerts, Erasmus MC Cancer Centre, Netherlands

15:26 OA13.07: Intrapleural Modified Vaccine Strain Measles Virus Therapy for Patients with Malignant Pleural Mesothelioma
Tobias Peikert, Mayo Clinic, USA

15:35 OA13.08: Discussant
Anna Nowak, University of Western Australia, Australia
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:20 – 15:50</td>
<td>MA09: Immunotherapy Combinations</td>
</tr>
<tr>
<td><strong>TRACK:</strong></td>
<td>CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY</td>
</tr>
<tr>
<td><strong>ROOM:</strong></td>
<td>STRAUSS 2</td>
</tr>
<tr>
<td><strong>CHAIRS:</strong></td>
<td>MARTIN SEBASTIAN, GOETHE UNIVERSITY, GERMANY &amp; EDWARD GARON, UCLA MEDICAL CENTER, USA</td>
</tr>
<tr>
<td>14:20</td>
<td>MA09.01: Dual Blockade of PD–1 and C5a/C5aR Synergistically Protects against Non–Small Cell Lung Cancer Tumor Growth Ruben Pio, CIMA–University of Navarra, Spain</td>
</tr>
<tr>
<td>14:26</td>
<td>MA09.02: Pemetrexed and Carboplatin and Pemetrexed as 1st–Line Therapy for Advanced Non–Small Cell Lung Cancer: KEYNOTE–021 Cohort 6 Corey Langer, University of Pennsylvania, USA</td>
</tr>
<tr>
<td>14:32</td>
<td>MA09.03: Cisplatin/Pemetrexed + Durvalumab +/- Tremelimumab in Pts with Advanced Non–Squamous NSCLC: A CTG Phase IB Study – IND.226 Rosalyn Juergens, McMaster University – Jurfavinski Cancer Centre, Canada</td>
</tr>
<tr>
<td>14:38</td>
<td>MA09.04: Discussant David Planchard, Gustave Roussy, France</td>
</tr>
<tr>
<td>14:50</td>
<td>MA09.05: Nivolumab Alone or with Ipilimumab in Recurrent Small Cell Lung Cancer (SCLC): 2-Year Survival and Updated Analyses from the Checkmate 032 Trial Matthew Hellmann, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>14:56</td>
<td>MA09.06: Viagpumaturacel–L Bolsters Response to Nivolumab Therapy in Advanced Lung Adenocarcinoma: Preliminary Data from the DURGA Trial Daniel Morgenszttern, Washington University School of Medicine in St. Louis, USA</td>
</tr>
<tr>
<td>15:02</td>
<td>MA09.07: Phase I Trial of in situ Vaccination with CCL21 Gene–Modified DC Induces Specific Systemic Immune Response and Tumor Infiltrating CD8+ T Cells Steven Dubinett, University of California, Los Angeles, USA</td>
</tr>
<tr>
<td>15:08</td>
<td>MA09.08: Discussant Lubos Petruzelka, Charles University, Czech Republic</td>
</tr>
<tr>
<td>15:20</td>
<td>MA09.09: First–In–Human Phase 1 Study of ABBV–399, an Antibody–Drug Conjugate (ADC) Targeting C–Met, in Patients with Non–Small Cell Lung Cancer (NSCLC) Eric Angevine, Gustave Roussy, France</td>
</tr>
<tr>
<td>15:26</td>
<td>MA09.10: A NaPi2b Antibody–Drug Conjugate Induces Durable Complete Tumor Regressions in Patient–Derived Xenograft Models of NSCLC Donald Bergstrom, Mersana Therapeutics, USA</td>
</tr>
<tr>
<td>15:32</td>
<td>MA09.11: Efficacy and Safety of Necitumumab and Pembrozilumab Combination Therapy in Stage IV Nonsquamous Non–Small Cell Lung Cancer (NSCLC) Benjamin Besse, Gustave Roussy, France</td>
</tr>
<tr>
<td>15:38</td>
<td>MA09.12: Discussant Clarissa Baldotto, Brazil</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>TRACK:</strong></td>
<td>RADIOLOGY/STAGING/SCREENING</td>
</tr>
<tr>
<td><strong>ROOM:</strong></td>
<td>STOLZ 2</td>
</tr>
<tr>
<td><strong>CHAIRS:</strong></td>
<td>PARIS KOSMIDS, HYGIENE HOSPITAL, GREECE &amp; MIROSLAW KOZŁOWSKI, MEDICAL UNIVERSITY OF BIAŁYSTOK, POLAND</td>
</tr>
<tr>
<td>14:20</td>
<td>MA10.01: Validations of the 8th AJCC/UICC Lung Cancer Staging System in a Large North America Cohort Lin Yang, Cancer Hospital, Chinese Academy of Medical Sciences, China</td>
</tr>
<tr>
<td>14:26</td>
<td>MA10.02: Clinical Staging in the 8th Edition TNM for Lung Cancer is Inaccurate Aleksander Mani, St Bartholomew’s Hospital, UK</td>
</tr>
<tr>
<td>14:32</td>
<td>MA10.03: Investigating the Potential Utility of the Alternative 9th Edition IASLC Nodal Staging Classification in NSCLC Haval Balata, University Hospitals of South Manchester, UK</td>
</tr>
<tr>
<td>14:38</td>
<td>MA10.04: Discussant Raymond Osarogiagbon, Baptist Cancer Center, USA</td>
</tr>
<tr>
<td>14:50</td>
<td>MA10.05: Proposals for the Novel Clinical T Categories Based on the Presence of Ground Glass Opacity Component in Lung Adenocarcinoma Aritoshi Hattori, Juntendo University, Japan</td>
</tr>
<tr>
<td>14:56</td>
<td>MA10.06: Centrality Definition in Non Small Cell Lung Cancer. Predictor For Occult Mediastinal Lymph Node Involvement David Sanchez–Lorente, Hospital Clinic of Barcelona, Spain</td>
</tr>
<tr>
<td>15:02</td>
<td>MA10.07: 18F–Fluorodeoxyglucose Positron Emission Tomography Scan in Solid–Type Stage–1 Pulmonary Adenocarcinomas: What Cause False–Negative Cases? Tommaso Ricchetti, Arcispedale –IRCCS Santa Maria Nuova di Reggio Emilia, Italy</td>
</tr>
<tr>
<td>15:08</td>
<td>MA10.08: Discussant Amir Onn, Israe</td>
</tr>
<tr>
<td>15:20</td>
<td>MA10.09: Comparison between CT Scan Evaluation Criteria and PERCIST for Evaluation of Immune Check–Point Inhibitors Response Giovanni Rossi, San Martino Hospital – National Institute for Cancer Research, Italy</td>
</tr>
<tr>
<td>15:26</td>
<td>MA10.10: [18F]–FDG–PET/CT Early Response to Nivolumab in NSCLC Alexis Cortot, Lille University Hospital, France</td>
</tr>
<tr>
<td>15:38</td>
<td>MA10.12: Discussant Prasanta Mohapatra, All India Institute of Medical Sciences, India</td>
</tr>
</tbody>
</table>
14:20 – 15:50 MA11: Novel Approaches in SCLC and Neuroendocrine Tumors

**TRACK:** SCLC/NEUROENDOCRINE TUMORS
**ROOM:** STRAUSS 3
**CHAIRS:** PRIMO LARA, UNIVERSITY OF CALIFORNIA DAVIS COMPREHENSIVE CANCER CENTER, USA & ANDREA MOHN–STAUDNER, OTTO WAGNER HOSPITAL, AUSTRIA

**14:20 MA11.01:** Molecular Profiling of Large Cell Neuroendocrine Carcinoma Using Capture–Based Targeted Sequencing
Zhen Zhou, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**14:26 MA11.02:** Mutational Burden in Pulmonary Neuroendocrine Tumors (puNETs)
Ivana Sullivan, Gustave Roussy, France

**14:32 MA11.03:** INSM1 is a Novel Biomarker and a Crucial Regulator of the Neuroendocrine Differentiation Pathway in Neuroendocrine Tumours of the Lung
Fujino Kosuke, University Health Network, Canada

**14:38 MA11.04:** Discussant
Jean Luis Pujol, France

**14:50 MA11.05:** A Case–Control Study to Test the Use of ctDNA in the Early Detection of SCLC Reveals TP53 Mutations in Non–Cancer Controls
Lynnette Fernandez–Cuesta, International Agency for Research on Cancer (IARC–WHO), France

**14:56 MA11.06:** SWOG 0124: Platinum–Sensitivity Status and Post–Progression Survival in Patients with Extensive–Stage Small Cell Lung Cancer
Primà Lara, UC Davis Comprehensive Cancer Center, USA

**15:02 MA11.07:** Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial
Lauren Averett Byers, University of Texas MD Anderson Cancer Center, USA

**15:08 MA11.08:** Discussant
Andrea Ardizzoni, S. Orsola–Malpighi University Hospital, Italy

**15:20 MA11.09:** Progastrin–Releasing Peptide (ProGRP) to Rule out Progressive Disease in Patients with Small Cell Lung Carcinoma (SCLC)
Xiaotong Zhang, Peking Union Medical College Hospital (PUMCH), China

**15:26 MA11.10:** Prospective Study of Genome–Wide Strexome and Transcriptome Profiling in Patients with Small Cell Lung Cancer Progressing after 1st Line Therapy
Glen Weiss, Western Regional Medical Center, Cancer Treatment Centers of America, USA

**15:32 MA11.11:** Is Hippocampal Avoidance during Whole Brain Radiotherapy Risky for Small Cell Lung Cancer Patients?
Esra Kirakli, Dr. Suat Senen Göğüs Hastalıkları ve Cerrahisi eğitim ve Araştırma Hastanesi, Turkey

**15:38 MA11.12:** Discussant
Hideo Kunitoh, Japanese Red Cross Medical Center, Japan

14:20 – 15:50 MA12: Miscellaneous Biology/Pathology

**TRACK:** BIOLOGY/PATHOLOGY
**ROOM:** SCHUBERT 1, LEVEL ONE
**CHAIRS:** BALA2S DOME, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA & WILLIAM TRAVIS, USA

**14:20 MA12.01:** Next Generation Sequencing Based Clinical Framework for Analyses of Treatment Predictive Mutations and Gene Fusions in Lung Cancer
Anna Karlsson, Lund University, Sweden

**14:26 MA12.02:** MMP12 and LMO7, Two Key Players on opposite Sides of Early Lung Squamous Cell Carcinoma Development
Angela Barrett, University College London, UK

**14:32 MA12.03:** Discussant
Elisabeth Brambilla, Institut Albert Bonniot, Hopital Albert Michallon, France

**14:50 MA12.05:** A Case–Control Study to Test the Use of ctDNA in the Early Detection of SCLC Reveals TP53 Mutations in Non–Cancer Controls
Lynnette Fernandez–Cuesta, International Agency for Research on Cancer (IARC–WHO), France

**14:56 MA12.06:** SWOG 0124: Platinum–Sensitivity Status and Post–Progression Survival in Patients with Extensive–Stage Small Cell Lung Cancer
Primà Lara, UC Davis Comprehensive Cancer Center, USA

**15:02 MA12.07:** Improved Small Cell Lung Cancer (SCLC) Response Rates with Veliparib and Temozolomide: Results from a Phase II Trial
Lauren Averett Byers, University of Texas MD Anderson Cancer Center, USA

**15:08 MA12.08:** Discussant
Andrea Ardizzoni, S. Orsola–Malpighi University Hospital, Italy

**15:20 MA12.09:** Progastrin–Releasing Peptide (ProGRP) to Rule out Progressive Disease in Patients with Small Cell Lung Carcinoma (SCLC)
Xiaotong Zhang, Peking Union Medical College Hospital (PUMCH), China

**15:26 MA12.10:** Prospective Study of Genome–Wide Strexome and Transcriptome Profiling in Patients with Small Cell Lung Cancer Progressing after 1st Line Therapy
Glen Weiss, Western Regional Medical Center, Cancer Treatment Centers of America, USA

**15:32 MA12.11:** Is Hippocampal Avoidance during Whole Brain Radiotherapy Risky for Small Cell Lung Cancer Patients?
Esra Kirakli, Dr. Suat Senen Göğüs Hastalıkları ve Cerrahisi eğitim ve Araştırma Hastanesi, Turkey

**15:38 MA12.12:** Discussant
Hideo Kunitoh, Japanese Red Cross Medical Center, Japan
14:30 – 15:50  ED09: Advances in Lung Cancer Screening
TRACK:  RADIOLOGY/STAGING/SCREENING
ROOM:  HALL C8
CHAIRS:  CHRISTINE BERG, JOHNS HOPKINS MEDICINE, USA & RUDOLF HUBER, UNIVERSITY OF MUNICH, THORACIC ONCOLOGY CENTRE MUNICH, GERMANY

14:30  ED09.01: Radiological Advances in Lung Cancer Screening
Mathias Prokop, Radboud University Medical Center, Netherlands

14:50  ED09.02: Risk Prediction Modelling in Lung Cancer Screening Programs
Martin Tammemägi, Brock University, Canada

15:10  ED09.03: Overdiagnosis in Lung Cancer Screening
Charles Powell, Mount Sinai Hospital, USA

15:30  ED09.04: Cost Effectiveness of CT Screening
Bruce Pyenson, Milliman, Inc., USA

14:30 – 15:55  SC16: Superior Sulcus Tumors
TRACK:  LOCALLY ADVANCED NSCLC
ROOM:  LEHAR 1–2
CHAIR:  DAVID JONES, MEMORIAL SLOAN KETTERING CANCER CENTER, USA & WALTER KLEPETKO, MEDICAL UNIVERSITY VIENNA, AUSTRIA

14:30  SC16.01: Imaging Techniques for Staging and Restaging of Superior Sulcus Tumors
Helmut Prosch, Medical University of Vienna, Austria

14:50  SC16.02: Surgical Approaches in Superior Sulcus Tumors
Dominique Grunenwald, University of Paris VI, France

15:10  SC16.03: Radiotherapy for Sulcus Superior Tumors
Maria Werner–Wasik, Sidney Kimmel Cancer Center at Thomas Jefferson University, USA

Qinghua Zhou, Shanghai Pulmonary Hospital, Tongji University, China

TRACK:  REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH
ROOM:  STRAUSS 1
CHAIR:  CARLOS VALLEJOS, ONCOSALUD, PERU

14:25  SC17.01: Lung Cancer in Russia: Challenges and Perspectives
Vera Gorbunova, Institution of Russian Academy of Medical Science, Russia

14:40  SC17.02: Lung Cancer in China: Challenges and Perspectives
Li Zhang, Sun Yat–Sen University Cancer Center, China
14:55  SC17.03: Lung Cancer in India: Challenges and Perspectives
Digambar Behera, Postgraduate Institute of Medical Education and Research (PGIMER), India

15:10  SC17.04: Lung Cancer in Latin America: Challenges and Perspectives
Eduardo Richardet, IONC (Instituto Oncologico de Cordoba), Argentina

15:25  SC17.05: Lung Cancer in Africa: Challenges and Perspectives
Rabab Gaafar, National Cancer Institute, Egypt

15:40  SC17.06: Lung Cancer in Low and Middle Income Countries: A Comprehensive Cancer Control Approach
Nelly Enwerem-Bromson, IAEA/PACT, Austria

14:30 – 15:45  PA04: Focus on Advocacy and Communication: Joint IASLC/Global Lung Cancer Coalition Session (GLCC)
TRACK: PATIENT SUPPORT AND ADVOCACY GROUPS
ROOM: SCHUBERT 6
CHAIRS: AOIFE MCNAMARA, IRISH CANCER SOCIETY, IRELAND & ANDREJA ŠAJNI, INSTITUTION, CROATIA

14:30  PA04.01: A Realistic Goal? Achieving a Tobacco Free Ireland by 2025
Donal Buggy, Irish Cancer Society, Ireland

14:45  PA04.02: The Global State of Lung Cancer Research – Communicating the Messages
Sarah Winstone, Incisive Health, UK

15:05  PA04.03: Helpline: Adapting to Changing Needs and Evolving Science
Jennifer King, Lung Cancer Alliance, USA

15:25  PA04.04: How it Feels Campaign: The Impact of a Large General Public Campaign
Kay Bayne, Institution, USA

14:30 – 15:45  Poster Presenters Present for P2 Posters
ROOM: HALL B (EXHIBIT HALL)

14:30 – 15:45  NU04: Managing Toxicity
TRACK: NURSES
ROOM: SCHUBERT 5
CHAIRS: MARY HESDORFFER, MESOTHELIOMA APPLIED RESEARCH FOUNDATION, USA & MARIANNE DAVIES, YALE CANCER CENTER, USA

14:30  NU04.01: Management of Toxicities Associated with Immunotherapy in the Lung Cancer Patients
Michelle Turner, Maryland Proton Treatment Center Affiliated with the Marlene & Stewart Greenebaum Cancer Center, USA
### SC19: Interventional Pulmonology in Diagnosis and Treatment of Thoracic Malignancies

**Track:** Pulmonology  
**Room:** Lehar 3–4  
**Chairs:** Yoichi Nakanishi, Kyushu University, Japan & Ruxandra Ulmeanu, Institutul Marius Nasta Bucureti, Romania

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16:00 | SC19.01: Diagnosis of Lung Cancer: Multimodal Devices for Peripheral Pulmonary Lesions  
Noriaki Kurimoto, Kanagawa Prefecture, Japan |
| 16:20 | SC19.02: Invasive Staging of Lung Cancer: EBUS, EUS and Beyond  
Kazuhiro Yasufuku, Toronto General Hospital, University of Toronto, Canada |
| 16:40 | SC19.03: Medical Thoracoscopy  
Ales Rozman, University Clinic for respiratory and allergic diseases, Slovenia |

### SC20: Small is Beautiful: Impact of Surgical Approach

**Track:** Surgery  
**Room:** Strauss 1  
**Chairs:** Alan Sihoie, The University of Hong Kong, Hong Kong & Alper Toker, Istanbul University Medical School, Turkey

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16:00 | SC20.01: Muscle–Sparing Thoracotomy: Can It Still Be Considered a Standard?  
Clemens Aigner, Ruhrlandklinik – University Clinic Essen, Germany |
| 16:20 | SC20.02: What Have We Achieved? Should It Be Performed for Stages Higher Than Stage I Disease?  
Walter Klepetko, Medical University Vienna, Austria |
| 16:40 | SC20.03: Robotic Surgery: What Can Be Done?  
Eva De Pفت, University Hospital of Pisa, Italy |

### SC18: Precision Screening for Lung Cancer

**Track:** Radiology/Staging/Screening  
**Room:** Lehar 1–2  
**Chairs:** Andrew Nicholson, Royal Brompton and Harefield NHS Foundation Trust, UK & Gyula Ostoros, Orszagos Koranyi TBC Es Pulmonogiai Intezet, Hungary

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16:00 | SC18.01: Field Cancerization in the Airways and its Application to Lung Cancer Early Detection  
Ignacio Wistuba, The University of Texas MD Anderson Cancer Center, USA |
| 16:20 | SC18.02: Integrating Lung Cancer Biomarkers into Future Screening Programs  
Pierre Massion, Vanderbilt–Ingram Cancer Center, USA |
| 16:40 | SC18.03: Lung Cancer Screening, COPD and Cardiovascular Diseases  
Rudolf Huber, University of Munich, Thoracic Oncology Centre Munich, Germany |
| 17:00 | SC18.04: Exhaled Biomarker Fingerprints for Early Detection  
Ildiko Horvath, Semmelweis University, Hungary |
| 17:15 | SC18.05: UK Lung Screening Trial Cost Effectiveness and Current Planning Status of International Lung Cancer Screening Programs  
John Field, The University of Liverpool, UK |

### ED10: Locally Advanced NSCLC: State–of–the–Art Treatment

**Track:** Locally Advanced NSCLC  
**Room:** Hall C1  
**Chairs:** Wilfried Eberhardt, University of Essen, Germany & Kenji Suzuki, Juntendo University Hospital, Japan

<table>
<thead>
<tr>
<th>Time</th>
<th>Event</th>
</tr>
</thead>
</table>
| 16:00 | ED10.01: Chemoradiotherapy of Stage III NSCLC  
Francoise Mornex, Institution, France |
| 16:25 | ED10.02: The Role of Surgery in Stage III NSCLC  
Walter Klepetko, Medical University Vienna, Austria |
| 16:45 | ED10.03: New Developments in Radiotherapy of Stage III NSCLC  
Jacek Jassem, Medical University of Gdansk, Poland |
| 17:05 | ED10.04: New Developments for Systemic Therapies in Stage III NSCLC  
Everett Vokes, University of Chicago, USA |
| 17:20 | Q&A |
16:00 – 17:30 SC21: Predictive Biomarkers for Outcome of Systemic Therapy in NSCLC
TRACK: BIOLOGY/PATHOLOGY
ROOM: HALL C7
CHAIRS: KEITH KERR, ABERDEEN UNIVERSITY MEDICAL SCHOOL, UK & TETSUYA MITSUDOMI, KINDAI UNIVERSITY FACULTY OF MEDICINE, JAPAN

16:00 SC21.01: Predictive Biomarkers in NSCLC: The Impact of Tumor Heterogeneity
Yasushi Yatabe, Aichi Cancer Center, Japan

16:20 SC21.02: Predictive Biomarkers for Chemotherapy of NSCLC
Martin Filipits, Medical University of Vienna, Austria

16:40 SC21.03: Predictive Biomarkers for Immune Checkpoint Inhibitors in Lung Cancer
Fred R. Hirsch, University of Colorado Cancer Center, USA

17:00 SC21.04: Patient-Derived Xenografts for Guiding Therapy of Lung Cancer
Byoung Chul Cho, Yonsei Cancer Center, South Korea

17:15 SC21.05: Emerging Role of Liquid Biopsies in NSCLC
Philipp Mack, UC Davis Comprehensive Cancer Center, USA

16:00 – 17:30 SC22: Selection and Monitoring of Patients for Immune Checkpoint Inhibitors
TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: HALL C8
CHAIR: JOHAN VANSTEENKISTE, UNIVERSITY HOSPITAL KU LEUVEN, BELGIUM & GIORGIO SCAGLIOTTI, ITALY

16:00 SC22.01: How Do I Define Optimal Candidates for Immunotherapy in My Practice?
Johan Vansteenkiste, University Hospital KU Leuven, Belgium

16:20 SC22.02: How Do I Monitor for Efficacy?
Naiyer Rizvi, Columbia University Medical Center, USA

16:40 SC22.03: How Do I Monitor for and Treat Immune-Related Events?
Alexander Spira, Virginia Cancer Specialists, USA

17:00 SC22.04: How Can Immunotherapy Be Implemented in a Cost-Effective Strategy?
Christoph Zielinski, Medical University Vienna, Austria

17:20 Q&A

16:00 SC23.01: Cooperative Groups in Latin America
Clarissa Mathias, NOB, Brazil

16:15 SC23.02: Cooperative Groups in Europe: Lessons Learned and Perspectives
Solange Peters, Lausanne University Hospital CHUV, Switzerland

16:30 SC23.03: How Could High-Volume Centers in Developing Countries Access Cooperative Group Trials?
Ugur Yilmaz, Izmir, Dr. Suat Seren Chest Disease and Surgery Training and Research Hospital, Turkey

16:45 SC23.04: Cooperative Groups in China: The CSCO Experience
Qing Zhou, Guangdong Lung Cancer Institute; Guangdong General Hospital (GGH) & Guangdong Academy of Medical Sciences, China

17:00 SC23.05: Cooperative Groups in North America
Shakun Malik, NCI, USA

17:15 SC23.06: Challenges and Costs of Cooperative Group Trials
Thomas Brodowicz, Medical University Vienna – General Hospital, Austria

16:00 – 17:30 IA07: Interactive Session Target Delineation: Group II (Ticketed Session)
TRACK: RADIOTherapy
ROOM: SCHUBERT 3
COORDINATORS: KAREN DIECKMANN, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA & HELMUT PROSCH, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA

16:00 IA07.01: Interactive Session Target Delineation
Corinne Faivre-Finn, UK, Laurie Gaspar, USA & Billy Loo, USA
16:00 – 17:30  |  OA08: Tobacco & Youth  
**TRACK:** Epidemiology/Tobacco Control and Cessation/Prevention  
**ROOM:** HALL C2  
**CHAIRS:** Corneli Radu, The European Network for Smoking and Tobacco Prevention (ENSP), Romania & Martina Potschke-Langer, Germany

16:00  |  OA08.01: Tobacco Use in Low-Income Countries  
Nise Yamaguchi, Hospital Albert Einstein, Brazil

16:20  |  OA08.02: Tobacco Use in Austrian Young People  
Daniela Jahn-Kuch, LKH-Universitätsklinikum Graz, Austria

16:40  |  OA08.03: How Technology can Assist in Lung Cancer Prevention  
Alexander Prokhorov, The University of Texas MD Anderson Cancer Center, USA

17:00  |  OA08.04: Tobacco Control Policies and Youth Smoking  
Florin Mihaltan, National Institute of Pneumology, Romania

17:20  |  Q&A

16:00 – 17:30  |  OA14: Nurses in Care for Lung Cancer and in Research  
**TRACK:** Nurses  
**ROOM:** SCHUBERT 5  
**CHAIRS:** Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA & Massey Nematiolla, Canada

16:00  |  OA14.01: Acceptability of an Advanced Practice Nurse in Lung Cancer by Health Professionals and Patients: A Qualitative Exploration  
Andrea Serena, Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne, Switzerland

16:10  |  OA14.02: Nursing and Allied Healthcare Practitioner Driven Initiative to Develop an Integrated Educational and Assessment Program for Immunotherapy  
Marianne Davies, Yale Cancer Center, USA

16:20  |  OA14.03: Integrating Therapies into a Specialist Lung Cancer Nursing Team: An Evaluation  
Carol Brimacombe, Churchill Hospital, UK

16:30  |  OA14.04: Discussant  
Beth Eaby-Sandy, USA

16:45  |  OA14.05: A Framework to Support the Lung Cancer Nurse Specialist in the Development and Evaluation of Nurse-Led Clinics  
Sharon Savory, University Hospitals of Leicester, UK

16:55  |  OA14.06: The Role of a Multi-Disciplinary Team Approach to Early Rehabilitation and Symptom Management in Thoracic Oncology  
Pippa Labuc, Guy’s & St Thomas’ NHS Foundation Trust, UK

17:00  |  OA14.07: The Relationship between Lung Cancer Stigma and Patient Reported Outcomes  
Liane Lewis, University of Surrey, UK

17:15  |  OA14.08: Discussant  
Mary Duffy, Australia

16:00 – 17:30  |  OA15: Sublobar Resections for Early Stage NSCLC  
**TRACK:** Surgery  
**ROOM:** STOLZ 2  
**CHAIRS:** Mir Hoda, Medical University Vienna, Austria & David Waller, Glenfield Hospital, UK

16:00  |  OA15.01: Limited Resection Trial for Pulmonary Sub-solid Nodules: Case Selection Based on High Resolution CT: Outcome at Median Follow-up of 105 Months  
Junji Yoshida, National Cancer Center Hospital East, Japan

16:10  |  OA15.02: Survival Outcomes in Sublobar Resection for Clinical T1N0M0 Non-Small Cell Lung Cancer: Wedge Resection or Segmentectomy  
Aki Kobayashi, Mie University Graduate School of Medicine, Japan

16:20  |  OA15.03: Comparison of Prognosis between Lobectomy and Sublobar Resection for Clinical Stage I Non-Small Cell Lung Cancer with Interstitial Lung Disease  
Yasuhiro Tsutani, Hiroshima University, Japan

16:30  |  OA15.04: Discussant  
Stefan Watzka, Abteilung für Thoraxchirurgie, Austria

16:45  |  OA15.05: Anatomical Pulmonary Segmentectomy and Sub-Subsegmentectomy for Lung Cancer Using the Novel Fluorescence Technique with Vitamin B2  
Ryuichi Waseda, Fukuoka University, Japan

17:00  |  OA15.06: The Efficacy of Lung Volume Analyzer for Measuring Resection Margin in Pulmonary Segmentectomy for Malignant Diseases  
Yasuo Tsutani, Hiroshima University, Japan

17:20  |  Q&A

16:00 – 17:30  |  IA08: Tobacco & Youth  
**TRACK:** Epidemiology/Tobacco Control and Cessation/Prevention  
**ROOM:** HALL C2  
**CHAIRS:** Corneli Radu, The European Network for Smoking and Tobacco Prevention (ENSP), Romania & Martina Potschke-Langer, Germany

16:00  |  IA08.01: Tobacco Use in Low-Income Countries  
Nise Yamaguchi, Hospital Albert Einstein, Brazil

16:20  |  IA08.02: Tobacco Use in Austrian Young People  
Daniela Jahn-Kuch, LKH-Universitätsklinikum Graz, Austria

16:40  |  IA08.03: How Technology can Assist in Lung Cancer Prevention  
Alexander Prokhorov, The University of Texas MD Anderson Cancer Center, USA

17:00  |  IA08.04: Tobacco Control Policies and Youth Smoking  
Florin Mihaltan, National Institute of Pneumology, Romania

17:20  |  Q&A

16:00 – 17:30  |  OA14: Nurses in Care for Lung Cancer and in Research  
**TRACK:** Nurses  
**ROOM:** SCHUBERT 5  
**CHAIRS:** Melissa Culligan, University of Maryland Medical Center – Thoracic Surgery, USA & Massey Nematiolla, Canada

16:00  |  OA14.01: Acceptability of an Advanced Practice Nurse in Lung Cancer by Health Professionals and Patients: A Qualitative Exploration  
Andrea Serena, Institute of Higher Education and Research in Healthcare, Faculty of Biology and Medicine, University of Lausanne, Switzerland

16:10  |  OA14.02: Nursing and Allied Healthcare Practitioner Driven Initiative to Develop an Integrated Educational and Assessment Program for Immunotherapy  
Marianne Davies, Yale Cancer Center, USA

16:20  |  OA14.03: Integrating Therapies into a Specialist Lung Cancer Nursing Team: An Evaluation  
Carol Brimacombe, Churchill Hospital, UK

16:30  |  OA14.04: Discussant  
Beth Eaby-Sandy, USA

16:45  |  OA14.05: A Framework to Support the Lung Cancer Nurse Specialist in the Development and Evaluation of Nurse-Led Clinics  
Sharon Savory, University Hospitals of Leicester, UK

16:55  |  OA14.06: The Role of a Multi-Disciplinary Team Approach to Early Rehabilitation and Symptom Management in Thoracic Oncology  
Pippa Labuc, Guy’s & St Thomas’ NHS Foundation Trust, UK

17:05  |  OA14.07: The Relationship between Lung Cancer Stigma and Patient Reported Outcomes  
Liane Lewis, University of Surrey, UK

17:15  |  OA14.08: Discussant  
Mary Duffy, Australia
<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Track</th>
<th>Room</th>
<th>Chairs</th>
</tr>
</thead>
<tbody>
<tr>
<td>16:00</td>
<td>OA16: Improving the Quality of Lung Cancer Care – Patients Perspective</td>
<td>Patient Support and Advocacy Groups</td>
<td>Schubert 6</td>
<td>Gudrun Kreye, Austria &amp; Daniel Shao-Weng Tan, National Cancer Centre Singapore, Singapore</td>
</tr>
<tr>
<td>16:00</td>
<td>OA16.01: The Role of Patient Groups in Integrating the Patient Voice into Drug Decisions</td>
<td></td>
<td></td>
<td>Christina Sit, Lung Cancer Canada, Canada</td>
</tr>
<tr>
<td>16:10</td>
<td>OA16.02: Shared Decision Making (SDM) and Patient Decision Aids (PDAs) in Lung Cancer: Survey of Patients, Significant Others or Caregivers</td>
<td></td>
<td></td>
<td>Laurie Gaspar, University of Colorado, USA</td>
</tr>
<tr>
<td>16:20</td>
<td>OA16.03: The ALCF Centers of Excellence Model Delivers a Standard of Care to the Community Similar to Academic and Research Centers</td>
<td></td>
<td></td>
<td>Raymond Osarogiagbon, Baptist Cancer Center, USA</td>
</tr>
<tr>
<td>16:30</td>
<td>OA16.04: Discussant</td>
<td></td>
<td></td>
<td>Joan Schiller, UT Southwestern, USA</td>
</tr>
<tr>
<td>16:45</td>
<td>OA16.05: Socioeconomic Determinants of Late Diagnosis of Lung Cancer in France: A Nationwide Study (the TERRITOIRE Study)</td>
<td></td>
<td></td>
<td>Pierre Jean Souquet, Lyon Sud Hospital – Civils Hospices, France</td>
</tr>
<tr>
<td>16:55</td>
<td>OA16.06: Willingness for Multiple Biopsies to Improve Quality of Lung Cancer Care: Understanding the Patient Perspective</td>
<td></td>
<td></td>
<td>Utpal Basu Roy, LUNGevity Foundation, USA</td>
</tr>
<tr>
<td>17:05</td>
<td>OA16.07: Patient–Driven Epidemiologic Assessment of ROS1–Fusion Driven Cancers</td>
<td></td>
<td></td>
<td>Guneet Walia, Bonnie J. Addario Lung Cancer Foundation, USA</td>
</tr>
<tr>
<td>17:15</td>
<td>OA16.08: Discussant</td>
<td></td>
<td></td>
<td>Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, Slovakia</td>
</tr>
<tr>
<td>16:00</td>
<td>OA17: Aspects of Health Policies and Public Health</td>
<td>Regional Aspects/Health Policy/Public Health</td>
<td>Schubert 1, Level One</td>
<td>Meinhard Kneussel, Austria &amp; Tudor Ciuleanu, Romania</td>
</tr>
<tr>
<td>16:00</td>
<td>OA17.01: Estimate of Economic Impact of Immune Checkpoint Inhibitors for NSCLC Relative to PD–L1 Expression in the US</td>
<td></td>
<td></td>
<td>Gilberto Lopes, Centro Paulista de Oncologia and Oncoclinicas Group, Brazil</td>
</tr>
<tr>
<td>16:10</td>
<td>OA17.02: Potential Health and Economic Consequences of Organized vs Opportunistic Lung Cancer Screening in Canada</td>
<td></td>
<td></td>
<td>William Evans, Cancer Care Ontario, Canada</td>
</tr>
<tr>
<td>16:20</td>
<td>OA17.03: Insurance Type Influences Stage, Treatment, and Survival in Asian American Lung Cancer Patients</td>
<td></td>
<td></td>
<td>Apichat Tantraworasin, Icahn Medical School at Mount Sinai, USA</td>
</tr>
<tr>
<td>16:30</td>
<td>OA17.04: Discussant</td>
<td></td>
<td></td>
<td>Joan Schiller, UT Southwestern, USA</td>
</tr>
<tr>
<td>16:45</td>
<td>OA17.05: Survival in a Cohort of Patients with Lung Cancer: The Role of Age and Gender on Prognosis</td>
<td></td>
<td></td>
<td>Juliana Franceschini, Universidade Federal de São Paulo, Brazil</td>
</tr>
<tr>
<td>16:55</td>
<td>OA17.06: Make the World Beautiful and Healthy by Making Your Country Smoke Free: Case Study between Iceland and Thailand?</td>
<td></td>
<td></td>
<td>May Cho, Southeast Asia Tobacco Control Alliance, Thailand</td>
</tr>
<tr>
<td>17:05</td>
<td>OA17.07: Time from the Identification of a Suspicious Pulmonary Lesion to the Treatment of Non–Small Cell Lung Cancer</td>
<td></td>
<td></td>
<td>Claire Hiles, San Antonio Military Medical Center, USA</td>
</tr>
<tr>
<td>17:15</td>
<td>OA17.08: Discussant</td>
<td></td>
<td></td>
<td>Govind Babu, Kidwai Memorial Institute of Oncology, India</td>
</tr>
</tbody>
</table>
16:00 – 17:30 | MA13: Modern Technologies and Biological Factors in Radiotherapy

**TRACK:** RADIOThERAPY  
**ROOM:** STOLZ 1  
**CHAIRS:** MICHAEL THOMAS, THORAXKLINIK/UNIVERSITY OF HEIDELBERG, GERMANY & PAUL MITCHELL, AUSTIN HEALTH, AUSTRALIA

- **16:00** | MA13.01: Markerless Tumour Tracking during Lung Radiotherapy Using Intrafraction X-Ray Imaging  
  Chun-Chien (Andy) Shieh, University of Sydney, Australia

- **16:06** | MA13.02: First-In-Human Clinical Experience with Real-Time Tumor Targeting via MLC Tracking for Stereotactic Radiotherapy of Lung Cancer  
  Jeremy Booth, Northern Sydney Cancer Centre, Royal North Shore Hospital, Australia

- **16:12** | MA13.03: Analysis of Intra-Thoracic Anatomical Changes Observed in Clinical Workflow of Cone-Beam CT Guided Radiotherapy for Lung Cancer  
  José Belderbos, The Netherlands Cancer Institute, Netherlands

- **16:18** | MA13.04: Discussant  
  Christoph Pöttgen, Germany

- **16:30** | MA13.05: Nivolumab in Non-Small Cell Lung Cancer (NSCLC): The Real-Life Data  
  Elizabeth Dudnik, Thoracic Cancer Service, Davidoff Cancer Center, Israel

- **16:36** | MA13.06: Integrative Genomic Profiling Identifies BRAF Mutations as Novel Radiotherapeutic Targets in Adenocarcinomas of the Lung  
  Mohamed Abazeed, Cleveland Clinic, USA

- **16:42** | MA13.07: Tumor-Targeted Radiation Promotes Abscopal Efficacy of Regionally Administered CAR T Cells: A Rationale for Clinical Trial  
  Masha Zeltsman, Memorial Sloan Kettering Cancer Center, USA

- **16:48** | MA13.08: Discussant  
  Miklos Pless, Kantonsspital Winterthur, Switzerland

- **17:00** | MA13.09: Serial FDG and FLT PET/CT during Curative-Intent Chemotherapy for NSCLC: Impacts Patient Management and May Predict Clinical Outcomes  
  David Ball, Peter MacCallum Cancer Centre, Australia

- **17:06** | MA13.10: Magnetic Resonance Imaging-Guided Delivery of Lung Stereotactic Radiotherapy Using Patient-Controlled Visual Guidance  
  Shyama Tetar, VU University Medical Center, Netherlands

- **17:12** | MA13.11: Investigating the Feasibility of Establishing a Prospective Cohort of Lung Cancer Patients Following Radiotherapy with Curative Inten  
  Lynn Calman, University of Southampton, UK

- **17:18** | MA13.12: Discussant  
  Antonio Juretic, School of Medicine University of Zagreb and University Hospital Center “Zagreb”, Croatia

16:00 – 17:30 | MA14: Immunotherapy in Advanced NSCLC: Biomarkers and Costs

**TRACK:** ADVANCED NSCLC  
**ROOM:** STRAUSS 2  
**CHAIRS:** MARTIN RECK, LUNGEN CLINIC GROSSHANSDORF, GERMANY & DAVID SPIGEL, SARAH CANNON RESEARCH INSTITUTE/TENNESSEE ONCOLOGY, USA

- **16:00** | MA14.01: Updated Dataset Assessing Tumor Mutation Burden (TMB) as a Biomarker for Response to PD-1/PD-L1 Targeted Therapies in Lung Cancer (LC)  
  Siraj Ali, Foundation Medicine, USA

- **16:06** | MA14.02: Evaluation of PD1/PDL1 Expression on Peripheral Blood Cells Subpopulations in Patients with Non-Small Cell Lung Cancer  
  Oscar Arrieta, National Cancer Institute, Mexico

- **16:12** | MA14.03: The Impact of Genomic Landscape of EGFR Mutant NSCLC on Response to Targeted and Immune Therapy  
  Yasir Elamin, MD Anderson Cancer Center, USA

- **16:18** | MA14.04: Discussant  
  Marcin Moniuszko, Medical University of Bialystok, Poland

- **16:30** | MA14.05: Implications of Implementation of a PD-L1 Biomarker-Based Strategy for Treatment of Advanced NSCLC  
  Thomas Burke, Merck & Co., Inc., USA

- **16:36** | MA14.06: Nivolumab in Never Smoker Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)  
  Giuseppe Lo Russo, Fondazione IRCCS – Istituto Nazionale dei Tumori, Italy

- **16:42** | MA14.07: Real Life Experience with Immunotherapy in the Netherlands  
  Robert Schouten, Netherlands Cancer Institute/Antoni van Leeuwenhoek, Netherlands

- **16:48** | MA14.08: Discussant  
  Luis Raez, Memorial Cancer Institute, USA

- **17:00** | MA14.09: Demonstrating Life Expectancy Gains with Immuno-Oncology (IO) Therapies  
  Robert Figlin, Cedars-Sinai Medical Center, USA

- **17:06** | MA14.10: Relative Impact of Disease Management Costs in the Economics of Pembrolizumab in Previously Treated PD-L1 Positive Advanced NSCLC  
  Thomas Burke, Merck & Co., Inc., USA

- **17:12** | MA14.11: An Estimate of the Economic Impact of Immunotherapy Relative to PD-L1 Expression in Brazil – An Update with Brazilian Costs  
  Gilberto Lopes, HCor Cancer Center, Brazil

- **17:18** | MA14.12: Discussant  
  George Simon, MD Anderson Cancer Center, USA
17:45 – 19:15  ISS11: Harnessing the Power of Immunotherapy and Targeted Therapy: Translating Evidence into Practice – Roche  
TRACK: INDUSTRY SUPPORTED SYMPOSIUM  
ROOM: HALL C2  
CHAIR: DAVID SPIGEL, USA  

17:45  Introduction  
David Spigel, Sarah Cannon Research Institute, USA  

17:50  ALK: The Power of Targeted Therapy  
Frank Griesinger, Pius-Hospital Oldenburg, Germany  

18:15  Latest Developments in the Treatment of EGFR Mut+ NSCLC  
Federico Cappuzzo, AUSL Romagna, Italy  

18:30  The Power of the Immune System: Immunotherapy in Practice  
Achim Rittmeyer, Lungenfachklinik Immenhausen, Germany  

19:10  Summary and Close  
David Spigel, Sarah Cannon Research Institute, USA
**WEDNESDAY ▶ DECEMBER 7**

**07:00 – 18:00**
**WARDROBE OPEN**
Hall C
Exit U2 Station ‘Krieau’

**07:00 – 16:00**
**REGISTRATION OPEN**
Foyer D
Exit U2 Station ‘Krieau’

**07:00 – 16:00**
**SPEAKER READY ROOM OPEN**
Hall C

**09:30 – 16:30**
**EXHIBIT HALL OPEN**
Hall B (Exhibit Hall)
Refreshments provided all day

**07:30 – 08:30**
**SH06: WCLC 2016 Scientific Highlights – Radiotherapy, Palliative Care, Regional Aspects**

- **TRACK:** RADIOTHERAPY, PALLIATIVE CARE, REGIONAL ASPECTS
- **ROOM:** HALL C7
- **CHAIRS:** PETER BERZINEC, SLOVAKIA & HERBERT WATZKE, AUSTRIA

**07:30**
SH06.01: Radiotherapy
Christoph Pöttgen, Germany

**07:50**
SH06.02: Palliative Care/Ethics
Corey Langer, University of Pennsylvania, USA

**08:10**
SH06.03: Regional Aspects/Education
Prasanta Mohapatra, All India Institute of Medical Sciences, India

**07:30 – 08:30**
**MTE21: Next Generation Sequencing (Ticketed Session)**

- **TRACK:** BIOLOGY/PATHOLOGY
- **ROOM:** SCHUBERT 1, LEVEL ONE

**07:30**
MTE21.01: Next Generation Sequencing
Xuefei Li, Shanghai Pulmonary Hospital, China & Ignacio Wistuba, The University of Texas MD Anderson Cancer Center, USA

**07:30 – 08:30**
**SH05: WCLC 2016 Scientific Highlights – Chemotherapy, Targeted Therapy and Immunotherapy of Advanced NSCLC**

- **TRACK:** CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
- **ROOM:** HALL C1
- **CHAIRS:** JANA SRŠNÍKOVÁ, UNIVERSITY HOSPITAL AND MEDICAL FACULTY BRNO, CZECH REPUBLIC & MIROSLAV SAMARŽIJA, UNIVERSITY HOSPITAL CENTER ZAGREB, CROATIA

**07:30**
SH05.01: Chemotherapy of Advanced NSCLC
Chandra Belani, Penn State Hershey Cancer Institute, USA

**07:50**
SH05.02: Targeted Therapy of Advanced NSCLC
James Spicer, Guy’s & St. Thomas’ NHS Trust; King’s College London, UK

**08:10**
SH05.03: Immunotherapy of Advanced NSCLC
Lucio Crinò, Perugia Hospital, Italy

**07:30 – 08:30**
**MTE22: Perspectives in Lung Cancer Imaging (Ticketed Session)**

- **TRACK:** RADIOLOGY/STAGING/SCREENING
- **ROOM:** SCHUBERT 2, LEVEL ONE

**07:30**
MTE22.01: Perspectives in Lung Cancer Imaging
Thomas Henzler, Germany & Georgios Karanikas, Austria

**07:00 – 18:00**
**WARDROBE OPEN**
Hall C
Exit U2 Station ‘Krieau’

**07:00 – 16:00**
**REGISTRATION OPEN**
Foyer D
Exit U2 Station ‘Krieau’

**07:00 – 16:00**
**SPEAKER READY ROOM OPEN**
Hall C

**09:30 – 16:30**
**EXHIBIT HALL OPEN**
Hall B (Exhibit Hall)
Refreshments provided all day

**07:30 – 08:30**
**SH06: WCLC 2016 Scientific Highlights – Radiotherapy, Palliative Care, Regional Aspects**

- **TRACK:** RADIOTHERAPY, PALLIATIVE CARE, REGIONAL ASPECTS
- **ROOM:** HALL C7
- **CHAIRS:** PETER BERZINEC, SLOVAKIA & HERBERT WATZKE, AUSTRIA

**07:30**
SH06.01: Radiotherapy
Christoph Pöttgen, Germany

**07:50**
SH06.02: Palliative Care/Ethics
Corey Langer, University of Pennsylvania, USA

**08:10**
SH06.03: Regional Aspects/Education
Prasanta Mohapatra, All India Institute of Medical Sciences, India

**07:30 – 08:30**
**MTE21: Next Generation Sequencing (Ticketed Session)**

- **TRACK:** BIOLOGY/PATHOLOGY
- **ROOM:** SCHUBERT 1, LEVEL ONE

**07:30**
MTE21.01: Next Generation Sequencing
Xuefei Li, Shanghai Pulmonary Hospital, China & Ignacio Wistuba, The University of Texas MD Anderson Cancer Center, USA

**07:30 – 08:30**
**SH05: WCLC 2016 Scientific Highlights – Chemotherapy, Targeted Therapy and Immunotherapy of Advanced NSCLC**

- **TRACK:** CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
- **ROOM:** HALL C1
- **CHAIRS:** JANA SRŠNÍKOVÁ, UNIVERSITY HOSPITAL AND MEDICAL FACULTY BRNO, CZECH REPUBLIC & MIROSLAV SAMARŽIJA, UNIVERSITY HOSPITAL CENTER ZAGREB, CROATIA

**07:30**
SH05.01: Chemotherapy of Advanced NSCLC
Chandra Belani, Penn State Hershey Cancer Institute, USA

**07:50**
SH05.02: Targeted Therapy of Advanced NSCLC
James Spicer, Guy’s & St. Thomas’ NHS Trust; King’s College London, UK

**08:10**
SH05.03: Immunotherapy of Advanced NSCLC
Lucio Crinò, Perugia Hospital, Italy

**07:30 – 08:30**
**MTE22: Perspectives in Lung Cancer Imaging (Ticketed Session)**

- **TRACK:** RADIOLOGY/STAGING/SCREENING
- **ROOM:** SCHUBERT 2, LEVEL ONE

**07:30**
MTE22.01: Perspectives in Lung Cancer Imaging
Thomas Henzler, Germany & Georgios Karanikas, Austria
07:30 – 08:30  MTE23: Biomarker Characterization: Challenges and Perspectives
(Ticketed Session)
TRACK: BIOLOGY/PATHOLOGY
ROOM: SCHUBERT 3
Leonhard Müllauer, Medical University Vienna, Austria
Rafael Rosell, Catalan Institute of Oncology, Germans Trias i Pujol Health Sciences Institute and Hospital, Spain

07:30 – 08:30  MTE24: Immunohistochemical Assessment of Biomarkers for Immune Checkpoint Inhibitors
(Ticketed Session)
TRACK: BIOLOGY/PATHOLOGY
ROOM: SCHUBERT 4
Vera Capelozzi, Faculty of Medicine, University of São Paulo, Brazil

07:30 – 08:30  MTE25: Radiotherapy in Small Cell Lung Cancer
(Ticketed Session)
TRACK: SCLC/NEUROENDOCRINE TUMORS
ROOM: SCHUBERT 5
Cecile Le Pechoux, Gustave Roussy, France & Andrew Turrisi, Institution, Germany

07:30 – 08:30  MTE26: EGFR Targeted Therapies: Lessons Learned
(Ticketed Session)
TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: SCHUBERT 6
Frederico Cappuzzo, AUSL della Romagna, Italy & Shun Lu, Shanghai Chest Hospital, Jiao Tong University, China

07:30 – 08:30  MTE27: Treatment of Lung Cancer Patients with Poor Performance Status
(Ticketed Session)
TRACK: PALLIATIVE CARE/ETHICS
ROOM: LEHAR 1–2
Rogério Lilienbaum, Yale Cancer Center, USA & Luboš Petruzelka, Charles University, Czech Republic

07:30 – 08:30  MTE28: Implementation of Precision Medicine in Routine Practice: The Latin American Experience
(Ticketed Session)
TRACK: REGIONAL ASPECTS/HEALTH POLICY/PUBLIC HEALTH
ROOM: LEHAR 3–4
Mercedes Dalurzo, Hospital Italiano de Buenos Aires, Argentina
Marileila Varella–Garcia, University of Colorado School of Medicine, USA

07:30 – 08:30  MTE29: Advances in Malignant Pleural Mesothelioma
(Ticketed Session)
TRACK: MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES
ROOM: STOLZ 1
Paolo Boffetta, Icahn School of Medicine at Mount Sinai, USA
Shun Lu, Shanghai Chest Hospital, Jiao Tong University, China
07:30 – 08:30  MTE30: Non-intubated Thoracic Surgery (Ticketed Session)  
TRACK: SURGERY  
ROOM: STOLZ 2

07:30  MTE30.01: Non-intubated Thoracic Surgery  
Teodor Horvath, Czech Republic, Jin-Shing Chen, Taiwan & Ya-Jung Cheng, Taiwan

07:30 – 08:30  WS09: Special Workshop: Tobacco Free Portfolios  
TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION  
ROOM: STRAUSS 2

07:30  WS09.01: Learn How to Change the World for the Better – One Pension Fund at a Time!  
Bronwyn King, Tobacco Free Portfolios, Australia

08:45 – 09:40  PL04a: Immune Checkpoint Inhibitors in Advanced NSCLC  
TRACK: ADVANCED NSCLC  
ROOM: HALL D (PLENARY HALL)  
CHAIRS: JEAN-CHARLES SORIA, FRANCE & CAICUN ZHOU, CHINA

08:45  PL04a.01: Health–Related Quality of Life for Pembrolizumab vs Chemotherapy in Advanced NSCLC with PD–L1 TPS ≥50%: Data from KEYNOTE–024  
Julie Brahmer, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

08:55  PL04a.02: OAK, a Randomized Ph III Study of Atezolizumab vs Docetaxel in Patients with Advanced NSCLC: Results from Subgroup Analyses  
Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA

09:05  PL04a.03: Durvalumab in ≥3rd–Line Locally Advanced or Metastatic, EGFR/ALK Wild–Type NSCLC: Results from the Phase 2 ATLANTIC Study  
Marina Garassino, Fondazione IRCCS Istituto Nazionale dei Tumori, Italy

09:15  PL04a.04: Multicentric French Harmonization Study for PD–L1 IHC Testing in NSCLC  
Julien Adam, Gustave Roussy Cancer Campus, France

09:25  PL04a.05: Discussant  
Michael Boyer, Chris O’Brien Lifehouse, Australia

09:45 – 10:15  PL04b: Plenary Keynote Lecture  
ROOM: HALL D (PLENARY HALL)  
CHAIRS: FRED HIRSCH, USA & ROBERT PIRKER, AUSTRIA

09:45  PL04b.01: The Role of Doctors in a Globalized World  
Alfred Gusenbauer, Former Federal Chancellor of the Republic of Austria

10:25 – 11:00  NETWORKING OPPORTUNITY & POSTER PRESENTERS PRESENT FOR P3 POSTERS  
Hall B (Exhibit Hall)  
Refreshments provided

10:30 – 11:45  PR04: Press Conference  
ROOM: SCHUBERT 1, LEVEL ONE  
For information on topics and speakers, please visit the Press & Media page on the Conference website at wclc2016.iaslc.org/press-media/press-media/

11:00 – 12:30  ED11: Advanced NSCLC: State–of–the–Art Treatment  
TRACK: ADVANCED NSCLC  
ROOM: HALL C8  
CHAIRS: CHRISTIAN MANEGOLD, MEDICAL FACULTY MANNHEIM, UNIVERSITY OF HEIDELBERG, GERMANY & CAICUN ZHOU, SHANGHAI PULMONARY HOSPITAL, TONGJI UNIVERSITY, CHINA

11:00  ED11.01: Systemic Therapy for Advanced Oncogene–Driven NSCLC  
David R. Gandara, UC Davis Comprehensive Cancer Center, USA

11:25  ED11.02: Systemic Therapy for Advanced Non–Oncogene–Driven NSCLC  
Giorgio Scagliotti, University of Torino, Italy

11:50  ED11.03: Management of Oligo–Metastatic NSCLC  
Jaroslaw Kuzdzal, Jagiellonian University, Poland

12:10  ED11.04: Palliative Radiotherapy of Advanced NSCLC  
Karim Dieckmann, Medical University of Vienna, Austria
11:00 – 12:30  ED12: Regional Tobacco Control Policies: Advances & Challenges

TRACK: EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION
ROOM: HALL C7
CHAIRS: ZARIHAA ZAIN, LINCOLN UNIVERSITY COLLEGE MALAYSIA, MALAYSIA & FLORIN MIHALTAN, NATIONAL INSTITUTE OF PNEUMOLOGY, ROMANIA

11:00 ED12.01: Tobacco Control Policies in Eastern Europe
Gábor Kovács, National Körányi Institute for TB and Pulmonology, Hungary

11:15 ED12.02: Tobacco Control: The Turkish Experience
Nazmi Bilir, Hacettepe University, Turkey

11:30 ED12.03: Tobacco Control: The Indian Experience
Surendra Shastri, Tata Memorial Center, India

11:45 ED12.04: Tobacco Control Policies in China
Xiuyi Zhi, Xuanwu Hospital, Capital Medical University, China

12:00 ED12.05: Tobacco Control Policies in Japan
Tomotaka Sobe, Osaka University, Japan

12:15 ED12.06: Tobacco Control Policies in Latin America
Nise Yamaguchi, Hospital Albert Einstein, Brazil

11:00 – 12:30  ED13: Treatment of Malignant Pleural Mesothelioma

TRACK: MESOTHELIOMA/THYMIC MALIGNancies/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNancies
ROOM: HALL C1
CHAIRS: HEDY KINDLER, UNIVERSITY OF CHICAGO, USA & NICO VAN ZANDWIJK, UNIVERSITY OF SYDNEY, AUSTRALIA

11:00 ED13.01: Biomarkers in Malignant Pleural Mesothelioma
Harvey Pass, NYU Langone Medical Center, USA

11:15 ED13.02: Tissue-Based Biomarkers
Glen Reid, Asbestos Diseases Research Institute, Australia

11:30 ED13.03: Surgery with Adjuvant or Induction Radiotherapy
Marc De Perrot, Institution, Canada

11:45 ED13.04: Systemic Induction Therapy of Malignant Pleural Mesothelioma
Paul Baas, Netherlands Cancer Institute, Netherlands

12:00 ED13.05: Systemic Therapy of Inoperable Malignant Pleural Mesothelioma
Arnaud Scherpereel, Hospital of the University (CHRU) of Lille, France

12:15 ED13.06: Mesothelioma in a Setting of Germline BAP1 Mutations
Michele Carbone, University of Hawaii Cancer Center, USA

11:00 – 12:30  SC24: Management of Indeterminate Pulmonary Nodules

TRACK: PULMONOLOGY
ROOM: HALL C2
CHAIRS: NEVENA SECEN, INSTITUTE FOR PULMONARY DISEASES OF VOJVODINA, SERBIA & OLEG PIKIN, HERTZEN RESEARCH INSTITUTE OF ONCOLOGY, RUSSIA

11:00 SC24.01: Risk Assessment in the Management of Pulmonary Nodules
Satoshi Shiono, Yamagata Prefectural Central Hospital, Japan

11:20 SC24.02: Radiological Techniques for the Evaluation of Pulmonary Nodules
Reginald Munden, Wake Forest Baptist Medical Center, USA

11:35 SC24.03: The Role of the Pulmonologist in the Management of Pulmonary Nodules
Philippe Lambin, The Netherlands

11:50 SC24.04: The Role of the Pathologist in the Management of Indeterminate Pulmonary Nodules
Keith Kerr, Aberdeen University Medical School, UK

12:10 SC24.05: Indication and Techniques of Surgery
Ugo Pastorino, Fondazione IRCCS Istituto Nazionale Tumori, Italy
### SC25: The Role of Surgeons in Multimodality Clinical Trials
**Track:** SURGERY  
**Room:** STRAUSS 2  
**Chair:** NORIHIKO IKEDA, TOKYO MEDICAL UNIVERSITY, JAPAN & GEORGIOS STAMATIS, RUHRLANDKLINIK/UNIVERSITY ESSEN, GERMANY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>SC25.01</td>
<td>Trial Design for Multimodality Treatment of NSCLC</td>
<td>David Jones, Memorial Sloan Kettering Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>SC25.02</td>
<td>Quality of Resection in Induction and Adjuvant Clinical Trials</td>
<td>Eric Vallieres, Swedish Cancer Institute, USA</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>SC25.03</td>
<td>Quality of Centers and Patient Inclusion</td>
<td>John Edwards, Sheffield Teaching Hospitals NHS Foundation Trust, UK</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>SC25.04</td>
<td>The Importance of Cooperation: The Essen Experience</td>
<td>Wilfried Eberhardt, University of Essen, Germany</td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td></td>
<td>Multimodality Trials: The Chinese Experience</td>
<td>Ke-Neng Chen, China</td>
<td></td>
</tr>
</tbody>
</table>

### SC26: Angiogenesis Inhibition: Advances & Perspectives
**Track:** BIOLOGY/PATHOLOGY  
**Room:** LEHAR 3–4  
**Chairs:** TAKASHI SETO, NATIONAL KYUSHU CANCER CENTER, JAPAN & ROSS SOO, NATIONAL UNIVERSITY HEALTH SYSTEM, SINGAPORE

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>SC26.01</td>
<td>Biology of Angiogenesis</td>
<td>John Heymach, The University of Texas MD Anderson Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>SC26.02</td>
<td>Angiogenesis Inhibition in Lung Cancer: Recent Advances and Perspectives</td>
<td>Michael Boyer, Chris O’Brien Lifehouse, Australia</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>SC26.03</td>
<td>Predictive Biomarkers for Angiogenesis Inhibitors: An Update</td>
<td>Martin Reck, Lungen Clinic Grosshansdorf, Germany</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>SC26.04</td>
<td>Novel Imaging Technique</td>
<td>Stefan Schönberg, University Medical Center Mannheim, Medical Faculty Mannheim, Heidelberg University, Germany</td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td></td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SC27: P53 and KRAS Mutations in NSCLC
**Track:** BIOLOGY/PATHOLOGY  
**Room:** STRAUSS 3  
**Chairs:** FILIPPO DE MARINIS, EUROPEAN INSTITUTE OF ONCOLOGY, ITALY & HIDEO KUNITOH, JAPANESE RED CROSS MEDICAL CENTER, JAPAN

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>SC27.01</td>
<td>The Role of p53 in Lung Cancer</td>
<td>Pierre Hainaut, International Agency for Research on Cancer, France</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>SC27.02</td>
<td>Biology of KRAS Mutations</td>
<td>József Tímár, Semmelweis University (SE), Hungary</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>SC27.03</td>
<td>Transforming KRAS into a Clinically Relevant Biomarker</td>
<td>Kenneth O’Byrne, Princess Alexandra Hospital, Australia</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>SC27.04</td>
<td>KRAS–Directed Drug Therapy in Advanced NSCLC</td>
<td>Pasi Jänne, Dana Farber Cancer Institute, USA</td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td></td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### SC28: Novel Clinical Trial Designs
**Track:** TRIAL DESIGN/STATISTICS  
**Room:** LEHAR 1–2  
**Chairs:** STEFAN MICHELS, GUSTAVE ROUSSY, FRANCE & LOTHAR PILZ, UNIVERSITY OF HEIDEBERG, MEDICAL FACULTY MANNHEIM, GERMANY

<table>
<thead>
<tr>
<th>Time</th>
<th>Session</th>
<th>Title</th>
<th>Speaker</th>
<th>Institution</th>
</tr>
</thead>
<tbody>
<tr>
<td>11:00</td>
<td>SC28.01</td>
<td>Phase I Trials of Targeted Therapies</td>
<td>Alex Adjei, Roswell Park Cancer Institute, USA</td>
<td></td>
</tr>
<tr>
<td>11:20</td>
<td>SC28.02</td>
<td>Umbrella and Basket Designs</td>
<td>Daniel Shao–Weng Tan, National Cancer Centre Singapore, Singapore</td>
<td></td>
</tr>
<tr>
<td>11:40</td>
<td>SC28.03</td>
<td>Biomarker “Test and Validation” Designs</td>
<td>Mary Redman, Fred Hutchinson Cancer Research Center, USA</td>
<td></td>
</tr>
<tr>
<td>12:00</td>
<td>SC28.04</td>
<td>Adaptive Clinical Trial Designs</td>
<td>Vassiliki Papadimitrakopoulou, MD Anderson Cancer Center, USA</td>
<td></td>
</tr>
<tr>
<td>12:20</td>
<td></td>
<td>Q&amp;A</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
### SC29: Access, Value Assessments and Affordability of Novel Therapies

#### 11:00 SC29.01: Affordability of Novel Therapies: A Global Challenge
Richard Sullivan, Institute of Cancer Policy, UK

#### 12:00 SC29.04: Solutions for Low-Income Countries
Gilberto Lopes, Sylvester Comprehensive Cancer Center at the University of Miami, USA

#### 12:15 SC29.05: The Thai Experience to Overcome High Cost Drug in Cancer
Sumitra Thongprasert, Bangkok Chiangmai Hospital, Thailand

### SC29: Access, Value Assessments and Affordability of Novel Therapies

#### Track: Patient Support and Advocacy Groups

#### Room: Strauss 1

#### Chairs: Maciej Krzakowski, The Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Poland & Eduardo Richarret, Ionc (Instituto Oncologico de Cordoba), Argentina

#### 11:00 SC29.01: Affordability of Novel Therapies: A Global Challenge
Richard Sullivan, Institute of Cancer Policy, UK

#### 11:20 SC29.02: Value-Based Assessments in Lung Cancer Therapy: The North American Perspective
Ronan Kelly, USA

#### 11:40 SC29.03: Value-Based Assessments in Lung Cancer Therapy: The ESMO Perspective
Nathan Cherny, Shaare Zedek Medical Center, Israel

#### 12:00 SC29.04: Solutions for Low-Income Countries
Gilberto Lopes, Sylvester Comprehensive Cancer Center at the University of Miami, USA

#### 12:15 SC29.05: The Thai Experience to Overcome High Cost Drug in Cancer
Sumitra Thongprasert, Bangkok Chiangmai Hospital, Thailand

### OA18: New Insights in the Treatment of Thymic Malignancies

#### Track: Mesothelioma/Thymic Malignancies/Esophageal Cancer/Other Thoracic Malignancies

#### Room: Schubert 2, Level One

#### Chair: Nicolas Girard, Hospices Civils de Lyon, France & Stefan Watzka, Austria

#### 11:00 OA18.01: Postoperative Radiotherapy in Thymic Epithelial Tumors: Insights from the RYTHMIC Prospective Cohort
Clemence Basse, Cancer Center, France

#### 11:10 OA18.02: Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma
Arun Rajan, Center for Cancer Research, NCI, NIH, USA

#### 11:20 OA18.03: Safety and Clinical Activity of Avelumab (MSB0010718C; Anti-PD-L1) in Patients with Advanced Thymic Epithelial Tumors (TETs)
Arun Rajan, Center for Cancer Research, NCI, NIH, USA

### OA19: Translational Research in Early Stage NSCLC

#### Track: Early Stage NSCLC

#### Room: Schubert 3

#### Chairs: Gerwin Heller, Medical University of Vienna, Austria & Glenwood Goss, University of Ottawa, Canada

#### 11:00 OA19.01: A Standardized and Validation of Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium
Raphael Bueno, Brigham and Women's Hospital/Harvard Medical School, USA

#### 11:10 OA19.02: Sex Differences Are Detected in the Profile of Tumor Associated Inflammatory Cells (TAICs) Are Lung Adenocarcinoma
Carmen Behrens, Thoracic/Head and Neck Medical Oncology, USA

#### 11:20 OA19.03: Identify Lung Adenocarcinoma in Situ Among Pulmonary Micro-Nodules Through Blood Gene Expression Profiles
Baohui Han, Shanghai Chest Hospital, China

#### 11:30 OA19.04: Discussant
Charles Rudin, Memorial Sloan Kettering Cancer Center, USA

#### 11:45 OA19.05: High Oncofetal Chondroitin Sulfate Expression is an Independent Prognostic Factor of Poor Survival in Early-Stage NSCLC
Zoltan Lohinai, National Koranyi Institute of Pulmonology, Hungary
11:55 OA19.06: Adjuvant Chemotherapy Decisions Based on Molecular Risk Status Improves Outcomes in Early Stage, Non–Small Cell Lung Cancer
Gavitt Woodard, University of California, San Francisco, USA

12:05 OA19.07: Difference of Postoperative Survival Due to the Type of EGFR Gene Mutation in Surgically Resected Lung Adenocarcinomas
Kazuki Hayasaka, Yamagata Prefectural Central Hospital, Japan

12:15 OA19.08: Discussant
Ken Olausen, Gustave Roussy, France

11:00 – 12:30 OA20: Immunotherapy and Markers
TRACK: BIOLOGY/PATHOLOGY
ROOM: STOLZ 2
CHAIR: MARTIN FRÜH, KANTONSSPITAL ST. GALLEN, SWITZERLAND & CLARISSA BALDOTTO, BRAZIL

11:00 OA20.01: Tumor Mutation Burden (TMB) is Associated with Improved Efficacy of Atezolizumab in 1L and 2L+ NSCLC Patients
Marcin Kowanetz, Genentech, Inc, USA

11:10 OA20.02: Neoadjuvant Targeting in NSCLC Patients with Complete Response to Anti–PD–1 Immunotherapy
Kellie Smith, Johns Hopkins University School of Medicine, USA

11:20 OA20.03: Tumoral IL–7 Receptor is a Potential Target for Lung Adenocarcinoma Immunotherapy
Zachary Tano, Memorial Sloan Kettering Cancer Center, USA

11:30 OA20.04: Discussant
Wolfgang Hilbe, Austria

11:45 OA20.05: The Influence of Neoadjuvant Chemotherapy, on Immune Response Profile in Non–Small Cell Lung Carcinomas
Jaime Rodriguez–Canales, U.T.–M.D. Anderson Cancer Center, Translational Molecular Pathology, USA

11:55 OA20.06: Prospective Immunogenomic PrOfiling of Non–Small Cell Lung Cancer – The ICON Project
Boris Sepesi, UT MD Anderson Cancer Center, USA

12:05 OA20.07: HHLA2, a New Immune Checkpoint Member of the B7 Family, is Widely Expressed in Human Lung Cancer and Associated with Mutational Status
Haifying Cheng, Albert Einstein College of Medicine/ Montefiore Medical Center, USA

12:15 OA20.08: Discussant
Helmut Popper, Medical University Graz, Austria

11:00 – 12:30 OA21: Palliative and Supportive Care for Lung Cancer Patients
TRACK: PALLIATIVE CARE/ETHICS
ROOM: SCHUBERT 5
CHAIRS: CARLOS SILVA, HOSPITAL BRITANICO DE BUENOS AIRES, ARGENTINIA & HERBERT WATZKE, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA

11:00 OA21.01: Pooled Analysis of the Incidence and Risk of Treatment–Related Pneumonitis with Anti–PD–1/PD–L1 Therapies in Cancer Patients
Shaodong Hong, Sun Yat–sen University Cancer Center, China

11:10 OA21.02: ALK–Rearranged Non–Small Cell Lung Cancer is Associated with a High Rate of Venous Thromboembolism
Alona Zer, Rabin Medical Center, Israel

11:20 OA21.03: Unmet Needs in Physical and Emotional Side Effects during Lung Cancer Treatment and Survivorship
Jennifer King, Lung Cancer Alliance, USA

11:30 OA21.04: Discussant
Navneet Singh, Postgraduate Institute of Medical Education and Research (PGIMER), India

11:45 OA21.05: Wet M1a Non–Small Cell Lung Cancer: Is It Possible to Predict Recurrence of Pleural Effusion?
Riad Younes, Oncology Center Hospital Alemão Oswaldo Cruz, Brazil

11:55 OA21.06: Turning Best Supportive Care into Active Care. A Service Development for Patients with Advanced Lung Cancer in NHS Fife, Scotland
Joanna Bowden, NHS Fife, UK

12:05 OA21.07: Discussant
Eva Masel, Medical University of Vienna, Austria

12:20 Q&A

TRACK: INDUSTRY SUPPORTED SYMPOSIUM
ROOM: LEHAR 3–4
CHAIR: DAVID CARBONE, THE OHIO STATE WEXNER MEDICAL CENTER, USA

12:45 ISS12.01: Welcome and Opening Remarks
David Carbone, The Ohio State Wexner Medical Center, USA

12:50 ISS12.02: Immunotherapy Experience in Lung Cancer
Naiyer Rizvi, Columbia University Medical Center, USA

13:05 ISS12.03: The Value of Biomarkers in Lung Cancer
Keith Kerr, Aberdeen University Medical School, UK
13:20 ISS12.04: Patient Management
Thomas Newsom-Davis, Chelsea & Westminster Hospital, UK

13:35 ISS12.05: Lung Cancer Landscape: Future Directions
David Carbone, The Ohio State Wexner Medical Center, USA

13:50 ISS12.06: Panel Discussion – Faculty
David Carbone, The Ohio State Wexner Medical Center, USA

14:15 ISS12.07: Closing Remarks
David Carbone, The Ohio State Wexner Medical Center, USA

14:20 – 15:50 OA22: Novel Trials and Biomarkers in Malignant Pleural Mesothelioma

14:20 OA22.01: STELLAR – Interim Results of a Phase 2 Trial of TTFIELDS with Chemotherapy for First Line Treatment of Malignant Mesothelioma
Giovanni Ceresoli, Cliniche Humanitas Gavazzeni, Italy

14:30 OA22.02: Nintedanib plus Pemetrexed/Cisplatin in Patients with Malignant Pleural Mesothelioma: Phase II Findings from the Placebo-Controlled LUME-Meso Trial
Federica Grosso, SS Antonio e Biagio Hospital, Italy

14:40 OA22.03: HMGB1, a Target for Mesothelioma Therapy and a Biomarker to Detect Asbestos Exposure and to Identify Mesothelioma Patients
Haining Yang, University of Hawaii Cancer Center, USA

14:50 OA22.04: Discussant
Christian Rolfo, Antwerp University Hospital, Belgium

15:05 OA22.05: Breath Analysis by Gas Chromatography–Mass Spectrometry Can Be Used to Screen for Pleural Mesothelioma
Kevin Lamote, Ghent University, Belgium

15:15 OA22.06: Refinement of the Prognostic miR–Score for Use in Diagnostic Specimens from Chemo–Naïve Malignant Pleural Mesothelioma Patients
Michaela Kirschner, University Hospital Zurich, Division of Thoracic Surgery, Switzerland

15:25 OA22.07: Correlation of CT Scan Based Tumor Volume Measurement to Actual Resected Tumor Volume – A New T-Factor?
Isabelle Opitz, University Hospital Zurich, Division of Thoracic Surgery, Switzerland

15:35 OA22.08: Discussant
Viktoria Laszlo, Medical University Vienna, Austria

14:20 – 15:50 OA23: EGFR Targeted Therapies in Advanced NSCLC

14:20 OA23.01: Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First–Line Treatment of Advanced NSCLC: A Meta–Analysis
Gilberto Lopes, HCor Cancer Center, Brazil

14:30 OA23.02: Efficacy and Safety of Necitumumab Continuation Monotherapy in Patients with EGFR–Expressing Tumors in SQUIRE, a Phase 3 Study
Tudor Ciuleanu, Institute of Oncology Ion Chiricuta and UMF Iuliu Hatieganu, Romania

14:40 OA23.03: Second–Line Afatinib for Advanced Squamous Cell Carcinoma of the Lung: Analysis of Afatinib Long–Term Responders in the Phase III LUX–Lung 8 Trial
Glenwood Goss, University of Ottawa, Canada

14:50 OA23.04: Discussant
Martin Sebastian, Goethe University, Germany

15:05 OA23.05: First–Line Afatinib versus Gefitinib in EGFRm+ Advanced NSCLC: Updated Overall Survival Analysis of LUX–Lung 7
Keunchil Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

15:15 OA23.06: Overall Survival (OS) of EGFR Mutation Positive Non–Small Cell Lung Cancer Patients: Real–World Treatment Patterns of 1,660 Japanese Patients
Kazushi Yoshida, National Cancer Center Hospital, Japan

15:25 OA23.07: Analysis of Outcomes in US IRESSA Clinical Access Program (ICAP) Patients on Gefitinib for More Than 10 Years
Fred R. Hirsch, University of Colorado Cancer Center, USA

15:35 OA23.08: Discussant
Melissa Johnson, Sarah Cannon Research Institute, USA
14:20 – 15:50  OA24: Radiotherapy of Lung Cancer: Recent Developments

TRACK: RADIOTHERAPY
ROOM: STOLZ 2
CHAIR: KARIN DIECKMANN, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA & STEFAN RIEKEN, GERMANY

14:20  OA24.01: Radiotherapy Quality Assurance of Concurrent Chemoradiotherapy in PROCLAIM Phase III Trial
Anthony Brade, Trillium Health Partners, Canada

14:30  OA24.02: Locally Advanced Non–Small Cell Lung Cancer: RadioTherapy with Adaptive Strategy (LARTIA Trial)
Sara Ramella, Campus Bio–Medico University, Italy

14:40  OA24.03: Cardiac Toxicity after Radiation for Stage III NSCLC: Pooled Analysis of Dose–Escalation Trials Delivering 70–90 Gy
Kyle Wang, University of North Carolina Hospitals, USA

14:50  OA24.04: Discussant
Fiona McDonald, UK

15:05  OA24.05: The Nordic HILUS–Trial – First Report of a Phase II Trial of SBRT of Centrally Located Lung Tumors
Karin Lindberg, Karolinska Institutet, Sweden

15:15  OA24.06: Histologic Subtype of Early–Stage Lung Adenocarcinoma is a Predictor of Failure Patterns after Stereotactic Body Radiation Therapy
Abraham Wu, Memorial Sloan Kettering Cancer Center, USA

15:25  OA24.07: The Impact of Population Heterogeneity on the Efficacy of SBRT to the Lung
Mohamed Abazeed, Cleveland Clinic, USA

15:35  OA24.08: Discussant
Feng-Ming (Spring) Kong, USA

14:20 – 15:50  MA15: Immunotherapy Prediction

TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: SCHUBERT 1, LEVEL ONE
CHAIRS: MAYA GOTTFRIED, MEIR MEDICAL CENTER, ISRAEL & OSCAR ARRIETA, MEXICO

14:20  MA15.01: Immunogram for Cancer–Immunity Cycle towards Personalized Immunotherapy of Lung Cancer
Takahiro Karasaki, Graduate School of Medicine, The University of Tokyo, Japan

14:26  MA15.02: Non–Synonymous Mutation Burden in Lung Carcinoma is Associated with Durable Clinical Response to Immune Checkpoint Blockade
Navin Mahadevan, Brigham and Women’s Hospital, USA

14:32  MA15.03: The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD–1 Blockade in Advanced NSCLC
Weijing Cai, Shanghai Pulmonary Hospital, China

14:38  MA15.04: Discussant
Jürgen Fischer, Allergologie–Palliativmedizin–Psychotherapie, Germany

14:50  MA15.05: PD–L1 Immunohistochemistry as Biomarker in Non–Small Cell Lung Cancer (NSCLC)
Dagmar Krenbek, Otto Wagner Hospital, Department of Pathology, Austria

14:56  MA15.06: Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD–1 Axis Therapy in Non–Small Cell Lung Cancer (NSCLC)
Kurt Schalper, Yale University, USA

15:02  MA15.07: Molecular Determinants of Lack of Tumor Immune Infiltration in NSCLC
Thomas Hensing, NorthShore University Health System, USA

15:08  MA15.08: Discussant
Izidor Kern, Slovenia

14:20 – 15:50  MA16: Novel Strategies in Targeted Therapy

TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: STRAUSS 2
CHAIRS: GUNTA PURKALNE, LATVIA & JOACHIM VON PAWEL, GERMANY

14:20  MA16.01: Targeted Gene Therapy for Tobacco Carcinogen–Induced Lung Cancer
Nomundelger Gankhuyag, Seoul National University, South Korea

14:26  MA16.02: Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas
Katerina Politi, Yale University, USA

14:32  MA16.03: Global RET Registry (GLORY): Activity of RET–Directed Targeted Therapies in RET–Rearranged Lung Cancers
Zhong–Yi Dong, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

14:38  MA16.04: Discussant
Martin Früh, Kantonsspital St. Gallen, Switzerland

14:20 – 15:50  OA24: Radiotherapy of Lung Cancer: Recent Developments

TRACK: RADIOTHERAPY
ROOM: STOLZ 2
CHAIR: KARIN DIECKMANN, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA & STEFAN RIEKEN, GERMANY

14:20  OA24.01: Radiotherapy Quality Assurance of Concurrent Chemoradiotherapy in PROCLAIM Phase III Trial
Anthony Brade, Trillium Health Partners, Canada

14:30  OA24.02: Locally Advanced Non–Small Cell Lung Cancer: RadioTherapy with Adaptive Strategy (LARTIA Trial)
Sara Ramella, Campus Bio–Medico University, Italy

14:40  OA24.03: Cardiac Toxicity after Radiation for Stage III NSCLC: Pooled Analysis of Dose–Escalation Trials Delivering 70–90 Gy
Kyle Wang, University of North Carolina Hospitals, USA

14:50  OA24.04: Discussant
Fiona McDonald, UK

15:05  OA24.05: The Nordic HILUS–Trial – First Report of a Phase II Trial of SBRT of Centrally Located Lung Tumors
Karin Lindberg, Karolinska Institutet, Sweden

15:15  OA24.06: Histologic Subtype of Early–Stage Lung Adenocarcinoma is a Predictor of Failure Patterns after Stereotactic Body Radiation Therapy
Abraham Wu, Memorial Sloan Kettering Cancer Center, USA

15:25  OA24.07: The Impact of Population Heterogeneity on the Efficacy of SBRT to the Lung
Mohamed Abazeed, Cleveland Clinic, USA

15:35  OA24.08: Discussant
Feng-Ming (Spring) Kong, USA

14:20 – 15:50  MA15: Immunotherapy Prediction

TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: SCHUBERT 1, LEVEL ONE
CHAIRS: MAYA GOTTFRIED, MEIR MEDICAL CENTER, ISRAEL & OSCAR ARRIETA, MEXICO

14:20  MA15.01: Immunogram for Cancer–Immunity Cycle towards Personalized Immunotherapy of Lung Cancer
Takahiro Karasaki, Graduate School of Medicine, The University of Tokyo, Japan

14:26  MA15.02: Non–Synonymous Mutation Burden in Lung Carcinoma is Associated with Durable Clinical Response to Immune Checkpoint Blockade
Navin Mahadevan, Brigham and Women’s Hospital, USA

14:32  MA15.03: The Predictive Value of Mutation/Neoantigen Burden from ctDNA on the Efficacy of PD–1 Blockade in Advanced NSCLC
Weijing Cai, Shanghai Pulmonary Hospital, China

14:38  MA15.04: Discussant
Jürgen Fischer, Allergologie–Palliativmedizin–Psychotherapie, Germany

14:50  MA15.05: PD–L1 Immunohistochemistry as Biomarker in Non–Small Cell Lung Cancer (NSCLC)
Dagmar Krenbek, Otto Wagner Hospital, Department of Pathology, Austria

14:56  MA15.06: Predictive Value of Measuring Somatic Mutations and Tumor Infiltrating Lymphocytes for PD–1 Axis Therapy in Non–Small Cell Lung Cancer (NSCLC)
Kurt Schalper, Yale University, USA

15:02  MA15.07: Molecular Determinants of Lack of Tumor Immune Infiltration in NSCLC
Thomas Hensing, NorthShore University Health System, USA

15:08  MA15.08: Discussant
Izidor Kern, Slovenia

14:20 – 15:50  MA16: Novel Strategies in Targeted Therapy

TRACK: CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
ROOM: STRAUSS 2
CHAIRS: GUNTA PURKALNE, LATVIA & JOACHIM VON PAWEL, GERMANY

14:20  MA16.01: Targeted Gene Therapy for Tobacco Carcinogen–Induced Lung Cancer
Nomundelger Gankhuyag, Seoul National University, South Korea

14:26  MA16.02: Mutational Landscape of TKI Naïve and Resistant EGFR Mutant Lung Adenocarcinomas
Katerina Politi, Yale University, USA

14:32  MA16.03: Global RET Registry (GLORY): Activity of RET–Directed Targeted Therapies in RET–Rearranged Lung Cancers
Zhong–Yi Dong, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

14:38  MA16.04: Discussant
Martin Früh, Kantonsspital St. Gallen, Switzerland
14:50 MA16.05: For EGFR Mutant Non–Small Cell Lung Cancer, Treatment Sequence Matters? Ho Jung An, St. Vincent’s Hospital, The Catholic University of Korea, South Korea

14:56 MA16.06: Phase I/II Study of AC0010, Mutant–Selective EGFR Inhibitor, in Non–Small Cell Lung Cancer (NSCLC) Patients with EGFR T790M Mutation Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, China

15:02 MA16.07: Drug Repurposing to Overcome De Novo Resistance of Non–Traditional EGFR Mutations Jacqueyne Robichaux, University of Texas MD Anderson Cancer Center, USA

15:08 MA16.08: Discussant Thanyanan Reungwetwattana, Ramathibodi Hospital, Thailand

15:20 MA16.09: Antitumor Activity and Safety of Crizotinib in Patients with MET Exon 14–Altered Advanced Non–Small Cell Lung Cancer Alex Drilon, Memorial Sloan Kettering Cancer Center, USA

15:26 MA16.10: Lung–MAP (S1400) Lung Master Protocol: Accrual and Genomic Screening Updates Vassiliki Papadimitrakopoulou, MD Anderson Cancer Center, USA

15:26 MA16.11: CNS Response to Osimertinib in Patients with T790M–Positive Advanced NSCLC: Pooled Data from Two Phase II Trials Glenwood Goss, The Ottawa Hospital Cancer Centre, University of Ottawa, Canada

15:38 MA16.12: Discussant Edgardo Santos, Lynn Cancer Institute, USA

14:20 – 15:50 MA17: Genetic Drivers TRACK: BIOLOGY/PATHOLOGY ROOM: LEHAR 1–2 CHAIRS: MIYAKO SATOUCHI, HYOGO CANCER CENTER, JAPAN GEORGE SIMON, MD ANDERSON CANCER CENTER, USA

14:20 MA17.01: Microarray Identification of Genetic Drivers of Brain Metastasis in Lung Adenocarcinoma Gavitt Woodard, University of California, San Francisco, USA

14:26 MA17.02: Genome–Wide Copy Number and Mutational Analysis in Longitudinal Biopsies of Matched Primary and Metastatic Pulmonary Adenocarcinomas Thomas Lorber, Institute for Pathology, Switzerland

14:32 MA17.03: Identifying Genomic Alteration and Inter–Tumor Heterogeneity of Multiple Primary Lung Cancers by Targeted NGS of Tumor Tissue and ctDNA Kezhong Chen, Peking University People’s Hospital, China

14:38 MA17.04: Discussant József Tímár, Semmelweis University, Hungary

14:50 MA17.05: Evolutionary Trajectories of Molecular Progression in Different Subtypes of Primary Lung Adenocarcinomas Hao–ran Zhai, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University, China

14:56 MA17.06: Landscape of Somatic Mutations Involving Lung Cancer Associated Genes in Non–Small Cell Lung Cancer (NSCLC) Patient–Derived Xenografts Vibha Raghavan, Princess Margaret Cancer Centre, Canada

15:02 MA17.07: Circulating Tumor DNA Detects Minimal Residual Disease and Predicts Outcome in Localized Lung Cancer Maximilian Diehn, Stanford University, USA

15:08 MA17.08: Discussant Leonhard Müllauer, Medical University Vienna, Austria

15:20 MA17.09: Premature Fibroblast Senescence in Large Cell Carcinoma Provides Enhanced Growth and Invasive Advantages to Cancer Cells in Culture and in vivo Marta Gabasa, Facultat de Medicina, Universitat de Barcelona, Spain

15:26 MA17.10: YES1 Kinase is a New Therapeutic Target in Non–small Cell Lung Cancer Luis Montuenga, CIMA. University of Navarra, Spain

15:32 MA17.11: Knockdown of Akt2 Suppresses Tumorigenesis and Raf1 Overexpression Offsets This Effect in Non–Small Cell Lung Cancer Shuang Zhao, Department of Respiratory Medicine, West China Hospital, Sichuan University, Chengdu 610041, China., China

15:38 MA17.12: Discussant Sanja Dacic, University of Pittsburgh, USA
<table>
<thead>
<tr>
<th>Time</th>
<th>Session Title</th>
<th>Track/Room</th>
<th>Chairs/Location</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30 – 15:45</td>
<td>ED14: Small Cell Lung Cancer</td>
<td>SCLC/NEUROENDOCRINE TUMORS (Hall C2)</td>
<td>JENS BENN SORENSEN, FINSEN CENTRE/NATIONAL UNIVERSITY HOSPITAL, DENMARK &amp; SABINE ZOCHBAUER–MULLER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA</td>
</tr>
<tr>
<td>14:30</td>
<td>ED14.01: Chemotherapy of Small Cell Lung Cancer</td>
<td>SCLC/NEUROENDOCRINE TUMORS (Hall C2)</td>
<td>JENS BENN SORENSEN, FINSEN CENTRE/NATIONAL UNIVERSITY HOSPITAL, DENMARK &amp; SABINE ZOCHBAUER–MULLER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA</td>
</tr>
<tr>
<td>14:45</td>
<td>ED14.02: Thoracic Radiotherapy of SCLC</td>
<td>SCLC/NEUROENDOCRINE TUMORS (Hall C2)</td>
<td>JENS BENN SORENSEN, FINSEN CENTRE/NATIONAL UNIVERSITY HOSPITAL, DENMARK &amp; SABINE ZOCHBAUER–MULLER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA</td>
</tr>
<tr>
<td>15:00</td>
<td>ED14.03: Update on Prophylactic Cranial Irradiation in SCLC</td>
<td>SCLC/NEUROENDOCRINE TUMORS (Hall C2)</td>
<td>JENS BENN SORENSEN, FINSEN CENTRE/NATIONAL UNIVERSITY HOSPITAL, DENMARK &amp; SABINE ZOCHBAUER–MULLER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA</td>
</tr>
<tr>
<td>15:15</td>
<td>ED14.04: Is There a Role for Surgery in SCLC?</td>
<td>SCLC/NEUROENDOCRINE TUMORS (Hall C2)</td>
<td>JENS BENN SORENSEN, FINSEN CENTRE/NATIONAL UNIVERSITY HOSPITAL, DENMARK &amp; SABINE ZOCHBAUER–MULLER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA</td>
</tr>
<tr>
<td>15:30</td>
<td>ED14.05: Immunotherapy of Small Cell Lung Cancer</td>
<td>SCLC/NEUROENDOCRINE TUMORS (Hall C2)</td>
<td>JENS BENN SORENSEN, FINSEN CENTRE/NATIONAL UNIVERSITY HOSPITAL, DENMARK &amp; SABINE ZOCHBAUER–MULLER, MEDICAL UNIVERSITY OF VIENNA, AUSTRIA</td>
</tr>
<tr>
<td>14:30 – 15:50</td>
<td>ED15: Thymic Malignancies: Update on Treatment</td>
<td>MALIGNANCIES (Hall C1)</td>
<td>HEATHER WAKELEE, STANFORD CANCER INSTITUTE, USA &amp; PAUL VAN SCHIL, ANwerp university hospital, belgium</td>
</tr>
<tr>
<td>14:30</td>
<td>ED15.01: Biology of Thymic Epithelial Tumors</td>
<td>MALIGNANCIES (Hall C1)</td>
<td>HEATHER WAKELEE, STANFORD CANCER INSTITUTE, USA &amp; PAUL VAN SCHIL, ANwerp university hospital, belgium</td>
</tr>
<tr>
<td>14:50</td>
<td>ED15.02: Chemotherapy and Targeted Therapies of Thymic Malignancies</td>
<td>MALIGNANCIES (Hall C1)</td>
<td>HEATHER WAKELEE, STANFORD CANCER INSTITUTE, USA &amp; PAUL VAN SCHIL, ANwerp university hospital, belgium</td>
</tr>
<tr>
<td>15:10</td>
<td>ED15.03: Surgery of Thymic Malignancies</td>
<td>MALIGNANCIES (Hall C1)</td>
<td>HEATHER WAKELEE, STANFORD CANCER INSTITUTE, USA &amp; PAUL VAN SCHIL, ANwerp university hospital, belgium</td>
</tr>
<tr>
<td>15:30</td>
<td>ED15.04: Radiation of Thymic Malignancies</td>
<td>MALIGNANCIES (Hall C1)</td>
<td>HEATHER WAKELEE, STANFORD CANCER INSTITUTE, USA &amp; PAUL VAN SCHIL, ANwerp university hospital, belgium</td>
</tr>
<tr>
<td>14:30 – 15:45</td>
<td>SC30: Novel Approaches and Regulation in Surgical Education</td>
<td>SURGERY (Hall C8)</td>
<td>DOMINIQUE GRUNENWALD, UNIVERSITY OF PARIS VI, FRANCE &amp; YOUNG TAE KIM, SEOUL NATIONAL UNIVERSITY HOSPITAL, SOUTH KOREA</td>
</tr>
<tr>
<td>14:30</td>
<td>SC30.01: Robotic Surgery: The Future in Thoracic Surgery?</td>
<td>SURGERY (Hall C8)</td>
<td>DOMINIQUE GRUNENWALD, UNIVERSITY OF PARIS VI, FRANCE &amp; YOUNG TAE KIM, SEOUL NATIONAL UNIVERSITY HOSPITAL, SOUTH KOREA</td>
</tr>
<tr>
<td>14:50</td>
<td>SC30.02: Animal Models for Training of Thoracic Surgeons</td>
<td>SURGERY (Hall C8)</td>
<td>DOMINIQUE GRUNENWALD, UNIVERSITY OF PARIS VI, FRANCE &amp; YOUNG TAE KIM, SEOUL NATIONAL UNIVERSITY HOSPITAL, SOUTH KOREA</td>
</tr>
<tr>
<td>15:10</td>
<td>SC30.03: E-Learning in Thoracic Oncology</td>
<td>SURGERY (Hall C8)</td>
<td>DOMINIQUE GRUNENWALD, UNIVERSITY OF PARIS VI, FRANCE &amp; YOUNG TAE KIM, SEOUL NATIONAL UNIVERSITY HOSPITAL, SOUTH KOREA</td>
</tr>
<tr>
<td>15:30</td>
<td>SC30.04: Impact of Working Time Directives on Thoracic Surgical Training</td>
<td>SURGERY (Hall C8)</td>
<td>DOMINIQUE GRUNENWALD, UNIVERSITY OF PARIS VI, FRANCE &amp; YOUNG TAE KIM, SEOUL NATIONAL UNIVERSITY HOSPITAL, SOUTH KOREA</td>
</tr>
<tr>
<td>14:30 – 15:50</td>
<td>SC31: Together Against Lung Cancer – A Strategy for Success in the 21st Century</td>
<td>SCIENTIFIC CO-OPERATION/RESEARCH GROUPS (Hall C7)</td>
<td>MICHAEL BOYER, CHRIS O'BRIEN LIFEHOUSE, AUSTRALIA &amp; PIETER POSTMUS, INDEPENDENT, UK</td>
</tr>
<tr>
<td>14:30</td>
<td>SC31.01: The Role of Scientific Organizations</td>
<td>SCIENTIFIC CO-OPERATION/RESEARCH GROUPS (Hall C7)</td>
<td>MICHAEL BOYER, CHRIS O'BRIEN LIFEHOUSE, AUSTRALIA &amp; PIETER POSTMUS, INDEPENDENT, UK</td>
</tr>
<tr>
<td>14:50</td>
<td>SC31.02: The Role of Patient Advocacy Groups</td>
<td>SCIENTIFIC CO-OPERATION/RESEARCH GROUPS (Hall C7)</td>
<td>MICHAEL BOYER, CHRIS O'BRIEN LIFEHOUSE, AUSTRALIA &amp; PIETER POSTMUS, INDEPENDENT, UK</td>
</tr>
<tr>
<td>15:10</td>
<td>SC31.03: The Role of Medical Journals</td>
<td>SCIENTIFIC CO-OPERATION/RESEARCH GROUPS (Hall C7)</td>
<td>MICHAEL BOYER, CHRIS O'BRIEN LIFEHOUSE, AUSTRALIA &amp; PIETER POSTMUS, INDEPENDENT, UK</td>
</tr>
<tr>
<td>15:30</td>
<td>SC31.04: The Possibilities of Print &amp; Social Media</td>
<td>SCIENTIFIC CO-OPERATION/RESEARCH GROUPS (Hall C7)</td>
<td>MICHAEL BOYER, CHRIS O'BRIEN LIFEHOUSE, AUSTRALIA &amp; PIETER POSTMUS, INDEPENDENT, UK</td>
</tr>
</tbody>
</table>
### 14:30 – 15:45 NU05: Survivorship

**Track:** Nurses

**Room:** Schubert 5

**Chairs:** Beth Ivimey, Chris O’Brien Lifehouse, Australia & Maria Guerin, Aintree University Hospital, UK

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>NU05.01: Use of Inspiratory Muscle Training in Managing Dyspnoea in Lung Cancer Patients</td>
<td>Andreas Charalambous, Cyprus University of Technology, Cyprus</td>
</tr>
<tr>
<td>14:50</td>
<td>NU05.02: Comprehensive Long-Term Care of Lung Cancer Patients: Development of a Novel Thoracic Survivorship Program</td>
<td>James Huang, Institution, USA</td>
</tr>
<tr>
<td>15:10</td>
<td>NU05.03: What can we Learn from Other Tumor Sites About Survivorship</td>
<td>Natalie Doyle, The Royal Marsden NHS Foundation Trust, UK</td>
</tr>
<tr>
<td>15:30</td>
<td>Q&amp;A</td>
<td></td>
</tr>
</tbody>
</table>

### 14:30 – 15:45 YI02: Basics of Radio-Oncology

**Track:** Radiotherapy

**Room:** Strauss 1

**Chairs:** Corinne Faivre-Finn, The University of Manchester and The Christie NHS Foundation Trust, UK & Rolf Lewensohn, Karolinska University Hospital, Sweden

<table>
<thead>
<tr>
<th>Time</th>
<th>Title</th>
<th>Speaker</th>
</tr>
</thead>
<tbody>
<tr>
<td>14:30</td>
<td>YI02.01: PET–CT and MRI for Radiotherapy Planning of Lung Cancer</td>
<td>Ursula Nestle, University Medical Center Freiburg, Germany</td>
</tr>
<tr>
<td>14:50</td>
<td>YI02.02: Modern Treatment Techniques in Lung Cancer: The Advantages of Conformal Radiotherapy, IMRT and Proton Therapy</td>
<td>Satoshi Ishikura, Koshigaya Municipal Hospital, Japan</td>
</tr>
<tr>
<td>15:10</td>
<td>YI02.03: Dose Limitations for Radiotherapy of Lung Cancer</td>
<td>Antonio Juretic, School of Medicine, University of Zagreb and University Hospital Center “Zagreb”, Croatia</td>
</tr>
<tr>
<td>15:30</td>
<td>YI02.04: Career Development in Radiation Oncology</td>
<td>Laurie Gaspar, University of Colorado Denver Health Science Center, USA</td>
</tr>
</tbody>
</table>
16:00 – 18:00

**PL05: Closing Plenary Session: A Life in Thoracic Oncology – Reflections from Giants on Milestones in the Treatment Advances in Lung Cancer**

**ROOM:** HALL C1

**CHAIRS:** PAUL BUNN, JR., UNIVERSITY OF COLORADO DENVER, USA & TONY MOK, THE CHINESE UNIVERSITY OF HONG KONG, HONG KONG

16:00 **PL05.01: Pathology**
Adi Gazdar, University of Texas Southwestern Medical Center, USA

16:15 **PL05.02: Surgery**
Peter Goldstraw, National Heart and Lung Institute, Imperial College, UK

16:30 **PL05.03: Radio–Oncology**
David Ball, Peter MacCallum Cancer Centre, Australia

16:45 **PL05.04: Translational Lung Cancer Research**
Nagahiro Saijo, Japanese Society of Medical Oncology, Japan

17:00 **PL05.05: Chemotherapy**
Thierry Le Chevalier, Gustave Roussy Hospital, France

17:15 **PL05.06: Targeted Therapy**
Frances Shepherd, Princess Margaret Cancer Centre, Canada

17:30 **PL05.07: A Wise Man’s Conclusion**
Lawrence Einhorn, Indiana University, USA

17:45 **PL05.08: Welcome to Yokohama for WCLC 2017**
Hisao Asamura, Keio University School of Medicine, Japan & Keunchil Park, Samsung Med Ctr, Sungkyunkwan University School of Medicine, South Korea

17:55 **PL05.09: Farewell**
Robert Pirker, Medical University of Vienna, Austria

---

Thank you for attending.

We look forward to seeing you in Yokohama in October 2017.
### Poster Sessions

<table>
<thead>
<tr>
<th>Date</th>
<th>Page</th>
</tr>
</thead>
<tbody>
<tr>
<td>Monday, December 5</td>
<td>144</td>
</tr>
<tr>
<td>Tuesday, December 6</td>
<td>166</td>
</tr>
<tr>
<td>Wednesday, December 7</td>
<td>188</td>
</tr>
</tbody>
</table>
### P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSION/PREVENTION
- Tobacco, radon, air pollution, other risk factors: P1.01–001 – P1.01–014
- Protective factors, risk reduction, smoking cessation: P1.01–015 – P1.01–026
- Lung cancer screening, diagnosis: P1.01–027 – P1.01–034
- Prognostic factors, treatment: P1.01–035 – P1.01–051
- Descriptive epidemiology: P1.01–052 – P1.01–059

### P1.02 BIOLOGY/PATHOLOGY
- Driver genes in NSCLC, resistance, and other: P1.02–001 – P1.02–061
- Other thoracic malignancies: P1.02–062 – P1.02–086
- Miscellaneous: P1.02–087

### P1.03 RADIOLOGY/STAGING/SCREENING
- Biology: P1.03–001 – P1.03–007
- Pneumonology: P1.03–008 – P1.03–011
- Radiology: P1.03–012 – P1.03–032
- Screening: P1.03–033 – P1.03–064
- Staging: P1.03–065 – P1.03–084

### P1.04 PULMONOLOGY
- Pulmonology: P1.04–001 – P1.04–028

### P1.05 EARLY STAGE NSCLC
- Translational research & biomarkers: P1.05–001 – P1.05–028
- SBRT: P1.05–029 – P1.05–035
- Surgery: P1.05–036 – P1.05–044
- Neoadjuvant and adjuvant chemotherapy: P1.05–045 – P1.05–054
- Recurrence: P1.05–055 – P1.05–059
- Miscellaneous: P1.05–060 – P1.05–079

### P1.06 ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
- Advanced general: P1.06–001 – P1.06–045
- Advanced elderly: P1.06–046 – P1.06–047

### P1.07 SCLC/NEUROENDOCRINE TUMORS
- Drug treatment alone and in combination with radiotherapy: P1.07–001 – P1.07–015
- Local treatment: P1.07–016 – P1.07–022
- Molecular changes: P1.07–023 – P1.07–035
- Pathology: P1.07–036 – P1.07–039
- Prognostic factors: P1.07–040 – P1.07–043
- SCLC/NEUROENDOCRINE TUMORS IN GENERAL: P1.07–044 – P1.07–055

### P1.08 SURGERY
- Risk assessment & prognostic factors: P1.08–001 – P1.08–024
- Epidemiologic studies in surgery for NSCLC: P1.08–025 – P1.08–031
- Translational studies: P1.08–032 – P1.08–035
- Minimal invasive surgery: P1.08–036 – P1.08–058
- Surgery for locally advanced and advanced NSCLC: P1.08–059 – P1.08–083
- Miscellaneous: P1.08–084
### MONDAY > DECEMBER 5 / POSTERS IN DETAIL

<table>
<thead>
<tr>
<th>Poster Session with Presenters Present</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Presenting Author Stand By Time</strong></td>
<td><strong>Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates.</strong></td>
</tr>
<tr>
<td><strong>Monday, December 5</strong></td>
<td><strong>10:25 - 11:00</strong></td>
</tr>
<tr>
<td></td>
<td><strong>14:30 – 15:45</strong></td>
</tr>
<tr>
<td>Hall B (Exhibit Hall) – Poster Area</td>
<td></td>
</tr>
</tbody>
</table>

### P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION

<table>
<thead>
<tr>
<th>P1.01–001</th>
<th>Reduction of Cigarette Consumption through a National Policy for Tobacco Control in Brazil</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ana Paula Teixeira, National Cancer Institute–Ministry of Health, Brazil</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–002</th>
<th>Environmental Tobacco Smoke Exposure and EGFR Mutations/ALK Translocation in Never Smokers. A Multicentre Study in Spanish Never–Smokers</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mónica Pérez–Ríos, University of Santiago de Compostela, Spain</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–003</th>
<th>Novel Associations between Lung Cancer–Related Genes and Indoor Radon Exposure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Jung Ran Choi, Yonsei University Wonju College of Medicine, South Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–004</th>
<th>Is There Any Role of Residential Radon in Non-Small Cell Lung Cancer (NSCLC) Patients Harboring Molecular Alterations?</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Mezquita, Gustave Roussy, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–005</th>
<th>First of Its Kind Study in India Finds That Government’s Ban on Gutka (Highly Popular Smokeless Tobacco Product) DID NOT Increase Smoking at All</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gaurav Kumar, GMERS Medical College, India</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–006</th>
<th>Interstitial Lung Diseases Are an Antecedent of Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Wonil Choi, Keimyung University School of Medicine, South Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–007</th>
<th>A Cross–Sectional Study on Tobacco Consumption Pattern among Auto Rickshaw Drivers in Chennai City, Tamil Nadu, India</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delfin Lovelina Francis, Tagore Dental College and Hospital, India</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–008</th>
<th>Knowledge, Attitudes, and Smoking Behaviours Among Dental and Medical Students in Chennai, Tamil Nadu, India</th>
</tr>
</thead>
<tbody>
<tr>
<td>Delfin Lovelina Francis, Tagore Dental College and Hospital, India</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–009</th>
<th>Smoking and Lung Cancer: Data from the Single Center in Albania</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fatmir Caushi, University Hospital of Lung Diseases, Albania</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–010</th>
<th>Awareness of Lung Cancer Risk Factors among Lay Persons and Physicians</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laurent Greillier, Hôpital Nord, France</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–011</th>
<th>Roflumilast Attenuates Benzo(a)Pyrene–Induced Lung Cancer via Suppression of Airway Inflammation in Murine Model</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chang Dong Yeo, Catholic University of Korea, South Korea</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–012</th>
<th>Kava Effects on the Metabolism of Tobacco–Specific Carcinogen 4–(Methylnitrosamino)–1–(3–Pyridyl)–1–Butanone (NNK) in Humans</th>
</tr>
</thead>
<tbody>
<tr>
<td>Drew Oostra, University of Minnesota, USA</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–013</th>
<th>Emphysematous Changes and Pulmonary Function for Asbestos–Related Lung Cancer in Japan</th>
</tr>
</thead>
<tbody>
<tr>
<td>Takumi Kishimoto, Okayama Rosai Hospital, Japan</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–014</th>
<th>The Role of Hereditary Factor, Profession and the Habit of Cigarette Smoking in Developing Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Irina Pavlovska, Institute of Epidemiology and Biostatistics, Macedonia</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–015</th>
<th>Polyphenols–Rich Fruit Extracts Prevent Tobacco Specific Nitrosamine–Induced DNA Damage in Lung Epithelial Cells</th>
</tr>
</thead>
<tbody>
<tr>
<td>D.I.M. Amararathna, Dalhousie University, Canada</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–016</th>
<th>An International Epidemiological Analysis of Young Patients Diagnosed with NSCLC (Adjuv – CLICaP)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luis Corrales–Rodriguez, CIMCA / Hospital San Juan de Dios, Costa Rica</td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.01–017</th>
<th>The Dramatic Shift of Lung Cancer toward Young in Prisons</th>
</tr>
</thead>
<tbody>
<tr>
<td>Luc Renault, Hospices Civils de Lyon, Hôpital Lyon Sud, France</td>
<td></td>
</tr>
</tbody>
</table>

---

**Poster Setup Time:**
Monday, December 5
08:30 – 10:15

**Poster Takedown Time:**
Monday, December 5
15:45 – 18:00

(Posters not taken down by 18:00 will be discarded by management)
P1.01–018: Tobacco Use and Perceptions about Cessation Training among Health Professions Students: Estimates by Countries and WHO Regions
Chandrashekar Sreramareddy, International Medical University, Malaysia

P1.01–019: Integration of Tobacco Cessation Counseling in a Lung Screening Program
Matthew Steliga, University of Arkansas for Medical Sciences, USA

P1.01–020: Chemopreventive Effect of Catechin Hydrates against Benzo(a)Pyrene Induced Lung Carcinogenesis in Mice: Plausible Role of ALDH1
Ayaz Shahid, Jamia Hamdard University, India

P1.01–021: The Impact of Smoking Status on Overall Survival in a Population–Based Non–Small Cell Lung Cancer (NSCLC) Surgical Resection Cohort
Nicholas Faris, Baptist Cancer Center, USA

P1.01–022: Smoking Cessation Related to Lung Resection
Tanel Laisaar, Tartu University, Estonia

P1.01–023: Smoking Cessation before Initiation of Chemotherapy in Metastatic Non–Small Lung Cancer: Influence on Prognosis
Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P1.01–024: University Students’ Perceptions about Effectiveness of MPOWER Policies on Tobacco Control in Panama City Panama
Omar Castillo–Fernandez, Instituto Oncologico Nacional, Panama

P1.01–025: Mass Media and Tobacco in Bangladesh: An Investigation on the Role of Mass Media in the Light of Tobacco Control
Tahsina Sadeque, Somoy Television, Bangladesh

P1.01–026: Tobacco Use, Awareness and Cessation among Malayali Tribes, Telagiri Hills, Tamil Nadu, India
Delfin Lovelina Francis, Tagore Dental College and Hospital, India

P1.01 EPIDEMIOLOGY/TOBACCO CONTROL AND CESSATION/PREVENTION – LUNG CANCER SCREENING, DIAGNOSIS

P1.01–027: Increased Risk of Lung Cancer among Women with Superficial TCC: A Potential Risk Cohort for Lung Cancer Screening
Yaakov Tolwin, Tel Aviv University, Israel

P1.01–028: High Risk Older Smokers’ Perceptions, Attitudes and Beliefs About Lung Cancer Screening
Janine Cataldo, University of California, San Francisco, USA

P1.01–029: Personal and Hospital Factors Associated with Limited Surgical Resection, In–Hospital Mortality and Complications in New York State
Wil Lieberman–Cribbin, Icahn School of Medicine at Mount Sinai, USA

P1.01–030: Factors Associated with Margin Positive Resections for Non–Small Cell Lung Cancer (NSCLC) in the Mid–South Region of the US
Matthew Smeltzer, University of Memphis School of Public Health, USA

P1.01–031: Does Malignant Pleural Mesothelioma (MPM) Behaviour Differ among Decades?
Fatma Abou Elkasem, National Cancer Institute, Egypt

P1.01–032: Emergency Department Visits by Lung Cancer Patients in Korea
Dong Won Park, Hanyang University College of Medicine, South Korea

P1.01–033: EGFR Mutation and ALK: Are Patients Being Adequately Tested in Brazil?
Gilberto Lopes, Núcleo de Oncologia da Bahia, Brazil

P1.01–034: ECOG Scale of Performance Status in Lung Cancer at the First Consultation at a National Cancer Institute in a Developing Country in Latin America
Silvia Josefina Ayala Leon, National Cancer Institute Prof.Manuel Riveros, Paraguay

P1.01–035: Trends, Patterns of Treatment and Outcomes in Non–Small Cell Lung Cancer (NSCLC) as a Second Primary: A National Cancer Data Base (NCDB) Analysis
Madhusmita Behera, Winship Cancer Institute of Emory University, USA

P1.01–036: Lung Cancer Screening Program Is Cost Effective in French Setting: A Model Based Study
Christos Chouaid, GRC OncoEst Creteil, France

P1.01–037: Baseline Demographics and Comorbidities of Patients with Advanced NSCLC Compared to the General Population from Two Regions in Sweden
Patrice Verpillat, Boehringer Ingelheim, Germany

P1.01–038: Prognosis Value of Body Mass Index (BMI) and Weight Loss at Diagnosis in Primary Lung Cancer: Results of KBP–2010–CPHG Study
Didier Debieuvre, Groupe Hospitalier Régional Mulhouse Sud Alsace (GHRMSA) – Hôpital Emile Muller, France

P1.01–039: Does Distance between Chest and Surgery Departments Impact Outcome in Lung Cancer Patients? Results of KBP–2010–CPHG Study
Didier Debieuvre, Groupe Hospitalier Régional Mulhouse Sud Alsace (GHRMSA) – Hôpital Emile Muller, France

P1.01–040: Long–Term Survival in Metastatic Non–Small–Cell Lung Cancer: An Investigation Using Surveillance, Epidemiology and End Results Data
Eva Szabo, National Cancer Institute, USA

P1.01–041: Quantitative Imaging Features Predict Response of Immunotherapy in Non–Small Cell Lung Cancer Patients
Ilke Tunali, Namik Kemal University, Turkey
P1.01–042: Molecular Epidemiology of Programmed Cell Death 1–Ligand 1 (PD–L1) Protein Expression in Non–Small Cell Lung Cancer
Matthew Schabath, H Lee Moffitt Cancer Center and Research Institute, USA

P1.01–043: Comparison of Gender, Race Distribution, and Survival in the 1990s to 2010s in Lung Cancer Patients at a Single Institution
Bahar Laderian, University of Miami, Miller School of Medicine, USA

P1.01–044: Accelerometer–Determined Physical Activity and Sedentary Time among Lung Cancer Survivors
Adriana D’Silva, University of Calgary, Canada

P1.01–045: Patient to Hospital Distance in Access to Care and Lung Cancer Surgical Treatment
Wil Lieberman–Cribbin, Icahn School of Medicine at Mount Sinai, USA

P1.01–046: Heterogeneity of NSCLC Surgery Exists in Treatment Patterns and Hospital Costs among Different Centers of China, a Study of 5060 Patients
Jian Zhou, Peking University People’s Hospital, China

P1.01–047: Clinical Presentation and Outcome of Neuroendocrine Lung Tumors in a Brazilian Cohort from 2000 to 2016
Marcelo Corassa, A.C.Camargo Cancer Center, Brazil

P1.01–048: Factors Contributing Delays during Management of Lung Cancer: A Study from Tertiary Level Hospital in Nepal
Sandhya Acharya, National Academy Of Medical Sciences, Bir Hospital, Nepal

P1.01–049: Predictors of High Grade Toxicity of Chemotherapy among Malignant Pleural Mesothelioma Patients
Fatma Abou Elkasem, National Cancer Institute, Egypt

P1.01–050: Overall Survival in Advanced Lung Cancer Patients Treated at Oncosalud–AUNA
Alfredo Aguilar, Oncosalud – AUNA, Peru

P1.01–051: Predictor Variables to ECOG Scale of Performance Status in Lung Cancer at a Developing Country in Latin America
Silvia Josefina Ayala Leon, National Cancer Institute Prof. Manuel Riveros, Paraguay

P1.02  BIOLOGY/PATHOLOGY

P1.02–001: Expressions of Resistance EGFR TKIs in Non Small Cell Lung Cancer At Pham Ngoc Thach Hospital – Viet Nam
Nguyen Lam, Pham Ngoc Thach Hospital, Vietnam

P1.02–002: Is T790M Mutation A “Regulator” for EGFR Signal Pathway Not an Oncogene?
Zheng Wang, Beijing Hospital, China

P1.02–003: ROS1 (D4D6) is Reliable for Immunohistochemistry Detecting of ROS1 Fusion Lung Adenocarcinoma in Malignant Pleural Effusion
Zheng Wang, Beijing Hospital, China

P1.02–004: A Retrospective Analysis of Frequency of ALK Gene Rearrangement in Saudi Lung Patients
Fouad Al Dayel, King Faisal Specialist Hospital and Research Centre, Saudi Arabia

P1.02–005: Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR)
Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

P1.02–006: Interlaboratory Variation in Molecular Testing (EGFR, KRAS and ALK) in Stage IV Non–Squamous Non–Small Cell Lung Cancer in the Netherlands in 2013
Chantal Kuijpers, University Medical Center Utrecht, Netherlands

P1.02–007: Alk Translocated NSCLC in the West of Scotland: Patient Demographics and Outcomes
Nicola Steele, Beatson West of Scotland Cancer Centre, UK

P1.02–008: 2–Year Single Institution Experience with EGFR Plasma Testing in Advanced NSCLC
Izidor Kern, University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia

P1.01  EPIDEMIOLOGY/TOBACCO CONTROL AND CESSION/PREVENTION – DESCRIPTIVE EPIDEMIOLOGY

P1.01–052: Lung Cancer Mortality in Mexico, 1990–2014
Oscar Arrieta, Instituto Nacional de Cancerologa, Mexico

P1.01–053: Lung Cancer in Brazil: Men and Women Differences
Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

P1.01–054: Lung Cancer: Histology, Gender and Age Changes Over Past 30 Years in Brazil
Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

P1.01–055: Clinicopeidemiological Trends of Lung Cancer from a Premier Regional Cancer Centre in South India
Abhijit Das, Cancer Institute (WIA), India

P1.01–056: Lung Cancer Epidemiology in Croatia
Robert Zorica, University Hospital “Split”, Croatia

P1.01–057: Metastatic Lung Cancer at a Tertiary Cancer Centre in South India
Govind Babu, Kidwai Memorial Institute Of Oncology, India

P1.01–058: Demographic Profile of Lung Cancer from Eastern India
Prasanta Mohapatra, All India Institute of Medical Sciences, India

P1.01–059: Lung Cancer Epidemiology among the Bahraini Population, 2000–2011
Randah Hamadeh, Arabian Gulf University, Bahrain

P1.01–040: Molecular Epidemiology of Programmed Cell Death 1–Ligand 1 (PD–L1) Protein Expression in Non–Small Cell Lung Cancer
Matthew Schabath, H Lee Moffitt Cancer Center and Research Institute, USA

P1.01–041: Comparison of Gender, Race Distribution, and Survival in the 1990s to 2010s in Lung Cancer Patients at a Single Institution
Bahar Laderian, University of Miami, Miller School of Medicine, USA

P1.01–042: Accelerometer–Determined Physical Activity and Sedentary Time among Lung Cancer Survivors
Adriana D’Silva, University of Calgary, Canada

P1.01–043: Patient to Hospital Distance in Access to Care and Lung Cancer Surgical Treatment
Wil Lieberman–Cribbin, Icahn School of Medicine at Mount Sinai, USA

P1.01–044: Heterogeneity of NSCLC Surgery Exists in Treatment Patterns and Hospital Costs among Different Centers of China, a Study of 5060 Patients
Jian Zhou, Peking University People’s Hospital, China

P1.01–045: Clinical Presentation and Outcome of Neuroendocrine Lung Tumors in a Brazilian Cohort from 2000 to 2016
Marcelo Corassa, A.C.Camargo Cancer Center, Brazil

P1.01–046: Factors Contributing Delays during Management of Lung Cancer: A Study from Tertiary Level Hospital in Nepal
Sandhya Acharya, National Academy Of Medical Sciences, Bir Hospital, Nepal

P1.01–047: Predictors of High Grade Toxicity of Chemotherapy among Malignant Pleural Mesothelioma Patients
Fatma Abou Elkasem, National Cancer Institute, Egypt

P1.01–048: Overall Survival in Advanced Lung Cancer Patients Treated at Oncosalud–AUNA
Alfredo Aguilar, Oncosalud – AUNA, Peru

P1.01–049: Predictor Variables to ECOG Scale of Performance Status in Lung Cancer at a Developing Country in Latin America
Silvia Josefina Ayala Leon, National Cancer Institute Prof. Manuel Riveros, Paraguay

P1.02  BIOLOGY/PATHOLOGY

P1.02–001: Expressions of Resistance EGFR TKIs in Non Small Cell Lung Cancer At Pham Ngoc Thach Hospital – Viet Nam
Nguyen Lam, Pham Ngoc Thach Hospital, Vietnam

P1.02–002: Is T790M Mutation A “Regulator” for EGFR Signal Pathway Not an Oncogene?
Zheng Wang, Beijing Hospital, China

P1.02–003: ROS1 (D4D6) is Reliable for Immunohistochemistry Detecting of ROS1 Fusion Lung Adenocarcinoma in Malignant Pleural Effusion
Zheng Wang, Beijing Hospital, China

P1.02–004: A Retrospective Analysis of Frequency of ALK Gene Rearrangement in Saudi Lung Patients
Fouad Al Dayel, King Faisal Specialist Hospital and Research Centre, Saudi Arabia

P1.02–005: Frequency of Actionable Alterations in EGFR wt NSCLC: Experience of the Wide Catchment Area of Romagna (AVR)
Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

P1.02–006: Interlaboratory Variation in Molecular Testing (EGFR, KRAS and ALK) in Stage IV Non–Squamous Non–Small Cell Lung Cancer in the Netherlands in 2013
Chantal Kuijpers, University Medical Center Utrecht, Netherlands

P1.02–007: Alk Translocated NSCLC in the West of Scotland: Patient Demographics and Outcomes
Nicola Steele, Beatson West of Scotland Cancer Centre, UK

P1.02–008: 2–Year Single Institution Experience with EGFR Plasma Testing in Advanced NSCLC
Izidor Kern, University Clinic of Respiratory and Allergic Diseases Golnik, Slovenia
P1.02–009: High Concordance of ALK Rearrangement Testing between ALK RNA–In Situ Hybridization and IHC/FISH in Patients with Lung Adenocarcinoma
Akihiko Yoshizawa, Kyoto University Hospital, Japan

P1.02–010: Frequency of Uncommon EGFR Mutations in NSCLC in an Argentinean University Institution
Carolina Gabay, Instituto de Oncología Angel H.Roffo, University of Buenos Aires, Argentina

P1.02–011: Comparison of EGFR and KRAS Mutations in Archived Tissue and Circulating Tumor DNA: The Impact of Tumor Heterogeneity
Ying Wang, BC Cancer Agency, Canada

P1.02–012: Frequencies of Actionable Mutations and Survival in Variants of Invasive Adenocarcinoma of the Lung
Zhengbo Song, Zhejiang Cancer Hospital, China

P1.02–013: Clinicopathological Characteristics and Survival of ALK, ROS1 and RET Arrangements in Non–Adenocarcinoma Non–Small Cell Lung Cancer Patients
Zhengbo Song, Zhejiang Cancer Hospital, China

P1.02–014: HER2 Mutations in Chinese Patients with Non–Small Cell Lung Cancer
Zhengbo Song, Zhejiang Cancer Hospital, China

Zhengbo Song, Zhejiang Cancer Hospital, China

P1.02–016: HER4 Expression Was Related to the Sensitivity of EGFR–TKI in Non–Small Cell Lung Cancer
Masaaki Inoue, Shimonoseki City Hospital, Japan

P1.02–017: Relative Abundance of EGFR Mutations Predict Tumor Metastasis and EGFR–TKIs Prognosis in Patients with Non–Small Cell Lung Cancer
Qiming Wang, Affiliated Cancer Hospital of Zhengzhou University, Henan Cancer Hospital, China

P1.02–018: Osteosarcomatous Differentiation in the Rebiopsy Specimens of Patients Harboring Pulmonary Adenocarcinoma with EGFR–TKI Resistance
Hyun Jung Kwon, Seoul National University Bundang Hospital, South Korea

P1.02–019: Complex Mutation of Epidermal Growth Factor Receptor (EGFR) in Patients with Non–Small Lung Cancer
Hiromasa Arai, Kanagawa Cardiovascular and Respiratory Center, Japan

P1.02–020: The Effect of EGF–Pathway Targeted Immunization (EGF PTI) on STAT3 and Cancer Stem Cells in EGFR Mutant NSCLC Cells
Jordi Codony Servat, Pangaea Biotech SL, IOR Quirón–Dexeus University Institute, Spain

P1.02–021: Review of Clinical Outcomes Attributable to Next Generation Sequencing Based Broad Mutation Panel Testing in Lung Adenocarcinoma
Cathal O’Brien, St James’s Hospital, Ireland

P1.02–022: Establishing Reflex NGS Testing in NSCLC in a Regional Network of County Hospitals in Central Sweden
Johan Isaksson, Gävle Hospital, Sweden

P1.02–023: Application of an Amplicon–Based NGS Strategy in the Molecular Diagnosis of NSCLC: Comparable Performance with FISH and ARMS–PCR
Dongmei Lin, Peking University Cancer Hospital & Institute, China

P1.02–024: The Molecular Breakdown: A Comprehensive Look at Non–Small–Cell Lung Cancer with ALK Rearrangement
Ka–Won Noh, Sungkyunkwan University, South Korea

P1.02–025: Evaluation of NGS and RT–PCR Methods for ALK Assessment in European NSCLC Patients: Results from the ETOP Lungscape Project
Stephen Finn, St James’s Hospital, Ireland

P1.02–026: Detection of Low–Abundant EGFR Somatic Mutations by PNA Clamping–Assisted Fluorescence Melting Curve Analysis
Jihye Yoon, PANAGENE Inc., South Korea

P1.02–027: A Comparative Analysis of Different Cytological Samples for the Assessment of ALK Gene Rearrangements in NSCLC Patients
Maria Lozano Escario, University of Navarra, Spain

P1.02–028: Detection of Oncogenic Drivers in Pleural Effusions and Archived FNA Smears of Pulmonary Adenocarcinoma
Deepali Jain, All India Institute of Medical Sciences, India

P1.02–029: Infrequent Staining Patterns in ALK Immunohistochemistry: Correlation with Fish Analysis
Paola De La Iglesias, Hospital Italiano de Buenos Aires, Argentina

P1.02–030: Performance Evaluation of ALK/ROS1 Dual Break Apart FISH Probe Kit (RUO) in Non–Small–Cell Lung Cancer
Hyun Chang, Catholic Kwandong University International St. Mary’s Hospital, South Korea

P1.02–031: Mutations in TP53, PIK3CA, PTEN and Other Genes in EGFR Mutated Lung Cancers: Correlation with Clinical Outcomes
Paul Vanderlaan, Beth Israel Deaconess Medical Center, Harvard Medical School, USA

P1.02–032: Diagnosis and Treatment of EGFR Mutated NSCLC among Arabic Patients
Abed Agbaria, Bnay Zion Medical Center, Israel

P1.02–033: Mesenchymal Transformation is the Most Common Histomorphologic Changes in the Rebiopsy of Lung Cancer Patients with EGFR–TKI Resistance
Hyein Ahn, Seoul National University Bundang Hospital, South Korea

P1.02–034: EGFR Mutations and ALK Translocations in Lung Cancer – A National Study
Erik Jakobsen, Odense University Hospital, Denmark

P1.02–035: Concomitant Driver Mutation Determines Tumor Growth in EGFR Mutation–Positive Lung Adenocarcinoma
Kazuhiro Nagayama, The University of Tokyo Hospital, Japan
P1.02–036: An EGFR Tyrosine Kinase Inhibitor Sensitive Patient–Derived Lung Cancer Xenograft Model without Classical Sensitizing Mutations
Hirotugu Notsuda, Ontario Cancer Institute, Canada

P1.02–037: Mutations of EGFR and KRAS Genes in Belorussian Patients With Non–Small Cell Lung Cancer
Alena Mikhalenka, Institute of Genetics and Cytology of the National Academy of Sciences of Belarus, Belarus

P1.02–038: Over– Expression of Epidermal Growth Factor Receptor 1 (EGFR1) Gene in Serum of Adenocarcinoma Lung at a Tertiary Level Centre in North India
Ashraf Ansari, All India Institute of Medical Sciences, India

P1.02–039: Assessment of KRAS Mutations (by Digital PCR) in Circulating Tumoral DNA from Lung Adenocarcinoma Patients Álvaro Taus, Hospital del Mar, Spain

P1.02–040: Heterogeneity of the EGFR / KRAS Gene Mutation in Multifocal Lung Adenocarcinomas and the Clinical Significance Lin Li, Cancer Hospital, Chinese Academy of Medical Sciences, China

P1.02–041: Characterization of MET–N375S as an Activating Mutation in Squamous Cell Carcinoma of the Lung Li Ren Kong, Cancer Science Institute Singapore, Singapore

P1.02–042: Detection of ALK Protein Expression in Lung Adenocarcinomas, a Consecutive Series of Cases from Northeastern Brazil Ana Claudia Oliveira, Argos Patologia / Hospital de Messejana do Coração e do Pulmão, Brazil

P1.02–043: Multiplexed FISH (ALK/ROS1, RET, NTRK1) in Lung Adenocarcinomas: Novel Dual ALK/ROS1 Probe and Automated Scanning System Susana Hernandez, Hospital Universitario HM Sanchinarro, Spain

P1.02–044: EGFR Status in a Previously Untested Population from Northeastern Brazil Ana Claudia Oliveira, Argos Patologia / Hospital de Messejana do Coração e do Pulmão, Brazil

P1.02–045: Discordance (FISH+, IHC–) between FISH and IHC Analysis of ALK Status in Advanced Non Small Cell Lung Cancer (NSCLC): A Unexpected Issue in 7 Cases Annamaria Catino, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II” Bari, Italy, Italy

P1.02–046: ALK IHC is Highly Sensitive to Fixation Parameters Isabell Loftin, Ventana Medical Systems Inc., a member of the Roche Group, USA

P1.02–047: Effect of Dasatinib on EMT–Mediated–Mechanism of Resistance against EGFR Inhibitors in Lung Cancer Cells Yuichi Sesumi, Kindai University Faculty of Medicine, Japan

P1.02–048: MET Exon 14 Skipping Mutations and Gene Amplifications Are Not Simultaneous Events in NSCLC Sergi Clavé, Hospital del Mar, Spain

P1.02–049: EGFR, KRAS and ALK Gene Alterations in Lung Cancer Patients in Croatia Marko Jakopovic, University Hospital Centre Zagreb, Croatia

P1.02–050: Acquired Resistance to EGFR Tyrosine Kinase Inhibitors (TKIs) in EGFR–Mutant Lung Adenocarcinoma among Hispanics (Rbiop–CLICap)
Andrés Cardona, Clinical and Trasltional Oncology Group, Institute of Oncology, Clinica del Country, Colombia

P1.02–051: Concomitant Driver Mutations in Advanced Stage Non–Small–Cell Lung Cancer of Adenocarcinoma Subtype with Activating EGFR–Mutation
Jens Benn Sørensen, Finsen Centre/National University Hospital, Denmark

P1.02–052: Signal Regulatory Protein a (SIRPA): A Key Regulator of the EGFR Pathway Demonstrates Both Tumor Suppressive and Oncogenic Properties Erin Marshall, BC Cancer Research Centre, Canada

P1.02–053: Comparison of Two Different Commercially Available Probes for the Detection of ALK Rearrangements in Cytological Smears Maria Lozano Escario, University of Navarra, Spain

P1.02–054: Genomic Complexity in KRAS Mutant Non–Small Cell Lung Cancer (NSCLC) by Smoking Status with Comparison to EGFR Mutant NSCLC Amanda Redig, Dana–Farber Cancer Institute, USA

P1.02–055: Synthetic Lethality Dictates the Mutual Exclusivity of Oncogenic Mutations in Lung Adenocarcinoma William Lockwood, British Columbia Cancer Research Centre, Canada

P1.02–056: Tumor Heterogeneity in Lesion Specific Response Creates ROS1 Fusion Mediating Resistance to Gefitinib in EGFR 19 Deletion Lung Adenocarcinoma Xiaomin Niu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.02–057: Clinical Utility of ctDNA for Detecting ALK Fusions and Resistance Events in NSCLC: Analysis of a Laboratory Cohort Robert Doebele, University of Colorado, USA

P1.02–058: EGFR Amplification and Sensitizing Mutations Correlates with Survival from Erlotinib in Lung Adenocarcinoma Patients (MutP–CLICAP)
Andrés Cardona, Clinical and Trasltional Oncology Group, Institute of Oncology, Clinica del Country, Colombia

P1.02–059: Evaluation of Plasma DNA Extraction, Droplet PCR and Droplet next Generation Sequencing Methods for Liquid Biopsy Analysis Lina Salleh, National University of Singapore, Singapore

P1.02–060: EGFR Mediates Activation of RET in Lung Adenocarcinoma with Neuroendocrine Differentiation Characterized by ASCL1 Expression Farhad Kosari, Mayo Clinic, USA

P1.02–061: Kinase Fusions in Non–Small Cell Lung carcinoma Identified by Hybrid Capture Based ctDNA Assay Lauren Young, Foundation Medicine, USA
<p>| | |</p>
<table>
<thead>
<tr>
<th></th>
<th></th>
</tr>
</thead>
</table>
| **P1.02–062:** Consensus of Gene Expression Phenotypes and Prognostic Risk Predictors in Primary Lung Adenocarcinoma | **P1.02–076:** DNA Methylation Profiling Unravels a TGF–β Hyperresponse in Tumor Associated Fibroblasts from Lung Cancer Patients  
Johan Staaf, Lund University, Sweden  
Jordi Alcaraz, Facultat de Medicina, Universitat de Barcelona, Spain |
| **P1.02–063:** Mutation Profiling by Targeted Next–Generation Sequencing of an Unselected NSCLC Cohort | **P1.02–077:** Whole–Transcriptome Gene Expression Analysis of Pulmonary Sarcomatoid Carcinomas  
Linnea La Fleur, Uppsala University, Sweden  
Greta Ali, University Hospital of Pisa, Italy |
| **P1.02–064:** MET–Dependent Activation of STAT3 as Mediator of Resistance to MEK Inhibitors in KRAS–Mutant Lung Cancer | **P1.02–078:** Expression Profiling of LKB1 Pathway in Young and Old Lung Adenocarcinoma Patients  
Chiara Lazzari, Istituto Europeo di Oncologia – IEO, Italy  
Mirella Giordano, University of Pisa, Italy |
| **P1.02–065:** Elucidating the Role of PIM Kinase and Its Therapeutic Potential in NSCLC | **P1.02–079:** DNA Ploidy, CPA4 and Rel B Expression in Non Small Cell Lung Cancer: Correlation with Clinicopathologic Parameter  
Gillian Moore, Trinity College Dublin/St. James's Hospital, Ireland  
Eleftheria Haini, Corfu General Hospital, Greece |
| **P1.02–066:** Genomic Profiling in the Differential Diagnostics of Pulmonary Tumours: A Case Series | **P1.02–080:** Genomic Relationship between Lung Adenocarcinoma and Synchronous AIS/AAH Lesions in the Same Lobe  
Hans Brunnström, Lund University, Sweden  
Laura Tafe, Dartmouth–Hitchcock Medical Center, USA |
| **P1.02–067:** Repeated Biopsy for Immunohistochemical and Mutational Analysis of Non Small Cell Lung Cancer: Feasibility and Safety | **P1.02–081:** The Relationship of CDH3 Expression and DNA Methylation in Thymic Epithelial Tumors  
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain  
Koichiro Kajiura, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan |
| **P1.02–068:** The Impact of TP53 Overexpression on EMT and the Prognosis in Lung Adenocarcinoma Harboring Driver Mutations | **P1.02–082:** The Feasibility of Cell–Free DNA Sequencing for Mutation Detection in Non–Small Cell Lung Cancer Was Determined by Tumor Volume  
Shigeto Nishikawa, Graduate School of Medicine, Kyoto University, Japan  
Tatsuo Ohira, Tokyo Medical University, Japan |
| **P1.02–069:** Genomic Alterations and Survival in Young Patients under 60 Years with Completely Resected Non–Small Cell Lung Cancer | **P1.02–083:** Gene Fusion Profile in Lung Adenocarcinoma Patients in Brazil  
Zhengbo Song, Zhejiang Cancer Hospital, China  
Tatiane Montella, Neotorax, Brazil |
| **P1.02–070:** Gene Spectrum and Survival Analyses of Pathologic Subtypes in Resected Lung Squamous Cell Carcinoma | **P1.02–084:** Polo–Like Kinase 1 (PLK1) Inhibition Decreases Mutational Activity in Bronchial Epithelial Cells Exposed to Tobacco Carcinogens  
Zhengbo Song, Zhejiang Cancer Hospital, China  
Daniel Merrick, University of Colorado, Anschutz Medical Campus, USA |
| **P1.02–071:** Detection of Multiple Low–Frequency Mutations by Molecular–Barcode Sequencing | **P1.02–085:** Molecular Profile in NSCLC Biopsy Samples: A Multicenter Local Study  
Kei Namba, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan  
Norma Pilnik, School Of Medicine Cordoba University, Argentina |
| **P1.02–072:** Comprehensive Genomic Alterations Identified by Next–Generation Sequencing of Lung Adenocarcinoma in Japanese Population | **P1.02–086:** ATM Mutations in Lung Cancer Correlate to Higher Mutation Rates  
Seijiro Sato, Niigata University Graduate School of Medical and Dental Sciences, Japan  
Lars Petersen, University of Calgary, Canada |
| **P1.02–073:** Characterizing the Genomes of Lung Adenocarcinomas from Never Smokers Reveals SHPRH as a Novel Candidate Tumour Suppressor Gene | **P1.02–075:** Analysis of Driver Genes Alteration and Clinico pathological Features in Pulmonary Marker–Null Large Cell Carcinoma  
Tanya De Silva, British Columbia Cancer Research Centre, Canada  
Likun Hou, Tongji University School of Medicine, China |
| **P1.02–074:** The Gene Expression Signatures of Pulmonary Adenocarcinoma with Micropapillary Features | **P1.02–076:** DNA Methylation Profiling Unravels a TGF–β Hyperresponse in Tumor Associated Fibroblasts from Lung Cancer Patients  
Yuki Sata, Chiba University Graduate School of Medicine, Japan  
Fatma Abou Elkasem, National Cancer Institute, Egypt |
| **P1.02–075:** Analysis of Driver Genes Alteration and Clinico pathological Features in Pulmonary Marker–Null Large Cell Carcinoma |  |
P1.03 RADIOLOGY/STAGING/SCREENING

- BIOLOGY

P1.03–001: The Utility of Liquid–Biopsy for Detecting EGFR Mutation in Clinical Practice: 169 Cases in a Single Institution Research Study
Kentarou Ito, Matsusaka Municipal Hospital, Japan

P1.03–002: Can We Discriminate between Different Subtypes of Non–Small Cell Cancer Patients Based on Plasma Metabolic Fingerprint?
Michal Ciborowski, Medical University of Bialystok, Poland

P1.03–003: The Warburg Effect: Persistence of Stem Cell Metabolism in Lung Cancer as Failure of Differentiation
Robert Downey, Memorial Sloan Kettering Cancer Center, USA

P1.03–004: Percutaneous Lung Biopsy for Genomic Assessment: Comparison between Two Different next Generation Sequencing Platforms
Livia Maria Frota Lima, MD Anderson Cancer Center, USA

P1.03–005: High Resolution Metabolomics in Discovering Plasma Biomarkers of Lung Cancer Patients with EGFR Common Mutations (Exon 19 or 21)
Sung Yong Lee, College of Medicine, Korea University, South Korea

Amanda Chargin, IncellDx, USA

P1.03–007: Improvement in Performance of an Autoantibody Panel Test for Detection of Lung Cancer by Addition of a Single Novel Biomarker (EBB1)
Caroline Chapman, Queen’s Medical Centre, UK

P1.03 RADIOLOGY/STAGING/SCREENING

- PNEUMONOLOGY

P1.03–008: Clinical Importance of Indolent Lung Cancers
Gunnar Hillerdal, Gavle Hospital, Sweden

P1.03–009: Venous Thromboembolism (VTE) in Lung Cancer – Associations and Prognostic Role: Results of a Prospective Cohort Study from North India
R Lakshmi Narasimhan, Postgraduate Institute of Medical Education and Research (PGIMER), India

P1.03–010: Characteristics of Lung Cancer Patients Diagnosed Following Emergency Admission
Neal Navani, University College London, UK

P1.03–011: Clinical Characters of 19 Bronchial Asthmatic Patients with Lung Cancer
Jie Zhang, Second Affiliated Hospital of Jilin University, China

P1.03–012: Experience with BioSentryTM Tract Sealant System for Percutaneous CT–Guided Lung Nodule Biopsies in an Oncology Population
Patricia de Groot, UT MD Anderson Cancer Center, USA

P1.03–013: Diagnosis, Assessment and Prediction of Early Response to Chemotherapy by Using Diffusion–Weighted MRI in Lung Cancer
Jian Zhang, Department of Pulmonary Medicine, Xijing Hospital, Fourth Military Medical University, China

P1.03–014: Value of Performing Fine Needle Aspiration with Core Biopsy for Genomic Mutation Assessment in Percutaneous Lung Biopsies
Livia Maria Frota Lima, MD Anderson Cancer Center, USA

P1.03–015: Assessment of Response of FDG–PET Using Total Lesion Glycolysis (TLG) in NSCLC Patients Treated with Nivolumab: Results of a Pilot Study
Hector Soto Parra, A.O.U. Policlinico Vittorio Emanuele, Italy

P1.03–016: Diagnostic Accuracy of Visual Assessment on Growth of Non–Measurable Target Pulmonary Nodules According to RECIST Criteria
Jeong Min Ko, College of Medicine, St. Vincent’s Hospital, The Catholic University of Korea, South Korea

P1.03–017: Does PET/CT SUVmax Value Correlate with Long–Term Survival in Patients with Surgically Treated Stage I Non–Small Cell Lung Cancer
Akit Turna, Istanbul University Cerrahpasa Medical School, Turkey

P1.03–018: FDG–PET/CT in Patients with EGFR–Mutated NSCLC Treated with TKI. Can We Identify Early Lesions at Higher Risk of Progression?
Alexis Cortot, Lille University Hospital, France

P1.03–019: Imaging of Anti–PD1 Therapy Response in Advanced Non–Small Lung Cancer
Sharyn Katz, Hospital of the University of Pennsylvania, USA

P1.03–020: FDG–PET SUVmax Does Not Correlate with Glucose Metabolism in Non–Small Cell Lung Cancer
Kemp Kernstine, University of Texas Southwestern, USA

P1.03–021: Initial Results from A Novel and Low Cost Method For Measuring CT Image Quality
Ricardo Avila, Accumetra, LLC, USA

P1.03–022: Possibility of FDG–PET Predicting the Clinicopathological Characteristics and Prognosis of Lung Adenocarcinoma: Multicenter Study
Kumi Matsuura, Tokyo Medical University, Japan

P1.03–023: Ground–Glass Opacity (GGO) with Semi–Consolidation: Clinicopathological and Radiological Correlations Compared to Pure–GGOs of the Lung
Jun Suzuki, Juntendo University School of Medicine, Japan
P1.03–024: Accuracy of Combined Semantic and Computational CT Features in Predicting Non–Small Cell Lung Cancer Subtype
Andrea Bille, Guys’ & St. Thomas’ Hospitals, UK

P1.03–025: Serum KL–6 Levels in Patients with Lung Cancer
Tatsuya Yoshimasu, Wakayama Medical University, Japan

P1.03–026: Measurement of Pulmonary Artery on CT to Predict Acute Exacerbation of Interstitial Pneumonia after Pulmonary Resection for Lung Cancer
Akiko Uj, Tokyo Medical and Dental University, Japan

P1.03–027: Clinical and Histological Features Associated with SUV in FDG–PET–CT in Patients with Adenocarcinoma of the Lung
Amanda Tufman, Ludwig Maximilian University of Munich, Germany

P1.03–028: Wolf in Sheep’s Clothing – Primary Lung Cancer Mimicking Benign Diseases
Annemie Snoeckx, Antwerp University Hospital & Antwerp University, Belgium

P1.03–029: A Useful Algorithmic Model in Predicting the Likelihood of Lung Cancer in Solitary Pulmonary Nodules
Lin Gen, Fujian Provincial Cancer Hospital, The Affiliated Hospital of Fujian Medical University, China

P1.03–030: FDG–PET/CT Might Be a Predictor for Residual Disease in Advanced NSCLC after Chemoradiation
Toru Sawada, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

P1.03–031: Gynecological Malignancies and Imaging Patterns. An Interesting Case Report and Literature Surveillance
Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

P1.03–032: In vivo Imaging Models for Preclinical Screening of Molecular Targeted Drugs against Brain Metastasis
Akihiro Nishiyama, Kanazawa University, Japan

P1.03–033: Analysis of T0 Lung–RADS Scores in UI Health’s Minority–Based Lung Cancer Screening Program and Comparison to the NLST
Mary Pasquinelli, The University of Illinois Hospital and Health Sciences System, UI Cancer Center, USA

P1.03–034: Implementing Smartphone Application in Early Lung Cancer Detection and Screening
Zalan Szanto, University of Pécs, Hungary

P1.03–035: Does Screening with Low–Dose Computed Tomography (LDCT) of Asbestos Exposed Subjects Reduce Mortality for Lung Cancer (LC)?
Gianpiero Fasola, University hospital of Udine, Italy

P1.03–036: Adherence to Eligibility Criteria for Low–Dose CT Screening in an Academic Center
Jacob Bloom, Fred Hutchinson Cancer Research Center, USA

P1.03–037: Radio–Guided Localization and Resection of Small or Ill–Defined Pulmonary Lesions
Domenico Galetta, European Institute of Oncology, Italy

P1.03–038: Appropriateness of Lung Cancer Screening with Low Dose Computed Tomography
M Rivera, The University of North Carolina, USA

P1.03–039: Is It Necessary to Repeat Lung Cancer Screening with Low–Dose CT (LDCT) in Female Never Smokers?
Hyae Young Kim, National Cancer Center, South Korea

P1.03–040: Beliefs Surrounding Lung Cancer Screening among Physicians and Lay Populations: Results from the EDIFICE Survey
Alexis Cortot, Hôpital Calmette, France

P1.03–041: Do Several Rounds of Negative Screening Low Dose CT Scans Influence the Risk to Develop Lung Cancer?
Heidi Schmidt, University Health Network, Canada

P1.03–042: Nodule Size is Poorly Represented by Nodule Diameter in Low–Dose CT Lung Cancer Screening
Marjolein Heuvelmans, University of Groningen, University Medical Center Groningen, Netherlands

P1.03–043: Practical Difficulty of Low Dose Computerized Tomography as a Lung Cancer Screening Tool in an Endemic Area of Tuberculosis
Natthaya Triphuridet, Chulabhorn Hospital, Thailand

P1.03–044: EUS–Guided Sampling of Mediastinal Lymph Nodes and Abdominal Lesions in Lung Cancer
Toyoaki Hida, Aichi Cancer Center Hospital, Japan

P1.03–045: Screening for Lung Cancer with Early CDT–Lung Blood Biomarkers and Computed Tomography
James Finigan, National Jewish Health, USA

P1.03–046: Selection of Subjects at High–Risk for LDCT Lung Cancer Screening Using a Molecular Panel: Results by the ITALUNG Biomarker Study
Eugenio Paci, Institute for Cancer Prevention and Research (ISPO), Italy

P1.03–047: Community–Based Low–Dose Computed Tomography (LDCT) Lung Cancer Screening in the US Histoplasmosis Belt: One Year Followup
Emilia Porubcin, Rivermont Collegiate, USA

P1.03–048: A Structured Lung Cancer Screening Program Facilitates Patient and Provider Compliance
Thomas D’Amico, Duke University Medical Center, USA

P1.03–049: Smoking Patterns in a Predominantly African American Population Undergoing Lung Cancer Screening
Cherie Erkmen, Temple University Hospital, USA

P1.03–050: Outcomes after the Decision to Biopsy: Results from a Nurse Practitioner Run Multidisciplinary Lung Cancer Screening Program
Candice Wilshire, Swedish Medical Center and Cancer Institute, USA
P1.03–051: Medically Underserved and Geographically Remote Individuals May Be Underrepresented in Current Lung Cancer Screening Programs
Candice Wilshire, Swedish Medical Center and Cancer Institute, USA

P1.03–052: The Effect of Rounding on Rate of Positive Results on CT Screening for Lung Cancer
Kunwei Li, Icahn School of Medicine, USA

P1.03–053: The Effect of Primary Care Physician Knowledge of Lung Cancer Screening Guidelines on Perceptions and Utilization of Low Dose CT
Dan Raz, City of Hope, USA

P1.03–054: Quantitative Accuracy and Lesion Detectability of Low–Dose FDG–PET for Lung Cancer Screening
Ivan Tham, National University Cancer Institute Singapore, Singapore

P1.03–055: LuCaS DA: A Lung Cancer Screening Decision Aid to Improve Screening Decisions
Jamie Studts, University of Kentucky, USA

P1.03–056: Implementation of a Prospective Biospecimen Collection Study in an Established Lung Cancer Screening Program
Jacob Sands, Lahey Hospital & Medical Center, USA

P1.03–057: Assessment of Lung Cancer Risk– Regional Respiratory Disease Screening Report in Jilin, China
Jie Zhang, Second Affiliated Hospital of Jilin University, China

P1.03–058: Cost–Effectiveness of CT Screening in the Early Detection of Lung Cancer
Tomasz Szczesny, Franciszek Lukaszczyk Memorial Oncological Center in Bydgoszcz, Poland

P1.03–059: Organized High Risk Lung Cancer Screening in Ontario, Canada: A Multi–Centre Prospective Evaluation
Martin Tammemagi, Brock University, Canada

P1.03–060: Lung Cancer Screening: A Qualitative Study Exploring the Decision to Opt Out of Screening
Lisa Carter–Harris, Indiana University, USA

P1.03–061: Patient Motivations for Pursuing Low–Dose CT Lung Cancer Screening in an Integrated Healthcare System: A Qualitative Evaluation
Joshua Roth, Fred Hutchinson Cancer Research Center, USA

P1.03–062: Lung Cancer Screening with Low–Dose CT in China: Study Design and Baseline Results from the First Round Screening Arm
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.03–063: Quantitative Imaging Features Predict Incidence Lung Cancer in Low–Dose Computed Tomography (LDCT) Screening
Matthew Schabath, H Lee Moffitt Cancer Center and Research Institute, USA

P1.03–064: Chest X–Ray (CXR) Screening Improves Lung Cancer (LC) Survival in the Prostate Lung Colon and Ovary (PLCO) Randomized Population Trial (RPT)
John Paul Flores, Tufts Medical Center, USA

P1.03–065: Comparison of the Proposed IASLC 8th TNM Lung Cancer Staging System to the 7th Edition
Kwun Fong, University of Queensland Thoracic Research Centre, Australia

P1.03–066: Incorporation of a Molecular Prognostic Classifier Improves Conventional Non–Small Cell Lung Cancer TNM Staging
Gavitt Woodard, University of California, USA

P1.03–067: Validation of the IASLC 8th Edition (8E) TNM Classification for Non–Small Cell Lung Cancer by the Quality of Surgical Resection in a US Cohort
Matthew Smeltzer, University of Memphis School of Public Health, USA

P1.03–068: Impact of Positive Pleural Lavage Cytology or Malignant Effusion on Survival in Patients Having Lung Resection for NSCLC
Tomohiro Obata, Nagasaki Graduate School of Medicine, Japan

P1.03–069: EGFR Mutations Have Greater Influence on Survival Than Proposed M Descriptors of New TNM Classification for Lung Cancer
Karmen Stanic, Institute of Oncology, Slovenia

P1.03–070: The Impact of Advances in Systemic Staging on the Rate of Metachronous and Synchronous Metastases in Patients Lung Cancer
Kyle Wang, University of North Carolina Hospitals, USA

P1.03–071: Impact of Visceral Plural Invasion to T Descriptors: Based on the Forthcoming Eighth Edition of TNM Classification for Lung Cancer
Mikiko Suzuki, Juntendo University School of Medicine, Japan

P1.03–072: Mediastinal Lymphnodes Staging by PET CT for Resectable Non–Small Cell Lung Cancer in a Tuberculosis Endemic Country
Vinayakumar J R, IRCH, All India institute of Medical Sciences(AIIMS), India

P1.03–073: Predictors for Pathological N1 and N2 Disease in Clinical N1 Non–Small–Cell Lung Cancer
Takayuki Fukui, Nagoya University, Japan

P1.03–074: Combined Use of PET/CT and Clinical Features Yields a Higher Diagnostic Rate of Mediastinal Lymph Node Metastasis in Lung Adenocarcinoma
Miao Huang, Peking University Cancer Hospital and Institute, China

P1.03–075: Predictive Factors for Minimal Pleural Disease Detected at Thoracotomy or Positive Lavage Cytology
Akira Sakurada, Institute of Development, Aging and Cancer, Japan

P1.03–076: Quantitative Imaging Features Predict Incidence Lung Cancer in Low–Dose Computed Tomography (LDCT) Screening
Matthew Schabath, H Lee Moffitt Cancer Center and Research Institute, USA

P1.03–077: Predictors for Pathological N1 and N2 Disease in Clinical N1 Non–Small–Cell Lung Cancer
Takayuki Fukui, Nagoya University, Japan

P1.03–078: Combined Use of PET/CT and Clinical Features Yields a Higher Diagnostic Rate of Mediastinal Lymph Node Metastasis in Lung Adenocarcinoma
Miao Huang, Peking University Cancer Hospital and Institute, China

P1.03–079: Predictive Factors for Minimal Pleural Disease Detected at Thoracotomy or Positive Lavage Cytology
Akira Sakurada, Institute of Development, Aging and Cancer, Japan

P1.03–080: Nodal Staging of Patients with Pulmonary Malignancies – The Predictive Value of Different Patterns of Mediastinal 18FDG–PET Activity
Socrates Angelides, Westmead Hospital, Australia
P1.03–077: Analysis of the Early CDT–Blood Biomarker for Lung Cancer in Higher vs. Lower Risk Cohorts
James Finigan, National Jewish Health, USA

P1.03–078: Size Matters...but Don't Underestimate the Power of Morphology
Anнемie Snoeckx, Antwerp University Hospital & Antwerp University, Belgium

P1.03–079: Adequacy of Percutaneous Lung Biopsy for Assessing Clinically Requested Genetic Mutations in Lung Cancer
Livía Maria Frota Lima, MD Anderson Cancer Center, USA

P1.03–080: The SUVmax Ratio of Two Tumors on PET/CT May Differentially Separate Primary Lung Cancers and Intrapulmonary Metastases
Yi Liu, The Chinese People’s Liberation Army General Hospital, China

P1.03–081: Synchronous Triple Malignant Tumors of the Lung: A Case Report of Two Lung Adenocarcinomas, and Mucosa–Associated Lymphoid Tissue Lymphoma
Xun Wang, Nanjing Medical University Wuxi No.2 People’s Hospital, China

P1.03–082: 18F–FDG PET/CT Value Staging NSCLC Extension to the Lymph Nodes, Single Center Experience
Ruta Vosyljuite, Vilnius University, Lithuania

P1.03–083: Advances in Surgical Staging of NSCLC
Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

P1.03–084: Implications of 8th Edition TNM Proposal: Invasive vs. Total Size for T Descriptor in pT1a–2bN0M0 Lung Adenocarcinoma
Takashi Eguchi, Memorial Sloan Kettering Cancer Center, USA

P1.04–001: EGFR, EML4–ALK, ROS 1 and BRAF Testing in Austrian Patients with NSCLC: A Multicentre Study
Sophia Holzer, Otto Wagner Hospital, Austria

P1.04–002: Positive Airway Pressure–Enhanced CT to Improve Virtual Bronchoscopic Navigation
Marta Diez–Ferrer, Hospital Universitari de Bellvitge, Spain

P1.04–003: Incidence of Non–Caseating Granulomas Diagnosed in PET Avid Mediastinal/Hilar Nodes in Patients with Known Breast Cancer
Rabih Bechara, Cancer Treatment Centers of America, USA

P1.04–004: Bronchoscopic Cryosurgery with Carbon Dioxide; Experience in an Oncology Clinic in Colombia
Jaime Echeverri, Oncólogos del Occidente S.A., Colombia

P1.04–005: Efficacy of Photodynamic Therapy Combined with a Guide Sheath Method in Lung Cancer Patients with Endobronchial Stenosis
Masaumi Misawa, Kameda Medical Center, Japan

P1.04–006: Second Primary Lung Cancer: Five Years of a Single Center Experience in Its Diagnosis and Treatment
Fatmir Caushi, University Hospital of Lung Diseases, Albania

P1.04–007: Y Stents in Malignant Tumours – Long Time Follow up and Survival
Vitezslav Kolek, University Hospital, Czech Republic

P1.04–008: Tumor Pentaplicity – Case Report
Petra Smi ková, The University Hospital of Olomouc, Czech Republic

P1.04–009: Bacterial Population Dynamics in Colonization of Airway Stents in Patients with Cancer
Antoni Rosell, Hospital Universitari de Bellvitge, Spain

P1.04–010: Neutrophil to Lymphocyte, Platelet to Lymphocyte Ratios and Systemic Inflammation in Lung Cancer Stages
Erhan Ionela Mihaela, Marius Nasta Institute of Pulmonology, Romania

P1.04–011: Demographic, Clinical and Survival Characteristics of Lung Cancer among Elderly Patients in Turkey
Guntulu Ak, ESOGU, Turkey

P1.04–012: Single Center Experience with Nivolumab Administration in NSCLC Patients from EAP Program
Milos Pesek, Charles University in Prague, Czech Republic

P1.04–013: Diagnostics and Treatment of ALK–Positive NSCLC Patients – A Single Center Experience
Milos Pesek, Charles University in Prague, Czech Republic

P1.04–014: Diagnostic Yield in Patients Undergoing Endobronchial Ultrasound–Guided Transbronchial Needle Aspiration for Diagnosis of Lung Cancer
Sunkaru Touray, University of Massachusetts Medical School, USA

P1.04–015: Clinical Application of Virtual Navigated Bronchial Intervention
Naohiro Kajiwara, Tokyo Medical University, Japan

P1.04–016: EBUS plus Fluoroscopy–Guided Biopsy Compared to Fluoroscopy–Guided TBB for Obtaining Samples of Peripheral Pulmonary Lesions
Jian Ye, Affiliated Hangzhou Hospital of Nanjing Medical University, China

P1.04–017: The Survival of Our Patients Diagnosed with Lung Cancer in 2013
Sedat Ailtin, Yedikule Chest Diseases and Chest Surgery Hospital, Turkey

P1.04–018: Occurrence of Triple Multiple Malignancies with Last Lung Squamous Cell Carcinoma – Case Reports
Anna Romaszko, University of Warmia and Mazury, Poland

P1.04–019: Final Analysis of Lung Microbiome from Patients Undergoing Bronchoscopy
Glen Weiss, Western Regional Medical Center, Cancer Treatment Centers of America, USA
P1.04–020: Management of Lung Cancer in Patients with past Pulmonary Tuberculosis and Their Possible Causative Link Fatmir Caushi, University Hospital of Lung Diseases, Albania

P1.04–021: Medical Thoracoscopy for the Diagnosis and Management of Pleural Effusions: Results of a Retrospective Analysis Sofia Tsagouli, Medical School, University of Athens, Greece

P1.04–022: Use of Alternative Therapy in Patients with Lung Cancer Kristina Krpina, KBC Rebro, Croatia

P1.04–023: Thrombomodulin Inhibits the Growth and Angiogenesis of Human Lung Cancer via Blocking VEGFR2–Mediated JAK/STAT3 Signaling Pathway Shun Lu, Shanghai Chest Hospital, China

P1.04–024: Molecular Profiling and Survival of Primary Pulmonary Neuroendocrine Carcinoma with Completely Resection Zhengbo Song, Zhejiang Cancer Hospital, China

P1.04–025: The Impact of Emergency Presentation on Survival of Lung Cancer Patients Marko Jakopovic, University Hospital Center, Croatia

P1.04–026: Coexisting Lung Cancer and Interstitial Lung Disease: A Challenge in Clinical Practice Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P1.04–027: Changes in Pulmonary Function in Lung Cancer Patients after Thoracic Surgery Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P1.04–028: Collection of ICHOM–Defined Patient–Reported Outcome Measures (PROMs) during Routine Lung Cancer Treatment: A Pilot Study Jan van Meerbeeck, Antwerp University Hospital, Belgium

P1.05–001: Creation and Early Validation of Prognostic miRNA Signatures for Squamous Cell Lung Carcinoma by the SPECS Lung Consortium David Harpole, Duke University Medical Center, USA

P1.05–002: The Prognostic Impact of EGFR Mutation Status and Mutation Subtypes in Patients with Surgically Resected Lung Adenocarcinomas Kazuya Takamochi, Juntendo University School of Medicine, Japan

P1.05–003: Coexpression of CD8a and PD–L1 Frequently Observed in Resected NSCLC Tumors from Smokers Aaron Lisberg, UCLA Medical Center, USA

P1.05–004: Surfactant Protein C is a Prognostic Marker in Resected Non–Small Cell Lung Cancer Ivan Macla, Hospital Universitari de Bellvitge. IDIBELL, Institut d’Investigació Biomèdica de Bellvitge, Spain

P1.05–005: Programmed Death–Ligand 1 (PD–L1) in Resected Lung Adenocarcinomas (LA) in a University Hospital Maria Alvarez, Hospital Universitario Miguel Servet, Spain

P1.05–006: Identification of miRNAs and mRNAs Associated with Metastasis in Early–Stage Non–Small Cell Lung Cancer (NSCLC) Shirley Tam, University Health Network, Canada

P1.05–007: Analysis of RNA Sequencing Data along with PET SUV–max Can Discover Novel Gene Sets Which Can Predict Surgical Outcome of NSCLC Young Tae Kim, Seoul National University Hospital, South Korea

P1.05–008: Detection of EGFR Mutations in Pulmonary Vein and Peripheral Blood Plasma Cell–Free DNA for Analysis of Surgical Treatment in Early–Stage NSCLC Chengliang Yang, Shenyang tenth People’s Hospital & Shenyang Chest Hospital, China

P1.05–009: Clinical Value of Circulating Tumor Cell in the Differential Diagnosis of Solitary Pulmonary Nodule Lin Wang, Shanghai Chest Hospital, China

P1.05–010: Aberrant Promoter Methylation of ESR1 and CDH13 Gene Are an Independent Prognostic Marker in Surgically Resected Non–Small Cell Lung Cancer Milica Kontic, Clinical Centre of Serbia, Serbia

P1.05–011: Comparative Analysis of TTF–1 Copy Number Alterations and Protein Expression in Patients with Non–Small Cell Lung Cancer Katsuhiro Yoshimura, Hamamatsu University School of Medicine, Japan

P1.05–012: The Impact of EGFR Mutations on the Prognosis of Patients with Resected Stage I Lung Adenocarcinoma Jiro Kitamura, Massachusetts General Hospital, USA

P1.05–013: Lung Tumorspheres as a Platform for Testing New Therapeutic Strategies in Non–Small Cell Lung Cancer Eloisa Jantus–Lewintre, Fundación Investigación Hospital General Universitario, Spain

P1.05–014: Stemness Gene Expression Profile of Tumorspheres from Non–Small Cell Lung Cancer Eloisa Jantus–Lewintre, Fundación Investigación Hospital General Universitario, Spain

P1.05–015: Genomic Characterisation of Non–Small Cell Lung Cancer in an Australian Population Brielle Parris, University of Queensland Thoracic Research Centre, The Prince Charles Hospital, Australia

P1.05–016: Circulating BARD1 Antibodies for Early Detection of Lung Cancer Irmgard Irminger–Finger, University Hospitals Geneva, Switzerland

P1.05–017: The Prognostic Impact of EGFR, KRAS and TP53 Somatic Mutations in Curatively Resected Early–Stage Lung Adenocarcinomas Bonnie Gould Rothberg, Yale University School of Medicine, USA
P1.05–018: LncRNA16 is a Potential Biomarker for Early–Stage Lung Cancer That Promotes Cell Proliferation by Regulating the Cell Cycle
Xing Wang, Peking University Cancer Hospital & Institute, China

P1.05–019: Two Inflammatory Biomarkers MDC/CCL22 and BLC/ CXCL13 Are Independently Associated with the Significant Risk of Early Stage Lung Adenocarcinoma
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.05–020: Opposing Prognostic Roles of CD73 and A2A Adenosine Receptor in Non–Small–Cell Lung Cancer
Yusuke Inoue, Hamamatsu University School of Medicine, Japan

P1.05–021: circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer
Steven Gray, LabMed Directorate, Ireland

P1.05–022: Circulating Tumor Cell Isolation to Monitor NSCLC Patients over the Course of Treatment
Julia Herrmann, SRH Wald–Klinikum Gera, Germany

P1.05–023: Induction of Patient–Derived Xenograft Formation and Clinical Significance for PD–L1 in Lung Cancer Patients
Jiahui Si, Peking University Cancer Hospital & Institute, China

P1.05–024: Preoperative Neuron–Specific Enolase to Albumin Ratio is a Prognostic Biomarker for Patients with Operable Non–Small–Cell Lung Cancer
Hong Ren, The First Affiliated Hospital of Xi’an Jiaotong University, China

P1.05–025: Prognostic Significance of Hepatitis B Virus to Stage IB Non–Small Cell Lung Cancer Patients in China
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.05–026: High Resolution Metabolomics on Exhaled Breath Condensate to Discover Lung Cancer’s Biomarker
Sung Yong Lee, Korea University Medical Center, South Korea

P1.05–027: Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium
William Richards, Brigham and Women’s Hospital, USA

P1.05–028: Phenotypic and Functional Profiling of Tumor–Infiltrating Lymphocytes (TIL) in Early Stage Non–Small Cell Lung Cancer (NSCLC)
Lorenzo Federico, MD Anderson Cancer Center, USA

P1.05–029: SABRTOOTH—A Feasibility Study of SABR Compared to Surgery in Patients with Peripheral Stage I NSCLC Considered to Be at Higher Risk from Surgery
Kevin Franks, Leeds Teaching Hospitals/University of Leeds, UK

P1.05–030: Lung SABR for Early Stage Lung Cancer: Outcomes and Toxicity of 803 Patients Treated at the Leeds Cancer Centre
Patrick Murray, St James’ University Hospital, UK

P1.05–031: Primary Results of Dose Escalated Stereotactic Body Radiotherapy for Stage IA Non–Small Cell Lung Cancer
Takafumi Komiyama, University of Yamanashi School of Medicine, Japan

P1.05–032: Quality of Life after Stereotactic Body Radiotherapy and Surgery in Patients with Early Stage Non–Small Cell Lung Cancer
Elisabeth Kastelijn, St. Antonius Hospital, Netherlands

P1.05–033: Comparison of Single– and Five–Fraction Schedules of Stereotactic Body Radiation Therapy for Central Lung Tumors
Sung Jun Ma, Roswell Park Cancer Institute, USA

P1.05–034: Neutrophil–To–Lymphocyte and Platelet–To–Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR
Stephen McKay, Beatson West of Scotland Cancer Centre, UK

P1.05–035: SABR for Medically Inoperable Early Stage NSCLC at the Beatson West of Scotland Cancer Centre: Outcomes and Toxicity
Stephen McKay, Beatson West of Scotland Cancer Centre, UK

P1.05–036: A Propensity–Matched Study of Multi–Port versus Single–Port Video–Assisted Thoracoscopic Surgery for Early Lung Cancer
Kyoji Hirai, Nippon Medical School Chiba Hokusoh Hospital, Japan

P1.05–037: Histopathologic Results of Surgically Resected Pure Ground–Glass Opacity Lung Nodules
Geun Dong Lee, Gangnam Severance Hospital, Yonsei University College of Medicine, South Korea

P1.05–038: Patterns of Recurrence in Curatively Resected Stage I Lung Cancer
Kanghoon Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P1.05–039: Recurrence and Survival Outcome after Segmentectomy for Non–Small Cell Lung Cancer: A Long–Term Follow–Up Study at a Single Institute
Takamasa Koga, Kumamoto University Hospital, Japan

P1.05–040: Prognostic Factor of Node Involvement Pattern in Completely Resected pN1 Squamous Cell Carcinoma Patients
Kenta Tane, Hyogo Cancer Center, Japan

P1.05–041: Dynamics of Brain Metastasis for Curatively Resected Stage I or II Non–Small Cell Lung Cancer Patients
Sumin Shin, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P1.05–042: Treatment Strategy of Limited Surgery for Early Lung Cancer
Katsuji Kojima, Musashino Red–Cross Hospital, Japan

P1.05–018: LncRNA16 is a Potential Biomarker for Early–Stage Lung Cancer That Promotes Cell Proliferation by Regulating the Cell Cycle
Xing Wang, Peking University Cancer Hospital & Institute, China

P1.05–019: Two Inflammatory Biomarkers MDC/CCL22 and BLC/ CXCL13 Are Independently Associated with the Significant Risk of Early Stage Lung Adenocarcinoma
Baohui Han, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.05–020: Opposing Prognostic Roles of CD73 and A2A Adenosine Receptor in Non–Small–Cell Lung Cancer
Yusuke Inoue, Hamamatsu University School of Medicine, Japan

P1.05–021: circRNAs: Potential Novel Biomarkers for the Early Detection of Lung Cancer
Steven Gray, LabMed Directorate, Ireland

P1.05–022: Circulating Tumor Cell Isolation to Monitor NSCLC Patients over the Course of Treatment
Julia Herrmann, SRH Wald–Klinikum Gera, Germany

P1.05–023: Induction of Patient–Derived Xenograft Formation and Clinical Significance for PD–L1 in Lung Cancer Patients
Jiahui Si, Peking University Cancer Hospital & Institute, China

P1.05–024: Preoperative Neuron–Specific Enolase to Albumin Ratio is a Prognostic Biomarker for Patients with Operable Non–Small–Cell Lung Cancer
Hong Ren, The First Affiliated Hospital of Xi’an Jiaotong University, China

P1.05–025: Prognostic Significance of Hepatitis B Virus to Stage IB Non–Small Cell Lung Cancer Patients in China
Shun Lu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P1.05–026: High Resolution Metabolomics on Exhaled Breath Condensate to Discover Lung Cancer’s Biomarker
Sung Yong Lee, Korea University Medical Center, South Korea

P1.05–027: Novel Prognostic Gene Expression Signatures for Squamous Cell Lung Carcinoma: A Study by the SPECS Lung Consortium
William Richards, Brigham and Women’s Hospital, USA

P1.05–028: Phenotypic and Functional Profiling of Tumor–Infiltrating Lymphocytes (TIL) in Early Stage Non–Small Cell Lung Cancer (NSCLC)
Lorenzo Federico, MD Anderson Cancer Center, USA

P1.05–029: SABRTOOTH—A Feasibility Study of SABR Compared to Surgery in Patients with Peripheral Stage I NSCLC Considered to Be at Higher Risk from Surgery
Kevin Franks, Leeds Teaching Hospitals/University of Leeds, UK

P1.05–030: Lung SABR for Early Stage Lung Cancer: Outcomes and Toxicity of 803 Patients Treated at the Leeds Cancer Centre
Patrick Murray, St James’ University Hospital, UK

P1.05–031: Primary Results of Dose Escalated Stereotactic Body Radiotherapy for Stage IA Non–Small Cell Lung Cancer
Takafumi Komiyama, University of Yamanashi School of Medicine, Japan

P1.05–032: Quality of Life after Stereotactic Body Radiotherapy and Surgery in Patients with Early Stage Non–Small Cell Lung Cancer
Elisabeth Kastelijn, St. Antonius Hospital, Netherlands

P1.05–033: Comparison of Single– and Five–Fraction Schedules of Stereotactic Body Radiation Therapy for Central Lung Tumors
Sung Jun Ma, Roswell Park Cancer Institute, USA

P1.05–034: Neutrophil–To–Lymphocyte and Platelet–To–Lymphocyte Ratios as Prognostic Biomarkers in Early NSCLC Patients Treated with SABR
Stephen McKay, Beatson West of Scotland Cancer Centre, UK

P1.05–035: SABR for Medically Inoperable Early Stage NSCLC at the Beatson West of Scotland Cancer Centre: Outcomes and Toxicity
Stephen McKay, Beatson West of Scotland Cancer Centre, UK

P1.05–036: A Propensity–Matched Study of Multi–Port versus Single–Port Video–Assisted Thoracoscopic Surgery for Early Lung Cancer
Kyoji Hirai, Nippon Medical School Chiba Hokusoh Hospital, Japan

P1.05–037: Histopathologic Results of Surgically Resected Pure Ground–Glass Opacity Lung Nodules
Geun Dong Lee, Gangnam Severance Hospital, Yonsei University College of Medicine, South Korea

P1.05–038: Patterns of Recurrence in Curatively Resected Stage I Lung Cancer
Kanghoon Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P1.05–039: Recurrence and Survival Outcome after Segmentectomy for Non–Small Cell Lung Cancer: A Long–Term Follow–Up Study at a Single Institute
Takamasa Koga, Kumamoto University Hospital, Japan

P1.05–040: Prognostic Factor of Node Involvement Pattern in Completely Resected pN1 Squamous Cell Carcinoma Patients
Kenta Tane, Hyogo Cancer Center, Japan

P1.05–041: Dynamics of Brain Metastasis for Curatively Resected Stage I or II Non–Small Cell Lung Cancer Patients
Sumin Shin, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P1.05–042: Treatment Strategy of Limited Surgery for Early Lung Cancer
Katsuji Kojima, Musashino Red–Cross Hospital, Japan

P1.05–018: LncRNA16 is a Potential Biomarker for Early–Stage Lung Cancer That Promotes Cell Proliferation by Regulating the Cell Cycle
Xing Wang, Peking University Cancer Hospital & Institute, China
P1.05–043: Survival Following Surgical Resection of Lung Adenocarcinoma Stratified According to Morphological Sub–Type
Haval Balata, University Hospitals of South Manchester, UK

P1.05–044: The Impact of IASLC 8th Edition Updates for T–Classification for Lung Cancer in a US Population–Based Surgical Resection Cohort
Matthew Smeltzer, University of Memphis School of Public Health, USA

P1.05 EARLY STAGE NSCLC – NEOADJUVANT AND ADJUVANT CHEMOTHERAPY

P1.05–045: Adjuvant Chemotherapy for Patients with Stage IB Non Small Cell Lung Cancer
Jia Wang, Beijing Cancer Hospital, China

P1.05–046: Randomized Study of Adjuvant Docetaxel vs. Observation for Completely Resected StageIB–IIia NSCLC with 11 Years’ Median Follow–Up
Wen–zhao Zhong, Department of Pulmonary Oncology; Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P1.05–047: Early Mortality in Patients with Non–Small Cell Lung Cancer Undergoing Adjuvant Chemotherapy
Daniel Morgensztern, Washington University School of Medicine, USA

P1.05–048: Effect of Adjuvant Chemotherapy on the Patterns and Dynamics of Recurrences in Resected Stage II(N1) Lung Adenocarcinoma
Byung Jo Park, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P1.05–049: Neoadjuvant Erlotinib Treatment in Patients with Resectable Non–Small Cell Lung Carcinoma
Matthijs Van Gool, NKI–AVL, Netherlands

P1.05–050: External Validation of a Prognostic Model for Squamous–Cell Lung Cancer and Impact of Adjuvant Treatment in >1,300 Patients
Emilio Bria, University Oncology Unit, Department of Medicine, Italy

P1.05–051: Safety and Compliance Data of the Phase III Study of Adjuvant Chemotherapy in Completely Resected P–Stage I Non Small Cell Lung Cancer: JCOG0607
Hiroyuki Sakurai, National Cancer Center Hospital, Japan

P1.05–052: An Exploratory Analysis of Postoperative Adjuvant Chemotherapy with Tegafur–Uracil on Survival for Lung Adenocarcinoma
Masahiro Tsuboi, National Cancer Center Hospital East, Japan

P1.05–053: Impact of Gender Difference on Adjuvant Chemotherapy after Radical Resection in Patients with Non–Small Cell Lung Cancer
Lu Yang, Peking Union Medical College, China

P1.05–054: Adjuvant Chemotherapy Uptake in Patients with NSCLC after Complete Resection: Single Institution/Single Area Experience
Vitezslav Kolek, University Hospital, Czech Republic

P1.05 EARLY STAGE NSCLC – RECURRENCE

P1.05–055: Risk Factors of Postoperative Recurrence in Stage IA and IB Patients
Fumihiko Hoshi, Tohoku University Hospital, Japan

P1.05–056: Increased Risk of Postoperative Recurrence in EGFR–Positive Stage IA to IB Invasive Lung Adenocarcinoma
Masaoki Ito, Hiroshima University Hospital, Japan

P1.05–057: Prediction of Early Recurrence in Patients with Stage I and II Non–Small Cell Lung Cancer Using FDG PET Quantification
Sven Hillinger, University Hospital, Switzerland

P1.05–058: Prognostic Factors of Post–Recurrence Survival in Resected Stage I Non–Small Cell Lung Cancer
Yasuaki Kubouchi, Tottori University, Faculty of Medicine, Japan

P1.05–059: Factors Associated with Recurrence and Survival in Patients with Curatively Resected Stage IA Adenocarcinoma of the Lung
Masahiko Harada, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P1.05–060: Adherence to Surveillance Guidelines in Resected NSCLC: Physician Compliance and Impact on Outcomes
Cheryl Ho, BC Cancer Agency, Canada

P1.05–061: Increased Treatment–Related Toxicity in Patients with Early–Stage Non–Small Cell Lung Cancer and Co–Existing Interstitial Lung Disease
Hanbo Chen, London Health Sciences Centre, Canada

P1.05–062: Is Lung Microwave Thermoablation a Valid Alternative to Surgery in High Risk Patients? A Propensity Match Analysis
Paolo Mendogni, Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, Italy

P1.05–063: Multicenter Observational Study of Patients with Resected Early–Staged NSCLC, Who Were Excluded from an Adjuvant Chemotherapy Trial
Tomoyuki Hishida, National Cancer Center Hospital East, Japan

P1.05–064: Global Practice Patterns of Multifocal Lung Cancer
Aaron Mansfield, Mayo Clinic, USA

P1.05–065: Usage of Chest Radiography or Computed Tomography in Post–Treatment Surveillance for Stage I and II NSCLC: Influence on Survival
Leonie Alberts, St. Antonius hospital, Netherlands

P1.05–066: Impact of Micropapillary Pattern in Nodal Upstaging of Lung Adenocarcinoma 2cm or Less
Hirotsugu Yamazaki, Kitasato University School of Medicine, Japan

P1.05 EARLY STAGE NSCLC – MISCELLANEOUS

P1.05–067: Survival Following Surgical Resection of Lung Adenocarcinoma Stratified According to Morphological Sub–Type
Haval Balata, University Hospitals of South Manchester, UK

P1.05–068: The Impact of IASLC 8th Edition Updates for T–Classification for Lung Cancer in a US Population–Based Surgical Resection Cohort
Matthew Smeltzer, University of Memphis School of Public Health, USA
P1.05–067: Consultation with Medical Oncology Less Common in Elderly Patients with Resected Stage II Nonsmall Cell Lung Cancer
Gail Darling, Cancer Care Ontario, Canada

P1.05–068: Elderly Patients with Resected Stage II Nonsmall Cell Lung Cancer Are Less Likely to Have a Consultation with a Medical Oncologist
Gail Darling, University of Toronto, Canada

P1.05–069: Stage II NSCLC Treated with Non–Surgical Approaches: A Multi–Institution Report of Outcomes
Saan Dudani, University of Ottawa, Canada

P1.05–070: Diagnostic Yield and Efficacy of EBUS TBNA in Molecular Testing for NSCLC Mutations
Shashank Nuguru, IU Health, USA

P1.05–071: A Review of Quality of Life Measures Used in Lung Cancer Surgical Outcomes
Rowena Yip, Icahn School of Medicine, USA

P1.05–072: Predictors and Patterns of Lymph Node Metastasis in Small Peripheral Non Small Cell Lung Cancer
Jun–tao Lin, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Science, China

P1.05–073: Evaluation of Stage 1 Sub–Solid Lung Nodules Using PET Imaging
Claudia Henschke, Icahn School of Medicine at Mount Sinai, USA

P1.05–074: Factors Predicting Discordance between Clinical and Surgical–Pathologic Staging in Operable Non–Small Cell Lung Cancer
Kostas Syrigos, Medical School, University of Athens, Greece

P1.05–075: The Correlation between the Prognoses of Patients with Non–Small Cell Lung Cancer and Preoperative Platelet–Lymphocyte Ratio
Shunta Ishihara, Ayabe City Hospital, Japan

P1.05–076: Risk Factors in Patients with Pathological Stage I Non–Small Cell Lung Cancer
Yoshimasa Tokunaga, Kochi Health Sciences Center, Japan

P1.05–077: Outcome of N2 Disease in NSCLC – A Single Institution Experience
Marko Jakopovi, University Hospital Center Zagreb, Croatia

P1.05–078: The Relationship between IASLC/ATS/ERS Grading System of Adenocarcinoma of the Lung and Quantitative PET Parameters
Kyle Wang, University of North Carolina Hospitals, USA

P1.05–079: Lung Cancer in the Elderly: Factors Affecting Long–Term Survival Following Resection
Ulku Yilmaz, Ankara Ataturk Chest Disease and Thoracic Surgery Training and Research Hospital, Turkey

P1.06  ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY

P1.06–001: Incidence of Molecular Testing and Outcomes of Treatment with Tyrosine Kinase Inhibitors in Advanced Non–Small Cell Lung Cancer in a Dutch Population
Romina Sluga, St. Antonius Hospital, Netherlands

P1.06–002: Contralateral Axillary Lymph Node Metastasis of a Lung Cancer: A Case Report
Omer Giray Intepe, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey

P1.06–003: Anamorelin in Cachectic Patients with Advanced NSCLC, a Post–Hoc Pooled Efficacy Data Analysis of Two Phase 3 Trials
David Currrow, Flinders University, Australia

P1.06–004: Evaluating the Non–Small Cell Lung Cancer Symptom Assessment Questionnaire (NSCLC–SAQ): Preliminary Results from the Quantitative Pilot Study
Astra Liepa, Eli Lilly and Company, USA

P1.06–005: An International Cohort of Patients with Small Cell Lung Cancer after a Non–Small Cell Lung Carcinoma Oncogene or Non–Oncogene Addicted
Matteo Giaj Levra, Michallon University Hospital, France

P1.06–006: Treatment beyond Progression in Patients with Advanced Squamous NSCLC Participating in the Expanded Access Programme (EAP)
Frederico Cappuzzo, AUSL Romagna, Italy

P1.06–007: Radical Treatment of Synchronous Oligometastatic Non–Small Cell Lung Cancer (NSCLC)
Oscar Arrieta, Instituto Nacional de Cancerologica, Mexico

P1.06–008: Non–Small Cell Lung Cancer in Octogenarians: Real–Life Clinical Practice; Characteristics, Therapy and Survival
Hirsh Koyi, Gävle Hospital, Sweden

P1.06–009: Determining Optimal Array Layouts for Delivering TTFields to the Lungs Using Computer Simulations
Zeev Bomzon, Novocure Ltd., Israel

P1.06–010: Analysis of the Incidence of Cancer Cachexia in Patients with Advanced Lung Cancer at Referral to a Dietitian
Adele Hug, Royal Surrey County Hospital, UK

P1.06–011: Altered Body Composition and Fat Loss in Advanced Non–Small Cell Lung Cancer
Anant Mohan, All India Institute of Medical Sciences, India

P1.06–012: Central and Peripheral Lung Adenocarcinomas Exhibit Different Timing and Prediction for Distant Metastasis
Judit Moldvay, National Koranyi Institute of Pulmonology, Hungary
P1.06–013: Patient Characteristics and Survival: A Real–World Analysis of US Veterans With Stage IV Adenocarcinoma vs Squamous NSCLC
Monika Parisi, Celgene Corporation, USA

P1.06–014: What Factors Determine Treatment Satisfaction in Patients with Advanced NSCLC Receiving Chemotherapy?
Sabine Visser, Erasmus MC Cancer Institute, Netherlands

P1.06–015: Designing Transducer Arrays for the Delivery of TTFIELDS Whilst Maximizing Patient Comfort and Field Intensity in the Thorax
Zeev Bomzon, Novocure Ltd., Israel

P1.06–016: Pulmonary Tuberculosis among Newly Diagnosed–Therapy Naive Advanced NSCLC in Persahabatan Hospital Jakarta Indonesia
Sita Laksmi Andarini, Faculty Of Medicine Universitas Indonesia, Indonesia

P1.06–017: Observational Study on Prolonged Disease Stabilization in Advanced NSCLC EGFR WT/Unknown Patients Treated with Erlotinib in Second Line
Francesco Grossi, IRCCS AOU San Martino – IST, Italy

P1.06–018: Treatment Patterns and Clinical Practices of Advanced (Stage IV) Non–Small Cell Lung Cancer (NSCLC) in Europe – A Structured Literature Review
Thomas Brodowicz, Medical University Vienna – General Hospital, Austria & Central European Cooperative Oncology Group, Austria

P1.06–019: The Possibility of the Additional Local Therapy to Systemic Chemotherapy in Advanced Lung Cancer Cases with Multiple Metastases
Takeshi Honda, Teikyo University, Japan

P1.06–020: Prevalence of Autoimmune Disease in US Veterans With Non–Small Cell Lung Cancer (NSCLC)
Monika Parisi, Celgene Corporation, USA

P1.06–021: Treatment Patterns and Healthcare Resource Use from a Retrospective Cohort of Japanese Patients with Advanced Non–Small Cell Lung Cancer
Terufumi Kato, Kanagawa Cardiovascular and Respiratory Center, Japan

P1.06–022: Clinical Characteristics of Survival Outliers in Stage IV Adenocarcinoma Lung Cancer Patients
Andrea Fung, University of Calgary, Canada

P1.06–023: Clinicopathological Characteristics of Axillary Lymph Node Metastasis in Lung Cancer
Yue Kong, Zhejiang Cancer Hospital, China

P1.06–024: Distinctive Patterns of Primary Metastases and Clinical Outcomes According to the Histological Subtypes in Stage IV Non–Small Cell Lung Cancer
Dong Soo Lee, College of Medicine, The Catholic University of Korea, South Korea

P1.06–025: Analysis of Risk Factors for Development of Skeletal–Related Events in Women with Bone Metastases from NSCLC and Breast Cancer
Franco Lumachi, University of Padua, School of Medicine, Italy

P1.06–026: Adenosquamous Carcinoma of the Lung: A Single Institution Experience in the Era of Molecular Testing
Kamal Kishore Mandalapu, Merit Health Biloxi, USA

P1.06–027: Retrospective Study of Treatment for Postoperative Local Recurrence of Lung Cancer
Kenjiro Tsuruoka, Osaka Medical College Hospital, Japan

P1.06–028: Description of the Patients with Advanced Squamous NSCLC Treated in a Single Institution
Irene Torres, Hospital Universitario Miguel Servet, Spain

P1.06–029: Epidemiologic, Clinical Characteristics and Therapeutic Strategy of Elderly NSCLC Patients Treated in a Single Institution
Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

P1.06–030: Extended Lymph Node Dissection through Median Sternotomy in N3 Left NSCLC Surgical Results and Anatomical Findings
Shingo Ikeda, Mitsui Memorial Hospital, Japan

P1.06–031: A North Malaysia Pulmonology Center Experience in Management of Advanced Non–Small Cell Lung Cancer: Syazatul Syakirin Sirol Afiah, Hospital Sultanah Bahiyah, Malaysia

P1.06–032: The Humanistic Burden of Advanced Non–Small Cell Lung Cancer Patients in Europe – A Real World Survey
Oana Chirita, Bristol–Myers Squibb, UK

P1.06–033: Non–Small Cell Lung Cancer in Young Patients; Clinico–Pathologic Criteria and Prognostic Factors
Hala Aziz, National Cancer Institute, Egypt

P1.06–034: Outcomes after Pulmonary Metastasectomy for Metastatic Cancer
Prakash Balakrishnan, Wellington Regional Hospital, New Zealand

P1.06–035: Frequency and Clinical Relevance of EGFR–Mutations and EML4–ALK–Translocations in Octogenarians with NSCLC
Amanda Tufman, Ludwig Maximilian University of Munich, Germany

P1.06–036: Post–Recurrence Survival Analysis of Stage I Non–Small Cell Lung Cancer: Prognostic Significance of Local Treatment
Kanghoon Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P1.06–037: Non–Small Cell Lung Cancer Invading the Diaphragm: Outcome and Prognostic Factors
Domenico Galetta, European Institute of Oncology, Italy

Ugur Yilmaz, Ankara Ataturk Chest Disease and Thoracic Surgery Training and Research Hospital, Turkey

P1.06–039: Retrospective Study of the Incidence and Outcomes from Lung Cancer That Developed Following a Solid Organ Transplant
Kelvin Young, Princess Margaret Cancer Centre, Canada
P1.06–040: Home-Based Pulmonary Rehabilitation in Advanced Non Small Cell Lung Cancer Patients Treated by Oral Targeted Therapy: A Feasibility Study
Caroline Pagniez, Hospital of the University (CHRU) of Lille, France

Maria Planck, Lund University, Sweden

P1.06–042: The Importance of Medication Related Osteonecrosis of the Jaws (MRONJ)
Mark Krasnik, Rigshospitalet, Denmark

P1.06–043: A Study to Select Rational Therapeutics in Subjects with Advanced Malignancies (WINOTHER) – The Sheba Experience in Lung Cancer Patients
Amir Onn, Sheba Medical Center, Israel

P1.06–044: Costs of Adverse Events (AE) Associated with Cancer Therapies in Non–Small Cell Lung Cancer (NSCLC) in France
Christos Chouaid, Centre Hospitalier Intercommunal Créteil, France

P1.06–045: Multiple Neoplasms Consist of Lung Cancer and Hematological Malignancies
Kazuhiko Natori, Toho University Medical Center Oomori Hospital, Japan

P1.06  ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY – ADVANCED ELDERLY

P1.06–046: Can We Better Manage Advanced NSCLC in the Elderly with the New Therapeutic Agents? Preliminary Analysis of a Real–Life Multicenter Study
Tindara Franchina, Department of Human Pathology, University of Messina and Medical Oncology Unit, A.O. Papardo, Italy

P1.06–047: Management of Patients Aged over 70 Years with Newly Diagnosed Lung Cancer
Haider Abbas, Birmingham Heartlands Hospital, UK

P1.07  SCLC/NEUROENDOCRINE TUMORS

P1.07–001: A Phase II Study of Etirinotecan Pegol (NKTR–102), a Topoisomerase–I Inhibitor Polymer Conjugate, in Small Cell Lung Cancer
Hongbin Chen, Roswell Park Cancer Institute, USA

P1.07–002: GIT28, a Cyclin Dependent Kinase 4/6 Inhibitor, in Combination with Topotecan for Previously Treated Small Cell Lung Cancer: Preliminary Results
Lowell Hart, Florida Cancer Specialists, USA

P1.07–003: A Phase II Study Evaluating the Combination of Everolimus with Carboplatin/Paclitaxel as 1st Line Treatment in Patients with Advanced LCNEC
Christian Grohé, Evangelische Lungenklinik, Germany

P1.07–004: Updated Analysis of Phase II Study of HA–Irinotecan, a CD44–Targeting Formulation of Hyaluronic Acid and Irinotecan, in Small Cell Lung Cancer
Muhammad Alamgeer, Monash Cancer Centre, Australia

P1.07–005: A Retrospective Study of Sequential Chemoradiotherapy for LD–SCLC Patients in Whom Concurrent Therapy is Not Indicated
Sayaka Ohara, NTT Medical Center Tokyo, Japan

Bart Hendriks, Merrimack Pharmaceuticals, Inc., USA

P1.07–007: Clinical Outcomes of Patients with LS–SCLC Treated with Chemoradiotherapy. Can We Find Candidates for Salvage Surgery?
Junichi Shimizu, Aichi Cancer Center Hospital, Japan

P1.07–008: Lomustine Endoxan VP16 as Second or Further Line for Recurrent or Progressive Brain Metastases from SCLC
Pascal Dô, Baclesse, France

P1.07–009: Outcomes of Patients with Relapsed Small–Cell Lung Cancer Treated with Paclitaxel plus Gemcitabine. 10 Year–Analysis
Ana Laura Ortega Granados, Complejo Hospitalario de Jaén, Spain

P1.07–010: Influence of Creatinine Clearance on Survival Parameters in Small Cell Lung Cancer Treated with Cisplatin–Based Chemotherapy Regimen
Fatih Kose, Baskent University, Turkey

P1.07–011: Extensive–Stage Small Cell Lung Cancer in a 13–Year–Old Male Patient Treated with Bevacizumab Followed by High–Dose Chemotherapy
Michihiro Yano, Akita University Hospital, Japan

P1.07–012: Efficacy of Immune Checkpoint Inhibitors in Large Cell Neuroendocrine Lung Cancer: Results from a French Retrospective Cohort
Matteo Giaj Levra, Michallon Hospital – University Hospital, France

P1.07–013: Treatment Related Side Effects of Oral Topotecan in Small Cell Lung Cancer
Marko Jakopovic, University Hospital Center, Croatia

P1.07–014: Impact of Chemotherapy for Small Cell Lung Cancer in the Third Line and beyond, a SEER–MEDICARE Analysis
Taofeek Owonikoko, Emory University Winship Cancer Institute, USA

P1.07–015: STOMP: A UK National Cancer Research Network Randomised, Double Blind, Multicentre Phase II Trial of Olaparib as Maintenance Therapy in SCLC
Penella Woll, University of Sheffield, UK
### P1.07 SCLC/NEUROENDOCRINE TUMORS – LOCAL TREATMENT

<table>
<thead>
<tr>
<th>P1.07–016: Trends, Practice Patterns and Underuse of Surgery in the Treatment of Early Stage Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elliot Wakeam, University of Toronto, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–017: Indications for Adjvant Mediastinal Radiation in Surgically Resected Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elliot Wakeam, University of Toronto, Canada</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–018: Incidence of Brain Recurrence and Survival Outcomes in High–Grade Neuroendocrine Carcinomas of the Lung: Implications for Clinical Practice</th>
</tr>
</thead>
<tbody>
<tr>
<td>Giannis Mountzios, University of Athens School of Medicine, Greece</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–019: Large Cell Neuroendocrine Carcinoma of the Lung: Prognostic Factors of Survival and Recurrence after R0 Surgical Resection</th>
</tr>
</thead>
<tbody>
<tr>
<td>Maria Cattoni, Swedish Cancer Institute, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–020: Surgical Resected Small Cell Lung Cancers (SCLCs): A Monocentric Retrospective Analysis</th>
</tr>
</thead>
<tbody>
<tr>
<td>Laura Bonanno, Istituto Oncologico Veneto, Italy</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–021: Impact on Survival of High Dose Consolidative Thoracic Radiotherapy in Extensive Stage Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Josep Jové, Institut Catala Oncologia, Spain</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–022: The Role of Surgery in Combination Treatment of Patients with Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Aleksei Aksarin, Surgut District Clinical Hospital, Russia</td>
</tr>
</tbody>
</table>

### P1.07 SCLC/NEUROENDOCRINE TUMORS – MOLECULAR CHANGES

<table>
<thead>
<tr>
<th>P1.07–023: NGS May Discriminate Extreme Long–Term versus Short–Term Survival in Patients with Stage IV Small–Cell Lung Cancer (SCLC)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Zoltan Lohinai, Medical University Vienna, Austria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–024: EGFR Mutations in Small Cell Lung Cancer (SCLC): Genetic Heterogeneity and Prognostic Impact</th>
</tr>
</thead>
<tbody>
<tr>
<td>Huarong Tang, Zhejiang Cancer Hospital, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–025: MiR–495 Promotes Chemoresistance of SCLC through Epithelial–Mesenchymal Transition via Etk/BMX</th>
</tr>
</thead>
<tbody>
<tr>
<td>Linlang Guo, Zhujiang Hospital, Southern Medical University, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–026: Activin A is Associated with Poor Prognosis and Promotes Metastatic Growth in Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Anita Rozsas, Medical University Vienna, Austria</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–027: 13–Gene Signature of EMT Reveals Impact on Invasion and Metastasis of Neuroendocrine Carcinomas of the Lung: A Preliminary Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tabatha Prieto, Faculdade de Medicina da USP, Brazil</td>
</tr>
</tbody>
</table>

### P1.07 SCLC/NEUROENDOCRINE TUMORS – PATHOLOGY

<table>
<thead>
<tr>
<th>P1.07–031: Clinical Evaluation of Folate Receptor–Positive Circulating Tumor Cells Detection in Patients with Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chunxia Su, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–032: Most Common Genomic Alterations in SCLC</th>
</tr>
</thead>
<tbody>
<tr>
<td>Patricia Thompson, Cancer Treatment Centers of America, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–033: Trastuzumab Emtansine (T–DM1) Suppresses the Growth of HER2–Positive Small–Cell Lung Cancer in Preclinical Models</th>
</tr>
</thead>
<tbody>
<tr>
<td>Osamu Morimura, Osaka University Graduate School of Medicine, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–034: Somatostatin Receptors Expression in Small Cell Lung Cancer Patients</th>
</tr>
</thead>
<tbody>
<tr>
<td>Konstantinos Zarogoulidis, Aristotle University of Thessaloniki, Greece</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–035: Circulating Cell–Free Tumor DNA (cfDNA) Testing in Small Cell Lung Cancer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Daniel Morgensztern, Washington University School of Medicine in St. Louis, USA</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–036: Large Cell Neuroendocrine Carcinoma of the Lung: The Mayo Clinic Experience</th>
</tr>
</thead>
<tbody>
<tr>
<td>Kunlatida Maneenil, Rajavithi Hospital, College of Medicine, Rangsit University, Thailand</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–037: Clinicopathological Significance of Cancer Stem–Like Cell Markers in High–Grade Neuroendocrine Carcinoma of the Lung</th>
</tr>
</thead>
<tbody>
<tr>
<td>Masahiro Morise, Nagoya University Graduate School of Medicine, Japan</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–038: Typical Morphological Features Revealed Unfavorable Survival Benefits in High–Grade Neuroendocrine Carcinomas</th>
</tr>
</thead>
<tbody>
<tr>
<td>Hao–ran Zhai, Guangdong Lung Cancer Institute, Guangdong General Hospital and Guangdong Academy of Medical Sciences; Southern Medical University, China</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>P1.07–039: Insulinoma–Associated 1 (INSM1) Immunohistochemical Expression in Lung Neuroendocrine Tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Yasuyuki Shigematsu, The Cancer Institute, Japan</td>
</tr>
</tbody>
</table>
P1.07 SCLC/NEUROENDOCRINE TUMORS – PROGNOSTIC FACTORS

P1.07–040: Prognostic Factors in Extensive Disease (ED) Small Cell Lung Cancer (SCLC): An ELCWP Phase III Randomised Trial
Thierry Berghmans, Institut Jules Bordet, Belgium

P1.07–041: Validation of Prognostic Scores in Small Cell Lung Cancer
Sacha Rothschild, University Hospital Basel, Switzerland

P1.07–042: Neutrophil–Lymphocyte and Platelet–Lymphocyte Ratios Predict Prognosis in Early–Stage Resected Small–Cell Lung Cancer Patients
Virag Hollosi, National Koranyi Institute of Pulmonology, Hungary

P1.07–043: Patterns of Failure and the Prognostic Factors of the Patients with LD SCLC according to the TNM Staging; TOG–TROD Study
H Faizilet Dinçbaę, Istanbul University, Cerrahpasa Medical Faculty, Turkey

P1.07 SCLC/NEUROENDOCRINE TUMORS – SCLC/NEUROENDOCRINE TUMORS IN GENERAL

P1.07–044: Educational Level and Management in Small–Cell Lung Cancer (SCLC): A Population–Based Study
Salomon Tendler, Karolinska University Hospital, Sweden

P1.07–045: Characteristics of Exceptional Long Term Survivors in Extensive Stage Small Cell Lung Cancer
Kunlatida Maneenil, Rajavithi Hospital, College of Medicine, Rangsit University, Thailand

P1.07–046: Uptake of Recommended Treatment in Small Cell Lung Cancer: Trend over the Last 15 Years and Risk Factors
KM Islam, University of Nebraska Medical Center, USA

P1.07–047: Refusal of Chemoradiotherapy and Chemotherapy among SCLC Patients: Analysis of US National Facility–Based Data
KM Islam, University of Nebraska Medical Center, USA

P1.07–048: Clinical Impact of the Relationship between Post–Progression Survival and Overall Survival in Extensive Disease Small Cell Lung Cancer Patients
Hisao Imai, Gunma Prefectural Cancer Center, Japan

P1.07–049: Limited Stage Small Cell Lung Cancer: Patterns of Care and Outcomes of a Single Institution over 15 Years
Eunji Hwang, Prince of Wales Hospital, Australia

P1.07–050: Patterns of Relapse in Small Cell Lung Cancer (SCLC): A Retrospective Analysis of Outcomes from a Single Canadian Center
Abdulaziz Al Farsi, Juravinski Cancer Center, Canada

P1.07–051: Incidence and Clinical Characteristics of Pulmonary Large–Cell Neuroendocrine Carcinoma: An Overview of Our Own Data
Gordana Drpa, Clinic for Respiratory Diseases “Jordanovac”, University Hospital Centre Zagreb, Croatia

P1.07–052: Pulmonary Neuroendocrine Tumors: Single Institution Experience in Brazil
Maria Teresa Tsukazan, Universidade Federal do Rio Grande do Sul – UFRGS, Brazil

P1.07–053: Apatinib for Chemotherapy–Refractory Extensive Stage SCLC: Results from a Single–Center Retrospective Study
Wei Hong, Zhejiang Cancer Hospital, China

P1.07–054: Second Primary Small Cell Carcinoma of Lung in Previously Treated Carcinoma Breast
Prasanta Mohapatra, All India Institute of Medical Sciences, India

P1.07–055: Introducing the US National Cancer Institute’s Small Cell Lung Cancer Consortium
Peter Ujhazy, National Cancer Institute, USA

P1.08 SURGERY

P1.08–001: Log Odds as a Novel Prognostic Indicator Superior to the Number–Based and Ratio–Based Category for Non–Small Cell Lung Cancer
Dariusz Dziedzic, National Institute of Chest Diseases, Poland

P1.08–002: The Prognostic Significance of Pleural Lavage Cytology before and after Lung Resection
Yohei Yurugi, Tottori University, Japan

P1.08–003: Survival of Lung Cancer Patients was Depended on Tumor Characteristics, Blood Cell Circuit, Cell Ratio Factors, Hemostasis System
Oleg Kshivets, Saint–Petersburg Clinic, Russia

P1.08–004: Prediction of Surgical Outcome by Modeling Based on Risk Factors of Morbidity Following Pulmonary Resection for Lung Cancer in the Elderly
Yuzhao Wang, Peking University Cancer Hospital & Institute, China

P1.08–005: Stratification of pStage I Lung Adenocarcinoma by the Scoring System Based on Prognostic Factors
Naoya Kawakita, Institute of Health Biosciences, The University of Tokushima Graduate School, Japan

P1.08–006: Prognostic Impact of Incompletely Lobulated Fissures in Non–Small–Cell Lung Cancer
Junichi Okamoto, Nippon Medical School Musashikosugi Hospital, Japan
P1.08–007: The Significant Improvement of Lung Function after Preoperative Rehabilitation in Patients with Thoracic Tumors and Abnormal Spirometry
Maciej Głogowski, The Maria Skłodowska–Curie Memorial Cancer Centre & Institute of Oncology, Poland

P1.08–008: Impact of Perioperative Redox Balance on Long-Term Outcome in Patients Undergoing Lung Resection
Osamu Arai, Dokkyo Medical University, Japan

P1.08–009: Does Body Mass Index (BMI) Affect Outcomes Post Lung Resection Surgery?
Tomoyo Fujiwara, NHS Golden Jubilee National Hospital, UK

P1.08–010: Octogenarians Perform Equally to Younger Patients in Lung Cancer Surgery
Florian Kocher, Medical University Innsbruck, Austria

P1.08–011: Feasibility of Surgical Resection for Lung Cancer Patients Aged over 85 Years
Takehiro Ouchi, Juntendo University, Japan

P1.08–012: Characterizing Time to Care for Lung Cancer Surgical Patients
Michael Humer, Kelowna Thoracic Surgical Group, Canada

P1.08–013: Preoperative Management for Pulmonary Complications Using Inhalations in Lung Cancer Patients with Chronic Obstructive Pulmonary Disease
Kyoshiro Takegahara, Nippon Medical School Hospital, Japan

P1.08–014: Usefulness of Chest CT in Follow-Up of Patients with Completely Resected Lung Cancer
Jefferson Gross, AC Camargo Cancer Center, Brazil

P1.08–015: Surgery of Stage I Non-Small Cell Lung Cancer in Patients Aged 80 Years or Older
Osamu Kawamata, Onomichi Municipal Hospital, Japan

P1.08–016: BMI in Patients with Operated Lung Cancer in Comparison with the Scottish Health Survey 2014. Is there a Democracy in BMI?
Tomoyo Fujiwara, Golden Jubilee National Hospital, UK

P1.08–017: Does Mediastinal Lymph Node Dissection Affect Prognosis of Early Stage NSCLC?
Hye-seon Kim, Hanyang University Seoul Hospital, South Korea

P1.08–018: Positive N Stage is a Risk Factor for Survival in Five-Year Disease Free Survivors with Completely Resected Non-Small Cell Lung Cancer
Jin Gu Lee, Yonsei University College of Medicine, South Korea

P1.08–019: Risk Factors and Survival of Occult N2 Lymph Node Metastasis in NSCLC Patients with Clinical N0–1 Diagnosed by Preoperative PET-CT
KS Park, DCMC, South Korea

P1.08–020: The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)
Nicholas Faris, Baptist Cancer Center, USA

P1.08–021: Predictors of Post-Operative Mortality in Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Region of the US
Matthew Smeltzer, University of Memphis School of Public Health, USA

P1.08–022: Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables
Haval Balata, University Hospitals of South Manchester, UK

P1.08–023: Analysis of Prognostic Factors and Long-Term Results of Primary Pulmonary Pleomorphic Carcinoma
Domenico Galetta, European Institute of Oncology, Italy

P1.08–024: Surgical Outcomes and Prognostic Factors in the Treatment of Adenosquamous Carcinoma of the Lung
Domenico Galetta, European Institute of Oncology, Italy

P1.08–007: The Significant Improvement of Lung Function after Preoperative Rehabilitation in Patients with Thoracic Tumors and Abnormal Spirometry
Maciej Głogowski, The Maria Skłodowska–Curie Memorial Cancer Centre & Institute of Oncology, Poland

P1.08–008: Impact of Perioperative Redox Balance on Long-Term Outcome in Patients Undergoing Lung Resection
Osamu Arai, Dokkyo Medical University, Japan

P1.08–009: Does Body Mass Index (BMI) Affect Outcomes Post Lung Resection Surgery?
Tomoyo Fujiwara, NHS Golden Jubilee National Hospital, UK

P1.08–010: Octogenarians Perform Equally to Younger Patients in Lung Cancer Surgery
Florian Kocher, Medical University Innsbruck, Austria

P1.08–011: Feasibility of Surgical Resection for Lung Cancer Patients Aged over 85 Years
Takehiro Ouchi, Juntendo University, Japan

P1.08–012: Characterizing Time to Care for Lung Cancer Surgical Patients
Michael Humer, Kelowna Thoracic Surgical Group, Canada

P1.08–013: Preoperative Management for Pulmonary Complications Using Inhalations in Lung Cancer Patients with Chronic Obstructive Pulmonary Disease
Kyoshiro Takegahara, Nippon Medical School Hospital, Japan

P1.08–014: Usefulness of Chest CT in Follow-Up of Patients with Completely Resected Lung Cancer
Jefferson Gross, AC Camargo Cancer Center, Brazil

P1.08–015: Surgery of Stage I Non-Small Cell Lung Cancer in Patients Aged 80 Years or Older
Osamu Kawamata, Onomichi Municipal Hospital, Japan

P1.08–016: BMI in Patients with Operated Lung Cancer in Comparison with the Scottish Health Survey 2014. Is there a Democracy in BMI?
Tomoyo Fujiwara, Golden Jubilee National Hospital, UK

P1.08–017: Does Mediastinal Lymph Node Dissection Affect Prognosis of Early Stage NSCLC?
Hye-seon Kim, Hanyang University Seoul Hospital, South Korea

P1.08–018: Positive N Stage is a Risk Factor for Survival in Five-Year Disease Free Survivors with Completely Resected Non-Small Cell Lung Cancer
Jin Gu Lee, Yonsei University College of Medicine, South Korea

P1.08–019: Risk Factors and Survival of Occult N2 Lymph Node Metastasis in NSCLC Patients with Clinical N0–1 Diagnosed by Preoperative PET-CT
KS Park, DCMC, South Korea

P1.08–020: The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)
Nicholas Faris, Baptist Cancer Center, USA

P1.08–021: Predictors of Post-Operative Mortality in Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Region of the US
Matthew Smeltzer, University of Memphis School of Public Health, USA

P1.08–022: Risk Stratification Model to Predict Survival Following Surgical Resection for Lung Cancer Using Pathological Variables
Haval Balata, University Hospitals of South Manchester, UK

P1.08–023: Analysis of Prognostic Factors and Long-Term Results of Primary Pulmonary Pleomorphic Carcinoma
Domenico Galetta, European Institute of Oncology, Italy

P1.08–024: Surgical Outcomes and Prognostic Factors in the Treatment of Adenosquamous Carcinoma of the Lung
Domenico Galetta, European Institute of Oncology, Italy

P1.08–025: Long-Term Survival of Lung Cancer in Chile
Ruben Valenzuela, Clínica Santa María, Chile

P1.08–026: LUNG CANCER – Early and Late Outcomes of Surgical Patients of a New District Hospital
Paulo Calvinho, Hospital de Santa Marta, Portugal

P1.08–027: Evolution of Survival in a Regional Population–Based US Lung Cancer Resection Cohort
Raymond Osarogiagbon, Baptist Cancer Center, USA

P1.08–028: Nationwide Trends in Surgery for Lung Cancer in Finland from 2004 to 2014
Jarmo Gunn, Turku University Hospital, Finland

P1.08–029: Surgical Experience of Primary Salivary Gland Tumors of Lung: Experience from Tertiary Care Cancer Center in North India
Ashish Jakhetiya, All India Institute of Medical Sciences, India

P1.08–030: Female Lung Cancer and Our Five Year Experience
Fatmir Caushi, University Hospital of Lung Diseases, Albania

P1.08–031: Non-Small Cell Lung Cancer in Patients Aged 40 Years or Younger: Clinical, Surgical, and Long-Term Outcomes
Domenico Galetta, European Institute of Oncology, Italy

P1.08–032: Impact of the Oncogenic Status on the Mode of Recurrence in Resected Non-Small Cell Lung Cancer
Tetsuya Mizuno, Aichi Cancer Center Hospital, Japan

P1.08–033: Effect of EGFR Mutations on Survival in Patients following Surgical Resection of Lung Adenocarcinoma
Grace Laidlaw, Stanford University School of Medicine, USA

P1.08–034: Prognostic Impact of EGFR Mutation in Patients with Surgically Resected Lung Adenocarcinoma; Analysis about Subtypes of EGFR Mutations
Yohei Kawaguchi, Tokyo Medical University Hospital, Japan

P1.08–007: The Significant Improvement of Lung Function after Preoperative Rehabilitation in Patients with Thoracic Tumors and Abnormal Spirometry
Maciej Głogowski, The Maria Skłodowska–Curie Memorial Cancer Centre & Institute of Oncology, Poland

P1.08–008: Impact of Perioperative Redox Balance on Long-Term Outcome in Patients Undergoing Lung Resection
Osamu Arai, Dokkyo Medical University, Japan

P1.08–009: Does Body Mass Index (BMI) Affect Outcomes Post Lung Resection Surgery?
Tomoyo Fujiwara, NHS Golden Jubilee National Hospital, UK

P1.08–010: Octogenarians Perform Equally to Younger Patients in Lung Cancer Surgery
Florian Kocher, Medical University Innsbruck, Austria

P1.08–011: Feasibility of Surgical Resection for Lung Cancer Patients Aged over 85 Years
Takehiro Ouchi, Juntendo University, Japan

P1.08–012: Characterizing Time to Care for Lung Cancer Surgical Patients
Michael Humer, Kelowna Thoracic Surgical Group, Canada

P1.08–013: Preoperative Management for Pulmonary Complications Using Inhalations in Lung Cancer Patients with Chronic Obstructive Pulmonary Disease
Kyoshiro Takegahara, Nippon Medical School Hospital, Japan

P1.08–014: Usefulness of Chest CT in Follow-Up of Patients with Completely Resected Lung Cancer
Jefferson Gross, AC Camargo Cancer Center, Brazil

P1.08–015: Surgery of Stage I Non-Small Cell Lung Cancer in Patients Aged 80 Years or Older
Osamu Kawamata, Onomichi Municipal Hospital, Japan

P1.08–016: BMI in Patients with Operated Lung Cancer in Comparison with the Scottish Health Survey 2014. Is there a Democracy in BMI?
Tomoyo Fujiwara, Golden Jubilee National Hospital, UK

P1.08–017: Does Mediastinal Lymph Node Dissection Affect Prognosis of Early Stage NSCLC?
Hye-seon Kim, Hanyang University Seoul Hospital, South Korea

P1.08–018: Positive N Stage is a Risk Factor for Survival in Five-Year Disease Free Survivors with Completely Resected Non-Small Cell Lung Cancer
Jin Gu Lee, Yonsei University College of Medicine, South Korea

P1.08–019: Risk Factors and Survival of Occult N2 Lymph Node Metastasis in NSCLC Patients with Clinical N0–1 Diagnosed by Preoperative PET-CT
KS Park, DCMC, South Korea

P1.08–020: The Effect of Two Interventions on Attainment of Surgical Quality Measures in Resected Non-Small Cell Lung Cancer (NSCLC)
Nicholas Faris, Baptist Cancer Center, USA

P1.08–021: Predictors of Post-Operative Mortality in Non-Small Cell Lung Cancer (NSCLC) in a High Mortality Region of the US
Matthew Smeltzer, University of Memphis School of Public Health, USA
P1.08–035: Analysis of Post–Operative Recurrence in a Population with NSCLC Harboring an EGFR Mutation: A Single Institutional Retrospective Study  
Hayashi Kosuke, Matusaka Municipal Hospital, Japan

P1.08–036: Thoracotomy and VATS–Surgery in Local Non–Small Cell Lung Cancer: Differences in Long–Term Health Related Quality of Life  
Ville Rauma, Heart and Lung Center, Helsinki University Central Hospital, Finland

P1.08–037: Thoracoscopic Segmentectomy of Pulmonary Nodules after Computed Tomography–Assisted Bronchoscopic Metallic Coil Marking (2nd Version)  
Takanori Miyoshi, Tokushima Municipal Hospital, Japan

P1.08–038: VATS Sub–Lobar Anatomical Pulmonary Resections: Indications and Outcomes in Thoracic Oncological Practice  
Bibhusal Thapa, Olivia Newton John Cancer Research Institute, Australia

P1.08–039: Systematic Review and Updated Meta–Analysis of Uniportal versus Multiportal Video–Assisted Thoracoscopic Surgery for Lung Cancer  
Janusz Kowalewski, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

P1.08–040: Lymph Node Sampling in 3–Port Video Assisted Thoracoscopic Surgery (VATS) vs Uniportal VATS  
Michael Klimatsidas, Golden Jubilee National Hospital, UK

P1.08–041: Disease Free and Overall Survival is Equal in Open and VATS Resection for Early Lung Cancer in a Multivariate Analysis  
Caecilia Ng, Medical University Innsbruck, Austria

P1.08–042: Overall Survival and Tumor Recurrence after VATS Lobectomy of N1 Positive NSCLC is Equal to Open Resection  
Herbert Maier, Medical University Innsbruck, Austria

P1.08–043: Perioperative and Mid–Term Outcomes after Single Port versus Multi–Ports Thoracoscopic Lobectomy for Lung Cancer: A Propensity Matching Study  
Bong Soo Son, Pusan National University Yangsan Hospital, South Korea

P1.08–044: Comparison of Peri–Operative Outcomes after Robotic–Assisted Video–Thoracoscopic Lobectomies versus Segmentectomies  
Eric Toloza, Moffitt Cancer Center, USA

P1.08–045: Partial Lung Resection after Bronchoscopic Metallic Coil Marking Using Two Coins and C–Armed Shaped Fluoroscopic Guidance  
Koh Uyama, Tokushima Municipal Hospital, Japan

P1.08–046: Survival Following Thoracoscopic Pulmonary Metastasectomy for Osteosarcoma  
Takashi Tojo, Nara medical university, Japan

P1.08–047: Decreasing Use of Epidural Analgesia with Increasing Minimally Invasive Lobectomy: Impact on Postoperative Morbidity  
Masha Zeltsman, Memorial Sloan Kettering Cancer Center, USA

P1.08–048: Comparison of Pulmonary Function after Robotic–Assisted Video–Thoracoscopic Lobectomies vs Segmentectomies  
Eric Toloza, Moffitt Cancer Center, USA

P1.08–049: CT Guided Labeling with Indocyanine Green of Small Lung Nodules for Sublobar Resection Utilizing Robotic Assisted Thoracoscopic Surgery (RATS)  
K Adam Lee, Jupiter Medical Center, USA

P1.08–050: VATS Lobectomy in Locally Advanced NSCLC: A Single Centre Experience  
Davide Tosi, Fondazione IRCCS Ca’ Granda Policlinico, Italy

P1.08–051: VATS Lobectomy Combined with Limited Thoracotomy for Treatment of Superior Sulcus Tumors  
Davide Tosi, Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, Italy

P1.08–052: Comparison Study of Perioperative Outcomes in Robotic, Video–Assisted Thoracic Surgery, and Thoracotomy Approaches for Lung Cancer  
Hiroshige Nakamura, Tottori University Hospital, Japan

P1.08–053: Thoracoscopic Partial Resection for Peripheral Pulmonary Nodules without Using Stapler  
Toshiya Toyazaki, Tenri Hospital, Japan

P1.08–054: Uniportal VATS Lobectomy in the Treatment of NSCLC  
Nenad Ilic, University Surgical Hospital, Croatia

P1.08–055: Hand Assisted Thoracoscopic Surgery (HATS) for Metastatic Lung Tumors – Improved Technique for More Safety and Accuracy  
Shozo Fujino, University Hospital Mizonokuchi, Teikyo University School of Medicine, Japan

P1.08–056: Surgical Results of Thoracoscopic Anatomical Sublobar Resections for Early–Stage Lung Cancer  
Fumiaki Watanabe, Matsusaka Municipal Hospital, Japan

P1.08–057: Outcomes between Single Port, Two Port and Three Port VATS Pulmonary Resection  
Juwei Mu, National Cancer Center / Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

P1.08–058: VATS lung resection analysis from Brazilian Society of Thoracic Surgery Database  
Maria Teresa Ruiz Tsukazan, Hospital São Lucas da PUCRS, Brazil

P1.08–059: Timing of Surgery after Induction Chemoradiation Therapy for Locally Advanced NSCLC  
Huseyin Melek, Uludag University, Turkey
P1.08–060: Survival of Patients with Unsuspected N2 (Stage IIIA) Non–Small Cell Lung Cancer
Takashi Yamamichi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P1.08–061: Clinical Experience of Rib Resection for Lung Cancer with Chest Wall Invasion Using a Pneumatic High Speed Power Drill System
Yuichiro Ueda, Tenri Hospital, Japan

P1.08–062: The Short and Long–Term Outcomes of Completion Pneumonectomy Compared with Primary Pneumonectomy
Takuya Ueda, National Cancer Center Hospital East, Japan

P1.08–063: Double Primary Malignancies Involving Lung Cancer and Hepatocellular Carcinoma
Han Pil Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P1.08–064: Surgery for Malignant Pulmonary Tumor Invading Proximal Left Main Pulmonary Artery
Fumihiro Tanaka, University of Occupational and Environmental Health, Japan

P1.08–065: Resection of Isolated Brain Metastasis Improves Outcome of Non Small–Cell Lung Cancer (NSCLC) Patients: A Retrospective Multicenter Study
Julia Fuchs, University Hospital Basel, Switzerland

P1.08–066: Prognostic Factors of Post–Recurrence Survival in Patients with Completely Resected Stage III–N2 Non–Small Cell Lung Cancer
Kyung Wook Shin, Seoul National University Bundang Hospital, South Korea

P1.08–067: The Feasibility of Lung Second Surgery for 2nd Primary Lung Cancer
Kazunori Hata, Juntendo University School of Medicine, Japan

P1.08–068: Salvage Surgical Resection after Curative–Intent Concurrent Chemoradiotherapy for N2–Stage III Lung Cancer
Motohiro Yamashita, Shikoku Cancer Center, Japan

P1.08–069: One Surgeon’s 30–Year Experience of Surgical Treatment for Pancoast Tumor
Hiroshi Niwa, Seirei Mikatahara General Hospital, Japan

P1.08–070: Salvage Lung Surgery: Difficulties and Results
Berna Komurcuoglu, Izmir Suat Seren Education Hospital for Chest Disease, Turkey

P1.08–071: Surgery for Lung Cancer with Mediastinal Lymph Node Metastasis – Effectiveness of Extended Bilateral Mediastinal Lymphadenectomy
Toshiya Yokota, Mitsui Memorial Hospital, Japan

P1.08–072: The Result of Completion Pneumonectomy for the Local Recurrent Lung Cancer after Radical Lobectomy
Takeshi Shiraishi, Fukuoka University School of Medicine, Japan

P1.08–073: Experience of Third Primary Lung Tumors after Treatment of First and Second Primary Lung Cancer
Takehiro Watanabe, Nishi–Niigata Chuo National Hospital, Japan

P1.08–074: Effect of Intrapleural Perfusion Hyperthermic Chemotherapy in Non–Small Cell Lung Cancer with Pleural Seeding
Kyung Wook Shin, Seoul National University Bundang Hospital, South Korea

P1.08–075: Salvage Surgery for Stage IV Non–Small Cell Lung Cancer
Hideaki Kojima, Shizuoka Cancer Center, Japan

P1.08–076: Recurrence Patterns in Lung Cancer Patients Treated with Protocol Based Multimodality Treatment at a Tertiary Care Cancer Center in India
Ashish Jakhetiya, All India Institute of Medical Sciences, India

P1.08–077: Comparison of Pulmonary Resection for Lung Cancer after Radical Chemoradiation with That after Induction Chemoradiation
Yasuhiro Hida, Hokkaido University Hospital, Japan

P1.08–078: Does Surgery Have Real Benefit in Resectable Oligometastatic NSCLC?
Oleg Pikin, Hertzen Research Institute of Oncology, Russia

P1.08–079: Salvage Surgery after Definitive Radiotherapy or Chemoradiotherapy for Lung Cancer
Naoya Yamasaki, Nagasaki University, Japan

P1.08–080: Bilobectomy for Lung Cancer: Analysis of Indications, Postoperative Results and Long–term Outcomes
Domenico Galetta, European Institute of Oncology, Italy

P1.08–081: Resection of T4 Non–Small Cell Lung Cancer Invading the Spine
Domenico Galetta, European Institute of Oncology, Italy

P1.08–082: Surgical Techniques and Long–Term Results of the Pulmonary Artery Reconstruction in Patients with Lung Cancer
Domenico Galetta, European Institute of Oncology, Italy

P1.08–083: Hyperthermic Pleural Lavage for Pleural Metastases
Patricia Thompson, Cancer Treatment Centers of America, USA

P1.08–060: Survival of Patients with Unsuspected N2 (Stage IIIA) Non–Small Cell Lung Cancer
Takashi Yamamichi, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P1.08–061: Clinical Experience of Rib Resection for Lung Cancer with Chest Wall Invasion Using a Pneumatic High Speed Power Drill System
Yuichiro Ueda, National Cancer Center Hospital East, Japan

P1.08–062: The Short and Long–Term Outcomes of Completion Pneumonectomy Compared with Primary Pneumonectomy
Takuya Ueda, National Cancer Center Hospital East, Japan

P1.08–063: Double Primary Malignancies Involving Lung Cancer and Hepatocellular Carcinoma
Han Pil Lee, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P1.08–064: Surgery for Malignant Pulmonary Tumor Invading Proximal Left Main Pulmonary Artery
Fumihiro Tanaka, University of Occupational and Environmental Health, Japan

P1.08–065: Resection of Isolated Brain Metastasis Improves Outcome of Non Small–Cell Lung Cancer (NSCLC) Patients: A Retrospective Multicenter Study
Julia Fuchs, University Hospital Basel, Switzerland

P1.08–066: Prognostic Factors of Post–Recurrence Survival in Patients with Completely Resected Stage III–N2 Non–Small Cell Lung Cancer
Kyung Wook Shin, Seoul National University Bundang Hospital, South Korea

P1.08–067: The Feasibility of Lung Second Surgery for 2nd Primary Lung Cancer
Kazunori Hata, Juntendo University School of Medicine, Japan

P1.08–068: Salvage Surgical Resection after Curative–Intent Concurrent Chemoradiotherapy for N2–Stage III Lung Cancer
Motohiro Yamashita, Shikoku Cancer Center, Japan

P1.08–069: One Surgeon’s 30–Year Experience of Surgical Treatment for Pancoast Tumor
Hiroshi Niwa, Seirei Mikatahara General Hospital, Japan

P1.08–070: Salvage Lung Surgery: Difficulties and Results
Berna Komurcuoglu, Izmir Suat Seren Education Hospital for Chest Disease, Turkey

P1.08–071: Surgery for Lung Cancer with Mediastinal Lymph Node Metastasis – Effectiveness of Extended Bilateral Mediastinal Lymphadenectomy
Toshiya Yokota, Mitsui Memorial Hospital, Japan

P1.08–072: The Result of Completion Pneumonectomy for the Local Recurrent Lung Cancer after Radical Lobectomy
Takeshi Shiraishi, Fukuoka University School of Medicine, Japan

P1.08–073: Experience of Third Primary Lung Tumors after Treatment of First and Second Primary Lung Cancer
Takehiro Watanabe, Nishi–Niigata Chuo National Hospital, Japan
### POSTERS AT A GLANCE

#### P2.01 BIOLOGY/PATHOLOGY
- **ANALYSIS OF BODY FLUIDS IN CANCER**
  - P2.01–001 – P2.01–009
- **ANALYSIS OF RNA**
  - P2.01–010 – P2.01–025
- **PROTEINS IN LUNG CANCER AND PROTEOMICS**
  - P2.01–026 – P2.01–041
- **IMMUNE MECHANISMS IN THORACIC CANCER AND TARGETED THERAPY**
  - P2.01–042 – P2.01–068
- **MARKER FOR PROGNOSIS, PREDICTION**
  - P2.01–069 – P2.01–085
- **TARGETS FOR TREATMENT PREDICTION**
  - P2.01–086 – P2.01–093
- **MISCELLANEOUS**
  - P2.01–094

#### P2.02 LOCALLY ADVANCED NSCLC
- **BIOLOGY**
  - P2.02–001 – P2.02–006
- **CLINICAL OUTCOME**
  - P2.02–007 – P2.02–022
- **MULTIMODALITY TREATMENT**
  - P2.02–023 – P2.02–043
- **PROGNOSTIC FACTOR**
  - P2.02–044 – P2.02–056
- **RT TECHNIQUES**
  - P2.02–057 – P2.02–060
- **TOXICITIES**
  - P2.02–061 – P2.02–062

#### P2.03a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
- **CLINICAL TRIALS**
  - P2.03a–001 – P2.03a–072

#### P2.03b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY
- **BRAIN META**
  - P2.03b–001 – P2.03b–020
- **BIOMARKERS**
  - P2.03b–021 – P2.03b–098

#### P2.04 MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES
- **THYMIC MALIGNANCIES CLINICAL & TRANSLATIONAL**
  - P2.04–001 – P2.04–024
- **ESOPHAGEAL CANCER AND OTHER MALIGNANCIES**
  - P2.04–025 – P2.04–054

#### P2.05 RADIOThERAPY
- **BIOLoGY**
  - P2.05–001 – P2.05–005
- **CLINICAL OUTCOME**
  - P2.05–006 – P2.05–025
- **MULTIMODALITY TREATMENT**
  - P2.05–026 – P2.05–032
- **RT TECHNIQUES**
  - P2.05–033 – P2.05–048
- **TOXICITIES**
  - P2.05–049 – P2.05–058

#### P2.06 SCIENTIFIC CO-OPERATION/RESEARCH GROUPS
- **PHASE I TRIALS**
  - P2.06–001 – P2.06–005
- **PHASE I/II TRIALS**
  - P2.06–006 – P2.06–009
- **PHASE II + NK**
  - P2.06–010 – P2.06–020
- **PHASE III**
  - P2.06–021 – P2.06–024
- **MESOTHELIOMA AND SCLCP**
  - 2.06–025 – P2.06–029
- **SUPPORTIVE, PREVENTIVE**
  - 2.06–030 – P2.06–033
- **RADIOThERAPY, TT FIELDSP LAB., OTHER**
  - 2.06–034 – P2.06–037
  - 2.06–038 – P2.06–047

#### P2.07 NURSES
- **INFORMATION FOR PATIENTS**
  - P2.07–001 – P2.07–003
- **DIFFERENT ASPECTS OF SYMPTOMS**
  - P2.07–004 – P2.07–006
- **RESEARCH, AUDITS**
  - P2.07–007 – P2.07–010

#### P2.08 PATIENT SUPPORT AND ADVOCACY GROUPS
- **PATIENTS’ VOICE, PATIENTS INFORMATION**
  - P2.08–001 – P2.08–007
- **OTHER**
  - P2.08–008 – P2.08–015
P2.01–007: Detection of Promoter DNA Methylation of APC, DAPK, and GSTP1 Genes in Tissue Biopsy and Matched Serum of Advanced Stage Lung Cancer Patients
Ashraf Ansari, All India Institute of Medical Sciences, India

P2.01–008: SiRe Next Generation Sequencing Panel: Effective Diagnostic Tool for Circulating Free DNA Analysis
Umberto Malapelle, University of Naples Federico II, Italy

P2.01–009: Serial Quantitative Assessment of Plasma Circulating Tumor DNA by Digital NGS in Patients with Lung Cancer
Yue Zhao, Fudan University Shanghai Cancer Center, China

P2.01–010: Downregulation of PFTK1 by shRNA Inhibits Migration and Invasion of Human Non–Small Cell Lung Cancer Cell Lines
Xiaoting Zhao, Beijing TB and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, China

P2.01–011: Identification of Differentially Expressed Circulating miRNAs in the Serum of NSCLC Patients Using next Generation Sequencing
Sachin Kumar, Amity University Uttar Pradesh, India

P2.01–012: Acquired Chemotherapy Resistance in vitro: miRNA Profiles of Chemotherapy Resistant Squamous Lung Cancer Cell Lines
Simon Haefliger, University of Sydney, Australia

P2.01–013: HA–Liposome Nanocarrier Containing CD44 siRNA as a Targeted Chemotherapy to CD44 Related Chemoresistant Non–Small Cell Lung Cancer
Hyun Koo Kim, Korea University Guro Hospital, South Korea

P2.01–014: miR–3941: A Novel microRNA That Controls IGBP1 Expression and is Associated with Malignant Progression of Lung Adenocarcinoma
Taiki Sato, University of Tsukuba, Japan

P2.01–015: Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes
Tomas Tokar, University Health Network, Canada

P2.01–016: Analysis of 5 Differential miRNA Expression in NSCLC Patients
Janusz Kowalewski, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland

Poster Setup Time:
Tuesday, December 6  08:30 – 10:15

Poster Takedown Time:
Tuesday, December 6  15:45 – 18:00
(Posters not taken down by 18:00 will be discarded by management)

Poster Session with Presenters Present
(Presenting Author Stand By Time)
Session in which Poster Presenters remains at his/her poster board and is available to discuss/present their research personally with interested delegates.
Tuesday, December 6  10:25 - 11:00
14:30 – 15:45
Hall B (Exhibit Hall) – Poster Area

P2.01  BIOLOGY/PATHOLOGY

P2.01–001: Enrichment–Free, Rapid Metabolic Assay for Detection of Tumor Cells in Pleural Effusion and Peripheral Blood
Qihui Shi, Shanghai Jiao Tong University, China

P2.01–002: Serum Protein Signature in Lung Cancer Patients and in Patients with Chronic Obstructive Pulmonary Disease
Janna Berg, Vestfold Hospital Trust, Norway

P2.01–003: Serum VEGF, MMP–7 and CYFRA 21–1 as Predictive Markers of Lung Metastases from Colorectal Cancer
Franco Lumachi, University of Padua, School of Medicine, Italy

P2.01–004: The Methylation Profiling of Multiple Tumor Suppressor Genes in Plasma Cell–Free DNA of Patients with NSCLC vs Benign Tumors
Mateusz Florczuk, National Institute of Tuberculosis and Lung Diseases, Poland

P2.01–005: Evaluation of Circulating Tumoral Microemboli (CTM) as a Prognostic Factor in Non–Small Cell Lung Cancer (NSCLC)
Marcelo Corassa, A.C.Camargo Cancer Center, Brazil

P2.01–006: Sensitive Detection of CTCs in Thoracic Malignant Tumors With “Universal” CTC–Chip
Kazue Yoneda, University of Occupational and Environmental Health, Japan

P2.01–010: Downregulation of PFTK1 by shRNA Inhibits Migration and Invasion of Human Non–Small Cell Lung Cancer Cell Lines
Xiaoting Zhao, Beijing TB and Thoracic Tumor Research Institute/Beijing Chest Hospital, Capital Medical University, China

P2.01–012: Acquired Chemotherapy Resistance in vitro: miRNA Profiles of Chemotherapy Resistant Squamous Lung Cancer Cell Lines
Simon Haefliger, University of Sydney, Australia

P2.01–013: HA–Liposome Nanocarrier Containing CD44 siRNA as a Targeted Chemotherapy to CD44 Related Chemoresistant Non–Small Cell Lung Cancer
Hyun Koo Kim, Korea University Guro Hospital, South Korea

P2.01–014: miR–3941: A Novel microRNA That Controls IGBP1 Expression and is Associated with Malignant Progression of Lung Adenocarcinoma
Taiki Sato, University of Tsukuba, Japan

P2.01–015: Differentially Expressed microRNAs in Lung Adenocarcinoma Invert Effects of Copy Number Aberrations of Prognostic Genes
Tomas Tokar, University Health Network, Canada

P2.01–016: Analysis of 5 Differential miRNA Expression in NSCLC Patients
Janusz Kowalewski, Collegium Medicum in Bydgoszcz, Nicolaus Copernicus University in Torun, Poland
P2.01–017: Circulating miRNAs in Lung Cancer Are Associated to Pro–Tumorigenic and Immunosuppressive Microenvironment
Orazio Fortunato, Fondazione IRCCS Istituto Nazionale dei Tumori INT, Italy

P2.01–018: Differential microRNA Expression Profile between Young and Old Lung Adenocarcinoma Patients
Mirella Giordano, University of Pisa, Italy

P2.01–019: Three microRNAs Associated with Poor Prognosis Are Up–Regulated in Amplified Regions of Squamous Cell Lung Carcinoma
Sana Yokoi, Chiba Cancer Center Research Institute, Japan

P2.01–020: Identification of a Three–InRNA Signature for Lung Cancer Diagnosis and Prognosis
Changli Wang, Tianjin Medical University Cancer Institute and Hospital, China

P2.01–021: miRNA Deep Sequencing of Early–Stage Lung Cancer Patients to Evaluate the Dynamic Change of Circulating Biomarkers in Response to Surgery
Daniela Petriella, IRCCS, Istituto Tumori Giovanni Paolo II, Italy

P2.01–022: A PIWI–Interacting RNAs Co–Expression Networks as a Prognostic Factor in Lung Cancer
Brenda Minatel, British Columbia Cancer Research Centre, Canada

P2.01–023: Deregulation of Small Non–Coding RNAs at the DLK1–DIO3 Imprinted Locus Predicts Lung Adenocarcinoma Patient Outcome
John Enterina, BC Cancer Research Centre, Canada

P2.01–024: Expression of miR–106 Paralogs Improves Prognostic Value of Mesenchymal Signatures but Only miR–106b Promotes Invasiveness
Sonia Kung, British Columbia Cancer Research Centre, Canada

P2.01–025: MiR–146b Functions as a Suppressor miRNA and Prognosis Predictor in Non–Small Cell Lung Cancer
Jun Chen, Tianjin Medical University General Hospital, China

P2.01–026: A Mass Spectrometry Based Stem Cell–Oriented Phylogeny of Intra–Tumoral NSCLC Subclones
Robert Downey, Memorial Sloan Kettering Cancer Center, USA

P2.01–027: A Comparison of Five Different Immunohistochemistry Assays for Programmed Death Ligand–1 Expression in Non–Small Cell Lung Cancer Samples
Joey Lim, National University of Singapore, Singapore

P2.01–028: Prognostic Significance of GLUT1 and CAIX Expression: Correlation with Volume–Based PET Parameters in Non–Small Cell Lung Cancer
Young Wha Koh, Ajou University School of Medicine, South Korea

P2.01–029: Tumor B7–H3 (CD276) Protein Expression, Smoking History, and Survival in Lung Adenocarcinoma Patients
Kentaro Inamura, The Cancer Institute, JFCR, Japan

P2.01–030: Prognostic Impact of Stathmin1 Expression in Patients with Non–Small Lung Cancer
Kimihiro Shimizu, Gunma University Graduate School of Medicine, Japan

P2.01–031: CCL Chemokines May Play an Important Role in Cisplatin Resistance
Sarah–Louise Ryan, Queensland University of Technology, Australia

P2.01–032: Impact of Preoperative Serum Anti–60S Ribosomal Protein L29 Levels on Prognosis in Patients Who Underwent Surgery for Non–Small Cell Lung Cancer
Hiromasa Yamamoto, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P2.01–033: Exosomal Proteomics Analysis Reveal New Targets for Radiation–Induced Lung Toxicity Diagnosis
Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

P2.01–034: The Pregnancy Associated Endometrial Protein Glycodelin as a Biomarker for Malignant Pleural Mesothelioma
Marc Schneider, Thoraxklinik at Heidelberg University Hospital, Germany

P2.01–035: Protein and Molecular Alterations in EMT Pathways of Lung Cancer: A Comparative Analysis between NSCLCs
Vera Capelozzi, University of São Paulo, Brazil

P2.01–036: Identification of a Novel Oncogenic Ubiquitin Ligase from a Lung Cancer Epigenome–Wide Association Study (EWAS)
Christian Faltus, Division of Epigenomics and Cancer Risk Factors, DKFZ – German Cancer Resarch Center; University of Salzburg, Austria

P2.01–037: Molecular Biology Underlying COPD and Lung Cancer Converge on FOXO1 Network
Victor Martinez, British Columbia Cancer Research Centre, Canada

P2.01–038: Discrimination of NSCLC Cases from Cancer–Free Controls and Adenocarcinoma from Squamous Cell Carcinoma Using Plasma Metabolomics Profiles
Michael Abdalmassih, University of Manitoba, Canada

P2.01–039: Prognostic Significance of Claudin Protein Expression in Histological Subtypes of Non–Small Cell Lung Cancer
Judit Moldvay, National Korányi Institute of Pulmonology, Hungary

P2.01–040: CXC Chemokine Receptor 3 and ELR Motif Negative CXC Chemokine Ligand Axis in Non–Small Cell Lung Cancer
Artjoms Spaks, Pauls Stradins Clinical University Hospital, Latvia

P2.01–041: Integrated Proteo–Genomics Analyses Reveal Extensive Tumor Heterogeneity and Novel Somatic Variants in Lung Adenocarcinoma
Udayan Guha, Center for Cancer Research, NCI, NIH, USA
P2.01–042: T Cells Subsets with INF–Gamma, TNF–Alpha and ADA in Distinguishing Tuberculous from Malignant Pleural Effusions
Abdellah Ali, Sohag University, Egypt

P2.01–043: Pathologist Agreement Rates of PD–L1 Tumor and Immune Cell Quantitation Using Digital Read, Field–Of–View, and Whole Tumor Image Analysis
Christoph Guetter, Roche Diagnostics, USA

P2.01–044: Baseline Peripheral Blood Cell Subsets Associated with Survival Outcomes in Advanced NSCLC Treated with Nivolumab in Second–Line Setting
Antonio Passaro, European Institute of Oncology, Italy

P2.01–045: Nintedanib Improves Anti–Tumor Efficacy in Combination with Anti PD–1 in Syngeneic Tumor Models Sensitive and Refractory to IO Inhibition
Frank Hilberg, Boehringer Ingelheim RCV, Austria

P2.01–046: Quantitative Measurement of B7–H3 Protein Expression and Its Association with B7–H4, PD–L1 and TILs in NSCLC
Mehmet Altan, Yale Cancer Center, USA

P2.01–047: Intra– and Inter–Observer Reproducibility Study of PD–L1 Biomarker in Non–Small Cell Lung Cancer (NSCLC) – The DREAM STUDY
Wendy Cooper, Royal Prince Alfred Hospital, Australia

P2.01–048: Paired Comparison of PDL1 Assessment on Cytology and Histology from Malignancies in the Lung
Birgit Skov, Copenhagen University Hospital, Rigshospitalet, Denmark

P2.01–049: A Comparative Study of PD–L1 IHC 28–8 pharmDx and PD–L1 IHC 22C3 pharmDx on Malignancies from the Lung
Birgit Skov, Copenhagen University Hospital, Rigshospitalet, Denmark

P2.01–050: Clinicopathological Characteristics of PD–L1 Expression in Lung Adenocarcinoma
Xuan Zeng, Peking Union Medical College Hospital, China

P2.01–051: Myeloid–Derived Suppressor Cell Expression within the Microenvironment of Lung Adenocarcinoma
Yasuto Jin, Hiratsuka Kyosai Hospital, Japan

P2.01–052: High PD–L1 Expression is Associated with Worse Prognosis in Primary Resected Squamous Cell Carcinomas of the Lung
Manuel Keller, Institute of Pathology, University of Bern, Switzerland

P2.01–053: PD–L1 Expression in Patients with Small Cell Lung Cancer
Haiyue Wang, Peking University Cancer Hospital, China

P2.01–054: Lung Cancer PD–L1 mRNA Expression Profile and Clinical Outcomes – An Analysis From The Cancer Genome Atlas and Cancer Cell Line Encyclopedia
Boris Sepesi, UT MD Anderson Cancer Center, USA

P2.01–055: Lymphocytes’ Subtypes Differentiation after Stimulation with Synthetic Antigen–Pulsed Dendritic Cells in Lung Adenocarcinoma Patients
Paweł Krawczyk, Medical University, Poland

P2.01–056: Distinct PD–L1 Expression in Different Components of Pulmonary Sarcomatoid Carcinoma and Its Association with MET Mutation
Janaki Sharma, Albert Einstein College of Medicine/Montefiore Medical Center, USA

P2.01–057: Association of Tumor Infiltrating Lymphocytes Quantification with EGFR Mutations in Completely Resected Stage IIIA(N2) Lung Adenocarcinoma
Wen Feng, Shanghai Chest Hospital, Shanghai jiao Tong University, China

P2.01–058: Mutational Features Associated with Immunoreactivity in Non–Small Cell Lung Cancer
Nicholas Syn, National University Cancer Institute, Singapore

P2.01–059: Regulation of Glycodelin Expression – An Immunomodulatory and Pregnancy Associated Protein in NSCLC
Nicholas Syn, National University Cancer Institute, Singapore

P2.01–060: Comparative Analysis of PD–L1 Expression between Circulating Tumor Cells and Tumor Tissues in Patients with Lung Cancer
Yasuhiro Koh, Wakayama Medical University, Japan

P2.01–061: Image Analysis–Based Expression of Nine Immune Checkpoints Identifies Distinct Immunoprofiling Patterns in Non–Small Cell Lung Carcinomas
Jaime Rodríguez–Canales, U.T.–M.D. Anderson Cancer Center, Translational Molecular Pathology, USA

P2.01–062: Impact of the Tissue Distribution of Subpopulations of TILs and PD–L1 Expression on the Clinical Outcome of NSCLC
Giovanni Bocchialini, University of Parma, Italy

P2.01–063: PDL1, JAK2 and PTEN Copy Number Alterations Synergistically Upregulate PD–L1 Expression in NSCLC
Sergi Clavé, Hospital del Mar, Spain

P2.01–064: Molecular Context of Immune Microenvironment in Early–Stage Lung Squamous Cell Carcinoma
Esther Conde, Hospital Universitario HM Sanchinarro, Spain

P2.01–065: Quantification of Tumour–Immune Cell Spatial Relationships in the Lung Tumour Microenvironment Using Single Cell Profiling
Katey Enfield, BC Cancer Research Centre, Canada

P2.01–066: PD–L1 Tumor Expression and Its Effect on Overall Survival among Patients with Resected Non–Small Cell Lung Cancer (NSCLC)
Jane Sui, St. James’s Hospital, Ireland

P2.01–067: The Relevance of CEA and CYFRA21–1 as Predictive Factors in Nivolumab Treated Advanced Non–Small Cell Lung Cancer (NSCLC) Patients
Giulia Barletta, San Martino Hospital – National Institute for Cancer Research, Italy

P2.01–068: Analysis of Epithelial–Stromal Interactions and their Relevance to Lung Cancer
César Márquez, Stanford University School of Medicine, USA
P2.01 BIOLOGY/PATHOLOGY – MARKER FOR PROGNOSIS, PREDICTION

P2.01–069: Erythron Reaction Shows High Malignant Tumor Process in Lung Cancer Patients
Yury Ragulin, Medical Radiological Research Center, Russia

P2.01–070: Circulating Biomarkers of Frailty Are Associated with a Poor Prognosis in Patients with Advanced Non–Small Cell Lung Cancer (NSCLC)
Alastair Greystoke, Newcastle University, UK

P2.01–071: Biological Implication of Cytoplasmic ECT2 in Malignant Progression of Lung Adenocarcinoma
Zeinab Kosibaty, University of Tsukuba, Japan

P2.01–072: Clinical Associations of MUC1 Expression in Human Lung Cancer and Precancerous Lesions
Andreas Saltos, Moffitt Cancer Center, USA

P2.01–073: The Diagnostic Value of Carcinoembryonic Antigen and Squamous Cell Carcinoma Antigen in Lung Adenosquamous Carcinoma
Hongyang Lu, Zhejiang Cancer Hospital, China

P2.01–074: Increased AIMP2–DX2/AIMP2 Autoantibody Ratio is Associated with Poor Prognosis in Lung Cancer
Eun Young Kim, Yonsei University College of Medicine, South Korea

P2.01–075: Prognostic Value of Angiogenesis and Cell Adhesion Biomarkers in Non–small Cell Lung Cancer
Kostas Syrigos, Medical School, University of Athens, Greece

P2.01–076: Drebrin: A New Targetable Molecular Marker of Lung Adenocarcinoma
Shinji Iyama, University of Tsukuba, Japan

P2.01–077: Serum CYFRA 21–1 and CEA Level as a Predicting Marker for Advanced Non–Small Cell Lung Cancer
Busyamas Chewaskulyong, Faculty of Medicine, Chiangmai university, Thailand

P2.01–078: Frequent High TIM–3 (HAVCR2) Expression in Resected NSCLC Specimens, Most Notably in Adenocarcinoma Histology
Aaron Lisberg, UCLA Medical Center, USA

P2.01–079: The Serum Levels of Alpha–1 Antitrypsin Are Strongly Associated with Its Local Production by Tumor Cells in NSCLC Patients
Adam Szpechinski, National Institute of Tuberculosis and Lung Diseases, Poland

P2.01–080: Mitosis Count of Lung Adenocarcinomas: Correlation between the Phosphorylated Histone 3, Number of Cancer Cells, Nuclear Grade, and Prognosis
Takashi Inoue, Dokkyo Medical University, Japan

P2.01–081: CDCA3 is a Novel Prognostic Cell Cycle Protein and Target for Therapy in Non–Small Cell Lung Cancer
Mark Adams, Institute of Health and Biomedical Innovation, Australia

P2.01–082: Transcriptional Profiling Identified the Anti–Proliferative Effect of Mitofusin–2 Deficiency and Its Risk in Lung Adenocarcinoma
Yuqing Lou, Shanghai Chest Hospital, Shanghai Jiaotong University, China

P2.01–083: Prognostic Factors of Overall Survival in 150 Resected Lung Adenocarcinoma Patients
Yue Cheng, West China School of Medicine, West China Hospital, Sichuan University, China

P2.01–084: Linker–Phosphorylated Smad2 and STAT3 Induce Resistance to Tyrosine Kinase Inhibition in Lung Cancer
Yojiro Makino, Tokyo Medical University Hospital, Japan

P2.01–085: Epigenetic Profile of Oligoprogressive versus Widespread Non–Small Cell Lung Cancer Patients
Carolina Gabay, Instituto Angel H Roffo, Argentina

P2.01 BIOLOGY/PATHOLOGY – TARGETS FOR TREATMENT PREDICTION

P2.01–086: Luteolin is a Novel Target of Axl Receptor Tyrosine Kinase to Inhibit Cell Proliferation and Circumvent Chemoresistance in Lung Cancer Cells
Kyungchan Kim, Catholic University of Daegu Hospital, South Korea

P2.01–087: Prognostic Significance of CA IX Overexpression in Stage III NSCLC Patients Received Neoadjuvant Treatment
Sezer Saglam, Istanbul Bilim University, Turkey

P2.01–088: Prenylation Inhibitors in Lung Adenocarcinoma: Comparison of Zoledronic Acid and a Novel Lipophilic Bisphosphonate
Balazs Hegedus, Medical University of Vienna, Austria

P2.01–089: Predictive Value of AEG–1 Expression on Tumor Response by Liquid biopsy in NSCLC Patients Treated with Chemotherapy
Chung–Yu Chen, National Taiwan University Hospital Yunlin Branch, Taiwan

P2.01–090: Platin Induced Phosphorylation of ATM and ATM–Deficiency as a Predictive Marker of Platin Sensitivity in Non–Small Cell Lung Cancer
Jarrett Moore, University of Calgary, Canada

P2.01–091: The Anticancer Effect of Techoic Acids on Lewis Lung Carcinoma Model
Viktoriia Nikulina, Taras Shevchenko National University of Kyiv, Ukraine

P2.01–092: PRMT5 is a Poor Prognostic Marker for NSCLC and Inhibition of PRMT5 Results in Increased Lung Cancer Sensitivity to Cisplatin and Radiotherapy
Meng Welliver, The Ohio State University CCC, USA

P2.01–093: Exo–ALK Proof of Concept: Exosomal Analysis of ALK Alterations in Advanced NSCLC Patients
Christian Rolfo, Antwerp University Hospital & Antwerp University, Belgium
P2.02  LOCALLY ADVANCED NSCLC

P2.02–001: Advanced Large Cell Lung Cancer; Biological Behavior and Prognostic Factors
Hala Aziz, National Cancer Institute, Egypt

P2.02–002: Association between VEGF Gene Functional Polymorphisms and Clinical and Pathological Characteristics of Non–Small Cell Lung Cancer
Anna Shchayuk, National Academy of Sciences of Belarus, Belarus

P2.02–003: Increased Circulating Cytokeratin–19 (Cyfra 21–1) is Predictive of Poor Outcome of Locally Advanced Squamous Cell Carcinoma in Lung
Jingbo Wang, Cancer Hospital, Chinese Academy of Medical Sciences, China

P2.02–004: Real–time Monitoring of Circulating Tumor Cells to Evaluate Response of Neoadjuvant Chemotherapy in Locally Advanced NSCLC
Miao Huang, Peking University Cancer Hospital and Institute, China

P2.02–005: A Rare Clinical Presentation Of EGFR–Mutant Non–Small Cell Lung Cancer With Oligo–Acrometastasis
Ugur Yilmaz, Ankara Atatürk Chest Disease and Thoracic Surgery Training and Research Hospital, Turkey

P2.02–006: Targeted Next Generation Sequencing Reveals Prognostic Recurrent Somatic Mutations in the GNAQ Oncogene in NSCLC
Norma Hernández–Pedro, Instituto Nacional de Cancerología, Mexico

P2.02–007: Treatment Outcomes of Combine Chemoradiation in Locally Advanced Non–Small Cell Lung Cancer: A Single Institution Study
Pitchayaponne Klunklin, Chiangmai University, Thailand

P2.02–008: How Do We Really Treat Patients with Stage III Non–Small Cell Lung Cancer (NSCLC)?
Allan Price, Western General Hospital, UK

P2.02–009: Clinical Outcomes of Induction Chemoradiotherapy with High Dose Chest Radiation for Locally Advanced Non–Small Cell Lung Cancer Patients
Hidejiro Torigoe, Okayama University Hospital, Japan

P2.02–010: Prognosis Impact of Oligoprogression Following Definitive Chemo–Radiotherapy in Stage III Non–Small Cell Lung Cancer
Maria Saigi, Department of Medical Oncology, Catalan Institute of Oncology, Hospitalet, Spain

P2.02–011: Management of Non–Small–Cell Lung Cancer (NSCLC) Stage III Patients in Central European Countries
Milada Zemanová, Faculty of Medicine of Charles University in Prague, Czech Republic

P2.02–012: Long–Term Survival of Phase II of Full–Dose Oral Vinorelbine Combined with cisplatin & Radiotherapy in Locally Advanced NSCLC
Óscar Juan, Hospital Universitari i Politècnic La Fe, Spain

P2.02–013: Costing Analysis of PROCLAIM Non–Small Cell Lung Cancer Trial Data
Katherine Winfree, Eli Lilly and Company, USA

P2.02–014: Perioperative Outcomes and Downstaging Following Neoadjuvant Therapy For Lung Cancer – Analysis of the National Cancer Database
Boris Sepesi, MD Anderson Cancer Center, USA

P2.02–015: Guideline Concordant Care is Associated with Better Survival for Patients with Stage III Non–Small Cell Lung Cancer
Hiba Ahmed, Winship Cancer Institute, Emory University, USA

P2.02–016: Real World Experience with Chemoradiotherapy in Locally Advanced NSCLC
Irene Torres, Hospital Universitario Miguel Servet, Spain

P2.02–017: A Clinical Outcome of Resected Small–Sized Non–Small Cell Lung Cancer 1 cm or Less in Diameter with N2 Lymph Node Metastasis
Yasufumi Kato, Tokyo Medical University Ibaraki Medical Center, Japan

P2.02–018: Chemoradiotherapy in Elderly Patients with Locally Advanced Non–Small Cell Lung Cancer
Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P2.02–019: Lung Cancer in Young Adults (Age Group 18–50 yrs): Presentation, Clinical Features and Treatment
Balaji Varadhan, Leicester Royal Infirmary, UK

P2.02–020: Pattern of Care of Inoperable Locally Advanced (LA) NSCLC in Elderly Patients: Analysis of the Experience of Two Academic Italian Hospitals
Marco Perna, Radiation Oncology Unit, Italy

P2.02–021: Extracranial Progression (ePD) after Chemoradiotherapy (CRT) for Stage III NSCLC: Does the Chemotherapy Regimen Matter?
Anne–Marie Dingemans, Maastricht University Medical Center, Netherlands

P2.02–022: For down Staged Clinical N3 M0 Non–Small Cell Lung Cancer Patients Chemo–Radiotherapy Followed by Surgery Can Improve Survival
Jitian Zhang, University of Hong Kong Shenzhen Hospital, China
P2.02 – LOCALLY ADVANCED NSCLC – MULTIMODALITY TREATMENT

P2.02–023: Neoadjuvant Chemotherapy and Concurrent Full-Dose Radiation Therapy Followed by Surgery for Stage IIIIB Non-Small Cell Carcinoma of the Lung
Sherry Yan, Columbia University Medical Center, USA

P2.02–024: Phase I and II Trial of Intrapeural Paclitaxel Injection for Non–Small–Cell Lung Cancer Patients with Malignant Pleural Effusions
Masato Sasaki, University of Fukui, Japan

P2.02–025: Continuous Intravenous Pumping Endostar Combined with Radiochemotherapy in Unresectable Stage ? Non–Small–Cell Lung Cancer
Hong Lian Ma, Zhejiang Cancer Hospital, Zhejiang Key Laboratory of Radiation Oncology, China

P2.02–026: Individualized Adjuvant Chemotherapy for Resected Lung Cancer According to Collagen Gel Droplet–Embedded Culture Drug Sensitivity Test
Masayoshi Inoue, Kyoto Prefectural University of Medicine, Japan

P2.02–027: A Randomized Phase II Trial of S–1 plus Cisplatin or Docetaxel plus Cisplatin with Concurrent Thoracic Radiotherapy for Stage III NSCLC: TORG1018
Kazuhiko Yamada, Kurume University School of Medicine, Japan

P2.02–028: A Phase I/II Study of Carboplatin, Pemetrexed, and Concurrent Radiation Therapy for Patients with Locally Advanced NSCLC. CJLSG0912
Naohiko Murata, University of Red Cross Nagoya Daini Hospital, Japan

P2.02–029: Concomitant Chemoradiotherapy for Locally Advanced Non–Small–Cell Lung Cancer: A Phase II Study from the Galician Lung Cancer Group
Joaquin Casal Rubio, Complejo Hospitalario Universitario de Vigo, Spain

P2.02–030: Consolidation Chemotherapy Following Concurrent Chemoradiation for Stage III Non–Small–Cell Lung Cancer: A Brazilian Multicentric Cohort
Vladimir Cordeiro De Lima, A.C. Camargo Cancer Center, Brazil

P2.02–031: Survival Data of Postoperative Adjuvant Chemotherapy of Cisplatin plus Vinorelbine for Completely Resected NSCLC: A Retrospective Study
Hirotugu Kenmotsu, Shizuoka Cancer Center, Japan

P2.02–032: Induction Histology–Based Combination Chemotherapy for Elderly Patients with Inoperable Non–Small Cell Lung Cancer (NSCLC)
Giuseppe Banna, Cannizzaro Hospital, Italy

P2.02–033: The Advantage of Induction Chemoradiotherapy in Bronchoplastic Procedure for Non Small Cell Lung Cancer Accompanied with Central Disease Region
Hiroki Sato, Okayama University Graduate School of Medicine, Japan

P2.02–034: Both Induction and Adjuvant Treatment Improve Outcomes of Surgically–Resected IIIA(N2) NSCLC When Compared to Definitive Chemoradiotherapy
Patrick Villeneuve, The Ottawa Hospital, Canada

P2.02–035: The Advantage of Induction Chemoradiotherapy in Bronchoplastic Procedure for Non Small Cell Lung Cancer Accompanied with Central Disease Region
Hiroki Sato, Okayama University Graduate School of Medicine, Japan

P2.02–036: Double Plasty Operation; A Procedure with Pulmonary Arterioplasty and Bronchoplasty against Centrally Located Non–Small–Cell Lung Cancer
Koji Takahashi, Graduate School of Medicine, Kyoto University, Japan

P2.02–037: Final Results of Prospective Phase II Study of Adding Erlotinib to Chemoradiation for patients with Stage III Non–Small–Cell Lung Cancer
Ritsuko Komaki, MD Anderson Cancer Center, USA

P2.02–038: Surgical Outcome of Stage III A–cN2/pN2 Non–Small Cell Lung Cancer
Ryotaro Kamohara, Nagasaki University Graduate School of Biomedical Sciences, Japan

P2.02–039: Intercalated EGFR and Chemotherapy in Locally Advanced NSCLC with EGFR Mutations: Data on 5 Patients and Clinical Study
Frank Griesinger, Pius Hospital Oldenburg, Germany

P2.02–040: Phase 3 Randomized Low–Dose Paclitaxel Chemoradiotherapy Study for Locally Advanced Non–Small Cell Lung Cancer
Yuhchya Chen, University of Rochester, USA

P2.02–041: The Impact of Surgical Resection after Concurrent Chemotherapy and High Dose (61 Gy) Radiation in Stage IIIA/N2 Non–Small Cell Lung Cancer
Akif Turna, Istanbul University, Cerrahpasa Medical Faculty, Turkey

P2.02–042: Surgical Management of Squamous Cell Carcinoma of the Lung: Survival and Functional Outcomes
Jun Chen, Tianjin Medical University General Hospital, China

P2.02–043: Randomized Ph II Trial of Allogeneic DPV–001 Cancer Vaccine Alone or with Adjuvant for Curatively–Treated Stage III NSCLC
Rachel Sanborn, Robert W. Franz Cancer Center, Earle A. Chiles Research Institute, USA

P2.02–044: Impact of N2 Extent and Nodal Response on Survival after Trimodal Treatment for Stage IIIA–N2 Non–Small Cell Lung Cancer
Hong Kwan Kim, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P2.02–045: Prognostic Value of Metabolic FDG–PET Response in Locally Advanced NSCLC: A Literature Review
Charlotte Van De Kerkhove, University Hospital KU Leuven, Belgium

P2.02–046: Prognostic Value of Early Tumor Regression during Chemotherapy in Locally Advanced Non–Small Cell Lung Cancer
Alexander Sun, University of Toronto, Canada
P2.02–047: Association of FDG PET, Complete Pathological Response and Overall Survival in Patients with Pancoast Tumors Treated with Trimodality Therapy
Bibhusal Thapa, Austin Health, Australia

P2.02–048: Predictive Factors of Outcome in Locally Advanced NSCLC Patients Treated with Neo–Adjuvant Chemotherapy in Resource–Constrained Settings
Vinayak R, IRCH, All India institute of Medical Sciences(AllIMS), India

P2.02–049: Gender and Risk of Cessation of Oral Vinorelbine in a Randomized Trial of Concurrent Chemoradiation of Locally Advanced NSCLC
Olfred Hansen, Odense University Hospital, Denmark

P2.02–050: Gender and Smoking Influence on Non Small Cell Lung Cancer Histology and Tnm Stage in a Brazilian Population
Ricardo Terra, University of Sao Paulo Medical School, Brazil

P2.02–051: Prognostic Value of the Pretreatment Peripheral Blood Markers in Patients with Non–Small Cell Lung Cancer
Marko Jakopovic, University Clinical Hospital Center Zagreb, Croatia

P2.02–052: Does Delay from Diagnosis to Start of Radiotherapy, or Modified Comorbidity Score Impact Survival in Curatively Treated Non Small Cell Lung Cancer
Jeremy Ruben, William Buckland Radiotherapy Centre and Monash University, Australia

P2.02–053: Does the Method of Mediastinal Staging Cause the Mediastinal Nodal Clearance Following Trimodality Therapy?
Jong Ho Cho, Sungkyunkwan University School of Medicine, Samsung Medical Center, South Korea

P2.02–054: Impact of Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non–Small Lung Cancers
Junichi Soh, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P2.02–055: Pathologic Mediastinal Nodal and Metabolic Tumor Response to Predict Overall Survival in Stage IIIA–N2 NSCLC after Neoadjuvant Chemotherapy
Christophe Dooms, University Hospitals KU Leuven, Belgium

P2.02–056: FGFR Gene Mutation is an Independent Prognostic Factor in Squamous Non–Small Cell Lung Cancer, and Associated with Lymph Node Metastasis
Wu Nan, Peking University Cancer Hospital & Institute, China

P2.02–047: Association of FDG PET, Complete Pathological Response and Overall Survival in Patients with Pancoast Tumors Treated with Trimodality Therapy
Bibhusal Thapa, Austin Health, Australia

P2.02–048: Predictive Factors of Outcome in Locally Advanced NSCLC Patients Treated with Neo–Adjuvant Chemotherapy in Resource–Constrained Settings
Vinayak R, IRCH, All India institute of Medical Sciences(AllIMS), India

P2.02–049: Gender and Risk of Cessation of Oral Vinorelbine in a Randomized Trial of Concurrent Chemoradiation of Locally Advanced NSCLC
Olfred Hansen, Odense University Hospital, Denmark

P2.02–050: Gender and Smoking Influence on Non Small Cell Lung Cancer Histology and Tnm Stage in a Brazilian Population
Ricardo Terra, University of Sao Paulo Medical School, Brazil

P2.02–051: Prognostic Value of the Pretreatment Peripheral Blood Markers in Patients with Non–Small Cell Lung Cancer
Marko Jakopovic, University Clinical Hospital Center Zagreb, Croatia

P2.02–052: Does Delay from Diagnosis to Start of Radiotherapy, or Modified Comorbidity Score Impact Survival in Curatively Treated Non Small Cell Lung Cancer
Jeremy Ruben, William Buckland Radiotherapy Centre and Monash University, Australia

P2.02–053: Does the Method of Mediastinal Staging Cause the Mediastinal Nodal Clearance Following Trimodality Therapy?
Jong Ho Cho, Sungkyunkwan University School of Medicine, Samsung Medical Center, South Korea

P2.02–054: Impact of Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non–Small Lung Cancers
Junichi Soh, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P2.02–055: Pathologic Mediastinal Nodal and Metabolic Tumor Response to Predict Overall Survival in Stage IIIA–N2 NSCLC after Neoadjuvant Chemotherapy
Christophe Dooms, University Hospitals KU Leuven, Belgium

P2.02–056: FGFR Gene Mutation is an Independent Prognostic Factor in Squamous Non–Small Cell Lung Cancer, and Associated with Lymph Node Metastasis
Wu Nan, Peking University Cancer Hospital & Institute, China

P2.02–057: The Importance of Adaptive Radiotherapy in the Radical Treatment of Locally Advanced Non Small Cell Lung Cancer
Slavica Maric, International Medical Centers Banja Luka, Bosnia and Herzegovina

P2.02–058: Moderately Hypofractionated Radiotherapy in Locally Advanced Non Small Cell Lung Cancer: A Single Institution Retrospective Analysis
Alessio Bruni, Aou Policlinico Of Modena, Italy

P2.02–059: New Treatment Strategy in Inoperable Locoregionally Advanced NSCLC: C Arm Cone Beam CT – GuııDed Selective Intraarterial Chemotherapy
Mustafa Ozdogan, Mediterranean Integrative Oncology Group, Turkey

P2.02–060: SBRT and Sequential Chemotherapy for Stage IIA to IIIA Non–Small Cell Lung Cancer – A Phase I Dose Escalation Study
Andreas Rimner, Memorial Sloan Kettering Cancer Center, USA

P2.02–050: Gender and Smoking Influence on Non Small Cell Lung Cancer Histology and Tnm Stage in a Brazilian Population
Ricardo Terra, University of Sao Paulo Medical School, Brazil

P2.02–051: Prognostic Value of the Pretreatment Peripheral Blood Markers in Patients with Non–Small Cell Lung Cancer
Marko Jakopovic, University Clinical Hospital Center Zagreb, Croatia

P2.02–052: Does Delay from Diagnosis to Start of Radiotherapy, or Modified Comorbidity Score Impact Survival in Curatively Treated Non Small Cell Lung Cancer
Jeremy Ruben, William Buckland Radiotherapy Centre and Monash University, Australia

P2.02–053: Does the Method of Mediastinal Staging Cause the Mediastinal Nodal Clearance Following Trimodality Therapy?
Jong Ho Cho, Sungkyunkwan University School of Medicine, Samsung Medical Center, South Korea

P2.02–054: Impact of Prognostic Nutrition Index for Induction Chemoradiotherapy Followed by Surgery in Locally Advanced Non–Small Lung Cancers
Junichi Soh, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P2.02–055: Pathologic Mediastinal Nodal and Metabolic Tumor Response to Predict Overall Survival in Stage IIIA–N2 NSCLC after Neoadjuvant Chemotherapy
Christophe Dooms, University Hospitals KU Leuven, Belgium

P2.02–056: FGFR Gene Mutation is an Independent Prognostic Factor in Squamous Non–Small Cell Lung Cancer, and Associated with Lymph Node Metastasis
Wu Nan, Peking University Cancer Hospital & Institute, China

P2.02–057: The Importance of Adaptive Radiotherapy in the Radical Treatment of Locally Advanced Non Small Cell Lung Cancer
Slavica Maric, International Medical Centers Banja Luka, Bosnia and Herzegovina

P2.02–058: Moderately Hypofractionated Radiotherapy in Locally Advanced Non Small Cell Lung Cancer: A Single Institution Retrospective Analysis
Alessio Bruni, Aou Policlinico Of Modena, Italy

P2.02–059: New Treatment Strategy in Inoperable Locoregionally Advanced NSCLC: C Arm Cone Beam CT – GuııDed Selective Intraarterial Chemotherapy
Mustafa Ozdogan, Mediterranean Integrative Oncology Group, Turkey

P2.02–060: SBRT and Sequential Chemotherapy for Stage IIA to IIIA Non–Small Cell Lung Cancer – A Phase I Dose Escalation Study
Andreas Rimner, Memorial Sloan Kettering Cancer Center, USA
P2.03a–006: Frequency of 2 Year PFS Milestone in Stage IV NSCLC Patients Treated with First Line Pemetrexed/Platinum and Pemetrexed Maintenance
Marta Batus, Rush University Medical Center, USA

P2.03a–007: Pem/CBP/Bev Followed by Pem/Bev in Hispanic Patients with NSCLC: Outcomes According to Combined Score of TS, ERCC1 and VEGF Expression
Andrés Cardona, Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Colombia

P2.03a–008: Relative Dose Intensity of First–Line Chemotherapy and Overall Survival in Patients With Advanced Non–Small–Cell Lung Cancer (NSCLC)
Jeffrey Crawford, Duke University School of Medicine, USA

P2.03a–009: Clinical Outcome of Node–Negative Oligometastatic Non–Small Cell Lung Cancer
Masayuki Takeda, Kinki University Faculty of Medicine, Japan

P2.03a–010: A Randomized Phase II Study of Platinum–Based Chemotherapy +/- Metformin in Chemotherapy–Naïve Advanced Non–squamous NSCLC
David Ettinger, Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, USA

P2.03a–011: Population Pharmacokinetic/Pharmacodynamic Monitoring of Pemetrexed to Predict Survival in Patients with Advanced NSCLC
Sabine Visser, Erasmus MC Cancer Institute, Netherlands

P2.03a–012: Nephrotoxicity in Patients with Advanced NSCLC Receiving Pemetrexed–Based Chemotherapy
Sabine Visser, Erasmus MC Cancer Institute, Netherlands

P2.03a–013: Chemotherapy is Beneficial for Octogenarians with Non–Small Cell Lung Cancer (NSCLC)
Hirsh Koyi, Gävle Hospital, Sweden

P2.03a–014: A Dose–Finding and Phase 2 Study of Ruxolitinib plus Pemetrexed/Cisplatin for Nonsquamous Non–Small Cell Lung Cancer (NSCLC)
Giuseppe Giaccone, Georgetown University, USA

P2.03a–015: Systemic Inflammation Alters Carboplatin Pharmacokinetics Explaining Poor Survival in Advanced Lung Cancer Patients
Benjamin Harris, University of Sydney, Australia

P2.03a–016: Weekly Paclitaxel with 4 Weekly Carboplatin as Salvage Treatment in Advanced Non–Small Cell Lung Cancer–HCG Centre Experience
Satheesh Thungappa, HCG Bangalore Institute of Oncology Speciality Centre, India

P2.03a–017: Chemotherapy–Induced Nausea and Vomiting (CINV) in Italian Lung Cancer Patients: Assessment by Physician, Nurse and Patient
Silvia Novello, Thoracic Oncology Unit, Italy

P2.03a–018: A Phase I/II Study of Alixertib, an Oral Aurora Kinase Inhibitor, in Combination with Erlotinib in Patients with Recurrent or Metastatic NSCLC
Hossein Borghaei, Fox Chase Cancer Center, USA

P2.03a–019: A Retrospective Analysis Of Nanoparticle Albumin Bound Paclitaxel In Chinese Patients With Recurrent Advanced Non–small Cell Lung Cancer In A Single Center
Yixiang Zhu, Cancer Institute and Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, China

P2.03a–020: Metronomic Oral Vinorelbine Monotherapy in Elderly Patients with Advanced NCSLC
Angeliki Rapti, Hospital of Chest Diseases of Athens, Greece

P2.03a–021: Vinorelbine/Carboplatin vs Gemcitabine/Carboplatin in Advanced Squamous Cell Lung Cancer
Ali Hasan, Damascus University, Syria

P2.03a–022: QOL and Febrile Neutropenia: Japanese Phase 2 Trial of Docetaxel with/out Antiangiogenic Agent in 2nd Line NSCLC
Yukie Omori, Eli Lilly Japan K.K., Japan

P2.03a–023: Induction–Maintenance Treatment Sequence in Non–squamous Non–Small Cell Lung Cancer (neNSCLC): Pemetrexed vs Vinorelbine–Based Induction
Xabier Mielgo Rubio, Hospital Universitario Fundación Alcorcón, Spain

P2.03a–024: The Clinical Efficacy and Safety of Paclitaxel Liposome on the Patients with Non–Small Cell Lung Cancer: A Meta–Analysis
Xingsheng Hu, Cancer Hospital,Chinese Academy of Medical Sciences & Peking Union Medical College, China

P2.03a–025: Randomized, Double–Blind, Phase 3 Study Comparing Biosimilar Candidate ABP 215 with Bevacizumab in Patients with Non–squamous NSCLC
Vladimir Hanes, Amgen, USA

P2.03a–026: Pemetrexed (Alimta) in Maintenance Therapy of 194 Patients with Advanced Non–Small–Cell Lung Cancer (NSCLC)
Jana Skrickova, University Hospital and Masaryk University Brno, Czech Republic

P2.03a–027: A Phase I Study of the Non–Receptor Tyrsine Kinase Inhibitor (NKI) Bosutinib in Combination with Pemetrexed in Patients with Advanced Solid Tumors
Nagla Karim, The University of Cincinnati, USA

P2.03a–028: Phase I/II Trial of Nab–Paclitaxel and Bevacizumab for Advanced Non–squamous Non–Small Cell Lung Cancer: Results of Phase I Part
Satoshi Ike, Kurashiki Central Hospital, Japan

P2.03a–029: Efficacy and Safety of Combined Carboplatin, Paclitaxel and Bevacizumab for Patients with Stage IIib and IV Non–squamous NSCLC
Nektarios Alezizopoulos, Evangelismos General Hospital, Greece

P2.03a–030: nab–Paclitaxel/Carboplatin Induction Therapy in Squamous (SCC) NSCLC: Interim Quality of Life (QoL) Results From ABOUND.sqm
Michael Thomas, Internistische Onkologie der Thoraxtumoren, Thoraxklinik im Universitätsklinikum Heidelberg, Germany

P2.03a–031: Metronomic Oral Vinorelbine as First–Line Treatment in Elderly (>65 Year) Patients with Advanced NSCLC
Franco Lumachi, University of Padua, School of Medicine, Italy
P2.03a–032: Palliative Chemotherapy with Oral Metronomic Vinorelbin in Advanced Non–Small Cell Lung Cancer (NSCLC) Patients Unsuitable for Chemotherapy
Giuseppe Banna, Cannizzaro Hospital, Italy

P2.03a–033: Prediction of Response to First Line Treatment for Metastatic Non–Small Cell Lung Cancer
Ahmed Badawy, Alexandria University, Egypt

P2.03a–034: RRM1 – A Prognostic Marker in Advanced NSCLC Among Male Smokers Receiving Chemotherapy
Maha Yehia, National Cancer Institute, Egypt

P2.03a–035: Down–Regulation of βIII–Tubulin and bFGF Sensitizes Non–Small Cell Lung Carcinoma A549/Taxol Cells Lines to Taxol
Qisen Guo, Shandong Cancer Hospital, China

P2.03a–036: Response of Additional Chemotherapy, Since First Line Chemotherapy in Non–Small Cell Lung Cancer
Jung Hyun Chang, Ewha Womans University, South Korea

P2.03a–037: Prognosis of Advanced Non–Small Cell Lung Cancer (NSCLC) Refractory to First–Line Platinum Chemotherapy
Hee Kyung Ahn, Gachon University Gil Medical Center, South Korea

P2.03a–038: Phase III Trial of Pemetrexed/Carboplatin vs Pemetrexed Only in Chemo–Naïve Elderly Non–SQCC NSCLC Patients Aged ≥70
Dae Ho Lee, University of Ulsan College of Medicine, Asan Medical Center, South Korea

P2.03a–039: ABOUND.70+: Interim Quality of Life (QoL) Results of nab–Paclitaxel/Carboplatin Treatment of Elderly Patients With NSCLC
Jared Weiss, Lineberger Comprehensive Cancer Center, USA

P2.03a–040: Safety and Efficacy of Nab–Paclitaxel for 2nd Line Treatment of Elderly Patients with Stage IV Non–Small Cell Lung Cancer
Jared Weiss, Lineberger Comprehensive Cancer Center at the University of North Carolina, USA

P2.03a–041: Comparison between Combination and Mono Chemotherapy for Elderly Patients with Advanced Non–Small Cell Lung Cancer: A Population–Based Study
Joung Soon Jang, Chung–Ang University College of Medicine, South Korea

P2.03a–042: Comorbidity as a Prognostic Factor in Elderly Non–Small Cell Lung Cancer Patients Treated with Platinum–Based Chemotherapy
Danica Sazdanic–Velikic, Institute for pulmonary Diseases of Vojvodina, Serbia

P2.03a–043: A Retrospective Analysis of the Chemotherapy for ‘Very Old’ Patients Aged 80 Years and Order with Advanced Lung Cancer
Yosuke Tamura, Osaka Medical College Hospital, Japan

P2.03a–044: Severe Adverse Events Impact Overall Survival (OS) and Costs in Elderly Patients with Advanced NSCLC on Second–Line Therapy
Hossein Borghaei, Fox Chase Cancer Center, USA

P2.03a–045: Safety of Bevacizumab (B) in Elderly Stage IV Non–Squamous NSCLC Patients Selected by Geriatric Assessment: A Phase II Study
Oscar Juan, Hospital Universitari i Politècnic La Fe, Spain

P2.03a–046: Safety and Efficacy Results From ABOUND.70+: nab–Paclitaxel/Carboplatin in Elderly Patients With Advanced NSCLC
Corey Langer, Abramson Cancer Center, University of Pennsylvania, USA

P2.03a–047: Clinical Trial Participation and Outcomes in Non–Small Cell Lung Cancer: Case–Control Study
Ana Laura Ortega Granados, Complejo Hospitalario de Jaén, Spain

P2.03a–048: The CDK4/6 Inhibitor GT28 Protects Immune Cells from Cisplatin–Induced Toxicity in vivo and Inhibits SCLC Tumor Growth
John Heymach, The University of Texas M.D. Anderson Cancer Center, USA

P2.03a–049: Response to Salvage Chemotherapy Following Exposure to PD–1 Inhibitors in Patients with Non–Small Cell Lung Cancer
Paul Leger, Vanderbilt University Medical Center, USA

P2.03a–050: Elevated Expression of CCP Genes is Associated with Absolute Chemotherapy Benefit in Early Stage Lung Adenocarcinoma Patients
Prasad Adusumilli, Memorial Sloan Kettering Cancer Center, USA

P2.03a–051: CMTM1_v17 Promotes Chemotherapy Resistance and is Associated with Poor Prognosis in Non–Small Cell Lung Cancer
Jiahui Si, Peking University Cancer Hospital & Institute, China

P2.03a–052: Phase I Study and Pharmacokinetics of Paclitaxel Micelles for Injection in Chinese Patients with Advanced–Stage Malignancies
Meiqi Shi, Jiangsu Cancer Hospital, China

P2.03a–053: Immuno–Inflammatory Markers in Advanced NSCLC Patients Undergone Fractioned Cisplatin, Oral Etoposide and Bevacizumab
Pierpaolo Correale, Azienda Ospedaliera Universitaria Senese, Italy

P2.03a–054: A Single–Arm Phase II Study of Nab–Paclitaxel for Patients with Chemorefractory Non–Small Cell Lung Cancer
Hisashi Tanaka, Hirosaki University, Japan

P2.03a–055: Predicting Risk of Chemotherapy–Induced Severe Neutropenia in Lung Patients: A Pooled Analysis of US Cooperative Group Trials
Herbert Pang, The University of Hong Kong, China

P2.03a–056: Phase II Trial of Weekly Nab–Paclitaxel for Previously Treated Advanced Non–Small Cell Lung Cancer: KTO SG Trial 1301
Shinya Sakata, Kumamoto University Hospital, Japan

P2.03a–057: Ligand Mediated Solid Lipid Nanoparticle of Paclitaxel for Effective Management of Bronchogenic Carcinoma
Saurabh Bhargava, Manav Bharti University, India

P2.03a–058: Is There a Place for Pemetrexed Rechallenge in Advanced Lung Adenocarcinoma?
Shun Lu, Shanghai Chest Hospital, China
**P2.03a–059: LCL161 Increases Paclitaxel–Induced Apoptosis by Degrading cIAP1 and cIAP2 in NSCLC**
Chengcheng Yang, The First Affiliated Hospital of Xi’an Jiaotong University, China

**P2.03a–060: Favorable Survival of TTF–1 Expression in Pemetrexed Based Treated NSCLC Patients**
Claus Steppert, Klinikum Bayreuth, Germany

**P2.03a–061: Randomized Phase II Trial Comparing Intercalation of Afatinib to Pemetrexed with Pemetrexed Alone after Failure of Platinum Doublet Therapy**
Shinkyo Yoon, Bundang Jesaeng General Hospital, South Korea

**P2.03a–062: Characterisation and Targeting of the DNA Repair Gene, XRCC6BP1, in Cisplatin Resistant NSCLC**
Martin Barr, St. James’s Hospital & Trinity College Dublin, Ireland

**P2.03a–063: Small Molecule Cancer Stemness Inhibitor, BB1608, Restores Cisplatin Sensitivity in Resistant NSCLC**
Martin Barr, Trinity College Dublin/St. James’s Hospital, Ireland

**P2.03a–064: Inhibition and Exploitation of Aldehyde Dehydrogenase 1 as a Cancer Stem Cell Marker to Overcome Cisplatin Resistant NSCLC**
Martin Barr, Trinity College Dublin/St. James’s Hospital, Ireland

**P2.03a–065: Lack of Drug–Drug Interaction (DDI) between Necitumumab and Gemcitabine or Cisplatin: A Phase 2, Open–Label, Nonrandomized Study**
James Lee, University of Pittsburgh Cancer Institute, USA

**P2.03a–066: Pemetrexed(P) in Third and Fourth Line Chemotherapy for Advanced Non–Small Cell Lung Cancer (Non–Squamous)–aNSCLns**
Alexandrelin Calin Grigorescu, Institute of Oncology Bucharest, Romania

**P2.03a–067: Therapy–Related Leukemia after Lung Cancer Chemotherapy**
Kazuhiro Natori, Toho University Medical Center Oomori Hospital, Japan

**P2.03a–068: Impact of Platinum/Pemetrexed versus Other Platinum–Based Regimens on Adjuvant Chemotherapy in Resected Adenocarcinoma Lung Cancer**
Wang Ziping, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China

**P2.03a–069: Effectiveness of Adjuvant Carboplatin–Based Chemotherapy Compared to Cisplatin in Resected Non–Small Cell Lung Cancer**
Pierre–Yves Gagnon, IUCPQ, Canada

**P2.03a–070: A Feasibility Study of Adjuvant Chemotherapy with Modified Weekly Nab–Paclitaxel and Carboplatin for Completely Resected NSCLC**
Hisashi Saji, St. Marianna University School of Medicine, Japan

**P2.03a–071: Adjuvant Chemotherapy Following Resection of NSCLC: An Audit of 5 Years of Practice and Outcomes in South West Wales**
Amy Case, Singleton Hospital, UK

---

**P2.03b ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY**

**P2.03b–001: A Phase I Dose Expansion Study of Epitinib to Evaluate Efficacy and Safety in EGFR Mutation Positive (EGFRm+) NSCLC Patients with Brain Metastasis**
Qing Zhou, Guangdong Lung Cancer Institute, Guangdong General Hospital (GGH) and Guangdong Academy of Medical Sciences, China

**P2.03b–002: Efficacy and Safety of WBRT Combined with Endostar in Patients with Advanced Non–Small Cell Lung Cancer**
Ruiguang Zhang, Union Hospital, China

**P2.03b–003: Mutation Profile & Histology According to ERS/ATC/IASCL Associated with IPFS to WBI in BM Patients with Recent Adenocarcinoma Lung Cancer**
Oscar Arrieta, National Cancer Institute, Mexico

**P2.03b–004: Factors Associated with Brain Metastasis in Patients with Lung Adenocarcinoma after Surgical Resection**
Jung–Yjh Hung, Taipei Veterans General Hospital and National Yang–Ming University, Taiwan

**P2.03b–005: Correlation between Primary Tumor Location and Brain Metastasis Development or Peritumoral Brain Edema in Lung Cancer**
Katalin Fabian, Semmelweis University Department of Pulmonology, Hungary

**P2.03b–006: Distinct MR Imaging Features of Metastatic Lesions in Brain with Non–Small Cell Lung Cancer According to EGFR Mutation Status**
Yan Cheng, Shanghai Chest Hospital, Shanghai jiao Tong University, China

**P2.03b–007: Palliative Whole Brain Radiotherapy in Advanced Non–Small Cell Lung Cancer (NSCLC), the University College London Hospital Experience**
Amy Ward, University College London, UK

**P2.03b–008: The Impact of Brain Metastases and Their Treatment on Health Utility Scores in Molecular Subsets of Lung Cancer Patients**
Grainne O’Kane, Princess Margaret Cancer Centre, Canada

**P2.03b–009: Brain Metastasis and Epidermal Growth Factor Receptor Mutations in Croatian Caucasians with Lung Adenocarcinoma**
Katherina Sereter, University Hospital Centre “Sestre Milosrdnice”, Croatia

**P2.03b–010: EGFR Mutation Status Analysis in Cerebrospinal Fluid and Plasma of Advanced Lung Adenocarcinoma with Brain Metastases**
Zhe Liu, Beijing Chest Hospital, Capital Medical University, China

**P2.03b–011: Screening for ALK Abnormalities in Central Nervous System Metastases of Non–Small–Cell Lung Cancer**
Pawel Krawczyk, Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland
P2.03b–012: A Phase II Study of Etrinotecan Pegol (NKTR–102) in Patients with Refractory Brain Metastases and Advanced Lung Cancer
Joel Neal, Stanford Cancer Institute, USA

P2.03b–013: Outcome of Patients with ALK+ NSCLC and Brain Metastases in Relation to Disease Burden and Clinical Management
Luigi De Petris, Karolinska University Hospital, Sweden

P2.03b–014: Atezolizumab in Advanced NSCLC Patients with Baseline Brain Metastases: A Pooled Cohort Safety Analysis
Rimas Lukas, The University of Chicago Medicine, USA

P2.03b–015: Efficacy of the Irreversible ErbB Family Blocker Afatinib in Treatment of an Intracerebral Non–Small Cell Lung Cancer in Mice
Shirong Zhang, Hangzhou First People’s Hospital, Nanjing Medical University, China

P2.03b–016: Tesevatinib in NSCLC Patients with EGFR Activating Mutations and Brain Metastases (BM) or Leptomeningeal Metastases (LM)
Davic Berz, Beverly Hills Cancer Center, USA

P2.03b–017: Differences of Central Nerve System Metastasis during Gefitinib or Erlotinib Therapy in Patients with EGFR–Mutated Lung Adenocarcinoma
Kazushi Yoshida, National Cancer Center Hospital, Japan

P2.03b–018: Clinical Data from the Real World: Efficacy of Crizotinib in Chinese Patients with Advanced ALK+ Non–Small Cell Lung Cancer and Brain Metastases
Shouzheng Wang, Cancer Hospital, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), China

P2.03b–019: Comparison of the Efficacy of First–Generation EGFR–TKIs in Brain Metastasis
Naoto Aiko, Yokohama Municipal Citizen’s Hospital, Japan

P2.03b–020: EGFR Exon 19 Deletion Mutation Patients Obtain Optimal Survival in Icotinib Treated Non–Small–Cell Lung Cancer Patient with Brain Metastases
Xiao–Ling Xu, Zhejiang Province Cancer Hospital, China

P2.03b–021: Screening for Major Oncogene Alterations in Adenosquamous Lung Carcinoma Using PCR Coupled with Next–Generation and Sanger Sequencing Methods
Xiaohua Shi, Peking Union Medical College Hospital, China

P2.03b–022: Outcome in Molecularly Defined NSCLC within the NOWEL Network: The Influence of Sequential 2nd and 3rd Generation TKI in EGFR mt+ and ALK+ pts
Julia Roeppe, Pius Hospital Oldenburg, Germany

P2.03b–023: Circulating Tumor DNA (ctDNA)–Based Genomic Profiling of Known Cancer Genes in Lung Squamous Cell Carcinoma (LUSC)
Vincent Lam, The University of Texas M.D. Anderson Cancer Center, USA

P2.03b–024: microRNA–330–3p Promotes Brain Metastasis of Non–Small Cell Lung Cancer (NSCLC) by Activating MAPK/MEK/ERK Signaling Pathway
Ruiguang Zhang, Union Hospital, China

P2.03b–025: Mutation Profile and Histology Subtype According to IASLC/ERS/ATC as Risk Factors for Brain Metastases in Lung Adenocarcinoma
Oscar Arrieta, Instituto Nacional de Cancerología, Mexico

P2.03b–026: Next–Generation Sequencing for Molecular Diagnosis of Tumour Specimens from Patients with Advanced Lung Adenocarcinoma
Maria Gabriela Fernandes, Centro Hospitalar São João, Portugal

P2.03b–027: Circulating Free DNA (cfDNA) Analysis from Patients with Advanced Lung Adenocarcinoma
Maria Gabriela Fernandes, Centro Hospitalar São João, Portugal

P2.03b–028: Improved Overall Survival Following Implementation of NGS in Routine Diagnostics of Advanced Lung Cancer in Germany: Results of the NGM
Anna Kostenko, University Hospital of Cologne, Germany

P2.03b–029: Analysis of Genomic Alterations and Heterogeneity in Pulmonary Adenoid Cystic Carcinoma by Next–Generation Sequencing
Min Li, Xiangya Hospital, Central South University, China

P2.03b–030: Retrospective Review Clinical Use of a cfDNA Blood Test for Identification of Targetable Molecular Alterations in Patients with Lung Cancer
Hai Tran, University of Texas M.D. Anderson Cancer Center, USA

P2.03b–031: Impact of PD–LI Status on Clinical Response in SELECT–1: Selumetinib + Docetaxel in KRAsm Advanced NSCLC
Pasi Jänne, Dana–Farber Cancer Institute, USA

P2.03b–032: The Peculiar Changing Pattern of Serum NSE Acts as an Indicator of Transformation from Adenocarcinoma to SCLC
Jie Zhang, Shanghai Pulmonary Hospital, China

P2.03b–033: Clinical Effectiveness of Hybrid Capture–Based Massive Parallel Sequencing in Therapeutic Strategy Planning in Lung Cancer
Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

P2.03b–034: Clinical Relevant Oncogenic Drivers in Advanced Adenocarcinoma Discloses New Therapeutic Targets in Negative EGFR/ALK/KRAS Patients
Vera Capelozzi, University of São Paulo, Brazil

P2.03b–035: EGFR FISH as Potential Predictor of Necitumumab Benefit with Chemotherapy in Squamous NSCLC: Subgroup Analyses from SQUIRE
Carlo Genova, IRCCS AOI San Martino – IST, Italy

P2.03b–036: Analysis of Potentially Targetable Mutations in 821 Patients with Squamouscell Lung Cancer Undergoing Routine NGS–Based Molecular Diagnostics
Sophia Koleczko, Lung Cancer Group Cologne, Germany

P2.03b–037: Prognostic Impact of 1st–Line Treatment and Molecular Testing in Advanced NSCLC in France – Results of the IFCT–PREDICT.amm Study
Jacques Cadranel, Assistance Publique Hôpitaux de Paris, Hôpital Tenon, France
**P2.03b–038:** The Diagnostic and Prognostic Value of CSF Cyfra 21–1 in Patients with Leptomeningeal Metastasis of Non–Small Cell Lung Cancer
Jae–Won Hyun, National Cancer Center, South Korea

**P2.03b–039:** Cell–Free (cf) DNA and cfRNA levels in Plasma of Lung Cancer Patients Indicate Disease Status and Predict Progression
Luis Raez, Memorial Cancer Institute, USA

**P2.03b–040:** NANOG Predicts Poor Outcome in Advanced Non–Small Cell Lung Cancer Patients Treated with Platinum–Based Chemotherapy
Seung Hyeun Lee, Kyung Hee University Medical Center, South Korea

**P2.03b–041:** Cerebrospinal Fluid Tumor Cells for Diagnosis of Leptomeningeal Metastases in Non–Small Cell Lung Cancer
Yang–si Li, Guangdong Lung Cancer Institute, Guangdong Provincial Key Laboratory of Translational Medicine in Lung Cancer, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

**P2.03b–042:** MET exon 14 Mutations Encode a Hyperactive Kinase and Therapeutic Target in Lung Adenocarcinoma
Nir Peled, Rabin Medical Center, Israel

**P2.03b–043:** Peripheral Blood CD45RA+CCR7+ Naive T Cells Were Correlated with Prognosis in Non–Small Cell Lung Cancer Patients
Shu–Mei Huang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

**P2.03b–044:** Treatment Outcome and the Role of Primary Tumor Therapy in a Cohort of Patients with Synchronous Oligometastatic NSCLC
Jose Carlos Ruffinelli, Medical Oncology Dept Catalan Institute of Oncology – ICO Hospital, Spain

**P2.03b–045:** Assessment of microRNAs in FFPE Tissue for Prediction of the Effect of Palliative Chemotherapy for Squamous Cell Carcinoma of the Lung
Martin Svaton, Charles University in Prague, Czech Republic

**P2.03b–046:** Clinicopathologic Characteristics, Genetic Variability and Therapeutic Options of RET Rearrangement Patients in Lung Adenocarcinoma
Zhengbo Song, Zhejiang Cancer Hospital, China

**P2.03b–047:** The Clinical Impact of Multiplex ctDNA Gene Analysis in Lung Cancer
Smadar Geva, Thoracic Cancer Service, Davidoff Cancer Center, Rabin Medical Center, Israel

**P2.03b–048:** Access to Biomarker Testing in Patients with Advanced Non–Small Cell Lung Cancer
Apar Ganti, Veteran’s Affairs Nebraska–Western Iowa Health Care System, University of Nebraska Medical Center, USA

**P2.03b–049:** Molecular & Clinical Status of Current Biomarkers: EGFR, ALK, ROS, MET of Lung Cancer in North Indian Patients
Mousumi Suryavanshi, Rajiv Gandhi Cancer Institute and Research Center, India

**P2.03b–050:** Prognostic Value of HLA–A2 Status in Advanced Non–Small Cell Lung Cancer (NSCLC) Patients
Laura Mezquita, Gustave Roussy, France

**P2.03b–051:** TrxR1: A Novel Biomarker Proved to Be Prognostic Factor and Evidence to Provide Newly Treatment Strategies in Metastatic EGFR Wild–Type NSCLC
Yongchang Zhang, Hunan Cancer Hospital, China

**P2.03b–052:** XRCC1 Arg399Gln and Rad51 G135C Gene Polymorphisms in Advanced Lung Adenocarcinoma in Serbia
Jelena Spasic, Institute for Oncology and Radiology of Serbia, Serbia

**P2.03b–053:** Role of KRAS Mutation Status in NSCLC Patients Treated on SWOG S0819, a Phase III Trial of Chemotherapy with or without Cetuximab
Philipp Mack, UC Davis Comprehensive Cancer Center, USA

**P2.03b–054:** Biomarker Predictors in NSCLC
Maha Yahia, National Cancer Institute, Egypt

**P2.03b–055:** Survival in Non–Small Cell Lung Cancer (NSCLC) Patients (pts) with Driver Mutations at Sandton Oncology Centre, South Africa
San Luigi, Italy

**P2.03b–056:** Prognostic Value of Neutrophil to Lymphocyte Ratio Was Influenced by Albumin Level
Zhen–Yu Ding, West China Hospital, China

**P2.03b–057:** Diagnostic Value of Tumor Markers in Lung Adenocarcinoma–Associated Cytologically Positive and Negative Pleural Effusions
Cheng–Chuan Su, Buddhist Dalin Tzu Chi Hospital, Taiwan

**P2.03b–058:** Blood Cell Count Ratios at Diagnosis as Prognostic Markers in Patients with Metastatic Non–Small Cell Lung Cancer (mNSCLC)
Eliza Ricardo, A.C. Camargo Cancer Center, Brazil

**P2.03b–059:** Detection of Circulating Tumor Cells Using Multiple mRNA in Situ Hybridization Predicts Metastasis in Non–Small Cell Lung Cancer
Shirong Zhang, Hangzhou First People’s Hospital, Nanjing Medical University, China

**P2.03b–060:** Baseline Skeletal Muscle Index (SMI) Values Are Associated with Biomarkers of Insulin Resistance in Stage IV Non–Small Cell Lung Cancer
Marta Batus, Rush University Medical Center, USA

**P2.03b–061:** Baseline Neutrophil–Lymphocyte Ratio is Related to Baseline Presence of Brain Metastases and Subsequent Brain Metastases in Stage IV NSCLC
Young Wha Koh, Ajou University School of Medicine, South Korea

**P2.03b–062:** Association of the FAACT Total Score and Subscales with Clinical Characteristics and Survival in Advanced Lung Cancer
Oscar Arrieta, National Cancer Institute, Mexico

**P2.03b–063:** Molecular Profiling in Advanced Non–Small–Cell Lung Cancer: Preliminary Data of an Italian Observational Prospective Study
Silvia Novello, Department of Oncology, University of Turin, AOU San Luigi, Italy

**P2.03b–064:** Genomic Profiling in Non Small Cell Lung Cancer: New Hope for Personalized Medicine
Satheesh Thungappa, HCG Bangalore Institute of Oncology Speciality Centre, India
P2.03b–065: Serum and Bronchoalveolar Lavage Levels of Adiponectin in Advanced Non–Small Cell Lung Cancer: Results of a Prospective Study
Kostas Syrigos, Medical School, University of Athens, Greece

P2.03b–066: Diagnostic Value of Pleural Cytology Together with Pleural CEA and VEGF in Patients with NSCLC and Lung Metastases from Breast Cancer
Franco Lumachi, University of Padua, School of Medicine, Italy

P2.03b–067: Predictors of Advanced Squamous Cell Lung Cancer Prior to Biopsy; Biological Behavior and Prognostic Factors
Hala Aziz, National Cancer Institute, Egypt

P2.03b–068: The Druggable Mutation Landscape of Lung Adenocarcinoma
Siraj Ali, Foundation Medicine, USA

P2.03b–069: LKB1 Loss is a Novel Determinant of MEK Sensitivity Due to Alterations in AKT/FOXO3 Signaling
Tadaaki Yamada, Kanazawa University, Japan

P2.03b–070: Establishment of Organoid Cell Lines from Lung Adenocarcinoma
Tadaaki Yamada, Kanazawa University, Japan

P2.03b–071: Therapeutic Targeting of the Phosphatidylinositol–3 Kinase Pathway in Lung Squamous Cell Carcinoma
Ruoshi Shi, Ontario Cancer Institute, Canada

P2.03b–072: Resistance to BET Inhibitors in Lung Adenocarcinoma is Mediated through a MYC Independent Mechanism
Jack Calder, BC Cancer Research Center, Canada

P2.03b–073: High Concordance of Somatic SNVs between Tumor–Only and Tumor–Normal Testing: Implications for Clinical Practice
Dongmei Lin, Peking University Cancer Hospital, China

P2.03b–074: NSCLC Homing Nanoparticles Selectively Transfect Tumor–Only and Tumor–Normal Testing: Implications for Clinical Practice
Dongmei Lin, Peking University Cancer Hospital, China

P2.03b–075: PD–1 Protein Expression Predicts Survival in Resected Adenocarcinomas of the Lung
Martin Filipits, Medical University of Vienna, Austria

P2.03b–076: MAP2K1 Mutations in NSCLC: Clinical Presentation and Co–Occurrence of Additional Genetic Aberrations
Alessandra Holzem, Department I of Internal medicine University Hospital of Cologne, Germany

P2.03b–077: EGFR/ALK+ Patient–Derived Xenografts from Advanced NSCLC for TKI Drug Selection & Resistance Development: The REAL–PDX Study
Michael Cabanero, University of Toronto, University Health Network, Canada

P2.03b–078: MET Gene Amplification and Overexpression in Chinese NSCLC Patients without EGFR Mutations
Zhengbo Song, Zhejiang Cancer Hospital, China

P2.03b–079: Decreased Expression of miR–125a–3p is Associated with the Clinical Outcome of Non–Small Cell Lung Cancer Patients
Likun Hou, Tongji University School of Medicine, China

P2.03b–080: A Comprehensive Test of Cancer Treatment–Related Genes for the Clinical Samples of Non–Small Cell Lung Cancer (NSCLC)
Yoshiaki Inoue, Saitama Medical University Saitama Medical Center, Japan

P2.03b–081: Comparison of Genomic Alterations Derived from Matched Tumor Tissue and Liquid Biopsy
Judith Müller–Eisert, NEO New Oncology, Germany

P2.03b–082: AQP11 as a Novel Factor of Lung Cancer Cell Resistance to Cisplatin
David Carbone, The Ohio State University, USA

P2.03b–083: Soluble Angiogenic Factors as Predictive Biomarkers of Response to Docetaxel plus Nintedanib as Second Line Therapy in NSCLC
Denisse Lee–Cervantes, Instituto Nacional de Cancerología, Mexico

P2.03b–084: Profiling of Eph Signaling in Malignant Pleural Effusions: Identification of Therapy Approaches and Associated Biomarkers
Metka Novak, Karolinska Institutet, Sweden

P2.03b–085: Programmed Cell Death Ligand 1 (PD–L1) Expression in Stage II and III Lung Adenocarcinomas
Hironori Uruga, Toranomon Hospital, Japan

P2.03b–086: High Expression of PDL–1 Correlates with Pleomorphic Features in Non–Small Cell Lung Carcinomas
Francois Kwong, Royal Brompton and Harefield NHS Foundation Trust, UK

P2.03b–087: PD–L1 Expression in Adenosquamous Lung Carcinoma and the Comparison with the Other Common Variants of Non–Small Cell Lung Cancer
Xiaohua Shi, Peking Union Medical College Hospital, China

P2.03b–088: PET–CT with 68Ga–RGD as Biomarker of Response to Nintedanib plus Docetaxel as Second Line Therapy in NSCLC
Denisse Lee–Cervantes, Instituto Nacional de Cancerología, Mexico

P2.03b–089: CD1C in Lung Adenocarcinoma: Prognosis and Cellular Origin
Chang–Qi Zhu, University Health Network, Canada

P2.03b–090: A CTLA–4 Antagonizing DNA Aptamer with Anti–Tumor Effect
Bo–Tsang Huang, Institute of Biomedical Science, Academia Sinica, Taiwan

P2.03b–091: CD47 Promotes Tumor Invasion and Metastasis in Non–small Cell Lung Cancer
Hui Zhao, The Second Affiliated Hospital, Dalian Medical University, China

P2.03b–092: Predictive and Prognostic Effect of Circulating Tumor Cells in Non–Small Cell Lung Cancer Treated with Targeted Therapy
Chunxiao Su, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P2.03b–093: Validation and Performance of a Standardized ctDNA NGS Assay across Two Laboratories
Emma Green, Inivata Ltd., UK
P2.04 – THYMIC MALIGNANCIES

**P2.04–004: Prognostic Value of Serum Carcinoembryonic Antigen during Conventional Chemotherapy in Advanced (Non-) Small Cell Lung Cancer**
C. De Jong, St Antonius Hospital, Netherlands

**P2.04–005: Retrospective Analysis of Correlation between ACEIs/ARBs and Clinical Outcome in Lung Cancer Patients with Bevacizumab-Based Chemotherapy**
Sachi Okawa, Kobe Red Cross Hospital, Japan

**P2.04–006: Utilisation of a Novel 3D Culture Technology for the Assessment of Chemo-Resistance in Non-Small Cell Lung Cancer**
Sarah Louise Ryan, Queensland University of Technology, Australia

**P2.04–007: Role of F-18-Choline Petscan in Recurrence of Thymic Epithelial Tumors (TET)**
Benjamin Besse, Gustave Roussy, France

**P2.04–008: Diagnostic Performance of PET-CT for Anterior Mediastinal Lesions – The DECIMAL Study**
Chiara Proli, Royal Brompton & Harefield NHS Foundation Trust, UK

**P2.04–009: Tumor Size Did Not Affect Masaoka Staging as Predictors of Recurrence in Thymoma**
Yen-Chiang Tseng, Kaohsiung Veterans General Hospital, Taiwan

**P2.04–010: Survival after Surgery and Radiotherapy for Thymic Epithelial Tumours: A Single-Centre Experience from the United Kingdom**
Hemal Ariyaratne, University College London Hospital, UK

**P2.04–011: Tumours of the Thymus: Northern Ireland 11 Year Experience**
Lynn Campbell, Belfast City Hospital, UK

**P2.04–012: A Risk of Death from a Second Cancer Following Complete Resection of Thymoma**
Masatsugu Hamaji, Kyoto University, Japan

**P2.04–013: Prognosis Factors and Survival Analysis in Thymic Epithelial Tumors**
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain

**P2.04–014: Retrospective Study of Pleuropneumonectomy for Thymoma with Dissemination**
Shiaki Oh, Juntendo University School of Medicine, Japan

**P2.04–015: Thymoma and Thymic Carcinoma – Our Experience**
Jana Kulísková, University Hospital Olomouc, Czech Republic

**P2.04–016: Is FDG-PET Useful for Distinguishing between Thymic Epithelial Tumors and Malignant Lymphoma?**
Hiroyuki Sakamaki, Keio University School of Medicine, Japan

**P2.04–017: Prognostic Relevance of PD-1/PD-L1 Pathway in Thymic Malignancies with Combined Immunohistochemical and Biomolecular Approach**
Rossana Berardi, Università Politecnica delle Marche – AOU Ospedali Riuniti, Italy

**P2.04–018: Comprehensive Copy Number Alteration and Gene Expression Analysis of Surgically Resected Thymic Carcinoma**
Takao Nakanishi, Graduate School of Medicine, Kyoto University, Japan

**P2.04–019: A Peripheral Immune Signature Associated with Clinical Activity of Sunitinib in Thymic Carcinoma**
Arun Rajan, Center for Cancer Research, NCI, NIH, USA

**P2.04–020: Expression Patterns and Prognostic Value of PD-L1 and PD-L1 in Thymoma and Thymic Carcinoma**
Dwight Owen, Ohio State University Comprehensive Cancer Center, USA

**P2.04–021: Role of Adjuvant Radiotherapy and Prognostic Factor Analysis in Thyroid Malignancies: A Retrospective Analysis of 129 Consecutive Patients**
Alessio Bruni, Aou Policlinico Of Modena, Italy

**P2.04–022: Impact of Metastasis Site for Survival of Patients with Advanced Thyroid Epithelial Tumors**
Zhengbo Song, Zhejiang Cancer Hospital, China
P2.04–023: Rare Frequency of Gene Variation and Survival Analysis in Thymic Epithelial Tumors
Zhengbo Song, Zhejiang Cancer Hospital, China

P2.04–024: Thymic Epithelial Tumors and Radiotherapy Results
Sureyya Sarihan, Uludag University, Turkey

P2.04–025: Recombinant Human Endostatin and/or Cisplatin in Treatment of Malignant Hydrothorax and Ascites: A Multicenter Randomized Study
Jun Liang, Beijing Cancer Hospital, China

P2.04–026: Expression Patterns of PD–L1 in Esophageal Adenocarcinomas: Comparison between Primary Tumors and Metastases
Rupert Langer, Institute of Pathology, University of Bern, Switzerland

P2.04–027: Targeting Adenosine A2B Receptor for Modulation of Tumor Microenvironment, Primary Tumor Growth, and Lung Metastasis
David Carbone, The Ohio State University, USA

P2.04–028: Cone–Beam CT Virtual Navigation–Guided Percutaneous Needle Biopsy of Suspicious Pleural Metastasis: Initial Experience
Hyun–ju Lim, Seoul National University Hospital, South Korea

P2.04–029: Primary Pulmonary Sarcoma: Risks and Optimal Surgical Treatment Options
Yoshito Yamada, Zurich University Hospital, Switzerland

P2.04–030: Airway Intervention in the Management of Low Grade Malignant Bronchogenic Neoplasms
Anne Hsu, Singapore General Hospital, Singapore

P2.04–031: Predictors of Pathological Complete Response (TRG=1) among Esophageal Cancer Cases; NCI Pooled Data
Fatma Abou Elkassem, National Cancer Institute, Egypt

P2.04–032: Pulmonary Sarcomatoid Carcinoma (PSC): Experience of 45 Patients at a Comprehensive Cancer Center
Nabeela Khan, State University of New York Downstate, USA

P2.04–033: Primary Salivary Gland Tumors of the Lung: A Systematic Review and Pooled Analysis
Pankaj Garg, University College of Medical Sciences and Guru Teg Bahadur Hospital, University of Delhi, India

P2.04–034: SPARC/β–Tubulin III Expressions for Clinical Outcomes of ESCC Patients Receiving Nab–Paclitaxel plus DDP Neoadjuvant Chemotherapy
Yun Fan, Zhejiang Cancer Hospital, China

P2.04–035: Surgical Perplexities in a Rare Case of Symptomatic Mediastinal Lymphangioma
Kingsfield Ong, Tan Tock Seng Hospital, Singapore

P2.04–036: Giant Primary Dedifferentiated Liposarcoma of the Anterior Mediastinum: An Extremely Rare Occurrence
Luigi Ventura, Thoracic Surgery, University Hospital of Parma, Italy

P2.04–037: Solitary Fibrous Tumor of the Pleura Associated with Severe Hypoglicemia: The Doege–Potter Syndrome
Luigi Ventura, Thoracic Surgery, University Hospital of Parma, Italy

P2.04–038: Primary Pulmonary Meningioma: Rare Tumour with Malignant Potential
Kingsfield Ong, Tan Tock Seng Hospital, Singapore

P2.04–039: Long–Term Risk of Recurrence in Benign Pleural Solitary Fibrous Tumors: A Single Institution Review
Gavitt Woodard, UCSF, USA

P2.04–040: Pleural Effusion Characteristics and Relationship with Outcomes in Cancer Patients
Patricia Thompson, Cancer Treatment Centers of America, USA

P2.04–041: Two Cases of Pulmonary Schwannoma
Tsunehiro li, Otsu Municipal Hospital, Japan

P2.04–042: Epithelial–Myoepithelial Tumour of Unknown Origin: An Interesting Case Report
Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

P2.04–043: Squamous Cell Carcinoma Arising from the Pleura. An Interesting Case Report
Nektarios Alevizopoulos, Evaggelismos General Hospital, Greece

P2.04–044: Mediastinal Neurogenic Tumors: Histopathological Characteristics and Surgical Treatment in a Single–Institutional Experience
Fatmir Caushi, University Hospital of Lung Diseases, Albania

P2.04–045: Management of Malignant Pleural Effusions: Ten Years Experience of a Single Center
Fatmir Caushi, University Hospital of Lung Diseases, Albania

P2.04–046: A Rare Case of Pleural–Pulmonary Epitheliod Hemangioendothelioma
Giulia Pacella, Ospedali Riuniti di Foggia, Italy

P2.04–047: A Rare Case of Extramedullary Plasmacytoma Occurring in the Posterior Mediastinum
Giulia Pacella, Ospedali Riuniti di Foggia, Italy

P2.04–048: Sarcomatoid Carcinoma of Lung
Berna Komurcuoglu, Izmir Suat Seren Education Hospital, Turkey

P2.04–049: Treatment for Three Cases Tracheal Carcinoma of Low–Grade Malignancy
Yutaka Oshima, Showa University Hospital, Japan

P2.04–050: Giant Solitary Fibrous Tumor of the Pleura Saved by Biopsy and Following Extended Resection: A Long Term Surviving Case
Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

P2.04–051: Palliative Treatment of Dysphagia Syndrome in Patients with Gastroesophageal Cancer
Irina Schetkina, Ministry of Healthcare of Perm region State Budget Health Care Establishment “Ordena “Znak Pocheta” Perm Regional Clinical Hospital”, Russia
P2.05–001: α7–nAchR Agonist GTS–21 Reduces Radiation–Induced Lung Injury by Inhibiting HMGB1/TLR–4/NF–κB Pathway
Conghua Xie, Zhongnan Hospital of Wuhan University, China

P2.05–002: CACNA2D1 Enhances Radio–Resistance in Cancer Stem–Like Cells in NSCLC
Siyuan Zhang, Peking University Cancer Hospital and Institute, China

P2.05–003: PIK3CA Mutation is Associated with Increased Local Failure in Lung Stereotactic Body Radiation Therapy (SBRT)
Abraham Wu, Memorial Sloan Kettering Cancer Center, USA

P2.05–004: ABT–737, a BH3 Mimetic, Enhances Therapeutic Effect of Ionizing Radiation in Murine Lung Cancer Model
Jung Mo Lee, Yonsei University College of Medicine, South Korea

P2.05–005: Mechanism of Radiotherapy in Reduction/Delay of T790M–Mediated EGFR TKI Resistance
Shirong Zhang, Hangzhou First People’s Hospital, Nanjing Medical University, China

P2.05–006: Radiotherapy as Definitive Treatment in Patients Aged 70 Years and Older with Non–Small Cell Lung Cancer
Sureyya Sarihan, Uludag University, Turkey

P2.05–007: Outcomes after Stereotactic Body Radiotherapy/Proton Beam Therapy or Wedge Resection for Stage I Non–Small–Cell Lung Cancer
Yasuhiro Ohde, Shizuoka Cancer Center, Japan

P2.05–008: Can Stereotactic Body Radiation Therapy (SBRT) Be an Effective Treatment for Lung Metastases From “Radioresistant” Histologies?
Davide Franceschini, Humanitas Clinical and Research Center, Italy

P2.05–009: The Outcome and Adverse Event of Chemoradiation ± Surgery for Stage III Non–Small Cell Lung Cancer
Shigehiro Kudo, Saitama Cancer Center, Japan

P2.05–010: Stereotactic Radiotherapy (SBRT) for Primary and Metastatic Lung Tumors in Elderly Patients
Luis Larrea, Hospital NISA Virgen del Consuelo, Spain

P2.05–011: The Current Status of Radiotherapy in the Definitive Treatment of Lung Cancer in a Developing Country: Turkey
Deniz Yalman, Ege University Faculty of Medicine, Turkey

P2.05–012: Definitive Radiotherapy and Survival in Lung Cancer: Results from a Brazilian Cohort Study
Matheus Leal, UFRGS, Brazil

Wai Kong Tsang, Prince of Wales Hospital, Hong Kong

P2.05–014: Sites of Recurrent Disease in SCLC Patients Treated with Radiochemotherapy – Is Selective Nodal Irradiation Safe?
Calogero Gumina, Medical Faculty and University Hospital Carl Gustav Carus, Germany

P2.05–015: Long–Term Outcomes of Prospective Phase II Clinical Trial for Stereotactic Ablation Radiotherapy in Recurrent NSCLC
Joe Chang, The University of Texas MD Anderson Cancer Center, USA

P2.05–016: Higher Dose of Radiotherapy Better for Outcome of Patients with Locally Advanced Non–Small Cell Lung Cancer
Martina Vrankar, Institute of Oncology Ljubljana, Slovenia

P2.05–017: Tumor Regression Gradient Predicts Disease Free Survival
Yolande Lievens, Ghent University Hospital, Belgium

P2.05–018: Re–Irradiation Using SBRT: A Good Option as a Salvage Treatment in Pulmonary Lesions
Arturo Navarro–Martin, Catalan Institute of Oncology –ICO Hospitalitat, Spain

P2.05–019: Stereotactic Body Radiotherapy (SBRT) for Central Lung Tumors: The Experience of Florence University–Careggi Hospital Radiotherapy
Vieri Scotti, Radiation Oncology Unit, Italy

P2.05–020: Survival Outcomes in Stage 1 NSCLC Following Stereotactic Ablative Radiotherapy or Conventional Radiotherapy
Gerard Hanna, Queen’s University of Belfast, UK

P2.05–021: Stereotactic Radiosurgery for Brain Metastasis in Non–Small Cell Lung Cancer: Predictor of Intracranial Progression
Yeon Sil Kim, Seoul St. Mary’s Hospital, The Catholic University of Korea, South Korea

P2.05–022: Is Post–Chemotherapy Tumor Volume Sufficient RT Target Volume in Patients with LD–SCLC?
Jae Myoung Noh, Samsung Medical Center, South Korea
P2.05–023: Patterns of Failure after Adjuvant Radiation Therapy Based on “Tumor Bed with Margin” for Stage III Thymic Epithelial Tumor
Jae Myoung Noh, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P2.05–024: Current Status of Stereotactic Body Radiation Therapy (SBRT) in Japan
Yasushi Nagata, Hiroshima University, Japan

P2.05–025: 9–Year Experience: Prophylactic Cranial Irradiation in Extensive Disease Small–Cell Lung Cancer
Denise Bernhardt, Heidelberg Institute of Radiation Oncology (HIRO), Germany

P2.05–026: Postoperative Radiotherapy in Non–Small Cell Lung Cancer: 20 Years’ Experience in a Single Centre
Deniz Yalman, Ege University Faculty of Medicine, Turkey

P2.05–027: Effects of Thermo–Chemotherapy for Lung Cancer Induced by Nano–Paclitaxel Magnetic Fluid
Runlei Hu, Hangzhou First People’s Hospital, China

P2.05–028: Comparison of Adjuvant Chemotherapy with or without Radiotherapy in NSCLC Patients with Stage IIIA–Single Station N2
Jian Ni, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P2.05–029: Microwave Thermal Therapy Enhances Radiosensitivity of Highly Invasive Human Non–Small Cell Lung Cancer H460 Cells via Inhibiting DNA Repair
Shirong Zhang, Hangzhou First People’s Hospital, Nanjing Medical University, China

P2.05–030: WBRT Prior EGFR TKIs is Effective Treatment Option for NSCLC Patients with CNS Metastases Harboring EGFR Mutation
Paweł Krawczyk, Pneumonology, Oncology and Allergology, Medical University of Lublin, Poland

P2.05–031: The Clinical Impact of Different Chemotherapy Regimen Combined with Radiotherapy in Locally Advanced Non–Small Cell Lung Cancer
Jiancheng Li, Fujian Cancer Hospital, China

P2.05–032: CT–Based Surrogates of Pulmonary Ventilation in Lung Cancer: A Voxel–Level Comparison with HP Gas MRI
Matthew Hatton, Weston Park Hospital, UK

P2.05–033: Predictors of Survival after Whole Brain Radiotherapy for Patients with Brain Metastasized Lung Cancer
Georgios Tsakonas, Karolinska Institute, Sweden

P2.05–034: New 3D «All in 1» Device for Fiducial Tumor Marking: A Pilot Animal Study
Bruno Escarguel, Hospital Saint Joseph, France

P2.05–035: Interim Analysis of the Phase II Trial Dose Risk Adapted FFF Using SBRT in Stage I NSCLC and Lung Metastases (NCT01823003)
Arturo Navarro–Martin, Catalan Institute of Oncology –ICO Hospitalet, Spain

P2.05–036: Single Fraction of SBRT for Pulmonary Lesions
Arturo Navarro–Martin, Catalan Institute of Oncology –ICO Hospitalet, Spain

P2.05–037: Higher Radiation Dose is Still Promising in Patients with Complete Response to 50 Gy of Early Thoracic Radiotherapy with Chemotherapy?
Sung–Ja Ahn, Chonnam National University Hwasun Hospital, South Korea

P2.05–038: Initial Clinical Experience of VMAT–SBRT with Flattening–Filter–Free Techniques in the University of Tokyo Hospital
Shuri Aoki, University of Tokyo Hospital, Japan

P2.05–039: Assessment of Lung Tumour Motion Comparing 4DCT, 4DCBCT and Motion of Implanted Beacons during Imaging and Irradiation
Elisabeth Steiner, University of Sydney, Australia

P2.05–040: Interobserver Variability in the Definition of the Primary Lung Cancer and Lymph Nodes on Different 4DCT Reconstructions
Susan Mercieca, University of Malta, Malta

P2.05–041: Accelerated Radical Radiotherapy for Non Small Cell Lung Cancer: Single Centre Experience of Two Fractionations
Stephen Robinson, Sheffield Teaching Hospitals, UK

P2.05–042: Development of Thoracic Magnetic Resonance Imaging (MRI) for Radiotherapy Planning
Fiona McDonald, Institute of Cancer Research & Royal Marsden Hospital, UK

P2.05–043: Lung Tumour Motion Kilovoltage Intrafraction Monitoring (KIM): First Clinical Results
Fiona Hegi–Johnson, University of Sydney, Australia

P2.05–044: Influence of Technological Advances and Institutional Experience on Outcome of Stereotactic Body Radiotherapy for Lung Metastases
Juliane Hoerner–Rieber, Universitätsklinikum Heidelberg, Germany

P2.05–045: Accelerated Radical Radiotherapy for Non Small Cell Lung Cancer: Single Centre Experience of Two Schedules in the Treatment of Elderly Patients
Stephen Robinson, Sheffield Teaching Hospitals, UK

P2.05–046: Is Delineating Clinical Target Volume a Must for Medium and Late Stages of Non–Small Cell Lung Cancer?
Jiancheng Li, Fujian Cancer Hospital, China

P2.05–047: Feasibility Study: Assessment of RT Dose Using Cardiac MRI Contouring Methodology on Retrospective Lung Planning CT Scans
Nazia Mohammed, Beatson West of Scotland Cancer Centre, UK
P2.05 – RADIOThERAPY – TOXICITIES

P2.05–049: Radical Treated NSCLC Radiotherapy Patients: A Prospective Study of Toxicities and Outcomes
Nathanial Hatton, University of Glasgow, UK

P2.05–050: Impact of Inflammation and Sarcopenia on Outcomes after Stereotactic Body Radiotherapy for T1N0M0 Non–Small Cell Lung Cancer
Yukinori Matsuo, Kyoto University, Japan

P2.05–051: Safety of Lung Stereotactic Body Radiotherapy (SBRT): A Single Institution Prospective Study Based on RTOG 0915 Protocol Constraints
Christine Seebacher, S. Maurizio Hospital, Italy

P2.05–052: A Systematic Review and Meta–Analysis of Pneumonitis in Radically Treated NSCLC Patients: SABR vs. Non–SABR Treatment
Fiona Hegi–Johnson, University of Sydney, Australia

P2.05–053: Discussion and Analysis of Pneumonitis Related to Stereotactic Radiotherapy in Our Hospital
Keisuke Imasaka, Saiseikai Yokohamashi Tobu Hospital, Japan

P2.05–054: Radiation Pneumonitis; Early Diagnosis and Protein Expression Profile in NSCLC Patients
Samantha Aso, Bellvitge Hospital, Spain

P2.05–055: 90 Day Mortality and Survival Following Radical Radiotherapy for Non–Small Cell Lung Cancer Treated in the Dorset Cancer Centre, UK
Matthew Roberts, Poole Hospital, UK

P2.05–056: Safety of Stereotactic Body Radiotherapy for Central, Ultracentral, and Paramediastinal Lung Tumors
Megan Daly, University of California Davis Comprehensive Cancer Center, USA

P2.05–057: Baseline Inflammatory and Immunological Profile Predict the Survival of NSCLC Patients Undergone Palliative Radiotherapy
Pierpaolo Pastina, Azienda Ospedaliera Universitaria Senese, Italy

P2.05–058: Blood Biomarkers of Inflammation, Tumour Burden and Proliferation Predict Radiotherapy Response and Toxicity in Lung Cancer
Ahmed Salem, University of Manchester, UK

P2.06 – SCIENTIFIC CO–OPERATION/RESEARCH GROUPS

P2.06–001: A Study of MGCD516, a Receptor Tyrosine Kinase (RTK) Inhibitor, in Molecularly Selected Patients with NSCLC or Other Advanced Solid Tumors
Matteo Levisetti, Mirati Therapeutics, USA

P2.06–002: Phase I Study of DS–6051b, a ROS1/NTRK Inhibitor, in Japanese Subjects with Advanced Solid Tumors Harboring Either a ROS1 or NTRK Fusion Gene
Kaname Nosaki, National Kyusyu Cancer Center, Japan

P2.06–003: A Phase Ib Study of the Combination of Afatinib and Ruxolitinib in EGFR Mutant Non–Small Cell Lung Cancer (NSCLC) Progressed on EGFR–TKI
Ji Soo Park, Yonsei Cancer Center, South Korea

P2.06–004: A Phase 1b Study of Erlotinib and Momelotinib for EGFR TKI Naïve EGFR Mutated Metastatic Non–Small Cell Lung Cancer
Sukhmani Padda, Stanford Cancer Institute/Stanford University School of Medicine, USA

P2.06–005: Phase 1 Study of Ramucirumab or Necitumumab in Combination with Osimertinib (AZD9291) in Advanced T790M–Positive EGFR–Mutant NSCLC
David Planchard, Gustave Roussy, France

P2.06–006: Dose Escalation Study of L–DOS47 as a Monotherapy in Non–Squamous Non–Small Cell Lung Cancer Patients
Heman Chao, Helix BioPharma Corp., Canada

P2.06–007: A Phase 1/2 Trial of the Oral EGFR/HER2 Inhibitor AP32788 in Non–Small Cell Lung Cancer (NSCLC)
Robert Doebele, University of Colorado Cancer Center, USA

P2.06–008: Phase 1/2 Study of Mocetinostat and Durvalumab (MEDI4736) in Patients with Advanced Solid Tumors and Non Small Cell Lung Cancer (NSCLC)
Matteo Levisetti, Mirati Therapeutics, USA

P2.06–009: Combined PKC- and mTOR Inhibition in Advanced or Recurrent Lung Cancer, Preliminary Report of an Ongoing Phase I/II Trial
Helen Ross, Mayo Clinic Arizona, USA

P2.05–048: Directional Characteristics of Motion Marker in CBCT for Target Localization for Lung Stereotactic Body Radiotherapy (SBRT)
Kaile Li, Associates in Medical Physics, USA
P2.06–010: AZD9291 as 1st-Line Therapy for EGFR Mutant NSCLC Patients with Concomitant Pretreatment EGFR T790M Mutation. The AZENT Study
Niki Karachaliou, Instituto Oncológico Dr Rosell (IOR), Hospital Universitario Quirón–Dexeus, Spain

P2.06–011: Phase 2 Study of MM-121 plus Chemotherapy vs. Chemotherapy Alone in Heregulin–Positive, Locally Advanced or Metastatic NSCLC
Arthur Kudla, Merrimack Pharmaceuticals, Inc., USA

P2.06–012: Phase 2 Study of Abemaciclib + Pembrolizumab in KRAS Mutation, PD–L1+, Stage IV Non–Small Cell or Squamous Cell Lung Cancer
Julien Mazieres, Hôpital Rangueil, France

P2.06–013: Afatinib in Patients with Advanced HER2 Mutation–Positive (M+) NSCLC Previously Treated with Chemotherapy
Caucun Zhou, Shanghai Pulmonary Hospital, China

P2.06–014: Phase 2 Study of Glesatinib or Sitravatibin with Nivolumab in Non–Small Cell Lung Cancer (NSCLC) after Checkpoint Inhibitor Therapy
Matteo LeviSetti, Mirati Therapeutics, USA

P2.06–015: The NICE Salvage Study: A Phase II Trial of Weekly Nab–Paclitaxel in the Salvage Setting for Advanced Non–Small Cell Lung Cancer
Takashi Niwa, Kurashiki Central Hospital, Japan

P2.06–016: Phase 2 Study of Ramucirumab plus Weekly Docetaxel in Stage IV NSCLC Following Progression after Platinum–Based Chemotherapy
Martin Sebastian, University Hospital Frankfurt, Goethe University, Germany

P2.06–017: Amethyst NSCLC Trial: Phase 2 Study of MGCD265 in Patients with Advanced or Metastatic NSCLC with Activating Genetic Alterations in MET
Lyudmila Bazhenova, University of California San Diego, USA

P2.06–018: Multicenter, Single–Arm Phase II Study of Nab–Paclitaxel/Carboplatin in Untreated PS2 Patients with Advanced NSCLC: TORG1426
Yasuaki Ichikawa, Teikyo University School of Medicine, Japan

P2.06–019: A Phase II Study of Atezolizumab as Neoadjuvant and Adjuvant Therapy in Patients (pts) with Resectable Non–Small Cell Lung Cancer (NSCLC)
Dwight Owen, Ohio State University Comprehensive Cancer Center, USA

P2.06–020: A Open–Label Randomised Controlled Trial of First–Line Genexol–PM/ CrEL–Based Paclitaxel plus Cisplatin in Advanced NSCLC Patients
Baohui Han, Shanghai Chest Hospital, China

P2.06–021: Efficacy and Safety of ASP8273 versus Erlotinib or Gefitinib as First–Line Treatment in Subjects with EGFRMut+ NSCLC
Ronan Kelly, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, USA

P2.06–022: First–Line Durvalumab plus Tremelimumab vs Platinum–Based Chemotherapy for Advanced/Metastatic NSCLC: Phase 3 NEPTUNE Study
Tony Mok, Department of Clinical Oncology, The Chinese University of Hong Kong, Prince of Wales Hospital, Hong Kong

P2.06–023: A Phase III Study Comparing Gefitinib and Inserted Cisplatin plus Pemetrexed with Gefitinib for EGFR–Mutated Advanced Non–Squamous NSCLC
Shintaro Kanda, National Cancer Center Hospital, Japan

P2.06–024: Tedopi vs Standard Treatment as 2nd or 3rd Line in HLA–A2 Positive Advanced NSCLC Patients in a Phase 3, Randomized Trial: ATALANTE–1
Benjamin Besse, Gustave Roussy, France

P2.06–025: DREAM – A Phase 2 Trial of DuRvalumab with First Line chEmotherApy in Mesothelioma with a Safety Run In
Anna Nowak, Sir Charles Gairdner Hospital, Australia

P2.06–026: A Phase II Trial of the Oral FGF Receptor Inhibitor AZD4547 as 2nd or 3rd Line Therapy in Malignant Pleural Mesothelioma – Trial in Progress
Anna Nowak, University of Western Australia, Australia

P2.06–027: Randomized Phase II Study of Anetumab Ravtansine or Vinorelbine in Patients with Metastatic Pleural Mesothelioma
Raffit Hassan, National Cancer Institute, USA

P2.06–028: A Phase 2 Study of Prexasertib in Patients with Extensive Stage Small Cell Lung Cancer
Lauren Averett Byers, The University of Texas MD Anderson Cancer Center, USA

P2.06–029: Pilot Window–Of–Opportunity Study of Pembrolizumab in Patients with Resectable Malignant Pleural Mesothelioma (MPM)
Hedy Kindler, University of Chicago, USA

P2.06–030: Optimum Duration of Vitamin B12/Folate Supplementation in NSCLC Patients on Pemetrexed Based Chemotherapy: The PEMVITASTART Randomized Trial
Navneet Singh, Postgraduate Institute of Medical Education and Research (PGIMER), India
P2.06–031: QUADRUPLE THREAT: A Pilot Phase 2 Study of RRx-001 in Advanced Lung Cancer Prior to Re-Administration of Platinum Doublets
Karen Zeman, Walter Reed National Military Medical Center, USA

P2.06–032: Oral Pioglitazone for the Chemoprevention of Lung Cancer in Current and Former Smokers
Robert Keith, Denver Veteran Affairs Medical Center, USA

P2.06–033: Long-Term Safety and Efficacy of Darbepoetin Alfa in Subjects with Advanced Stage NSCLC Receiving Multi-Cycle Chemotherapy
Jesús Cárdenas Sánchez, Centro Medico de Colima, Mexico

P2.06–034: METIS: A Phase 3 Study of Radiosurgery with TTFields for 1–10 Brain Metastases from NSCLC
Minesh Mehta, Miami Cancer Institute, USA

P2.06–035: Exploring Recruitment Factors in a Feasibility Trial of SABR versus Surgery
Janine Bestall, Leeds institute of Health Sciences, UK

P2.06–036: LUNAR – A Phase 3 Trial of TTFields in Combination with PD–1 Inhibitors or Docetaxel for 2nd Line Treatment of Non–Small–Cell Lung Cancer (NSCLC)
Uri Weinberg, Novocure GmbH, Switzerland

P2.06–037: A Feasibility Study of Concurrent Chemoradiation Followed by Surgery for Pathologically–Proven Clinical IIIA–N2 Non–Small Cell Lung Cancer
Hiroyasu Yokomise, Kagawa University Hospital, Japan

P2.06–038: An RCT of the Detection of Autoantibodies to Tumour Antigens in Lung Cancer Using the EarlyCDT–Lung Test in Scotland (ECLS) in 12 208 Study Subjects
Alistair Dorward, NHS Greater Glasgow & Clyde, UK

P2.06–039: Searching for Standards: Multicenter Ring Trials to Evaluate Technologies for the Enrichment of Circulating Tumor Cells
Sebastian Bender, Bayer AG, Germany

P2.06–040: WINNERS Study: Does a Formal Interactive Patient Education Program Positively Impact Patient Outcomes and Satisfaction after Thoracic Surgery
Melissa Culligan, University of Maryland Medical Center, USA

P2.06–041: TeleNursing: A Thoracic Surgery Nursing Initiative Aimed at Decreasing Hospital Readmissions and Increasing Patient Satisfaction
Melissa Culligan, University of Maryland Medical Center, USA

P2.06–042: Evaluate the Utility of the Computed Bioconductance Measurement in the Diagnosis of Lung Cancer
Dawei Yang, Zhongshan Hospital Fudan University, China

P2.06–043: 3-Dimensional High Throughput Multi–Drug Screening Using Patient–Derived Tumor Cells (PDC) Established from Surgical Specimens of NSCLC
Sumin Shin, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P2.06–044: Frequency of Mutations and Related Factors in Lung Adenocarcinoma Cases in Turkey
Senay Yılmaz, Eskisehir Osmangazi University, Turkey

P2.06–045: Initiative for Early Lung Cancer Research on Treatment (IELCART)
Claudia Henschke, Icahn School of Medicine at Mount Sinai, USA

P2.06–046: Shaping and Optimization of the Non–Small Cell Lung Cancer (NSCLC) Diagnostic Landscape in Australia and New Zealand (ANZ)
Anchit Khanna, Pfizer Oncology, Australia

P2.06–047: LRRK2–In–1 Inhibit Proliferation of Doublecortin and CaM Kinase–Like–1 (DCLK1)–Positive Lung Cancer Cells
Hiroyuki Tao, Yamaguchi Ube Medical Center, Japan

P2.07–001: Non–Negotiated Companion Influence on Information Exchange at Lung Cancer Clinic Consultations
Allison Smith, Greater Glasgow and Clyde Health Board, UK

P2.07–002: Evaluation of Providing Healthcare Information for Lung Mass Patients after Surgery
Daowan Khunyotying, Chiang Mai University, Thailand

P2.07–003: What Do People Living with and Surviving Lung Cancer and Mesothelioma Want and Need from a Recovery Care Package?
Josianne Roberts, The Rotherham NHS Foundation Trust, UK

P2.07–004: Social Support and Number of Symptoms One Month after Lung Cancer Surgery
Trine Oksholm, VID Specialized University, Norway

P2.07–005: Narratives from High Risk Respiratory Patients Who Had Bronchoscopy with Limited Sedation and Analgesia
Catherine Saxon, University of Queensland Thoracic Research Centre, Australia

P2.07–006: Combined Application of Two Biological Medicines with Healthcare and Health Education in Systemic Therapy Clinic
Irena Tominc, University Clinical Centre Maribor, Slovenia
P2.07 NURSES – RESEARCH, AUDITS

P2.07–007: Thoracic Oncology Research from Concept to Home-run (TORCH): Building Research Capacity in Lung Cancer Nursing
Mary Grace Coates, Barts Health NHS Trust, UK

P2.07–008: Victorian Comprehensive Cancer Centre Lung Cancer Clinical Audit: Collecting the UK National Lung Cancer Audit data from hospitals in Australia
Mark Shaw, Peter MacCallum Cancer Centre, Australia

P2.07–009: Lung Function after Pulmonary Resection in Lung Cancer
Pernille Mikkelsen, Odense University Hospital, Denmark

P2.07–010: Hospital Readmission Rates within 30 Days Following Thoracic Oncology Surgery
Maureen King, Papworth Hospital, UK

P2.08 PATIENT SUPPORT AND ADVOCACY GROUPS

P2.08–001: Giving a Voice to Patients and Caregivers through the Lung Cancer Canada ‘Faces of Lung Cancer’ Survey
Mark Doherty, Princess Margaret Cancer Centre, Canada

P2.08–002: Online Patient Education in Advanced Lung Cancer: Effect on Patient/Caregiver Knowledge
Elaine Hamarstrom, Medscape Education, USA

P2.08–003: Quality of Life and Patient Reported Outcome Measures for Lung Cancer Patients; Treatment Outcomes, and Patient Management
Maureen Rigney, Lung Cancer Alliance, USA

P2.08–004: The Importance of Patient Recall within Cancer Survivorship Care for Improved Post-Treatment Surveillance in Lung Cancer Survivors
Leah Backhus, Stanford University, USA

P2.08–005: Treating Cachexia–Anorexia in Lung Cancer Patients: Understanding the Patient Perspective on Novel Treatment Approaches
Upal Basu Roy, LUNGevity Foundation, USA

P2.08–006: Attempts to Improve the Patient Literacy in Japan
Tetsuya Yamaoka, Nikkei Business Publications, Inc., Japan

P2.08–007: Listen Advocate Voice – Web-Survey for the Japanese Model of Lung Cancer Advocacy by Society
Toshiyuki Sawa, Gifu Municipal Hospital, Japan

P2.08–008: Regional Clinical Pathway for Lung Cancer in Kumamoto University Hospital
Takeshi Mori, Kumamoto University Hospital, Japan

P2.08–009: Need for Consistent Language around Biomarker Testing in the Diagnosis and Treatment of Lung Cancer
Andrea Ferris, LUNGevity Foundation, USA

P2.08–010: The Reach and Adoption of a Multidisciplinary Thoracic Oncology Program within a U.S. Community Healthcare System
Fedoria Rugless, Baptist Cancer Center, USA

P2.08–011: Fashion Forward: Stigma Busting in Style in Egypt
Esraa Elsayed, CanSurvive, Egypt

P2.08–012: Evaluation of Lung Cancer Support Group Participation: Preliminary Results
Maureen Rigney, Lung Cancer Alliance, USA

Patricia Swann, East and North Herts NHS Trust, UK

P2.08–014: Lung Cancer Awareness and Barriers to Primary Care in Ireland
Aoife McNamara, Irish Cancer Society, Ireland

P2.08–015: Promoting Lung Cancer Awareness in Ireland – Balancing Traditional and Digital Platforms
Aoife McNamara, Irish Cancer Society, Ireland
### P3.01 Biology/Pathology

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Morphology</td>
<td>P3.01–001 – P3.01–033</td>
</tr>
<tr>
<td>Functional Biology in Lung Cancer</td>
<td>P3.01–034 – P3.01–051</td>
</tr>
<tr>
<td>Models of Lung Cancer</td>
<td>P3.01–052 – P3.01–054</td>
</tr>
<tr>
<td>Stem Cells in Lung Cancer</td>
<td>P3.01–055 – P3.01–062</td>
</tr>
<tr>
<td>Apoptosis in Lung Cancer</td>
<td>P3.01–063 – P3.01–064</td>
</tr>
</tbody>
</table>

### P3.02a Advanced NSCLC & Chemotherapy/Targeted Therapy/Immunotherapy

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALK</td>
<td>P3.02a–001 – P3.02a–004</td>
</tr>
<tr>
<td>ALK Biomarker</td>
<td>SP3.02a–005 – P3.02a–011</td>
</tr>
<tr>
<td>ALK Clinical</td>
<td>P3.02a–012 – P3.02a–028</td>
</tr>
<tr>
<td>ROS1</td>
<td>P3.02a–029 – P3.02a–031</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>P3.02a–032 – P3.02a–036</td>
</tr>
</tbody>
</table>

### P3.02b Advanced NSCLC & Chemotherapy/Targeted Therapy/Immunotherapy

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>EGFR</td>
<td>P3.02b–001 – P3.02b–005</td>
</tr>
<tr>
<td>EGFR Biomarkers</td>
<td>P3.02b–006 – P3.02b–043</td>
</tr>
<tr>
<td>EGFR Clinical</td>
<td>P3.02b–044 – P3.02b–093</td>
</tr>
<tr>
<td>EGFR RES</td>
<td>P3.02b–094 – P3.02b–127</td>
</tr>
</tbody>
</table>

### P3.02c Advanced NSCLC & Chemotherapy/Targeted Therapy/Immunotherapy

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Targeted Therapy</td>
<td>P3.02c–001 – P3.02c–025</td>
</tr>
<tr>
<td>IT</td>
<td>P3.02c–026 – P3.02c–057</td>
</tr>
<tr>
<td>IT Biomarkers</td>
<td>P3.02c–058 – P3.02c–090</td>
</tr>
<tr>
<td>IT Clinical</td>
<td>P3.02c–091 – P3.02c–103</td>
</tr>
</tbody>
</table>

### P3.03 Mesothelioma/Thymic Malignancies/Eosophageal Cancer/Other Thoracic Malignancies

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mesothelioma Translational</td>
<td>P3.03–001 – P3.03–027</td>
</tr>
<tr>
<td>Mesothelioma Clinical</td>
<td>P3.03–028 – P3.03–063</td>
</tr>
</tbody>
</table>

### P3.04 Surgery

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Miscellaneous</td>
<td>IP3.04–001 – P3.04–028</td>
</tr>
<tr>
<td>Miscellaneous</td>
<td>IIIP3.04–029 – P3.04–047</td>
</tr>
</tbody>
</table>

### P3.05 Palliative Care/Ethics

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Symptoms, Therapeutic Interventions</td>
<td>P3.05–001 – P3.05–009</td>
</tr>
<tr>
<td>QOL, Others</td>
<td>P3.05–010 – P3.05–020</td>
</tr>
</tbody>
</table>

### P3.06 Trial Design/Statistics

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Clinical Studies</td>
<td>P3.06–001 – P3.06–004</td>
</tr>
<tr>
<td>Others</td>
<td>P3.06–005 – P3.06–009</td>
</tr>
</tbody>
</table>

### P3.07 Regional Aspects/Health Policy/Public Health

<table>
<thead>
<tr>
<th>Section</th>
<th>Pages</th>
</tr>
</thead>
<tbody>
<tr>
<td>Therapy and Economics</td>
<td>P3.07–001 – P3.07–010</td>
</tr>
<tr>
<td>Other– Geographical Differences</td>
<td>P3.07–011 – P3.07–022</td>
</tr>
</tbody>
</table>
**P3.01–007: A Pulmonary Glomus Timor**
Satoshi Yamamoto, Medical Kouhoukai Takagi Hospital, Japan

**P3.01–008: Clinicopathological and Immunohistochemical Features in Lung Invasive Mucinous Adenocarcinoma According to Computed Tomography Findings**
Yuji Nojima, Kawasaki Medical School, Japan

**P3.01–009: A Prospective Study of ‘Spread through a Knife Surface’ (STAKS) in Non–Small Cell Lung Cancer Resection Specimens**
Hans Blaauwgeers, Onze Lieve Vrouwe Gasthuis, Netherlands

**P3.01–010: Primary Giant Cell Carcinomas of the Lung: Study of Seven Cases**
Lourdes Gutierrez Sanz, Hospital Universitario Puerta de Hierro, Spain

**P3.01–011: Clinocopathological Profile and Role of Immunohistochemistry in the Diagnosis of Primary Lung Cancer – A Prospective Study from Eastern India**
Pritinanda Mishra, All India Institute of Medical Sciences, India

**P3.01–012: P40 in Metastatic Pulmonary Trophoblastic Tumour: Potential Diagnostic Pitfall with Pulmonary Squamous Cell Carcinoma**
Deepali Jain, All India Institute of Medical Sciences, India

**P3.01–013: Case Report of Melanotic Schwannoma: A Challenging Diagnosis Made Clear through Genetic Testing**
Sue Wang, University of California San Francisco, USA

**P3.01–014: Differential Gene Expression of Lung Adenocarcinoma Histology Subtypes According to the IASLC/ATS/ERS Classification**
Oscar Arrieta, National Cancer Institute, Mexico

**P3.01–015: Prognostic Impact of Histologic Invasion Factors in Pulmonary Adenocarcinoma, with Particular Focus on the Pattern of Architectural Remodeling**
Masaya Yotsukura, National Cancer Center Hospital, Japan

**P3.01–016: Factors Influencing the Concordance of Histological Subtype Diagnosis by Biopsy and Resected Specimens of Lung Adenocarcinoma**
Reiko Matsuzawa, National Cancer Center Hospital East, Japan

**P3.01–017: Primary Lung Adenocarcinomas with Enteric Differentiation: A Retrospective Analysis**
Laura Bonanno, Istituto Oncologico Veneto, Italy

**P3.01–018: Reproducibility in Classification of Small Lung Adenocarcinomas: An International Interobserver Study**
Mari Mino–Kenudson, Massachusetts General Hospital, USA

**P3.01–019: Desmoplasia is Associated with Poor Prognosis and Adenocarcinoma–Associated Fibroblast Heterogeneity in Non–Small Cell Lung Cancer**
Roya Navab, Princess Margaret Hospital and Ontario Cancer Institute, Canada
<table>
<thead>
<tr>
<th>Session</th>
<th>Title</th>
<th>Author(s)</th>
</tr>
</thead>
<tbody>
<tr>
<td>P3.01</td>
<td><strong>BIOLOGY/PATHOLOGY</strong> – FUNCTIONAL BIOLOGY IN LUNG CANCER</td>
<td></td>
</tr>
<tr>
<td>P3.01–020</td>
<td>Evolving Trends in Lung Cancer Pathology</td>
<td>Karen Ege Olsen, Odense University Hospital, Denmark</td>
</tr>
<tr>
<td>P3.01–021</td>
<td>Reproducibility of Comprehensive Histologic Assessment and Refining Histologic Criteria in P Staging of Multiple Tumour Nodules</td>
<td>Andrew Nicholson, Royal Brompton and Harrowfield NHS Foundation Trust and National heart and Lung Institute, UK</td>
</tr>
<tr>
<td>P3.01–022</td>
<td>Impact of Histologic Subtype and Spread through Air Spaces (STAS) in Stage III (N2) Lung Adenocarcinoma</td>
<td>Yuriko Terada, The University of Tokyo, Japan</td>
</tr>
<tr>
<td>P3.01–023</td>
<td>Quality Assessment of Resampling Specimens in Primary Lung Cancers with Acquired Resistance to the Initial Therapy</td>
<td>Masashi Mikubo, Aichi Cancer Center Hospital, Japan</td>
</tr>
<tr>
<td>P3.01–024</td>
<td>Drastic Morphological and Molecular Differences between Lymph Node Micrometastatic Tumors and Micrometastatic Tumors of Lung Adenocarcinoma</td>
<td>Nao Aramaki, Tokyo Medical University, Japan</td>
</tr>
<tr>
<td>P3.01–025</td>
<td>Primary Pulmonary Sarcomas: An Entity Lost in Misdiagnosis</td>
<td>Kavneet Kaur, All India Institute of Medical Sciences, India</td>
</tr>
<tr>
<td>P3.01–026</td>
<td>Clinical and Pathological Reappraisal of Primary Lung Cancer with Lymphoepithelioma–Like Carcinoma Morphology</td>
<td>Yasufumi Goda, Kyoto University, Japan</td>
</tr>
<tr>
<td>P3.01–027</td>
<td>3D Telomere Nuclear Organization to Distinguish Multiple Synchronous Lung Adenocarcinoma from Metastatic Lung Adenocarcinoma</td>
<td>Nathalie Bastien, Quebec Heart and Lung Institute, Canada</td>
</tr>
<tr>
<td>P3.01–028</td>
<td>Comparison of Touch Imprint Cytology and Section Histopathology in the Diagnostic of the Small Peripheral Lung Tumors</td>
<td>Masatoshi Kakihana, Tokyo Medical University, Japan</td>
</tr>
<tr>
<td>P3.01–029</td>
<td>Cases Demonstrating Spread Through Air Spaces (STAS) Reflects Invasive Growth and Not an Artifact</td>
<td>Shaohua Lu, Memorial Sloan Kettering Cancer Center, USA</td>
</tr>
<tr>
<td>P3.01–030</td>
<td>Correlation of Preoperative CT Characteristics and Histologic Patterns of Pulmonary Adenocarcinoma</td>
<td>Yue Cheng, West China School of Medicine, West China Hospital, Sichuan University, China</td>
</tr>
<tr>
<td>P3.01–031</td>
<td>Impact of a Novel Lung Gross Dissection Method on Intrapulmonary Lymph Node Yield</td>
<td>G Spencer, Trumbull Laboratories, USA</td>
</tr>
<tr>
<td>P3.01–032</td>
<td>PELP1 Expression in Molecularly Classified Lung Adenocarcinomas</td>
<td>Charuhas Deshpande, University of Pennsylvania, USA</td>
</tr>
<tr>
<td>P3.01–033</td>
<td>Changes in the Tumor Microenvironment during Lymphatic Metastasis of Lung Squamous Cell Carcinoma</td>
<td>Shinnosuke Ikemura, Tokyo Dental Collage Ichikawa General Hospital, Japan</td>
</tr>
<tr>
<td>P3.01–034</td>
<td>Migration and Epithelial to Mesenchymal Transition of Lung Cancer Can Be Targeted via Translation Initiation Factors eIF4E and eIF4G1</td>
<td>Oshrat Attar–Schneider, Meir Medical Center, Israel</td>
</tr>
<tr>
<td>P3.01–035</td>
<td>Nicotine Enhances Hepatocyte Growth Factor–Mediated Lung Cancer Cell Migration</td>
<td>Remi Yoneyama, Tokyo Medical University, Japan</td>
</tr>
<tr>
<td>P3.01–036</td>
<td>Eukaryotic Translation Initiation Factors impact Non Small Cell Lung Cancer</td>
<td>Nadine Gantenbein, Medical University of Graz, Austria</td>
</tr>
<tr>
<td>P3.01–037</td>
<td>The Role of HIF3A Polymorphism in Lung Cancer Patients</td>
<td>Andika Putra, Faculty of Medicine, Universitas Indonesia–Persahabatan Hospital, Indonesia</td>
</tr>
<tr>
<td>P3.01–038</td>
<td>STAT3 and Src–YAP1 Inhibition Results in Greater Necitumumab Sensitivity in Lung Squamous Cell Carcinoma</td>
<td>Chiara Lazzari, Istituto Europeo di Oncologia – IEO, Italy</td>
</tr>
<tr>
<td>P3.01–039</td>
<td>JAK2 Participates in Lung Cancer Cells Proliferation, Migration and Invasion</td>
<td>Yun Fan, Zhejiang Cancer Hospital, China</td>
</tr>
<tr>
<td>P3.01–040</td>
<td>Difference of Graphene Oxide–Induced Autophagy between Adenocarcinoma and Macrophage Cell Line</td>
<td>Jong Wook Shin, Chung–Ang University Hospital, South Korea</td>
</tr>
<tr>
<td>P3.01–041</td>
<td>Anti–Cancer Effect of Hyperoxia on Human Lung Cancer Cells through Oxidative Stress Mediated ERK Signaling</td>
<td>Jin Young Mo, The Catholic University of Korea, South Korea</td>
</tr>
<tr>
<td>P3.01–042</td>
<td>Lung Cancer Cells Can Stimulate Functional and Genotypic Modifications in Normal Bronchial Epithelial Cells</td>
<td>Anne–Marie Baird, St. James’s Hospital &amp; Queensland University of Technology, Ireland</td>
</tr>
<tr>
<td>P3.01–043</td>
<td>Inhibition of Ornithine Decarboxylase Facilitates Pegylated Arginase Treatment in Lung Adenocarcinoma Xenograft Models</td>
<td>James Chung–Man Ho, The University of Hong Kong, Hong Kong</td>
</tr>
<tr>
<td>P3.01–044</td>
<td>Splicing Variant of Estrogen Receptor Alpha is Associated with Pathological Invasiveness in Smoking Independent Lung Cancer</td>
<td>Ayumi Suzuki, Nagoya City University Graduate School of Medical Sciences, Japan</td>
</tr>
<tr>
<td>P3.01–045</td>
<td>Sex Differences in CXCR4–Dependent Motility of NSCLC Cells</td>
<td>D. Gwyn Bebb, University of Calgary, Canada</td>
</tr>
<tr>
<td>P3.01–046</td>
<td>Klotho Regulates Epithelial–Mesenchymal Transition in Lung Squamous Cell Carcinoma</td>
<td>Takayuki Ibi, Nippon Medical School Hospital, Japan</td>
</tr>
<tr>
<td>P3.01–047</td>
<td>Food for Thought: Should We Analyze a Cancer Cell as a Biological Mechanism or as a Biological Computer?</td>
<td>Zarko Vrbica, University of Dubrovnik, Croatia</td>
</tr>
</tbody>
</table>
P3.01–048: Cigarette Smoking is Associated with Epithelio–Mesenchymal Transition in Human Adenocarcinoma
Toshi Menju, Kyoto University Graduate School of Medicine, Japan

P3.01–049: ELF3 Overexpression Leads to Oncogenic Reprogramming of Protein Interactions Exposing Therapeutically Actionable Targets
Katey Enfield, BC Cancer Research Centre, Canada

P3.01–050: Isolation and Characterization of Lymphatic Endothelial Cells from Neoplastic and Normal Human Lung
Giulia Mazzaschi, University of Parma, Italy

P3.01–051: Analysis of Molecular Aberrations Associated with COPD in Patients with Lung Cancer
Tomas Tokar, University Health Network, Canada

P3.01–052: DNA Adductomics to Identify the Role of Inflammation in NNK–Induced Lung Carcinogenesis
Silvia Balbo, Masonic Cancer Center, USA

P3.01–053: Mouse Models of Primary Lung Cancer – A Thorough Evaluation
Jae–Hwi Jang, University Hospital Zurich, Switzerland

P3.01–054: Antagonism of a Novel Kinase, MAP3K19, By Specific Small Molecule Inhibitors Blocks Human Primary NSCLC Tumor Growth in Murine Xenograft Models
Stefen Boehme, Axikin Pharmaceuticals, Inc., USA

P3.01–055: In vitro Construction of Lung Cancer Organoids from Induced Lung Cancer Stem Like Cells
Hiroyuki Ogawa, Kobe University Hospital, Japan

P3.01–056: Association of Angiogenesis, EMT and Stem Cell Characteristics Using Hypoxic Stress in Lung Cancer
ChanKwon Park, The Catholic University of Korea, South Korea

P3.01–057: TGF– Induced EMT and Stemness Characteristics in Lung Cancer
Seung Joon Kim, The Catholic University of Korea, South Korea

P3.01–058: Demethylation of CXCR4 and Stemness Acquisition in Lung Cancer
Seung Joon Kim, The Catholic University of Korea, South Korea

P3.01–059: A Stem–Cell Oriented Phylogeny of Non–Small Cell Lung Cancers
Robert Downey, Memorial Sloan Kettering Cancer Center, USA

P3.01–060: Aptamers as a Tool to Detect Lung Cancer Stem Cells
Isis Nascimento, University of São Paulo, Brazil

P3.01–061: Prognostic Significance of Stem Cell–Related Marker Expression and Its Correlation with Histologic Subtypes in Lung Adenocarcinoma
Hyojin Kim, Seoul National University Bundang Hospital, South Korea

P3.01–062: Profiling DNA Methylation and Gene Expression on Cancer Stemness Reprogramming in Lung Adenocarcinoma
Sheng–Fang Su, Academia Sinica, Taiwan

P3.01–063: XIAP Inhibits Mature Smac Induced Apoptosis by Degrading It through Ubiquitination in NSCLC
Sida Qin, The First Affiliated Hospital of Xi’an Jiaotong University, China

P3.01–064: The Overexpression and Cleavage of SASH1 by Caspase–3 Stimulates Cell Death in Lung Cancer Cells
Kenneth O’Byrne, Queensland University of Technology, Australia

P3.02a ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY

P3.02a–001: Response and Plasma Genotyping from Phase I/II Trial of Ensartinib (X–396) in Patients (Pts) with ALK+ NSCLC
Leora Horn, Vanderbilt University, USA

P3.02a–002: Pulmonary Sarcomatoid Carcinoma with ALK Rearrangement: Frequency, Clinical–Pathologic Characteristics, and Response to ALK Inhibitor
Likun Chen, Sun Yat–Sen University Cancer Center, China

P3.02a–003: ALK and ROS1 Rearrangements, Coexistence and Treatment in EGFR–Wild Type Lung Adenocarcinoma – A Multicentre Study of 732 Cases
Zhengbo Song, Zhejiang Cancer Hospital, China

P3.02a–004: NSCLC Patients Harboring ALK Translocation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02–14
Christos Chouaid, CHI Créteil, France
P3.02a ADVANCED NSCLC & CHEMOTHERAPY/Targeted Therapy/Immunotherapy – ALK Biomarkers

P3.02a–005: The Association between the Percentage of Anaplastic Lymphoma Kinase (ALK)–Positive Cells and Efficacy of ALK Inhibitor
Tae Tanaka, Kurashiki Central Hospital, Japan

P3.02a–006: Immune Recognition of ALK Fusion Proteins in Patients with ALK–Rearranged Non–Small Cell Lung Cancer
Mark Awad, Dana–Farber Cancer Institute, USA

Gero Streebbe, Novartis Pharmaceuticals Corporation, USA

P3.02a–008: EML4–ALK in Plasma Exosomes from a Cohort of NSCLC Patients
Kay Brinkmann, Exosome Diagnostics GmbH, Germany

P3.02a–009: TPX–0005: A Multi–Faceted Approach to Overcoming Clinical Resistances from Current ALK or ROS1 Inhibitor Treatment in Lung Cancer
J. Jean Cui, TP Therapeutics, Inc., USA

P3.02a–010: Evaluation of Aberrant ALK Expression in Lung Cancer by RT–PCR and Comparison with FISH and Immunohistochemistry
Mirella Giodano, University of Pisa, Italy

P3.02a–011: Analysis of ALK Status in Peripheral Blood to Predict the Clinical Activity of ALK Inhibitors and Assess Prognosis in Patients with Lung Cancer
Zhen Zhou, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P3.02a ADVANCED NSCLC & CHEMOTHERAPY/Targeted Therapy/Immunotherapy – ALK Clinical

P3.02a–012: Patient–Reported Symptoms and Quality of Life (QoL) in East Asian Patients with ALK+ NSCLC Treated with Crizotinib vs Chemotherapy
Yi Long Wu, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

P3.02a–013: Brigatinib in Crizotinib–Refractory ALK+ NSCLC: Central Assessment and Updates from ALTA, a Pivotal Randomized Phase 2 Trial
Marcello Tiseo, University Hospital of Parma, Italy

P3.02a–014: Patient Reported General Health Status in a Study of Crizotinib Versus Chemotherapy in Patients With Non–Small Cell Lung Cancer (NSCLC)
Karen Reckamp, City of Hope Comprehensive Cancer Center, USA

P3.02a–015: Ceritinib as First–Line Therapy in Patients with ALK–Rearranged Non–Small Cell Lung Cancer: ASCEND–1 Subgroup Analysis
Daniel Shao–Weng Tan, National Cancer Center Singapore

P3.02a–016: Pooled Efficacy and Safety Data from Two Phase II Studies (NP28673 and NP28761) of Alectinib in ALK+ Non–Small–Cell Lung Cancer (NSCLC)
James Chih–Hsin Yang, National Taiwan University, Taiwan

P3.02a–017: Indirect Naive Comparison of Post–Crizotinib Treatments for ALK+ Non–Small–Cell Lung Cancer (NSCLC)
Karen Reckamp, City of Hope Comprehensive Cancer Center, USA

P3.02a–018: Efficacy of Pemetrexed Based Chemotherapy Compared with Non–Pemetrexed Based Chemotherapy in Advanced, ALK–Positive NSCLC
Jaemin Jo, Seoul National University Bundang Hospital, South Korea

P3.02a–019: Real World Utilization and Outcomes of ALK–Positive Crizotinib Treated Metastatic NSCLC Patients in US Community Oncology Practice
Craig Reynolds, McKesson Specialty Health/The US Oncology Network, USA

P3.02a–020: Clinical Failure to Crizotinib in Patients with Anaplastic Lymphoma Kinase–Positive Advanced Non–Small–Cell Lung Cancers
Daniel Shao–Weng Tan, National Cancer Centre Singapore, Singapore

P3.02a–021: Clinical Benefit of Continuing Crizotinib Therapy after Initial Disease Progression in Chinese Patients with Advanced ALK –Rearranged NSCLC
Jin Kang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.02a–022: Experiences of Patients Receiving Treatment with Ceritinib to Treat ALK+ Non–Small Cell Lung Cancer: A Qualitative Study
Kenneth Culver, Novartis, USA

P3.02a–023: Treatment Patterns and Early Outcomes of ALK+ Non–Small Cell Lung Cancer Patients Receiving Ceritinib: A Chart Review Study
Gero Streebbe, Novartis Pharmaceuticals Corporation, USA

P3.02a–024: Response to Crizotinib in a Lung Adenocarcinoma Patient Harbouring EML4–ALK Translocation with Adnexal Metastasis
Wenxian Wang, Zhejiang Cancer Hospital, China

P3.02a–025: PROs With Ceritinib Versus Chemotherapy in Patients With Previously Untreated ALK–rearranged Nonsquamous NSCLC (ASCEND–4)
Daniel Shao–Weng Tan, National Cancer Centre Singapore, Singapore

P3.02a–026: Crizotinib in Clinical Practice and in Clinical Trials – How Much the Results Differ?
Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, Slovakia

P3.02a–027: A Retrospective Analysis of the Efficacy and Safety of ALK Inhibitors in ALK–Positive Lung Cancer Patients
Kazutoshi Komiya, Saga University, Japan

P3.02a–028: Anaplastic Lymphoma Kinase Fusion Oncogene Positive Non–Small Cell Lung Cancer – The Experience of an Institution
Sérgio Azevedo, Instituto Português de Oncologia do Porto Francisco Gentil, EPE, Porto, Portugal, Portugal
### P3.02b  ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY – EGFR

**P3.02b–001: Phase 1 Dose Escalation of PF-06747775 (EGFR-T790M Inhibitor) in Patients with Advanced EGFRm (Del 19 or L858R+/-T790M) NSCLC**
Hatim Husain, UC San Diego Moores Cancer Center, USA

**P3.02b–002: Treatment Outcome Comparison between Exon 19 and 21 EGFR Mutations after Second–Line TKIs in Advanced NSCLC Patients**
Xiance Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

**P3.02b–003: Second–Line Afatinib versus Erlotinib for Patients with Squamous Cell Carcinoma of the Lung (LUX–Lung 8): Analysis of Tumour and Serum Biomarkers**
Enriqueta Felip, Vall d´Hebron University, Spain

**P3.02b–004: EGFR Mutation in Squamous Cell Advanced NSCLC in Persahabatan Hospital, Jakarta Indonesia**
Sita Laksmi Andarini, Faculty Of Medicine Universitas Indonesia, Indonesia

**P3.02b–005: Phase Ib Trial of Afatinib and BI 836845 in Advanced NSCLC: Dose Escalation and Safety Results**
Byoung Chul Cho, Yonsei University Medical Center, South Korea

### P3.02b  ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY – MISCELLANEOUS

**P3.02b–006: Role of TP53 Mutations in Determining Primary Resistance to First–Line Tyrosine Kinase Inhibitors in EGFR–Mutated NSCLC Patients**
Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

**P3.02b–007: Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung**
Alok Goel, Tata Memorial Hospital, India

**P3.02b–008: Quantification and Monitoring of Treatment Response in EGFR Mutant NSCLC Patients by Digital–PCR in Plasma cfDNA**
Vienna Ludovini, Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

**P3.02b–009: Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR–TKIs and Association with VeriStrat Status**
Chiara Lazzari, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale San Raffaele, Italy

### P3.02a  ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY – ROS1

**P3.02a–029: Patients with ROS1 Rearrangement Positive Non–Small Cell Lung Cancer Benefit from Pemetrexed–Based Chemotherapy**
Zhengbo Song, Zhejiang Cancer Hospital, China

**P3.02a–030: ROS1 Fusion Chinese Lung Adenocarcinoma Patients Treated with Crizotinib Detected Using Next–Generation Genotyping from ctDNA**
Xiaomin Niu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

**P3.02a–031: Non–Small Cell Lung Cancer Targeted Therapy in Case of ROS1 Rearrangement**
Elena Reutova, Russian Cancer Research Center, Russia

### P3.02a  ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY – MISCELLANEOUS

**P3.02a–032: Multicenter Trial of Nintedanib in Combination with Docetaxel in Metastatic Lung Adenocarcinoma: Expertise in the Real–Life Setting**
Jeronimo Rodriguez Cid, Instituto Nacional de Enfermedades Respiratorias, Mexico

**P3.02a–033: The Humanistic Burden Associated with Caring for Advanced NSCLC Patients in Europe – A Real World Survey of Caregivers**
Oana Chirita, Bristol–Myers Squibb, UK

**P3.02a–034: Vemurafenib in Patients with Non–Small Cell Lung Cancer (NSCLC) Harboring BRAF Mutation. Preliminary Results of the AcSé Trial**
Julien Mazieres, CHU de Toulouse Hôpital Larrey, France

**P3.02a–035: Can Airway Stenting Avoid Suffocation Deaths Caused by Malignant Airway Obstruction?**
Naofumi Miyahara, Fukuoka University Hospital, Japan

**P3.02a–036: Phase 1 Study of Ceritinib 450 mg or 600 mg Taken with a Low-Fat Meal versus 750 mg in Fasted State in ALK+ Metastatic NSCLC**
Rafal Dziadziuszko, Medical University of Gdansk, Poland

### P3.02b  ADVANCED NSCLC & CHEMOTHERAPY/TARGETED THERAPY/IMMUNOTHERAPY – EGFR BIOMARKERS

**P3.02b–001: Role of TP53 Mutations in Determining Primary Resistance to First–Line Tyrosine Kinase Inhibitors in EGFR–Mutated NSCLC Patients**
Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

**P3.02b–007: Differential Efficacy of Gefitinib in Exon 19 or Exon 21 Mutated Adenocarcinoma Lung**
Alok Goel, Tata Memorial Hospital, India

**P3.02b–008: Quantification and Monitoring of Treatment Response in EGFR Mutant NSCLC Patients by Digital–PCR in Plasma cfDNA**
Vienna Ludovini, Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

**P3.02b–009: Plasma and Tissue Inflammatory and Angiogenic Biomarkers to Explore Resistance to EGFR–TKIs and Association with VeriStrat Status**
Chiara Lazzari, Istituto di Ricovero e Cura a Carattere Scientifico, Ospedale San Raffaele, Italy
P3.02b–010: Urine Detection of EGFR T790M Mutation in Non–Small–Cell Lung Cancer: An Outcomes and Total Cost of Care Analysis
Jacob Sands, Lahey Hospital & Medical Center, USA

P3.02b–011: Comparison of Four Leading Technologies for Detecting EGFR Mutations in Circulating Tumor DNA from Patients with Non–Small Cell Lung Carcinoma
Xiaozheng Kang, Peking University Cancer Hospital and Institute, China

P3.02b–012: Longitudinal Monitoring of ctDNA EGFR Mutation Burden from Urine Correlates with Patient Response to EGFR TKIs: A Case Series
David Berz, Beverly Hills Cancer Center, USA

P3.02b–013: Evaluation of Lung Specific GPA Score in Adenocarcinoma Patients with Brain Metastasis and EGFR Activating Mutation
Pascal Dö, Baclesse, France

P3.02b–014: Monitoring of T790M Mutation in Serum for Prediction of Response to Third Generation Inhibitors
Teresa Morán, Catalan Institute of Oncology–Hospital Germans Trias i Pujol, Spain

P3.02b–015: Impact of Metastatic Status on the Prognosis of Patients Treated with First Generation EGFR–TKIs
Yoshikiko Taniguchi, National Hospital Organization Kinki–chu Chest Medical Center, Japan

P3.02b–016: An Exploration Study of Mechanisms Underlying Primary Resistance to EGFR–TKIs in Patients Harboring TKI–Sensitive EGFR Mutations
Ee Ke, Guangdong Lung Cancer Institute; Guangdong General Hospital(GGH) & Guangdong Academy of Medical Sciences, China

P3.02b–017: Sequence of EGFR–TKI Therapy and BIM Deletion Polymorphism Affect the Outcome of Treatment in EGFR Positive NSCLC
Chanchai Charonponsuntorn, Ramathibodi Hospital, Thailand

P3.02b–018: Detection of Epidermal Growth Factor Receptor Mutations in Circulating Cell–Free DNA versus Tumor Biopsy
In–Jae Oh, Chonnam National University Hwasun Hospital, South Korea

P3.02b–019: TTF–1 Expression as a Predictor of Response to EGFR–TKIs in Patients with Lung Adenocarcinoma
Kostas Syrigos, Medical School, University of Athens, Greece

P3.02b–020: Gender and Ethnicity Influence on Outcome in EGFRmut+ NSCLC Patients Treated at a Single Canadian Institution
Roxana Tudor, University of Calgary, Canada

P3.02b–021: Comparing T790M Identification across Testing Strategies in Advanced EGFR NSCLC: A Diagnostic Outcomes and Cost Analysis
Carolyn Bodnar, AstraZeneca, UK

P3.02b–022: Early Experience of Detecting EGFR Activating Mutations in Cell Free DNA Using Droplet Digital PCR
Moushumi Suryavanshi, Rajiv Gandhi Cancer Institute and Research Center, India

P3.02b–023: Physician Patterns of Care in Patients with EGFR Mutation+ NSCLC: An International Survey into Testing and Treatment Choice
Bernd Tischer, Kantar Health, Germany

P3.02b–024: Dynamics of EGFR Mutational Load in Urine and Plasma Correlates with Treatment Response in Advanced NSCLC
Jhannelle Gray, Moffitt Cancer Center, USA

P3.02b–025: Rapid and Highly Sensitive EGFRdelEx19 and KRAS Exon 2 Mutation Detection in EBUS–TBNA Specimen of Lung Adenocarcinoma
Filiz Öezkan, Ruhrlandklinik, West German Lung Center, University Duisburg–Essen, Germany

P3.02b–026: Association of EGFR exon 19 Deletion and EGFR–TKI treatment duration with Frequency of T790M Mutation in EGFR–Mutant Lung Cancer Patients
Norikazu Matsuo, Kurume University School of Medicine, Japan

P3.02b–027: Detection of EGFR Mutations in Plasma of Lung Adenocarcinoma Patients Using Real–Time PCR and Mass Spectrometry
Rossella Bruno, University of Pisa, Italy

Erin Stewart, University of Toronto, Canada

P3.02b–029: Primary Double EGFR Mutations T790M and Mutation in Exon 19 or 21 – Prevalence and Treatment Results in Slovakian NSCLC Patients
Peter Berzinec, Specialised Hospital of St Zoerardus Zobor, Slovakia

P3.02b–030: Single Institution Experience with EGFR Gene Mutation Analysis and Treatment of EGFR Positive Patients in the Years 2010 to 2015
Ond ej Venclí ek, University Hospital Brno, Czech Republic

P3.02b–031: T790M: A Favorable Mutation?
Hong Jian, Shanghai Chest Hospital, China

P3.02b–032: Association between EGFR T790M Mutation Copy Numbers in Cell–Free Plasma DNA and Response to Osimertinib in Advanced NSCLC
Anna Buder, Medical University of Vienna, Austria

P3.02b–033: Filter Paper as Specimen Storage and Transport Medium of EGFR Mutation Testing Collected from Lung Cancer Patients in Remote Areas of Indonesia
Najmiatul Masykura, Stem–cell and Cancer Institute, Indonesia

P3.02b–034: Clinical Impact of Pretreatment EGFR T790M Mutation in Lung Adenocarcinoma Patients
Elisabetta Macerola, University of Pisa, Italy

P3.02b–035: Cell Free Tumor DNA to Monitor Response to Tyrosine Kinase Inhibitors in Patients with EGFR–Mutant Non–Small Cell Lung Cancer
Paola Ulivi, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Italy

P3.02b–036: The Predictive Factors for Post–Progression Survival after EGFR–TKI Failure in Advanced EGFR–Mutant Lung Cancer Patients
Toshiki Ebisudani, Kameda Medical Center, Japan
P3.02b–037: Does Tissue EGFR Mutation Status Predict Treatment Response and Mortality in Adenocarcinoma Lung? Anant Mohan, All India Institute of Medical Sciences, India

P3.02b–038: Molecular Dynamics Simulation of EGFR L844V Mutant Sensitive to AZD9291 in Non–Small Cell Lung Cancer Vahideh Assadollahi, Student Research Committee, Kurdistan University of Medical Sciences, Iran

P3.02b–039: Analysis of Prognostic Factor for Afatinib Treated Patients with EGFR Mutation Positive NSCLC Masafumi Sata, Kanagawa Cancer Center, Japan

P3.02b–040: A Comparison of ddPCR and ARMS for Detecting EGFR T790M Status from Advanced NSCLC Patients with Acquired EGFR–TKI Resistance Wenxiang Wang, Zhejiang Cancer Hospital, China

P3.02b–041: Genome–Wide Screen of DNA Methylation Changes Reveals GABBR2 as a Novel Potential Target for EGFR 19 Deletion Adenocarcinoma with Erlotinib Xiaomin Niu, Shanghai Chest Hospital, Shanghai Jiao Tong University, China

P3.02b–042: Reduction in Peripheral Blood Cytokine Levels Observed in EGFR Mutant (EGFRm) Patients Treated with Erlotinib Aaron Lisberg, UCLA Medical Center, USA

P3.02b–043: Inter–Laboratory Comparison of the Roche Cobas EGFR Mutation Test v2 in Plasma Cleo Keppens, KULeuven, Belgium

P3.02b–044: Afatinib versus Gefitinib as First–Line Treatment for EGFR Mutation–Positive NSCLC Patients Aged ≥75 Years: Subgroup Analysis of LUX–Lung 7 Ken O’Byrne, Princess Alexandra Hospital and Queensland University of Technology, Australia

P3.02b–045: Patritumab plus Erlotinib in EGFR Wild–Type Advanced Non–Small Cell Lung Cancer (NSCLC): Part a Results of LUX–LU1 Luis Paz–Arez, Hospital Universitario 12 de Octubre, Spain

P3.02b–046: Afatinib Benefits Patients with Confirmed/ Suspected EGFR Mutant NSCLC, Unsuitable for Chemotherapy (TIMELY Phase II Trial) Sanjay Popat, Royal Marsden Hospital, UK

P3.02b–047: Co–Activation of STAT3 and YAP1 Signaling Pathways Limits EGFR Inhibitor Response in Lung Cancer Erik Jakobsen, Odense University Hospital, Denmark

P3.02b–048: Oral Vinorelbine Monotherapy in Patients with EGFR+ NSCLC after Failure of EGFR–TKI in First Line: A Prospective Study Dariusz Kowalski, The Maria Sklodowska–Curie Memorial Cancer Centre & Institute of Oncology, Poland

P3.02b–049: EGFR–Mutated NSCLC: Clinical Practice Assessment and Gap Analysis Elaine Hamarstrom, Medscape Education, USA

P3.02b–050: A Phase I/II Study of Erlotinib, Carboplatin, Pemetrexed and Bevacizumab for Advanced Non–Squamous NSCLC Harboring EGFR Mutation Takashi Yokoi, Kansai Medical University, Japan

P3.02b–051: Outcome of Advanced EGFR–Mutated NSCLC Patients with MET–Driven Acquired Resistance to EGFR TKI. Results of the METEORE Study Simon Baldacci, CHU Lille, Univ. Lille, France

P3.02b–052: Afatinib with or without Cetuximab for First–Line Treatment of EGFR–Mutant NSCLC: Interim Safety Results of SWOG S1403 Sarah Goldberg, Yale School of Medicine, USA

P3.02b–053: A Randomized, Open Label, Phase II Study Comparing Pemetrexed plus Cisplatin versus Pemetrexed Alone in EGFR Mutant NSCLC after EGFR–TKI: QOL Data Kwai Han Yoo, Samsung Medical Center, Sungkyunkwan University School of Medicine, South Korea

P3.02b–054: EGFR Mutation Profile in Newly Diagnosed Lung Adenocarcinoma in Persahabatan Hospital, Jakarta–Indonesia Sita Laksmi Andarini, Faculty Of Medicine Universitas Indonesia, Indonesia

P3.02b–055: Impact of Pemetrexed Chemotherapy in Exon 19 or Exon 21 Mutated NSCLC Vikas Talreja, Tata Memorial Hospital, India

P3.02b–056: Survival in EGFR Mutated Advanced Lung Cancer Adenocarcinoma Patients – A National Study Erik Jakobsen, Odense University Hospital, Denmark

P3.02b–057: Network Meta–Analysis of First–Line and Maintenance Regimens in EGFR Mutated Advanced Non–Small–Cell Lung Cancer (NSCLC) Gilberto De Lima Lopes, Grupo Oncoclinicas, Brazil

P3.02b–058: Second–Line Therapy in EGFR Activating Mutation Positive Advanced NSCLC: Analysis from a Randomized Phase III First–Line Trial Arun Chandrasekharan, Tata Memorial Hospital, India

P3.02b–059: The Role of Epidermal Growth Factor Receptor in the Onset of Skeletal Related Events in Non–Small Cell Lung Cancer Shu–Mei Huang, Guangdong Lung Cancer Institute, Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.02b–060: Comparative Analysis of the Efficacy of Three 1st/2nd Generation EGFR–TKIs for EGFR Mutated NSCLC in Clinical Practice Kentaro Ito, Matsusaka Municipal Hospital, Japan

P3.02b–061: A Phase II Study of Nab–Paclitaxel (Nab–P) in Patients with Advanced Non–Small Cell Lung Cancer (NSCLC) with EGFR Mutations Christina Baik, University of Washington, Seattle Cancer Care Alliance, USA
P3.02b–062: Safety of Necitumumab and Abemaciclib Combination Therapy in Patients with Advanced Non–Small Cell Lung Cancer (NSCLC)
Benjamin Besse, Gustave Roussy, France

P3.02b–063: Analysis of Survival in EGFR–Mutation–Positive Advanced Non–Small–Cell Lung Cancer Patients with Miliary Pulmonary Metastasis
Kageaki Watanabe, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P3.02b–064: Time to EGFR–TKI Treatment for Patients with Advanced NSCLC and EGFR Activating Mutation in a Tertiary Cancer Center
Pascal Dö, Baclesse, France

P3.02b–065: Third Line Therapy in EGFR Positive Advanced Non–Small Cell Lung Cancer
Nikhil Pande, Tata Memorial Hospital, India

P3.02b–066: Phase II Trial of the C–Met Inhibitor Tepotinib in Advanced Lung Adenocarcinoma with MET Exon 14 Skipping Mutations after Failure of Prior Therapy
Paul Paik, Memorial Sloan Kettering Cancer Center, USA

Hiroyuki Minemura, Fukushima Medical University, Japan

P3.02b–068: Outcomes of Patients with Advanced EGFR Mutation Positive Adenocarcinoma of Lung Treated with Gefitinib in Northern Ireland 2010–2016
Michael–John Devlin, Northern Ireland Cancer Centre, UK

P3.02b–069: To Assess Efficacy of First Line TKIs in EGFR Mutant Advanced NSCLC Patients from North India
Ullas Batra, Rajiv Gandhi Cancer Institute and Research Centre, India

P3.02b–070: NSCLC with Detectable EGFR Mutation: Institutional Experience
Jose Minatta, Hospital Italiano, Argentina

P3.02b–071: First–Line Gefitinib for EGFR–Mutated Lung Adenocarcinoma Patients with Bone Metastases – A Single Institution Experience
Davorin Radosavljevic, Institute for Oncology and Radiology of Serbia, Serbia

P3.02b–072: A Multicenter Phase II Study of Gefitinib in Squamous NSCLC Patients Who Failed First–Line Chemotherapy
Tae Kyu Lim, Veterans Health Service Medical Center, South Korea

P3.02b–073: A Phase II, Liquid Biopsy Study Using Digital PCR in EGFR Mutated, Lung Cancer Patients Treated with Afatinib (WJOG 8114LTR)
Hiroaki Akamatsu, Wakayama Medical University, Japan

P3.02b–074: Brain Radiotherapy with EGFR–TKI Plays an Important Role in 181 EGFR Mutant Non–Small Cell Lung Cancer Patients with Brain Metastasis
Wenxian Wang, Zhejiang Cancer Hospital, China

P3.02b–075: Addition of Bevacizumab for Malignant Pleural Effusion as the Manifestation of Acquired EGFR–TKI Resistance in NSCLC Patients
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P3.02b–076: Bisphosphonates Enhance Effect of EGFR–TKIs in NSCLC Patients with EGFR Mutation and Bone Metastases
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P3.02b–077: Osimertinib Expanded Access Program for Previously Treated Patients With Advanced EGFR T790M Mutation–Positive NSCLC
Edgardo Santos, Lynn Cancer Institute, USA

P3.02b–078: Non–Small Cell Lung Cancer with De Novo EGFR T790M Mutation: Clinical Features of 22 Cases
Myung–Ju Ahn, Samsung Medical Center, South Korea

P3.02b–079: Effects of Icotinib with and without Radiation Therapy on Patients with EGFR Mutant Non–Small Cell Lung Cancer and Brain Metastases
Yun Fan, Zhejiang Cancer Hospital, China

P3.02b–080: Analysis of Patient–Reported Symptom Response with Osimertinib (AZD9291) Treatment for Advanced Non–Small–Cell Lung Cancer
Silvia Novello, University of Turin, Italy

P3.02b–081: Comparative Outcome Assessment of EGFR TKIs for the Treatment of Advanced Non–Small–Cell Lung Cancer: A Network Meta–Analysis
Ramon Andrade De Mello, University of Algarve, Portugal

P3.02b–082: Gefitinib in First–Line Treatment of Caucasian Patients with NSCLC and EGFR Mutations in Exons 19 or 21
Jana Skrickova, University Hospital and Medical Faculty Brno, Czech Republic

Taishi Harada, Fukushima City Hospital, Japan

P3.02b–084: Rational Combinations to Improve Outcome for EGFR–TKIs in NSCLCs with EGFR Mutations
Barbara Helfrich, University of Colorado Anschutz Medical Center, USA

P3.02b–085: The Combination Therapy of S–1 and the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors beyond Progressive Disease
Lu Yang, Peking Union Medical College, China

P3.02b–086: ASP8273 Tolerability and Antitumor Activity in TKI–Naive Japanese Subjects with EGFRmut+ NSCLC: Preliminary Results
Makoto Nishio, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, Japan

P3.02b–087: Dose Escalation Study of CDDP plus PEM with Erlotinib and Bev Followed by PIM with Erlotinib and Bev for Non–SQ NSCLC Harborng EGFR Mutations
Akihiro Tamiya, National Hospital Organization Kinki–chujo Chest Medical Center, Japan
P3.02b–088: TKI as First Line Treatment in Advanced Non–Small–Cell Lung Cancer with EGFR Mutations
Inês Guerreiro, Instituto Portugues de Oncologia Centro do Porto(IPO–Porto), Portugal

P3.02b–089: Treatment of NSCLC Patients with Malignant Pleural Effusion Harboring Exon 19 and 21 EGFR Mutations after First–Line and Second–Line TKIs
Xian Jin, The 1st Affiliated Hospital of Wenzhou Medical University, China

P3.02b–090: Pemetrexed versus Gefitinib in EGFR Mutation Positive Lung Cancer: Results of a Phase 3 Study from India
Kumar Prabhash, Tata Memorial Centre, India

P3.02b–091: Liver Metastases Is the Negative Predictive Factor for First–Line EGFR TKIs Therapy in NSCLC Patients with EGFR Mutation
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P3.02b–092: Central Nervous System (CNS) Responses to Osimertinib in Brain Metastases from Lung Cancer (NSCLC) with T790M: Effectiveness of the 80 Mg Dose
Raja Mudad, University of Miami, USA

P3.02b–093: Zoledronic Acid Enhances the Effects of Icotinib on Non–Small Cell Lung Cancer Patients with Bone Metastases
Wenxian Wang, Zhejiang Cancer Hospital, China

P3.02b–094: Rebiopsy Post Progression in EGFR Mutated Lung Cancer
Arun Chandrasekharan, Tata Memorial Hospital, India

P3.02b–095: Tracing Spatiotemporal T790M Heterogeneity in Patients with EGFR–Mutant Advanced NSCLC after Acquired Resistance to EGFR TKIs
Yi–Chen Zhang, Guangdong Lung Cancer Institute; Guangdong General Hospital(GGH) & Guangdong Academy of Medical Sciences, China

P3.02b–096: Osimertinib (AZD9291) in Asia–Pacific Patients with T790M Mutation–Positive Advanced NSCLC: Open–Label Phase II Study Results
Caicun Zhou, Shanghai Pulmonary Hospital, Tongji University, China

P3.02b–097: Experience of Re–Biopsy (Biopsy at Progression) of EGFR Mutant Non–Small Cell Lung Cancer Patients in Japan: A Retrospective Study
Kaname Nosaki, Department of Thoracic Oncology, National Kyushu Cancer Center, Japan

P3.02b–098: Plasma T790M Mutation Associates with Extensive Progression in Non–Small Cell Lung Cancer with Acquired Resistance to EGFR Inhibitors
Shirong Zhang, Hangzhou First People’s Hospital, Nanjing Medical University, China

P3.02b–099: Pharmacokinetics of Osimertinib (AZD9291) in Chinese Patients with Advanced NSCLC: A Phase I Study
Junning Cao, Fudan University Shanghai Cancer Center, China

P3.02b–100: Comparison of Three T790M Testing Methods for the Detection of Non–Small Cell Lung Cancer after Tyrosine Kinase Inhibitor Failure
Shirong Zhang, Hangzhou First People’s Hospital, Nanjing Medical University, China

P3.02b–101: EGFR T790M Resistance Mutation in NSCLC: Real–Life Data of Austrian Patients Treated with Osimertinib
Maximilian Hochmair, Otto Wagner Hospital, Austria

P3.02b–102: Osimertinib Benefit in ctDNA T790M Positive, EGFR–Mutant NSCLC Patients
Jordi Remon, Gustave Roussy, France

Jessica Lin, Massachusetts General Hospital, USA

P3.02b–104: Rebiopsy for Patients with Non–Small–Cell Lung Cancer after Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Failure
Xuefei Li, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P3.02b–105: Mutational Profiling of Non–Small Cell Lung Cancer Patients Resistant to First–Generation EGFR Tyrosine Kinase inhibitors Using Next Generation Sequencing
Ying Jin, Zhejiang Cancer Hospital, China

P3.02b–106: Local Experience of Osimertinib Use; Retrospective Review Based on Plasma EGFR Using ddPCR Technique
Jacky Li, Queen Elizabeth Hospital, Hong Kong

P3.02b–107: Efficacy of Afatinib and Gefitinib in Lung Adeno–carcinoma with EGFR Gene Mutation as 2nd or 3rd Line Treatment
Marisol Arroyo Hernandez, Instituto Nacional de Enfermedades Respiratorias Ismael Cosío Villegas, Mexico

P3.02b–108: Assessment of Clinical Usability of a cfDNA–Based Assay Detecting EGFR T790M Mutation in EGFR–TKI Refractory NSCLC Patients
Masaki Hanibuchi, Institute of Biomedical Sciences, Tokushima University Graduate School, Japan

Martin Faehling, Klinikum Esslingen, Germany

P3.02b–110: ROS1 Translocation as a Bystander Mutation in Non–Small Cell Lung Cancer after Epidermal Growth Factor Receptor Targeted Therapy
Yoo–Duk Choi, Chonnam National University Hwasun Hospital, South Korea
P3.02b–113: Clinical Course of NSCLC Patients with EGFR Mutation Undergoing Rebiopsy and Osimertinib Therapy
Kenichiro Hirai, Fukushima Medical University, Japan

P3.02b–114: Second Line Treatment of EGFR Positive Lung Adenocarcinoma – Our Experience
Marko Jakopovic, University Hospital Centre Zagreb, Croatia

P3.02b–115: Clinical Activity of Osimertinib in EGFR Mutation Positive Non Small Cell Lung Cancer (NSCLC) Patients (Pts) Previously Treated with Rociletinib
Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA

P3.02b–116: Molecular Mechanism of Transformation from Adenocarcinoma to Small–Cell Lung Cancer after EGFR–TKI Zheng–Yi Dong, Guangdong Lung Cancer Institute, Guangdong General Hospital, China

P3.02b–117: Phase Ib Results from a Study of Capmatinib (INC280) + EGF816 in Patients with EGFR–Mutant Non–Small Cell Lung Cancer (NSCLC)
Daniel Shao–Weng Tan, National Cancer Centre Singapore, Singapore

P3.02b–118: Potential Mechanism Revealed by Targeted Sequencing from Lung Adenocarcinoma Patients with Primary Resistance to EGFR–TKIs
Jie Wang, Cancer Hospital Chinese Academy of Medical Sciences, China

P3.02b–119: YH25448, a Highly Selective 3rd Generation EGFR TKI, Exhibits Superior Survival over Osimertinib in Animal Model with Brain Metastases from NSCLC
Min Hee Hong, Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, South Korea

P3.02b–120: EGFR T790M, L792F, and C797S Mutations as Mechanisms of Acquired Resistance to Afinatin Yoshisaka Kobayashi, Kindai University Faculty of Medicine, Japan

P3.02b–121: Targeting miR–200c/LIN28B Axis in Acquired EGFR–/KRAS–/ALK–/ROS1–/RET– Non–Small Cell Lung Cancer Cells Harboring EMT Features
Kazuhiko Shien, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Japan

P3.02b–122: Characterization of Afinatin Resistant Lung Cancer Cells (PC9/Afa) and Reversal of Resistance by T790M Specific Tyrosine Kinase Inhibitors
Anya Maan–Yuh Lin, Institute of Pharmacology, National Yang–Ming University, Taiwan

P3.02b–123: Lysimachia Capillipes Capilliposide Inhibits AKT Activation and Restores Sensitivity to Gefitinib in NSCLC with Acquired Gefitinib Resistance
Shirong Zhang, Hangzhou First People’s Hospital, Nanjing Medical University, China

P3.02b–124: Efficacy of Osimertinib in Patients with Non–Small–Cell Lung Cancer (NSCLC) and Pleural Effusion
Saki Manabe, Kanagawa Cancer Center, Japan

P3.02b–125: Failure to Tyrosine Kinase Inhibitors and Patterns of Progression in Patients with Advanced Non–Small Cell Lung Cancer
Oscar Arrieta, National Cancer Institute, Mexico

P3.02b–126: Clinical Activity of Olmutinib (HM61713) Used on a Compassionate IND Basis for Patients with Lung Adenocarcinoma (LADC) in Korea
Jin Soo Lee, National Cancer Center, South Korea

P3.02b–127: NSCLC Patients Harboring HER2 Mutation: Clinical Characteristics and Management in Real World Setting. EXPLORE GFPC 02-14
Jean Bernard Auliac, Hopital Quesnay, France

P3.02c–001: Phase I Study of Salazosulfapyridine Targeting Cancer Stem Cells in Combination with CDDP and Pemetrexed for Chemo–Naive Advanced Non–Sq NSCLC
Kohei Otsubo, Research Institute for Diseases of the Chest, Graduate School of Medical Sciences, Kyushu University, Japan

P3.02c–002: Mannosylated Poly (Propylene Imine) Dendrimer Mediated Lung Delivery of Anticancer Bioactive Mani Bhargava, ICFAI University, India

P3.02c–003: TAX–TORC: The Novel Combination of Weekly Paclitaxel and the Dual mTORC1/2 Inhibitor AZD2014 for the Treatment of Squamous NSCLC
Matthew Krebs, The University of Manchester and The Christie NHS Foundation Trust, UK

P3.02c–004: SB10206965, a Novel Inhibitor of Ulk1, Suppresses Non–Small Cell Lung Cancer Cell Growth via Modulating Both Autophagy and Apoptosis Pathways
Conghua Xie, Zhongnan Hospital of Wuhan University, China

P3.02c–005: MET Exon 14 Skipping in Quintuple–Negative (EGFR–/KRAS–/ALK–/ROS1–/RET–) Lung Adenocarcinoma
Geun Dong Lee, Gangnam Severance Hospital, Yonsei University College of Medicine, South Korea

P3.02c–006: EGFR and HER3 Inhibition – A Novel Therapy for Invasive Mucinous Non–Small Cell Lung Cancer Harboring an NRG1 Fusion Gene
Wolfgang Jacob, Roche Diagnostics GmbH, Germany

P3.02c–007: Assessment of Dianhydrogalactitol in the Treatment of Relapsed or Refractory Non–Small Cell Lung Cancer
Anne Steino, DelMar Pharmaceuticals, Inc, Canada

P3.02c–008: A MET Inhibitor in the Treatment of Metastatic Non Small Cell Lung Cancer with MET Amplification
Junling Li, Cancer Institute & Hospital, Peking Union Medical College/Chinese Academy of Medical Science, China

P3.02c–009: Anti–VEGF and Anti–EGFR Reduce Malignant Pleural Effusion and Morbidity in an Experimental Adenocarcinoma Model
Vera Capelozzi, Faculdade de Medicina da USP, Brazil
P3.02c–010: Resistance Mechanisms to PI3K–mTOR Inhibition in NSCLC
Gillian Moore, Trinity College Dublin/St. James’s Hospital, Ireland

P3.02c–011: A Phase 1b Open–Label Study of PEGPH20 Combined with Pembrolizumab in Patients with Selected Hyaluronan–High Solid Tumors
Alexander Spira, Virginia Cancer Specialists, USA

P3.02c–012: Apatinib, a New Small Molecular VEGFR2 Inhibitor, Suppresses the Activity of Lung Cancer Stem Cells
Caiyun Zhong, Nanjing Medical University, China

P3.02c–013: Combination Therapy of Oncolytic Herpes Simplex Virus Type 1 with Erlotinib in a Human Lung Cancer Xenograft Model
Yoshinori Sakata, Tokyo Medical University, Japan

P3.02c–014: Patients with Recurrence after Resection of Lung Cancer Are Good Candidates for the beyond over Progressive Disease Application of Bevacizumab
Tatsuya Yoshimatsu, Wakayama Medical University, Japan

Yusuke Okuma, Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Japan

P3.02c–016: Efficacy of Bevacizumab Combined with Chemotherapy in Lung Adenocarcinoma–Induced Malignant Pleural Effusion
Zhe Liu, Beijing Chest Hospital, Capital Medical University, China

P3.02c–017: ‘2nd Line’ RET–Inhibition in a Female Patient with Non–KIF5B RET–Translocation
Tobias Overbeck, Goettingen University, Germany

P3.02c–018: Could COX–2 Inhibitors Enhance the Outcomes of Chemotherapeutic Agents in Lung Cancer?
Konstantinos Zalogoulidis, Aristotle University of Thessaloniki, Greece

P3.02c–019: The Use of Metformin and the Incidence of Metastases at the Time of Diagnosis in Patients with Lung Cancer and Type 2 Diabetes
Gordana Drpa, Clinic for Respiratory Diseases “Jordanovac”, University Hospital Centre Zagreb, Croatia

P3.02c–020: More Than 3 Years Long–Term Maintenance Treatment of Bevacizumab for Advanced–Stage NSCLC: A Report of Three Cases
Hongxia Li, Beijing Chest Hospital, Capital Medical University, China

P3.02c–021: PD 033291, a Selective Cyclin D Kinase 4/6 Inhibitor, Sensitizes Lung Cancer Cells to Killing by EGFR TKIs
Jun Chen, Tianjin Medical University General Hospital, China

P3.02c–022: Anticancer Activity of Sorafenib in Combined Treatment with Betulin in Human Non–Small Cell Lung Cancer Cell Lines
Justyna Kikutowski, Ludwik Hirszfeld Institute of Immunology and Experimental Therapy Polish Academy of Science, Poland

P3.02c–023: Mutation and Prognostic Analyses of PIK3CA in Patients with Completely Resected Lung Adenocarcinoma
Zhengbo Song, Zhejiang Cancer Hospital, China

P3.02c–024: Detection of Novel Activating FGFR Rearrangements, Truncations, and Splice Site Alterations in NSCLC by Comprehensive Genomic Profiling
Shirish Gadgeel, Karmanos Cancer Institute/Wayne State University, USA

P3.02c–025: Safety and Efficacy of Apatinib in Patients with Previously Heavily Treated Advanced Non–Squamous Non–Small–Cell Lung Cancer
Feng Ying Wu, Shanghai Pulmonary Hospital, Tongji University, China

P3.02c–026: Is Nivolumab Safe and Effective in Elderly and PS2 Patients with Non–Small Cell Lung Cancer (NSCLC)? Results of CheckMate 153
David Spigel, Sarah Cannon Research Institute/Tennessee Oncology, PLLC, USA

P3.02c–027: Phase I and PK Study of the Folate Receptor–Targeted Small Molecule Drug Conjugate (SMDC) EC1456 in Advanced Cancer: Lung Cancer Subset
Martin Edelman, University of Maryland, USA

P3.02c–028: Outcomes of Nivolumab in Elderly Patients (pts) with Non–Small Cell Lung Cancer (NSCLC) Treated with Nivolumab
Stephen Bagley, University of Pennsylvania, USA

P3.02c–029: Immune–Related Adverse Events and Their Effect on Outcomes in Patients (pts) with Non–Small Cell Lung Cancer (NSCLC) Treated with Nivolumab
Stephen Bagley, University of Pennsylvania, USA

P3.02c–030: Use of a 200–Mg Fixed Dose of Pembrolizumab for the Treatment of Advanced Non–Small Cell Lung Cancer (NSCLC)
Edward Garon, David Geffen School of Medicine at UCLA/Translational Research in Oncology–US Network, USA

P3.02c–031: Immune Checkpoint Inhibitors (IC) and Paradoxical Progressive Disease (PPD) in a Subset of Non–Small Cell Lung Cancer (NSCLC) Patients
Jihene Lahmar, Gustave Roussy, France

P3.02c–032: Interstitial Pneumonitis Associated with Immune Checkpoint Inhibitors Treatment in Cancer Patients
Myriam Delaunay, EHU Iraeey, France

P3.02c–033: Patterns of Progression and Management of Acquired Resistance to Anti–PD–1 Antibodies in Advanced Non–Small Cell Lung Cancer
Antony Mersiades, Crown Princess Mary Cancer Care Centre, Westmead Hospital, Australia

P3.02c–034: A Single Institution Experience with Immunotherapy as an Effective Therapy Approach of Advance Non–Small Cell Lung Cancer (NSCLC)
Jesus Corral, Virgen del Rocio Hospital, Spain

P3.02c–035: Comparison of RECIST to Immune–Related Response Criteria (irRC) in Patients with NSCLC Treated with Immune–Check Point Inhibitor
Myung–Ju Ahn, Samsung Medical Center, South Korea
P3.02c–036: Management of Early Disease Progression during Treatment of Advanced Non–Small Cell Lung Cancer with Nivolumab
Carlo Genova, San Martino Hospital – National Institute for Cancer Research, Italy

P3.02c–037: Clinical Safety of Combinational Therapy of Immune Checkpoint Inhibitors and Viscum Album L. in Patients with Advanced or Metastasized Cancer
Anja Thronicke, Forschungsinstitut Havelhöhe gGmbH am Krankenhaus Havelhöhe, Germany

P3.02c–038: First–Line Atezolizumab plus Chemotherapy in Chemotherapy–Naïve Patients with Advanced NSCLC: A Phase III Clinical Program
Frederico Cappuzzo, Istituto Toscano Tumori, Ospedale Civile, Italy

P3.02c–039: Endocrinological Side–Effects of Nivolumab in Advanced Non–Small Cell Lung Cancer
Giovanni Rossi, San Martino Hospital – National Institute for Cancer Research, Italy

P3.02c–040: Checkmate 384: A Phase 3B/4 Dose–Frequency Optimization Trial of Nivolumab in Advanced or Metastatic Non–Small Cell Lung Cancer (NSCLC)
Ronald Harris, Broome Oncology and US Oncology Research, USA

P3.02c–041: IMpower133: A Phase I/II Study of 1L Atezolizumab with Carboplatin and Etoposide in Patients with Extensive–Stage SCLC
Stephen Liu, Lombardi Comprehensive Cancer Center, Georgetown University Medical Center, USA

P3.02c–042: IMpower110: Phase III Trial Comparing 1L Atezolizumab with Chemotherapy in PD–L1–Selected Chemotherapy–Naïve NSCLC Patients
Filippo De Marinis, European Institute of Oncology, Italy

P3.02c–043: Immunotherapy in Non–Small Cell Lung Cancer: A New Approach and a New Challenge
Ana Linhas, Centro Hospitalar Vila Nova de Gaia/Espinho, Portugal

P3.02c–044: Nivolumab–Response in a Patient with Advanced Squamous NSCLC Occurring Simultaneously with SIAD
Parvis Sadjadian, Johannes Wesling Medical Center Minden, UKRUB, University of Bochum, Germany

P3.02c–045: Experience with Nivolumab in Compassionate Use in Non–Small Lung Carcinoma Patients Who Have progressed to One or More Prior Lines of Chemotherapy
Maria Marin Alcala, Corporació Sanitaria Parc Taulí, Spain

P3.02c–046: Safety, Clinical Activity and Biomarker Results from a Phase Ib Study of Erlotinib plus Atezolizumab in Advanced NSCLC
Charles Rudin, Memorial Sloan Kettering Cancer Center, USA

P3.02c–047: Local Experience in an Expanded Access Program of Nivolumab in Advanced Non–Small Cell Lung Cancer in Brazil
Luiz H. Araujo, Instituto COI de Educação e Pesquisa (ICOI) and Núcleo de Oncologia Torácica (NOT), Brazil

P3.02c–048: A Phase I/II Trial Evaluating the Combination of Stereotactic Body Radiotherapy and Pembrolizumab in Metastatic NSCLC
Roy Deckey, Yale School of Medicine, USA

P3.02c–049: Dendritic Cells Modified with Tumor–Associated Antigen Gene Demonstrate Enhanced Antitumor Effect against Lung Cancer
Tao Jiang, Shanghai Pulmonary Hospital, Tongji University School of Medicine, China

P3.02c–050: IMpower010: Phase III Study of Atezolizumab vs BSC after Adjuvant Chemotherapy in Patients with Completely Resected NSCLC
Heather Wakelee, Stanford University School of Medicine, USA

P3.02c–051: A Pre–Treatment Serum Test Based on Complement and IL–10 Pathways Identifies Patients Benefiting from the Addition of Bavituximab to Docetaxel
Rachel Sanborn, Providence Portland Medical Center, USA

P3.02c–052: Electronic Nose: An Early Response Biomarker for Anti–PD1 Therapy in Patients with NSCLC
Mirte Muller, The Netherlands Cancer Institute, Netherlands

P3.02c–053: Clinical and Plasma Biomarkers for Disease Control with Nivolumab Treatment for Advanced Non–Small Cell Lung Cancer (NSCLC)
Sameh Daher, Chaim Sheba Medical Center, Israel

P3.02c–054: Prognostic Role of cfDNA in Patients with NSCLC under Treatment with Nivolumab
Federica Biello, San Martino Hospital – National Institute for Cancer Research, Italy

P3.02c–055: Incidence and Grade of Pneumonitis in Advanced Non–Small Cell Lung Cancer (NSCLC) Patients Treated with Anti–PD–1 Antibodies
Andrew Yam, Crown Princess Mary Cancer Care Centre, Westmead Hospital, Australia

P3.02c–056: Interim Results From the Phase I Study of Nivolumab + nab–Paclitaxel + Carboplatin in Non–Small Cell Lung Cancer (NSCLC)
Jonathan W. Goldman, David Geffen School of Medicine at the University of California, USA

P3.02c–057: Viroimmunotherapy with Vescular Stomatitis Virus Expressing Interferon–γ (Vsv–IFNγ) in a Murine Model of NSCLC
Manish Patel, University of Minnesota, USA
P3.02c–060: Dual Positive PD-L1 and CD8+ TIL Represents a Predominant Subtype in NSCLC and Correlates with Augmented Immunogenicity
Si-Yang Liu, Guangdong Lung Cancer Institute; Guangdong General Hospital & Guangdong Academy of Medical Sciences, China

P3.02c–061: Neutrophil/Lymphocyte Ratio Predicts the Efficacy of Anti–PD–1 Antibody in Patients with Advanced Lung Cancer
Koung Jin Suh, Seoul National University Bundang Hospital, South Korea

P3.02c–062: Anti–Lung Cancer Effect of CD8+ T Cells Transduced Retroviral Vector Encoding WT1–Specific TCRs and siRNAs Targeting Endogenous TCRs
Jun An, The Third Affiliated Hospital, Sun Yat–Sen University, China

P3.02c–063: Lactate Dehydrogenase (LDH) as a Surrogate Biomarker to Checkpoint–Inhibitors for Patient with Advanced Non–Small–Cell Lung Cancer (NSCLC)
AM Martinez De Castro, Vall d’ Hebron Institute of Oncology/Vall d’ Hebron University Hospital, Spain

P3.02c–064: Higher PD–L1 Expression Correlates with Solid and High Grade Lung Adenocarcinomas: Implications for Immunotherapy Selection
Ross Miller, Houston Methodist Hospital, USA

P3.02c–065: Neutrophil–To–Lymphocyte and Other Ratios as Prognostic and Predictive Markers of Immune Checkpoint Inhibitors in Advanced NSCLC Patients
Laura Mezquita, Gustave Roussy, France

P3.02c–066: HLA–A2 Status and Immune Checkpoint Inhibitors in Advanced Non–Small–Cell Lung Cancer (NSCLC) Patients
Laura Mezquita, Gustave Roussy, France

P3.02c–067: Validation of PD–L1 Expression on Circulating Tumor Cells in Lung Cancer
Veena Singh, Biocent, USA

P3.02c–068: Immunotherapy against Non Small Cell Lung Cancer (NSCLC): Looking for Predictive Factors to Avoid an Untargeted Shooting
Chiara Bennati, Medical Oncology, Santa Maria della Misericordia Hospital, Italy

P3.02c–069: Pretreatment Neutrophil–to–Lymphocyte Ratio (NLR) Predicts Outcomes with Nivolumab in Non–Small Cell Lung Cancer (NSCLC)
Stephan Bagley, University of Pennsylvania, USA

P3.02c–070: Combination Immunotherapy with MEK Inhibitor for Treatment of Kras–Mutant Lung Cancer in Animal Model
J. Peter Koo, Yale Cancer Center, Yale School of Medicine, USA

P3.02c–071: Spatially Selective Depletion of Regulatory T Cells with near Infrared Photoinmunotherapy for Syngeneic Lewis Lung Carcinoma
Kazuhide Sato, Nagoya University, Japan

P3.02c–072: Predictive Immunologic Markers of Response to Nivolumab in Non–Small Cell Lung Cancer
Carlo Genova, San Martino Hospital – National Institute for Cancer Research, Italy

P3.02c–073: Evidence Suggesting a Dichotomous "Present vs absent" Determinant of PDL1 Inhibitor Efficacy in Non–Small Cell Lung Cancer (NSCLC)
David Stewart, University of Ottawa, Canada

P3.02c–074: Evaluation of a Pretreatment Serum Tests for Nivolumab Benefit in Patients with Non–Small Cell Lung Cancer
Francesco Grossi, IRCCS San Martino–IST Istituto Nazionale per la Ricerca sul Cancro, Italy

P3.02c–075: Could Blood Levels of Lymphocytes and Eosinophils Help Us to Identify the Efficacy or Toxicity of Immunotherapy?
Pilar Garrido, University Hospital Ramon y Cajal, Spain

P3.02c–076: Correlation of Neutrophil to Lymphocyte Ratio (NLR) with Clinical Benefit from Checkpoint Inhibitors in Advanced Lung Cancer
Alona Zer, Princess Margaret Cancer Centre, Canada

P3.02c–077: Cardiac Troponin–I Elevation in Patients with Non–Small Cell Lung Cancer during PD1/PDL1 Inhibition with Nivolumab
Erika Rijavec, San Martino Hospital – National Institute for Cancer Research, Italy

P3.02c–078: The Utilization of Pre–Treatment Neutrophil to Lymphocyte Ratio as a Predictive Marker for Efficacy of Immunotherapy in Non Small Cell Lung Cancer
Isabel Preeshagul, North Shore Long Island Jewish/Northwell Health, USA

P3.02c–079: Immunotherapy in Non Small Cell Lung Cancer (NSCLC): Biomarkers Associated with Early Death
Ana Gomez, University Hospital Ramon y Cajal, Spain

P3.02c–080: The Beneficial Effect of Platelet Binding to Monocytes on the Clinical Response to Checkpoint Inhibitors
Margarita Majem, Hospital de la Santa Creu i Sant Pau, Spain

P3.02c–081: Complete Blood Count Parameters as Predictive Factors in Patients with Advanced Non–Small Cell Lung Cancer Treated with Nivolumab
Diana Saravia, University of Miami Miller School of Medicine, USA

P3.02c–082: Altered Expression of Programmed Death–Ligand 1 after Neo–Adjuvant Chemotherapy in Patients with Lung Squamous Cell Carcinoma
Zhengbo Song, Zhejiang Cancer Hospital, China

P3.02c–083: Treatment Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE–001 at a Single Center
Aaron Lisberg, UCLA Medical Center, USA

P3.02c–084: Predictive and Prognostic Clinical and Pathological Factors of Nivolumab Efficacy in Non–Small–Cell Lung Cancer (NSCLC) Patients
Javier Garde–Noguera, Hospital Arnau de Vilanova, Spain

P3.02c–085: Neutrophil/Lymphocyte Ratio in Advanced Non–Small Cell Lung Cancer: Correlation with Prognosis and Response to Anti–PD1 Therapy
Domenico Galetta, Medical Oncology Unit, Clinical Cancer Centre “Giovanni Paolo II”, Italy
P3.02c–086: Genomic Heterogeneity in Tumors Demonstrating a Mixed Response to Nivolumab for Stage IV Squamous Cell Carcinoma of the Lung  
Michael Menefee, Mayo Clinic, USA

P3.02c–087: The Relationship of TILs and PD–L1 Expression in NSCLC Adenocarcinoma in Little to Non–Smokers with Driver Mutations and Outcome Parameters  
Sacha Mignon, Vrije Universiteit Brussel, Belgium

P3.02c–088: Acquired Resistance to Programmed Death–1 Axis Inhibitors in Non–Small Cell Lung Cancer (NSCLC)  
Scott Gettinger, Yale School of Medicine, USA

P3.02c–089: ImmunoCHIC: A Prospective Nivolumab Monotherapy Cohort in Advanced Non–Small Cell Lung Cancer Patients in Routine Clinical Practice  
Christos Chouaid, GRC OncoEst Creteil, France

P3.02c–090: The Role of ERCC–1 Polymorphisms as Predictive Biomarker of Response to Nivolumab in Advanced NSCLC  
Marco Aiello, A.O.U. Policlinico Vittorio Emanuele, Italy

P3.02c–086: Genomic Heterogeneity in Tumors Demonstrating a Mixed Response to Nivolumab for Stage IV Squamous Cell Carcinoma of the Lung  
Michael Menefee, Mayo Clinic, USA

P3.02c–087: The Relationship of TILs and PD–L1 Expression in NSCLC Adenocarcinoma in Little to Non–Smokers with Driver Mutations and Outcome Parameters  
Sacha Mignon, Vrije Universiteit Brussel, Belgium

P3.02c–088: Acquired Resistance to Programmed Death–1 Axis Inhibitors in Non–Small Cell Lung Cancer (NSCLC)  
Scott Gettinger, Yale School of Medicine, USA

P3.02c–089: ImmunoCHIC: A Prospective Nivolumab Monotherapy Cohort in Advanced Non–Small Cell Lung Cancer Patients in Routine Clinical Practice  
Christos Chouaid, GRC OncoEst Creteil, France

P3.02c–090: The Role of ERCC–1 Polymorphisms as Predictive Biomarker of Response to Nivolumab in Advanced NSCLC  
Marco Aiello, A.O.U. Policlinico Vittorio Emanuele, Italy

P3.02c–091: Final Phase Ib Results of RNAactive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC  
Alexandros Papachristofilou, Universitatssspital Basel, Switzerland

P3.02c–092: Nivolumab in Multi–Treated Patients with Advanced Sq–NSCLC: Data from the Italian Cohort of Expanded Access Programme (EAP)  
Marcello Tiseo, University Hospital of Parma, Italy

P3.02c–093: A Prospective, Randomized, Multicenter, Phase III Study, Comparing rhTPO with rhIL–11 Treating CIT (NCT02344979)  
Shun Lu, Shanghai Chest Hospital, Shanghai Jiaotong University, China

P3.02c–094: Italian Nivolumab Advanced Squamous NSCLC Expanded Access Program: Efficacy and Safety in Patients with Brain Metastases  
Annamaria Catino, National Cancer Research Centre, Istituto Tumori “Giovanni Paolo II” Bari, Italy, Italy

P3.02c–095: Italian Nivolumab Expanded Access Programme: Efficacy and Safety Data in Squamous Non Small Cell Lung Cancer Patients  
Lucio Ciriò, Medical Oncology, Santa Maria della Misericordia Hospital, Azienda Ospedaliera di Perugia, Italy

P3.02c–096: Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)  
Francesco Grossi, National Institute for Cancer Research, Italy

P3.02c–097: Nivolumab in Elderly or Poor Performance Status Patients with Advanced Non–Small Cell Lung Cancer  
Sho Watanabe, National Cancer Center Hospital, Japan

P3.02c–098: An Observational Study of the Efficacy and Safety of Nivolumab in Patients with Advanced NSCLC. A Galician Lung Cancer Group  
Rosario García Campelo, Complejo Universitario de a Coruna, Spain

P3.02c–099: A Retrospective Study of the Efficacy and Safety of Nivolumab in Our Clinical Practice: A Single Institutional Experience  
Tadashi Sakaguchi, Matsusaka Municipal Hospital, Japan

P3.02c–100: Nivolumab Beyond First–Line (1L) Treatment in Metastatic Non–Small Cell Lung Cancer (NSCLC)  
Miguel Sotelo, Hospital Universitario Infanta Cristina, Spain

P3.02c–101: Immunotherapy with Nivolumab in NSCLC Patients: One Centre Preliminary Results  
Konstantinos Zarogoulidis, Aristotle University of Thessaloniki, Greece

P3.02c–102: Safety and Tolerability of Abemaciclib Combined with LY3023414 or with Pembrolizumab in Patients with Stage IV NSCLC  
Jonathan W. Goldman, UCLA Medical Center, USA

P3.02c–103: Effect of Anti-PD–1 Therapy on Immune Cells in the Peripheral Blood of Non–Small Cell Lung Cancer (NSCLC) Patients  
Athanasios Kotsakis, University Hospital of Heraklion, Greece

P3.03 – MESOTHELIOMA/THYMIC MALIGNANCIES/ESOPHAGEAL CANCER/OTHER THORACIC MALIGNANCIES

P3.03–001: Targeting Cullin Ubiquitin Ligase Leads to Growths Arrest in Malignant Pleural Mesothelioma Cells  
Mayura Meerang, University Hospital Zürich, Switzerland

P3.03–002: Inducible Changes in Cell Morphology and Gene Expression Reflecting the Histological Subtypes of Mesothelioma  
Karin Schelch, Medical University of Vienna, Austria

P3.03–003: Mesothelium Covering Pleural Plaque Is Not Primarily Involved in Asbestos–Induced Mesothelial Carcinogenesis in Human  
Yuichi Koda, Respiratory, Japan

P3.03–004: Mesothelioma Covering Pleural Plaque Is Not Primarily Involved in Asbestos–Induced Mesothelial Carcinogenesis in Human  
Yuichi Koda, Respiratory, Japan

P3.03–005: Inhibition of PRMT5 is Synthetic Lethal in Mesotheliomas Harboring MTAP Loss  
Annabel Sharkey, University of Leicester, UK

P3.03–006: Use of Nivolumab in Elderly Patients with Advanced Squamous NSCLC: Results from the Italian Expanded Access Programme (EAP)  
Francesco Grossi, National Institute for Cancer Research, Italy

P3.03–007: Nivolumab in Elderly or Poor Performance Status Patients with Advanced Non–Small Cell Lung Cancer  
Sho Watanabe, National Cancer Center Hospital, Japan
P3.03–006: Optical Control of Growth Factor Receptors to Advance Signal Transduction Research and Drug Screening
Michael Grusch, Medical University of Vienna, Austria

P3.03–007: miR–137 Acts as a Tumour Suppressor via the Down–Regulation of YB–1 in Malignant Pleural Mesothelioma
Thomas Johnson, Asbestos Diseases Research Institute, Australia

P3.03–008: Hypoxia–Induced Changes in microRNA Levels Contribute to Drug Resistance in a 3D Model of Malignant Pleural Mesothelioma
Yuen Yee Cheng, Asbestos Diseases Research Institute, Australia

P3.03–009: Role of microRNAs as Biomarkers of Malignant Mesothelioma in Patients with Pleural Effusion
Alessandro Palleschi, Fondazione IRCCS Ca’ Granda – Ospedale Maggiore Policlinico, Italy

P3.03–010: Activation of p53 in Malignant Mesothelioma
Chuong Hoang, National Cancer Institute, USA

P3.03–011: Downregulated Expression of miR–30d Contributes to Pleural Malignant Mesothelioma Progression
Lijin Zhu, Zhejiang Academy of Medical Sciences, China

P3.03–012: Tumor–Infiltrating Lymphocytes, PDL–1, BAP–1, VEGFR–2 and IGF–1R Expression in Malignant Pleural Mesothelioma
Luca Ampollini, Thoracic Surgery, University Hospital of Parma, Italy

P3.03–013: BAP1 Immunostaining and FISH Analysis of p16 Help Making Distinction among Subtypes of Mesothelioma
Kenzo Hiroshima, Tokyo Women’s Medical University, Japan

P3.03–014: Tumor Subtype–Specific Cells–Of–Origin of Malignant Pleural Mesothelioma
Hilda De Vries, Netherlands Cancer Institute, Netherlands

P3.03–015: BAP1 is Inactivated by Copy Number Loss, Mutation, and/or Loss of Expression in More Than 70% Malignant Peritoneal Mesotheliomas
Noémie Leblay, International Agency for Research on Cancer, France

P3.03–016: Association between the Stainability of the Neurofibromatosis Type 2 Gene–Related Protein Merlin and the Tumor Properties of Mesotheliomas
Kozo Kuribayashi, Hyogo College of Medicine, Japan

P3.03–017: Fluorescent in situ Hybridization Analysis of MET Gene Status in Malignant Mesothelioma
Antonella Vigani, ASLS Spezzino, Italy

P3.03–018: Suppression of Tumor Growth by Pegylated Arginase in Malignant Pleural Mesothelioma
James Chung–Man Ho, The University of Hong Kong, Hong Kong

P3.03–019: Molecular Characterization of Malignant Pleural Mesothelioma (MPM) by next Generation Sequencing
Alejandro Navarro, Vall d’ Hebron Institute of Oncology/Vall d’ Hebron University Hospital, Spain

P3.03–020: Cytotoxicology Assessment of MWCNT on MeT–SA Cells
Li Ju, Zhejiang Academy Of Medical Sciences, China

P3.03–021: When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?
Steven Gray, LabMed Directorate, Ireland

P3.03–022: Serum CEA, VEGF and MMP–7 in Patients with Malignant Pleural Effusion: A Prospective Study with Logistic Regression Analysis of Accuracy
Franco Lumachi, University of Padua, School of Medicine, Italy

P3.03–023: High Incidence of Somatic BAP1 Alterations in Sporadic Malignant Mesothelioma from Turkey
Salih Emri, Hacettepe University, School of Medicine, Turkey

P3.03–024: Malignant Pleural Mesothelioma: Gene Expression Profiling of the Main Histological Subtypes
Greta Ali, University Hospital of Pisa, Italy

P3.03–025: Investigating Phenotypic and Genomic Heterogeneity in Malignant Pleural Mesothelioma
Muhammad Alamgeer, Monash Cancer Centre, Australia

P3.03–026: Orotate Phosphoribosyltransferase is Overexpressed in Malignant Pleural Mesothelioma: Dramatically Responds One Case in High OPRT Expression
Yoichiro Hamamoto, National Hospital Organization Disaster Medical Center, Japan

P3.03–027: Growth Factor and Inflammatory Signaling Pathway Interactions Influence Outcomes Following Multimodality Therapy for Mesothelioma
Keith Cengel, University of Pennsylvania, USA

P3.03–028: Nivolumab for Advanced Malignant Pleural Mesothelioma outside of Clinical Trials: A Single Institution Experience
Jun Zhang, Baylor College of Medicine, USA

P3.03–029: EPP Followed by Hemithoracic IMRT – A Multicenter Study on Behalf of the Italian Association for Radiation Oncology Lung Cancer Study Group
Marco Trovo, CRO – Aviano, Italy

P3.03–030: Cisplatin with Pemetrexed or Gemcitabine in Prolonged Infusion for Inoperable Mesothelioma: A Phase II Randomized Trial
Danijela Strbac, CRO – Aviano, Italy

P3.03–031: Definitive Radiation Therapy is Associated with Improved Survival in Non–Metastatic Malignant Pleural Mesothelioma
Kenneth Rosenzweig, Mount Sinai, USA

P3.03–032: PET/CT for Patients with Very Early Clinical Stage of Malignant Pleural Mesothelioma: When Can PET/CT Detect Tumor Growth of T0/T1a Mesothelioma?
Yoshiki Negi, Hyogo College of Medicine, Japan
P3.03–033: The Influence of Geographic and Socioeconomic Factors on Prognosis and Treatment Provision in Malignant Pleural Mesothelioma
Anthony Linton, Asbestos Diseases Research Institute, Australia

P3.03–034: Comprehensive Immunophenotyping of the Blood and Pleural Fluid from Patients with Malignant Pleural Mesothelioma by Flow Cytometry
Tobias Peikert, Mayo Clinic, USA

P3.03–035: Prognostic Role of hENT1 and RRM1 in Patients with Advanced Pleural Mesothelioma Treated with Second Line Gemcitabine Based Regimens
Andrés Cardona, Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Colombia

P3.03–036: Prognostic Model for Mesothelioma Based on Cancer and Leukemia Group B (CALGB) Trials (Alliance)
Herbert Pang, The University of Hong Kong, China

P3.03–037: Impact of Sarcomatoid Component in Patients with Biphasic Mesothelioma: Review of 118 Patients
Andrea Bille, Guy’s and St Thomas’ NHS Foundation Trust, UK

P3.03–038: Improving Quality of Care and Outcomes for Patients Diagnosed with Pleural Mesothelioma in England
Susan Harden, Royal College of Physicians of London, UK

P3.03–039: Prognostic Biomarkers for Malignant Pleural Mesothelioma Treated with Chemotherapy
Hakan Akgun, Eskişehir Osmangazi University, Turkey

P3.03–040: Long Term Outcomes Following IMRT for Mesothelioma Post EPP and Unresectable
Aaron Allen, Davidoff Center, Israel

P3.03–041: FAS/FASL Genetic Polymorphisms Impact on Clinical Outcome of Malignant Pleural Mesothelioma
Ahmed Salem, Faculty of Pharmacy, Ain Shams University, Egypt

P3.03–042: Study Comparing Volume and TNM in Predicting Clinical Outcome in Malignant Pleural Mesothelioma
Marina Garassino, Fondazione IRCCS – Istituto Nazionale dei Tumori, Italy

P3.03–043: Trimodality Therapy with Extrapleural Pneumonectomy, Radiation Therapy, and Chemotherapy for Epithelioid Malignant Pleural Mesothelioma
Kazunori Okabe, Yamaguchi Ube Medical Center, Japan

P3.03–044: Is Toxicity Increased by Adding Intraoperative Chemotherapy to Preoperative Induction Chemotherapy for Mesothelioma Patients?
Isabelle Opitz, University Hospital Zürich, Switzerland

P3.03–045: Treatment of Malignant Pleural Mesothelioma beyond First–Line among Hispanics (MeSO–CLiCaP)
Luis Corrales, Hospital San Juan de Dios (San José, Costa Rica), Costa Rica

P3.03–046: Prognostic Fibrinogen/Leukocyte Score at Diagnosis Predicts Survival and Benefit from Multimodality Treatment in Malignant Pleural Mesothelioma
Thomas Klolkovits, Medical University Vienna, Austria

P3.03–047: Diagnostic Value of Secretary Leukocyte Peptide Inhibitor (SLPI) in Pleural Fluid in Malignant Pleural Mesothelioma
Nobukazu Fujimoto, Okayama Rosai Hospital, Japan

P3.03–048: Profiling Response to Chemotherapy in Malignant Pleural Mesothelioma among Hispanics (MeSO–CLiCaP)
Andrés Cardona, Clinical and Translational Oncology Group, Institute of Oncology, Clínica del Country, Colombia

P3.03–049: Optimisation of Malignant Mesothelioma Registration at the Belgian Cancer Registry
Jan Van Meerbeeck, University Hospital of Antwerp, Belgium

P3.03–050: Prognostic and Predictive Factors Affecting Course of Disease and Survival in Malignant Pleural Mesothelioma
Angela De Palma, University of Bari “Aldo Moro”, Italy

P3.03–051: Establishment of Consultation System for Mesothelioma Diagnosis Using Remote Medicine by Internet
Kouki Inai, Pathological Diagnostic Center, Inc., Japan

P3.03–052: Diagnostic Utility of Mesothelin, Osteopontin and Megakaryocyte Potentiation Factor in Turkish Patients with Malignant Mesothelioma
Salih Emri, Hacettepe University, School of Medicine, Turkey

P3.03–053: Malignant Mesothelioma in Iranian Patients: A Study from National Institute of Tuberculosis and Lung Disease
Sharareh Seifi, National Institute of Tuberculosis and Lung Disease (NRITLD), Iran

P3.03–054: Review and Descriptive Analysis of 140 Patients Diagnosed with Malignant Mesothelioma at Consorci Sanitàri Parc Taulí
Juan Carlos Pardo Ruiz, Corporacio Sanitaria Parc Taulí, Spain

P3.03–055: Results of Second–Line Chemotherapy in Pleural Mesothelioma: A Single–Centre, Retrospective Study
Juan Carlos Pardo Ruiz, Corporacio Sanitaria Parc Taulí, Spain

P3.03–056: Retrospective Study Comparing Two Frontline Chemotherapy Schemes in Unresectable Malignant Mesothelioma
Juan Carlos Pardo Ruiz, Corporacio Sanitaria Parc Taulí, Spain

P3.03–057: Granulocyte Colony–Stimulating Factor–Producing Malignant Pleural Mesothelioma: Report of Two Cases
Eisuke Matsuda, Saiseikai Imabari Hospital, Japan

P3.03–058: A Retrospective Evaluation of 64 Hospitalised Malignant Pleural Mesothelioma (MPM) Patients
Aida Ustamuji, Clinic for Lung Disease and TB Podhrastovi, Clinical Center University of Sarajevo, Bosnia and Herzegovina

P3.03–059: Diaphragmatic and Pericardial Reconstruction by Heterologous Pericardial Patch after Extrapleural Pneumonectomy for Mesothelioma
Domenico Galetta, European Institute of Oncology, Italy

P3.03–060: Characteristics and Long Term Outcomes of Advanced Pleural Mesothelioma in Latin America (MeSO–CLiCaP)
Oscar Arrieta, Instituto Nacional de Cancerologia, Mexico

P3.03–061: Burden of Disease and Management of Mesothelioma in France: A National Cohort Analysis
Christos Chouaid, GRC OncoEst Creteil, France
P3.04 – SURGERY

Andrey Akopov, Pavlov First State Medical University, Russia

P3.04–002: Reducing the Amount of Resection after Induction Photodynamic and Chemotherapy in Inoperable Non–Small Cell Lung Cancer
Andrey Akopov, Pavlov First State Medical University, Russia

P3.04–003: Incidence and Outcome of Female Patients with Previous Breast Cancer Undergoing Curative Resection for Lung Cancer
Sabrina Tahon, Medical University Vienna, Austria

P3.04–004: The Risk Factor of the Thrombus Formation in Pulmonary Vein Stump after Left Upper Lobectomy for Lung Cancer
Reiko Shimizu, Shizuoka Cancer Center, Japan

P3.04–005: Evaluation of Noninvasive Lung Adenocarcinoma Using 3D–CT Imaging
Katsuyuki Suzuki, Yamagata Prefectural Central Hospital, Japan

P3.04–006: The Effect of Preoperative Multi–Disciplinary Support Commenced at Outpatient Clinic on Lung Cancer Patients
Masafumi Kataoka, Okayama Saiseikai General Hospital, Japan

P3.04–007: Detection of Brain Metastasis in Resected Lung Cancer with the New Postoperative Follow–Up Program
Rie Nakahara, Tochigi Cancer Center, Japan

P3.04–008: CATS: Computed Tomography–Assisted Thoracoscopic Surgery – A Novel Approach in Patients with Deep Intrapulmonary Lesions of Unknown Dignity
Peter Hohenberger, Mannheim University Medical Center, Germany

P3.04–009: Photodynamic Therapy (PDT) Turns 21: Indications, Applications and Outcomes for NSCLC
Patrick Ross, Main Line Health System, USA

P3.04–010: Changes of Right Lung Volume after Right Upper Lobectomy for Lung Cancer
Hyeong Ryul Kim, Asan Medical Center, University of Ulsan College of Medicine, South Korea

P3.03–062: Response to Pembrolizumab in a Malignant Pleural Mesothelioma with Sarcomatoid Histology: A Case Report
Vera Wienhausen–Wille, Klinikum Esslingen, Germany

P3.03–063: Phase 1/2 Trial of WT1 TCR–Transduced Central Memory and Naive CD8+ T Cells for Patients with Mesothelioma and Non–Small Cell Lung Cancer
Sylvia Lee, University of Washington, Seattle Cancer Care Alliance, USA

P3.04–011: Salvage Surgery for Isolated Local Recurrence after Stereotactic Body Radiotherapy for Clinical Stage I Non–Small Cell Lung Cancer
Hiroshi Date, Kyoto University Graduate School of Medicine, Japan

P3.04–012: Bronchial Sutures in Anatomic Pulmonary Resections: The Clinical Experience of 865 Cases
Aleksei Aksarin, Surgut District Clinical Hospital, Russia

P3.04–013: The Role of Extent of Surgical Resection and Lymph Node Assessment for Clinical Stage I Pulmonary Lepidic Adenocarcinoma
Morgan Cox, Duke University, USA

P3.04–014: Surgical Outcome and Diagnosis of cN1 Lung Cancers after Introducing PET/CT
Satoshi Shiono, Yamagata Prefectural Central Hospital, Japan

P3.04–015: Usefulness of Carotid Ultrasonography for Postoperative Cerebrovascular Complication Prevention in Patients with Lung Cancer
Sadanori Takeo, National Kyusyu Medical Center, Japan

P3.04–016: Surgical Implications of the New Lung Adenocarcinoma Classification – Usefulness for Selecting Cases Undergoing Sublobar Resection
Akira Shimamoto, Mie University Graduate School of Medicine, Japan

P3.04–017: Wedge Resection for Clinical–n0 Non–Small Cell Lung Cancer
Hiroaki Tsunezuka, Kyoto Prefectural University of Medicine, Japan

In Kyu Park, Seoul National University Hospital, South Korea

P3.04–019: Nodal Upstaging in cN0 Lung Cancer is More Influenced by Tumor Size Than the Surgical Approach
Florian Augustin, Medical University Innsbruck, Austria

P3.04–020: Segmentectomy in Patients with Pulmonary Malignancies Using 3D–CT Reconstruction and Bronchovascular Separation
Oleg Pikin, Hertzen Research Institute of Oncology, Russia

P3.04–021: Readmission Rate is Not Increased with Shortened Hospital Stay after Lung Cancer Surgery
Kei Yarimizu, Yamagata Prefectural Central Hospital, Japan

P3.04–022: Unexpected Residual Carcinoma in the Bronchial Stump after Surgery for Lung Cancer
Yohei Kameda, Kanagawa Cardiovascular and Respiratory Center, Japan

P3.04–023: Perioperative Management of Antiplatelet Therapy in Patients with Coronary Stent Who Need Thoracic Surgery
Shunki Hirayama, Juntendo University School of Medicine, Japan

P3.04–024: Long–Term Outcome of Sublobar Resection versus Lobectomy for Stage I and II Non–Small Cell Lung Cancer
Su Kyung Hwang, Asan Medical Center, University of Ulsan College of Medicine, South Korea
P3.04–025: Repeated Lung Resection of Ipsilateral Lung Cancer That is Detected after Segmentectomy for Primary Lung Cancer Masanori Tsuchida, Niigata University Graduate School of Medical and Dental Sciences, Japan

P3.04–026: A Simultaneous Surgical Strategy for Patients with Lung Cancer and Severe Cardiac Diseases Requiring Surgical Treatment Jae Jun Jung, Sungkyunkwan University School of Medicine, Samsung Medical Center, South Korea

P3.04–027: Feasibility of Lung Surgery for the Patient with Previous History of Coronary Artery Bypass Grafting Yutaro Koike, Juntendo University Hospital, Japan

P3.04–028: The Left Upper Division Sacrifice for Bronchoplasty for an Adenoid Cystic Carcinoma of the Left Main Branch Satoshi Yamamoto, Medical Kouhoukai Takagi Hospital, Japan

P3.04–029: A Prospective Randomized Trial of Perioperative Administration of Neutrophil Elastase Inhibitor in Patients with Interstitial Pneumonias Mariko Fukui, Juntendo University School of Medicine, Japan

P3.04–030: Examination of the Relevance of Prolonged Air Leakage after Pulmonary Resection for Lung Cancer and Factors Affecting Delayed Wound Healing Koshi Nagano, Bell–Land General Hospital, Japan

P3.04–031: Intermittent Chest Tube Clamping May Shorten Chest Tube Duration and Postoperative Hospital Stay of Lung Cancer Surgery Shi Yan, Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), China


P3.04–033: Digital Drainage System Reduces Chest Tube Duration and Hospitalization after Anatomic Pulmonary Resections for Malignancies Ricardo Terra, Instituto do Câncer do Estado de São Paulo – ICESP, Brazil

P3.04–034: Differences between Pleurodesis Using Talc and Silver Nitrate at Different Times of Pleural Disease in Mice Ricardo Terra, University of Sao Paulo Medical School, Brazil

P3.04–035: Pleurodesis with a 50% Glucose Solution for Post–Operative Pneumothorax, after Curative Lung Cancer Resection Hiroyuki Sumitomo, Tokushima Municipal Hospital, Japan

P3.04–036: Clinical Analysis of the Association between Lung Cancer and Connective Tissue Disease Kazuhide Nii, Kagawa University, Japan

P3.04–037: Rare Giant Malignant Tumors of the Chest: Reconstructive Challenge Krzysztof Kurowski, Hospital Universitario del Vinalopo, Spain

P3.04–038: Pulmonary Resection for Metastatic Pancreaticobiliary Cancer: Can It Be Justified as a Treatment of Choice? Toshiki Okasaka, Nagoya University Graduate School of Medicine, Japan

P3.04–039: Solitary Fibrous Tumor of the Pleura Associated with Gynecomastia: A Case Report Omer Giray Intepe, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey

P3.04–040: A Rare Case of Intrathoracic Mass: Intrathoracic Desmoid Tumor Omer Giray Intepe, Dr. Siyami Ersek Thoracic and Cardiovascular Surgery Training and Research Hospital, Turkey

P3.04–041: Giant Solitary Fibrous Tumor of the Pleura Saved by Biopsy and Following Extended Resection: A Long Term Surviving Case Jun Zhang, China Medical University Lung Cancer Center, The First Hospital of China Medical University, China

P3.04–042: 2 Cases of Fast–Growing Emphysematous Bullae Following Lobectomy for Lung Cancer Hirofumi Suzuki, Saiseikai Suita Hospital, Japan

P3.04–043: Minimally Invasive Small Incision, Muscle– and Rib–Sparing Thoracotomy (miMRST) for Multiple Sclerosing Pneumocytomas Jun Zhang, The First Hospital Of China Medical University, China

P3.04–044: Surgical Management of Arteriovenous Malformations: Our Experience Fadil Gradica, University Hospital Shefqet Ndroqi, Albania

P3.04–045: Primary Lung Cancer Presenting as Pneumothorax Fadil Gradica, University Hospital Shefqet Ndroqi, Albania

P3.04–046: Cases of Surgical Resection of Post–Operative Lymph Node Recurrences from Primary Lung Cancer Ema Mitsui, Okayama Saiseikai General Hospital, Japan

P3.04–047: The Incidence and Outcome of Hoarseness after Systematic Upper Mediastinal Nodal Dissection by Radical Surgery for Primary Lung Cancer Yoshifumi Sano, Ehime University Medical School, Japan

P3.05  PALLIATIVE CARE/ETHICS

P3.05  PALLIATIVE CARE/ETHICS

P3.05  PALLIATIVE CARE/ETHICS

P3.05–001: Psychological Intervention to Treat Distress and Suffering Experienced by People with Lung Cancer Nearing the End–Of–Life Mary Duffy, Peter MacCallum Cancer Centre, Australia

P3.05–002: Malnutrition is an Independent Risk Factor on Survival on EGFR Mutated Patients Diagnosed with Non–Small Cell Lung Cancer Ana Gonzalez–Ling, Instituto Nacional de Cancerologia, Mexico
P3.05–003: Anxiety and Depression in Patients with EGFR+ NSCLC Receiving Treatment with TKIs
Ana Gonzalez-Ling, Instituto Nacional de Cancerologia, Mexico

P3.05–004: Psycho-Social Function and Caregiver’s Burden in Patients with Advanced Lung Cancer
Annamaria Catino, Clinical Cancer Center “Giovanni Paolo II”, Italy

P3.05–005: Geriatric Assessment and Functional Decline in Older Patients with Lung Cancer
Lore Decoster, UZ Brussel, Belgium

P3.05–006: Anxiolytic Effect of Acupuncture in a Phase II Study of Acupuncture and Morphine for Dyspnoea in Lung Cancer and Mesothelioma
Anna Minchom, Royal Marsden Hospital NHS Foundation Trust, UK

P3.05–007: Prospective Evaluation for Combination Antiemetic Therapy on CINV in NSCLC Receiving Carboplatin-Based Chemotherapy of MEC
Mototsugu Shimokawa, National Kyushu Cancer Center, Japan

P3.05–008: Mindfulness-Based Stress Reduction Added to Care as Usual for Lung Cancer Patients and Their Partners: A Randomized Controlled Trial
Miep Van Der Drift, Radboud University Medical Centre, Netherlands

P3.05–009: Medical Marijuana and Lung Cancer: Patients’ Knowledge and attitude towards its Use
Raja Mudad, University of Miami, USA

P3.05 PALLIATIVE CARE/ETHICS – QOL, OTHERS

P3.05–010: Developing Tools for a Successful Thoracic Rapid Tissue Donation Program
Andrea Shaffer, H Lee Moffitt Cancer Center and Research Institute, USA

P3.05–011: Importance of Assessment of Malnutrition Risk in Lung Cancer Patients
Tomi Kovacevic, Institute for Pulmonary Diseases of Vojvodina, Faculty of Medicine, University of Novi Sad, Serbia

P3.05–012: Assessment of the Impact of Palliative Care on the Quality of Life in Advanced Non-Small Cell Lung Cancer Patients – A Longitudinal Study
Fawaz Pullishery, Educare Institute of Dental Sciences, India

P3.05–013: Development of the Kentucky LEADS Collaborative Lung Cancer Survivorship Care Program
Jamie Studts, University of Kentucky College of Medicine, USA

P3.05–014: Evaluation of Hyponatraemia in Lung Cancer Patients: A U.K. Teaching Hospital Experience
Joyce Thompson, Heart of England NHS Trust, UK

P3.05–015: Sleep Quality and Fatigue in Patients with Lung Cancer
Nudra Malik, Lahore College Women University, Pakistan

P3.05–016: Mitochondrial Pathway Mediated Apoptosis is Involved in Erlotinib-Induced Cytotoxicity in Hepatic Cells
Xueqin Chen, Hangzhou First People’s Hospital, China

P3.05–017: Survivor Guilt: The Secret Burden of Lung Cancer Survivorship
Kay Bayne, Lung Cancer Alliance, USA

P3.05–018: Assessment of Skeletal Muscle Mass as a Predictive Factor for Chemotherapy Toxicity and TTP in Advanced NSCLC Patients with Cancer Cachexia
Drazena Srdic, University Hospital Centre Zagreb, Croatia

P3.05–019: Patients with Advanced Lung Cancer: What Do They Know, What Would They Like to Know, What Should They Know about Their Disease
Elke Vandenbroucke, AZ Monica, Belgium

P3.05–020: Patients’ Perception of Rapid Onset Opioids
Choonhee Son, Dong-A University Hospital, South Korea

P3.06 TRIAL DESIGN/STATISTICS – CLINICAL STUDIES

P3.06–001: Phase I/II Study to Evaluate Safety and Efficacy DCVAC/LuCa with 1st Line Chemotherapy +/- Immune Enhancers vs Chemotherapy, Stage IV NSCLC
Libor Havel, Thomayer Hospital, Czech Republic

P3.06–002: ATLANTIS Trial: Phase III Study of PM01183/Doxorubicin vs. CAV or Topotecan in SCLC after One Platinum-Containing Line
Anna Farago, Massachusetts General Hospital, USA

P3.06–003: SARON: Stereotactic Ablative Radiotherapy for Oligometastatic Non-Small Cell Lung Cancer (NSCLC). A UK Randomised Phase III Trial
David Landau, Guy’s and St Thomas’ NHS Foundation Trust, UK

P3.06–004: A Systematic Review of Outcome Reporting in Studies of Radical Radiotherapy and Chemoradiotherapy in Lung Cancer
Sarah Cruickshank, University of Aberdeen, UK

P3.06 TRIAL DESIGN/STATISTICS – OTHERS

P3.06–005: Blastomatoid Pulmonary Carcinosarcoma, Combined with Lepidic Adenocarcinoma
Yu-Deok Choi, Chonnam National University Medical School, South Korea

P3.06–006: Endpoints in Reports on Clinical Trials for Advanced Lung Cancer
Matjaz Zwitter, Institute of Oncology Ljubljana, Slovenia
Oliver Gautschi, Cantonal Hospital Luzern, Switzerland

P3.07–002: Complications and Costs of Diagnostic and Post–Progression Biopsies among Patients with Non–Small Cell Lung Cancer (NSCLC)
Ronan Kelly, Johns Hopkins University, USA

P3.07–003: Effectiveness of Pemetrexed in Advanced Non–Squamous NSCLC and Estimation of Its Impact on Public Health in France
Katherine Bellebaum Winfree, Eli Lilly and Company, USA

P3.07–004: Nivolumab for Non–Small Cell Lung Cancer (NSCLC): An Economic Model for Risk Sharing Based on Real–Life Data
Elizabeth Dudnik, Davidoff Cancer Center, Israel

P3.07–005: US Healthcare without Payer Restrictions or Out–Of–Pocket Costs: Treatment of Advanced NSCLC in the Military Health System
Matthew Peterson, San Antonio Military Medical Center, USA

Andrea Ferris, LUNGevity Foundation, USA

P3.07–007: Compassionate Use Program for New Cancer Drugs in Israel – Shortcut for Reimbursement Approval
Hiba Reches, Davidoff Cancer Center, Israel

P3.07–008: METASTATIC NSCLC: Treatment Reality from 182 Cases of Lung Adenocarcinoma in a Brazilian Public Cancer Health Service
Leonardo Lago, Hospital Sao Lucas da Pucrs, Brazil

P3.07–011: Geographical Variation in the Use of Radiotherapy and Surgical Resection for Treatment of Non–Small Cell Lung Cancer in England
Daniela Tataru, Public Health England, UK

David Harpole, Duke University, USA

P3.07–013: Determining EGFR and ALK Status in a Population–Based Cancer Registry: A Natural Language Processing Validation Study
Bernardo Goulart, Fred Hutchinson Cancer Research Center, USA

P3.07–014: Patient and Caregiver Experiences: Identifying Gaps in Access to High Quality Care for Lung Cancer Patients
Jennifer King, Lung Cancer Alliance, USA

P3.07–015: Patterns and Risk Factors of Patient Flows Across Different Geographic Health Service Units for Lung Cancer Surgery
Emanuela Taioli, Icahn School of Medicine at Mount Sinai, USA

P3.07–017: Joinpoint Regression Analysis of Lung Cancer Mortality, Turkey
Sedat Altin, Erzincan University Faculty of Medicine, Turkey

P3.07–018: New European Clinical Trial Regulation: What’s Going On?
Francesca Arizio, AOI San Luigi Gonzaga, Italy

P3.07–019: AMDAT Lung, An Ideal Lung Cancer MDT Dataset
Emily Stone, St Vincent’s Hospital, Australia

P3.07–020: Implementation of an International Value–Based Standard Set of Outcomes for Lung Cancer Patients in a Brazilian Center
Clarissa Baldotto, Instituto COI de Educação e Pesquisa (ICOI) and Núcleo de Oncologia Torácica (NOT), Brazil

P3.07–021: Prevalence of EGFR Mutations in Brazilian Patients with Advanced Non–Squamous Non–Small Cell Lung Cancer
Ellias Abreu Lima, Instituto Mário Penna, Brazil

P3.07–022: Progress against Non–Small–Cell Lung Cancer (NSCLC) Compared to Other Solid Tumors
Silvia Paddock, Rose Li and Associates, Inc., USA
Maps and Floor Plans
2017 CHICAGO
MULTIDISCIPLINARY SYMPOSIUM in
THORACIC ONCOLOGY
September 14–17, 2017

CO-SPONSORED BY:

THE UNIVERSITY OF CHICAGO
MEDICINE & BIOLOGICAL SCIENCES

INTERNATIONAL ASSOCIATION FOR THE STUDY OF LUNG CANCER

Small Cell Lung Cancer Workshop
MARCH 16–17, 2017 | NEW YORK

www.iaslc.org | pia.hirsch@iaslc.org
SAVE THE DATE!

Join us in Toronto, Canada September 23 - 26, 2018 for the 19th WCLC in 2018!

CONFERENCE PRESIDENT

Dr. Frances Shepherd, MD, FRCP(C), OOnt, OC
Division of Medical Oncology | Princess Margaret Cancer Centre Toronto, Canada
Every patient with cancer will face their own unique journey. Along with you, we are committed to helping to redefine that journey. At Janssen Oncology, our dedication lies in developing best-in-class research and solutions to help you and your patients discover everyday moments of victory.

Visit janssen.com/oncology to learn more.
**OPDIVO**

( nivolumab )

OPDIVO is the only PD-1 inhibitor that delivered superior OS vs. chemotherapy in two Phase III studies designed to include PD-L1 expressors and non-expressors with previously treated NSCLC.

OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.

Visit BMS at Booth N° 2000 to learn more.

Abbreviated SMPC

This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 in the SmPC for how to report adverse reactions.

**NAME OF THE MEDICINAL PRODUCT:** OPDIVO 10 mg/mL concentrate for solution for infusion. Pharmacotherapeutic Group: Antineoplastic agents, monoclonal antibodies. ATC code: L01XC17.

**QUALITATIVE AND QUANTITATIVE COMPOSITION:** Each mL of concentrate contains 10 mg of nivolumab. One vial of 4 mL contains 40 mg of nivolumab. One vial of 10 mL contains 100 mg of nivolumab. Nivolumab is produced in Chinese hamster ovary cells by recombinant DNA technology. List of excipients: Sodium citrate dihydrate, Sodium chloride, Mannitol (E421), Pentetic acid (diethylenetriaminepentaacetic acid), Polysorbate 80, Sodium hydroxide (for pH adjustment), Hydrochloric acid (for pH adjustment), Water for injections.

**THERAPEUTIC INDICATIONS:**

- **Melanoma** OPDIVO as monotherapy or in combination with ipilimumab is indicated for the treatment of advanced (unresectable or metastatic) melanoma in adults. Relative to nivolumab monotherapy, an increase in progression-free survival (PFS) for the combination of nivolumab with ipilimumab is established only in patients with low tumour PD-L1 expression (see sections 4.4 and 5.1 in the SmPC).
- **Non-Small Cell Lung Cancer (NSCLC)** OPDIVO is indicated for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) after prior chemotherapy in adults.
- **Renal Cell Carcinoma (RCC)** OPDIVO as monotherapy is indicated for the treatment of advanced renal cell carcinoma after prior therapy in adults.

**CONTRAINDICATIONS:**

Hypersensitivity to the active substance or to any of the excipients listed in section 6.1 in the SmPC.

**MARKETING AUTHORIZATION HOLDER:** Bristol Myers Squibb Pharma EERG, Uxbridge Business Park, Sanderson Road, Uxbridge UB8 1DH, United Kingdom

**CONTACT IN AUSTRIA:** Bristol-Myers Squibb GesmbH, Vienna, Tel. +43 1 60143 -0 NR, prescription only.

**DATE OF LAST REVISION:** July 2016

Further information, especially in regards to special warnings and precautions for use, interactions with other medicinal products or other forms of interaction, pregnancy and lactation as well as undesirable effects are to be extracted from the published Summary of Product Characteristics (SmPC).